

US011090379B2

# (12) United States Patent

## Pauza et al.

#### (54) HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY

- (71) Applicant: American Gene Technologies International Inc., Rockville, MD (US)
- (72) Inventors: Charles David Pauza, Baltimore, MD
   (US); Haishan Li, North Potomac, MD
   (US); Tyler Lahusen, Frederick, MD
   (US); Jeff Galvin, Rockville, MD (US)
- (73) Assignee: American Gene Technologies International Inc., Rockland, MD (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 16/593,882
- (22) Filed: Oct. 4, 2019

#### (65) **Prior Publication Data**

US 2020/0109417 A1 Apr. 9, 2020

#### **Related U.S. Application Data**

- (63) Continuation of application No. 16/218,010, filed on Dec. 12, 2018, now Pat. No. 10,494,647, which is a continuation of application No. 16/011,550, filed on Jun. 18, 2018, now Pat. No. 10,233,464, which is a continuation of application No. 15/668,223, filed on Aug. 3, 2017, now Pat. No. 10,036,038, which is a continuation of application No. PCT/US2017/013019, filed on Jan. 11, 2017.
- (60) Provisional application No. 62/409,270, filed on Oct.
  17, 2016, provisional application No. 62/385,864, filed on Sep. 9, 2016, provisional application No. 62/360,185, filed on Jul. 8, 2016.
- (51) Int. Cl.

A61K 39/00	(2006.01)
C12N 15/113	(2010.01)
A61K 48/00	(2006.01)
C12N 15/86	(2006.01)
A61K 35/17	(2015.01)
A61K 39/21	(2016.01)
A61P 31/18	(2006.01)
A61K A5/06	(2006.01)
ACTE 20/12	(2000.01)
A01A 39/12	(2006.01)
CO/K 14//15	(2006.01)
A61K 31/7105	(2006.01)
C12N 15/11	(2006.01)
A61K 35/14	(2015.01)
A61K 39/39	(2006.01)
C12N 5/078	(2010.01)
C12N 7/00	(2006.01)
C12N 5/0783	(2010.01)
A61K 35/15	(2015.01)
A61K 35/12	(2015.01)

(52) U.S. Cl.
 CPC ........... A61K 39/21 (2013.01); A61K 31/7105 (2013.01); A61K 35/14 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 45/06

# (10) Patent No.: US 11,090,379 B2

## (45) **Date of Patent:** Aug. 17, 2021

(2013.01); A61P 31/18 (2018.01); C07K 14/7158 (2013.01); C12N 5/0634 (2013.01); C12N 5/0636 (2013.01); C12N 7/00 (2013.01); C12N 15/111 (2013.01); C12N 15/1132 (2013.01); C12N 15/1138 (2013.01); C12N 15/86 (2013.01); A61K 35/15 (2013.01); A61K 35/17 (2013.01); A61K 2035/124 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01); C12N 2330/51 (2013.01); C12N 2510/00 (2013.01); C12N 2710/24143 (2013.01); C12N 2740/15021 (2013.01); C12N 2740/15034 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15052 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16043 (2013.01)

#### (58) Field of Classification Search

CPC ...... A61K 31/7105; A61K 35/17; C12N 2310/14; C12N 15/86; A61P 35/00 See application file for complete search history.

#### (56) **References Cited**

### U.S. PATENT DOCUMENTS

5,668,255 A	9/1997	Murphy
5,674,703 A	10/1997	Woo et al.
6,156,514 A	12/2000	Acevedo et al.
6,399,383 B1	6/2002	Apt et al.
6,635,472 B1	10/2003	Lauermann
7,371,542 B2	5/2008	Ivanova et al.
8,124,752 B2	2/2012	Bumcrot et al.
8,287,857 B2	10/2012	Dudley et al.
8,993,532 B2	3/2015	Hannon et al.
9,522,176 B2	12/2016	DeRosa et al.
	10	. 1

(Continued)

#### FOREIGN PATENT DOCUMENTS

BR	2515	3/2019
CN	101516365	8/2009
	(Cor	tinued)

#### OTHER PUBLICATIONS

Vargas, J. Jr. et al., "Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy," Antiviral Res. Dec. 2008 vol. 80 No. 3, pp. 288-294.

(Continued)

Primary Examiner — Barry A Chestnut

(74) Attorney, Agent, or Firm - Snell & Wilmer LLP

### (57) **ABSTRACT**

The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

#### 39 Claims, 40 Drawing Sheets

#### Specification includes a Sequence Listing.

## U.S. PATENT DOCUMENTS

9 527 904	B2	12/2016	Balazs
0.834.700	B1	$\frac{12}{2010}$	Dalazs Daliza et el
9,834,790	DI	12/2017	There
9,034,791	D2 D2	2/2017	Zhang Deces et al
9,914,938	B2	3/2018	Pauza et al.
10,023,880	B2	7/2018	Pauza et al.
10,036,038	B2	7/2018	Pauza et al.
10,036,040	B2	7/2018	Pauza et al.
10,137,144	B2	11/2018	Pauza et al.
10.208.295	B2	2/2019	DeRosa et al.
10.233.464	B2	3/2019	Pauza et al.
10,220,789	B2	9/2019	Pauza et al
10,472,640	B2	11/2010	Pauza et al
2002/0169245	DZ A 1	11/2019	Dama at al
2002/0108343	AI	11/2002	Dong et al.
2003/0013196	AI	1/2003	Engelman et al.
2003/0096787	Al	5/2003	Perridcaudet et al.
2003/0119770	A1	6/2003	Lai
2003/0138444	A1	7/2003	Zavitz et al.
2004/0142416	A1	7/2004	Laipis et al.
2004/0161412	A1	8/2004	Penn et al.
2004/0192629	A1	9/2004	Xu et al
2004/0214158	<b>A</b> 1	10/2004	Sethi et al
2004/0214156	A 1	10/2004 12/2004	Beresford et al
2004/0248290	A1	1/2004	Marlana at al
2005/0019927	AI	1/2005	Markus et al.
2005/0138677	AI	6/2005	Pfister et al.
2006/0057553	Al	3/2006	Aguilar-Cordova
2006/0183230	A1	8/2006	Silla et al.
2006/0246520	A1	11/2006	Champagne et al.
2007/0026521	A1	2/2007	Colosi
2007/0141679	A1	6/2007	Sodroski
2007/0203333	<u>A</u> 1	8/2007	McSwiggen et al
2007/0203333	A 1	1/2008	Vie et al
2008/0003223	A1	1/2008	Vie et al.
2008/0003082	AI	1/2008	Lois-Caballe et al.
2008/0039413	AI	2/2008	Morris et al.
2008/0131940	Al	6/2008	Chiu
2008/0153737	A1	6/2008	Lieberman et al.
2008/0199961	A1	8/2008	Rasko et al.
2008/0227736	A1	9/2008	Chen et al.
2008/0293142	A1	11/2008	Liu et al.
2009/0148936	A 1	6/2009	Stout et al
2009/01 10550	A 1	12/2009	Fournie et al
2009/0304088	A1	1/2010	Deviser at al
2010/001/911		2/2010	Dawson et al.
2010/0009372	AI	5/2010	Kazantsev
2010/0119511	AI	5/2010	Wang et al.
2010/0120155	Al	5/2010	Brennan et al.
2010/0286166	Al	11/2010	Pey Rodriguez et al.
2010/0316676	A1	12/2010	Sanders
2011/0008803	A1	1/2011	Stockwell et al.
2011/0177155	A1	7/2011	Peer et al.
2011/0207226	A1	8/2011	Ni et al
2012/0053223	A 1	1/2012	Benkirane et al
2012/0035225	A1	2/2012	Galvin at al
2012/0027723	AI	5/2012	
2012/0114007	AI	5/2012	Lai et al.
2012/0034197	AI	8/2012	Young et al.
2012/0201794	AI	9/2012	Chen et al.
2013/0078276	Al	3/2013	Robinson et al.
2013/0090371	A1	4/2013	Lu et al.
2013/0142766	A1	6/2013	Dodo et al.
2013/0122380	A1	8/2013	Aquino et al.
2013/0211380	A1	8/2013	Cabrera Aquino et al.
2014/0155468	A1	6/2014	Gregory et al
2014/0162804	A1	6/2014	Unterwell of al
2014/0102894		6/2014	Dabhing at al
2014/01/8340	AI	6/2014	Robbins et al.
2014/0234958	AI	8/2014	Kashara et al.
2014/0248277	Al	9/2014	Hoffman et al.
2014/0336245	A1	11/2014	Mingozzi et al.
2015/0010578	A1	1/2015	Balazs et al.
2015/0018539	A1	1/2015	Fellmann
2015/0126580	Aİ	5/2015	DePinho et al.
2015/0132255	AI	5/2015	Sorensen et al
2015/0176006	A 1	6/2015	Krausa at al
2015/01/0000	A1	0/2013	Kiause et al.
2010/0060/0/	AI	3/2016	Goldenberg et al.
2016/0243169	Al	8/2016	Chen et al.
2016/0289681	A1	10/2016	Rossi
2017/0015976	Al	1/2017	Nelson
2017/0028036	A 1	-2/2017	Mingazzi et al

2017/0037369	A1	2/2017	Ramsborg et al.
2017/0335344	A1	11/2017	Pauza et al.
2018/0010147	A1	1/2018	Pauza
2018/0142257	A1	5/2018	Pauza
2018/0142258	A1	5/2018	Pauza
2018/0161455	A1	6/2018	Pauza
2018/0177866	A1	6/2018	Pauza
2018/0195046	A1	7/2018	Deng
2018/0195050	A1	7/2018	Szalay
2018/0256624	A1	9/2018	Pauza
2018/0305716	A1	10/2018	Pauza et al.
2018/0355032	A1	12/2018	Roberts
2019/0046633	A1	2/2019	Pauza et al.
2019/0062786	A1	2/2019	Pauza et al.
2019/0078096	A1	3/2019	Lahusen et al.
2019/0083523	A1	3/2019	Pauza
2019/0388456	A1	12/2019	Pauza et al.
2020/0063161	A1	2/2020	Pauza
2020/0087682	A1	3/2020	Lahusen et al.
2020/0155590	A1	5/2020	Zhennan
2020/0181645	A1	6/2020	Pauza
2020/0318081	A1	10/2020	Lahusen et al.
2021/0047644	A1	2/2021	Lahusen

### FOREIGN PATENT DOCUMENTS

CN	101679466	3/2010
CN	101805750	8/2010
CN	103184224	7/2013
CN	105112370	12/2015
CN	108883100	11/2018
EP	1647595	4/2006
EP	3402483	11/2018
EP	3413926	12/2018
EP	3426777	1/2019
EP	3468617	4/2019
EP	3468618	4/2019
$\mathbf{EP}$	3481418	5/2019
EP	3481435	5/2019
IN	20194700153	2/2019
$_{\rm JP}$	2002506652	3/2002
JP	2007-527240	9/2007
JP	2008518591	6/2008
JP	2008-538174	10/2008
JP	2012508591	4/2012
JP	2013-5300152	7/2013
JP	2015-518838	7/2015
JP	2016-502404	1/2016
JP	2019509029	4/2019
WO	199947691	9/1999
WO	WO 2002020554	3/2002
WO	2003093436	11/2003
WO	WO 2004053137	6/2004
WO	2005028634	3/2005
WO	WO 2005033282	4/2005
WO	2006039721	4/2006
WO	WO 2006048215	5/2006
wo	WO 2007000668	1/2007
WO	2007015122	2/2007
WO	2007132292	11/2007
wo	WO 200/1336/4	11/2007
wo	WO 2008025025	2/2008
wo	2008090185	7/2008
wo	WO 2009100928	8/2009
wo	WO 200914/445	5/2019
wo	WO 2010051521	5/2010
wo	WO 2010117974 WO 2010127166	10/2010
WO	WO 201012/100 WO 2011008248	1/2010
WO	WO 2011008548	6/2011
wo	2011110042	0/2011
WO	WO 2012048202	4/2012
wo	WO 2012048505	5/2012
wo	WO 2012001073	10/2012
wo	WO 2012145024	6/2012
wo	2014016817	1/2014
wo	WO 2014117050	7/2014
wõ	WO 2014187881	11/2014
wõ	WO 2015017755	2/2015
		2,2010

#### FOREIGN PATENT DOCUMENTS

WO	WO 2015042308	3/2015
WO	2015061491	4/2015
WO	WO 2015078999	6/2015
WO	2015086854	8/2015
WO	WO2015164759	10/2015
WO	WO 2016046234	3/2016
WO	WO 2016061232	4/2016
WO	WO 2016069716	5/2016
WO	WO 2016200997	7/2016
WO	WO 2016189159	12/2016
WO	WO 2017007994	1/2017
WO	20170068077	4/2017
WO	WO 2017100551	6/2017
WO	WO 2017123918	7/2017
WO	WO 2017139065	8/2017
WO	WO 2017156311	9/2017
WO	20170173453	10/2017
WO	WO 2017213697	12/2017
WO	WO 2017214327	12/2017
WO	WO 2018009246	1/2018
WO	WO 2018009847	1/2018
WO	WO 2018017882	1/2018
WO	WO 2018126112	7/2018
WO	WO 2018129540	7/2018
WO	20180148443	8/2018
WO	WO 2018187231	10/2018
WO	WO 2018232359	12/2018
WO	WO 2019070674	4/2019
WO	2020097049	5/2020
WO	2020243717	12/2020

#### OTHER PUBLICATIONS

Thompson et al., "Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway," Blood, Jan. 15, 2006, vol. 107, pp. 651-654.

Gober et al., "Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells," J. of Experimental Med., Jan. 20, 2003, vol. 197, pp. 163-168.

Goepfert, et al., "Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-2 Virus-Like Particles," J. Infectious Diseases, Jul. 1, 2014, vol. 210, pp. 99-110.

Human papillomavirus type 16 (HPV16), complete genome; GenBank: K02718.1; Publication [online], Mar. 18, 1994, https://www.ncbi.nlm.nih.gov/nucleotide/333031?report=genbank&log\$=nucltop &blast\_rank=22&RID=H3E1THFU014; pp. 1-4.

{Long control region} [human papillomavirus, type 16, Genomic, 860 nt]; Accession 560559. Publication [online]. May 7, 1993, https://www.ncbi.nlm.nih.gov/nucleotide/237343?report=genbank &log\$=nucltop&blast\_rank=1&RID=H3FCKA00014; pp. 1.

Tebas, P. et al, "Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV," Blood, 2013, vol. 121, No. 9, pp. 1524-33.

Tebas, p. et al., "Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV," The New England Journal of Medicine, vol. 370 (10), pp. 901-910, Mar. 6, 2014.

Li et al., "Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by Vy2V82 T Cells," J. of Immunology, 2009, vol. 182, pp. 8118-8124.

Wang et al., "Indirect Stimulation of Human Vy2Vδ2 T Cells through Alterations in Isoprenoid Metabolism," J. of Immunology, vol. 187 pp. 5099-5113, (Nov. 15, 2011).

Stunkel et al., "The Chromatin Structure of the Long Control Region of Human Papillomavirus Type 16 Repress Viral Oncoprotein Expression," Journal of Virology, vol. 73, No. 3, pp. 1918-1930 (Mar. 1999).

Lu et al., "Anti-sense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance," Journal of Virology, vol. 79, No. 13, pp. 7079-7088 (Jul. 2004).

Dieli et al., "Targeting Human yð T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer," Europe PMC Funders Group, Cancer Research, vol. 67(15), pp. 7450-1451, (Aug. 1, 2007).

GenBank Accession No. 560559 "(long control region) [human papillomavirus, type 16, Genomic, 860 nt]" May 7, 1993 [located online Nov. 21, 2017 at https://ncbi.nlm.nih.gov/nuccore/S60559] entire DNA sequence.

GenBank Accession No. JG619773, MNESC1NG-T3-001\_L15\_ 6FEB2009\_054 MNESC1NG cell culture from Mahonia nervosa Berberis nervosa cDNA, mRNA sequence, Feb. 13, 2014 (online). [Retrieved on Dec. 5, 2017]. Retrieved from the internet:<URL: https://www.ncbi.nlm.nih.gov/nucest/JG619773 > entire document. Moser et al., "yð T cells: novel initiators of adaptive immunity," Immunological Reviews, vol. 215, pp. 89-102 (Feb. 2, 2007).

Capietto, A. H. et al., "Stimulated yo T Cells Increase the in Vivo Efficacy of Trastuzumab in HER-2' Breast Cancer," J Immunology, vol. 187(2), pp. 1031-1038, (2011).

Chen, Z. and M. S. Freedman, "CD16+ yô T Cells Mediate Antibody Dependent Cellular. Cytotoxicity: Potential Mechanism in the Pathogenesis of Multiple Sclerosis," Clin Immunology, vol. 128(2), pp. 219-227, (2008).

Couzi, L. et al., "Antibody-Dependent Anti-Cytomegalovirus Activity of Human yô T Cells. Expressing CD16 (FcyRIIIa)," Blood, vol. 119(6), pp. 1418-1427, (2012).

Fisher, J. P. et al., "Effective Combination Treatment of GD2-Expressing Neuroblastoma and Ewing's Sarcoma Using Anti-GD2 ch14.18/CHO Antibody with Vy9V82+ y8T Cells," OncoImmunology, vol. 5(1), pp. e1025194, (2016).

Gertner-Dardenne, J. et al., "Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies," Blood 113(20): 4875-4884, (2009).

Poonia, B. and C. D. Pauza, "Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity," Cytotherapy 14(2): 173-181, (2012).

Schiller, C. B. et al., "CD19-Specific Triplebody SPM-1 Engages NK and yo T Cells for Rapid and Efficient Lysis of Malignant B-Lymphoid Cells," Oncotarget, vol. 7(50), pp. 83392-83408, (2016). Tokuyama, H. et al., "Vy9Vo2 T Cell Cytotoxicity Against Tumor Cells is Enhanced by Monoclonal Antibody Drugs—Rituximab and Trastuzumab," Int J Cancer, vol. 122(11), pp. 2526-2534, (2008). Zufferey et al., "Self-Inactivating Lentivirus Vector for Safe and Efficient Lyvice Gene Delivery" Journal of Virelogy vol. 72(12)

Efficient In Vivo Gene Delivery," Journal of Virology, vol. 72(12), pp. 9873-9880, (1998). Ostertag et al., "Brain Tumor Eradication and Prolonged Survival

from Intratumoral Conversion of 5-Fluorocytosine to 5-fluorouracil Using a Nonlytic Retroviral Replicating Vector," Neoro-Oncology 14(2), pp. 145-159, Feb. 2012.

Twitty et al., "Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types, Human Gene Therapy. Methods", 27(1), pp. 17-31, Feb. 1, 2016.

Charron et al., "Dominant-Negative Interference in the Pahenu2 Mouse Model of PKU: Effectiveness of Vectors Expressing Either Modified Forms of Phenylalanine Hydroxylase (PAH) or Ribozymes Plus a Hardened PAH mRNA," Molecular Therapy, vol. 11, pp. S163-S164, (2005).

Fusetti, et al., "Structure of Tetrameric Human Phenylalanine Hydroxylase and Its Implications for Phenylketonuria," J. Bio. Chem., vol. 273, No. 27, pp. 16962-16967 (1998).

Hafid et al., "Phenylkeionuria: A Review of Current and Future Treatments," Translational Pediatrics, vol. 4(4), pp. 304-317, (2015). Blau et al., "Phenylkeionuria," The Lancet, vol. 376(9750), pp. 1417-1427, (2010).

Chandler et al., "Vector Design Influences Hepatic Genotoxicity After Adeno-Associated Virus Gene Therapy," Journal of Clinical Investigation, vol. 125(2), pp. 870-880, (2015).

#### OTHER PUBLICATIONS

Christophersen et al., "A Technique of Transumbilical Portal Vein Catheterization in Adults," The Archives of Surgery, vol. 95(6), pp. 960-963, (1967). (Abstract Only).

Bartholome, "Genetics and Biochemistry of the Phenylketonuria-Present State," Human Genetics, vol. 51(3), pp. 241-245, (1979). Donsante et al., "AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma," Science, vol. 317(5837, p. 477, (2007).

Eisensmith et al., "Multiple Origins for Phenylketonuria in Europe," American Journal of Human Genetics, vol. 51(6), pp. 1355-1365, (1992).

Fisher et al., "The Inhibition of Phenylalanine and Tyrosine Hydroxylases by High Oxygen Levels,". Journal of Neurochemistry, vol. 19(5), pp. 1359-1365, (1972). (Abstract Only).

Grisch-Chan et al., "Low-Dose Gene Therapy for Murine PKU Using Episomal Naked DNA Vectors Expressing PAH from Its Endogenous Liver Promoter," Molecular Therapy Nucleic Acids, vol. 7, pp. 339-349, (2017).

Guldberg et al., "Aberrant Phenylalanine Metabolism in Phenylketonuria Heterozygotes," Journal of Inherited Metabolic Disease, vol. 21(4), pp. 365-372, (1998).

Kaufman et al., "A Model of Human Phenylalanine Metabolism in Normal Subjects and in Phenylketonuric Patients," Proceedings of the National Academy of Sciences USA, vol. 96(6), pp. 3160-3164, (1999).

Kaufman et al., "Phenylalanine Hydroxylase Activity in Liver Biopsies from Hyperphenylalaninemia. Heterozygotes: Deviation from Proportionality with Gene Dosage," Pediatric Research, vol. 9(8), pp. 632-634, (1975).

Longo et al., "Single-Dose, Subcutaneous Recombinant Phenylalanine Ammonia Lyase Conjugated with Polyethylene Glycol in Adult Patients with Phenylketonuria: An Open-Label, Multicentre, Phase 1 Dose-Escalation Trial," The Lancet, vol. 384(9937), pp. 37-44, (2014).

Mochizuki et al., "Long-Term Correction of Hyperphenylalaninemia by AAV-Mediated Gene Transfer Leads to Behavioral Recovery in Phenylketonuria Mice," Gene Therapy, vol. 11(13), pp. 1081-1086, (2004).

Nault et al., "Adeno-Associated Virus Type 2 as an Oncogenic Virus in Human Hepatocellular Carcinoma," Molecular & Cellular Oncology, vol. 3(2), p. e1095271, (2016).

Oh et al., "Reversal of Gene Expression Profile in the Phenylketonuria Mouse Model After Adeno-Associated Virus Vector-Mediated Gene Therapy," Molecular Genetics and Metabolism, vol. 86(Supp. 1), pp. S124-S132, (2005).

Oh et al., "Long-Term Enzymatic and Phenotypic Correction in the Phenylketonuria Mouse Model by Adeno-Associated Virus Vector-Mediated Gene Transfer," Pediatric Research, vol. 56(2), pp. 278-284, (2004).

Oh et al. "Lentiviral Vector Design Using Alternative RNA Export Elements," Retrovirology, vol. 4:38, pp. 1-10, (2007).

Pan et al., "Biodistribution and Toxicity Studies of VSVG-Pseudotyped Lentiviral Vector After Intravenous Administration in Mice with the Observation of in Vivo Transduction of Bone Marrow," Molecular Therapy, vol. 6(1), pp. 19-29, (2002).

Shedlovsky et al., "Mouse Models of Human Phenylketonuria," Genetics, vol. 134(4), pp. 1205-1210, (1993).

Yagi et al., "Complete Restoration of Phenylalanine Oxidation in Phenylketonuria Mouse by a Self-Complementary Adeno-Associated Virus Vector," Journal of Gene Medicine, vol. 13(2), pp. 114-122, (2011).

Yano et al., "Evaluation of Tetmhydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters," PLoS One, vol. 11(8), p. e0160892, (2016).

Mason et al., "Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy," Journal of Virology, vol. 83(3), pp. 1501-1510, (2009). Blick et al., "Cyclophosphamide Enhances SB-728-T Engraftment to Levels Associated with HIV-RNA Control," CROI Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, p. 141, (2014), (Abstract Only).

De Rose et al., "Safety, Immunogenicity and Efficacy of Peptide-Pulsed Cellular Immunotherapy in Macaques," Journal of Medical Primatology, vol. 27(2), pp. 69-78, (2008).

Smith et al., "Developments in HIV-1 Immunotherapy and therapeutic Vaccination," F1000Prime Reports, vol. 6, p. 42, (2014).

Charron, "Gene Therapy for Phenylketonuria: Dominant-Negative Interference in a Recessive Disease," Dissertation, University of Florida 2005, http://etd.fcla.edu/UF/UFE0011392/charron\_c.pdf>, (retrieved Jul. 26, 2018) (2005).

Ding et al., "Administration-Route and Gender-Independent Longterm Therapeutic Correction of Phenylketonuria (PKU) in a Mouse Model by Recombinant Adeno-Associated Virus 8 Pseudotyped Vector-Mediated Gene Transfer," Gene Therapy, vol. 13, pp. 583-587, (Dec. 1, 2005).

Nowacki et al., "The PAH Mutation Analysis Consortium Database: Update 1996," Nucleic Acid Research, vol. 25(1), pp. 139-142, (Jan. 1, 1997).

Condiotti et al., "Prolonged Liver-Specific Transgene Expression by a Non-Primate Lentiviral Vector," Biochemical and Biophysical Research Communications, vol. 320(3), pp. 998-1006, (Jul. 30, 2004).

Wang et al., "Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human Vg2Vd2 T Cells," Journal of Immunology, vol. 191(3), pp. 1029-1042, (Jul. 5, 2013).

Jiang et al., "A Novel EST-Derived RNAi Screen Reveals a Critical Role for Farnesyl Diphosphate Synthase in Beta2-Adrenergic Receptor Internalization and Down-Regulation," FASEB Journal, vol. 26(5), pp. 1-13, (Jan. 25, 2012).

Miettinen et al., "Mevalonate Pathway Regulates Cell Size Homeostasis and Proteostasis Through Autophagy," Cell Reports, vol. 13(11), pp. 2610-2620, (Dec. 2015).

Tolmachov, "Designing Lentiviral Gene Vectors," Viral Gene Therapy, Chapter 13, pp. 263-284, (2011).

Tracey, "Human DNA Sequence from Clone RP1-288M22 on Chromosome 6q 12-13," Complete Sequence, National Center for Biotechnology. GenBank Entry. Retrieved from the internet: <a href="https://www.ncbi.nlm.nih.gov/nucleotide/AL035467.23?report=genbank">https://www.ncbi.nlm.nih.gov/nucleotide/AL035467.23?report=genbank</a> & logs=nucltop&blast\_rank=1&RID=UUD4GX2D014; pp. 1-34, (Jan. 24, 2013).

Gorziglia et al., "Elimination of Both E1 and E2A from Adenovirus Vectors Further Improves Prospects for In Vivo Human gene Therapy," Journal of Virology, vol. 70(6), pp. 4173-4178.

Vargas et al., "Novel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer," Human Gene Therapy, vol. 15(4), pp. 361-372, (Apr. 2004).

Wendelburg et al., "An Enhanced EBNA1 Variant with reduced IR3 Domain for Long-Term. Episomal Maintenance and Transgene Expression of ORIP-Based Plasmids in Human Cells," Gene Therapy, vol. 5, pp. 1389-1399, (Oct. 1998).

Westerhout et al., "A Conditionally Replicating HIV-Based Vector that Stably Expresses an Antiviral shRNA Against HIV-1 Replication," Molecular Therapy: The Journal of the American Society of Gene Therapy, vol. 14(2), pp. 268-275, (May 2006).

Lam et al., "T-Cell Therapies for HIV," Immunotherapy, Future Medicine, vol. 5(4), pp. 407-414, (Apr. 2013).

Munoz et al., "Ex Vivo Expansion and Lentiviral Transduction of Macaca Nemestrina CD4 + T Cells," Journal of Medical Primatology, vol. 38(6), pp. 438-443, (Dec. 2009).

Porichis et al., "HIV-Specific CD4 T Cells and Immune Control of Viral Replication," Current Opinion in HIV and Aids, vol. 6(3), pp. 174-180, (May 2011).

Kavanagh et al., "Expansion of HIV-Specific CD4+ and CD8+ T Cells by Dendritic Cells Transfected with mRNA Encoding Cytoplasm- or Lysosome-Targeted Nef," Blood, American Society of Hematology, vol. 107(5), pp. 1963-1969, (Mar. 2006).

Akinsheye et al., "Fetal Hemoglobin in Sickle Cell Anemia," Blood, vol. 118(1), pp. 19-27, (2011).

#### OTHER PUBLICATIONS

Lin et al., "Up-Regulation of Bc1-2 is Required for the Progression of Prostate Cancer Cells from an Androgen-Dependent to an Androgen-Independent Growth Stage," Cell Research, vol. 17, pp. 531-536, (2007).

GenBank Sequence M65141.1 Retrieved from the Internet <URL: https://www.ncbi.ntm.nih.gov/nuccore/M65141.1. Especially Sequence, nt 301-420, (Retrieved Mar. 31, 2019).

Hee Yeon Kim., "Farnesyl diphosphate synthase is important for the maintenance of glioblastoma. stemness," Experimental & Molecular Medicine, (2018).

Hong Wang "Indirect Stimulation of Human V2V2 Cells Through Alterations in Isoprenoid Metabolism," The Journal of Immunology, (2011).

Z. Li, "Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis in vitro," Clinical & Experimental Immunology, (2014).

Xiaofeng Jiang, "A novel EST-derived RNAi screen reveals a critical role for farnesyl diphophate in B2-adrenerigic receptor internalization and down-regulation," The FASEB Journal, vol. 26, pp. 1-13(1995).

Jian Yang, "Lentiviral-Mediated Silencing of Farnelsyl Pyrophosphate Synthase through RNA Interference in Mice," Biomed Research International, vol. 2015, Article ID 914026, 6 pages, (2015).

Yang Ye, "Knockdown of farnesyl pyrophosphate synthase prevents angiotensin II-medicated cardiac hypertrophy," The International Journal of Biochemistry & Cell Biology, vol. 42, pp. 2056-2064, (2010).

Jianqiang Li, "Reduced Expression of Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V9V2 Cells," The Journal of Immunology, pp. 8118-8124, (2019).

Daryl S. Schiller, "Parameters Influencing Measurement of the Gag Antigen-Specific T-Proliferative Response to HIV Type 1 Infection," AIDS Research and Human Retroviruses, vol. 16, No. 3, pp. 259-271, (2000).

Hassan et al., "Isolation of umbilical cord mesenchymal stem cells using human blood derivative accompanied with explant method," Stem Cell Investigation, pp. 1-8, (2019).

Huang et al., "An Efficient protocol to generate placental chorionic plate-derived mesenchymal stem cells with superior proliferative and immunomodulatory properties," Stem Cell Research & Therapy, pp. 1-15, (2019).

Pallikkuth et al., "Human Immunodeficiency Virus (HIV) gag Anti-Specific T-Helper and Granule-Dependent CD8 T-Cell Activities in Exposed but Uninfected Heterosexual Partners of HIV Type 1-Infected Individuals in North India," Clinical and Vaccine Immunology, vol. 14(9) pp. 1196-1202.

Quan Jun-Jie et al., "Parp3 interacts with FoxM1 to confer glioblastoma cell radio resistance", Tumor Biology, Karger, Basel, CH, vol. 36, No. 11, Jun. 4, 2015 (Jun. 4, 2015), pp. 8617-8624, XP036217799, ISSN: 1010-4283, DOI: 10.1007/S13277-015-3554-4 [retrieved on Jun. 4, 2015] \*whole document\*.

Jakobsson J. and Lundberg C.: "Lentiviral 1, 2, 4-10 vectors for use in the central nervous system", Molecular Therapy: The Journal of the American Society of Gene Therapy, Cell Press, US, vol. 13, No. 3, Mar. 1, 2006 (Mar. 1, 2006), pp. 484-493, XP005326761, ISSN: 1525-0016, DOI: 10.1016/ J.Ymthe.2005.11.012 \*the whole document\*.

Yun Jong Lee et al., "Poly (ADP-ribose) in 1-15 the pathogenesis of Parkinson's disease", BMB Reports, vol. 47, No. 8, Aug. 31, 2014 (Aug. 31, 2014), pp. 424-432, XP55671927, KR, ISSN: 1976-6696, DOI: 10.5483/BMBRep.2014.47.8.119 \*the whole document\*.

Lang Yoo et Al., "Parp-1 regulates the expression of caspase-11", Biochemical and Biophysical Research Communications, vol. 408, No. 3, Apr. 22, 2011 (Apr. 22, 2011), pp. 489-493, XP028209824, ISSN: 0006-291X, DOI: 10.1016/ J. BBRC.2011.04.070 [retrieved on Apr. 22, 2011] \*whole document\*.

on Apr. 22, 2011] \*whole document\*. Tae-In Kam et al., "Poly (ADP-ribose) derived pathologic [alpha]synuclein neurodegeneration in Parkinson's disease", Science, vol. 362, No. 6414, Nov. 1, 2018 (Nov. 1, 2018), p. eaat8407, XP55672116, US, ISSN: 00368075, DOI: 10.1126/science. aat8407 \*whole document\*.

Olsen A.L. and Feany M.B., "Parp Inhibitors and Parkinson's Disease", Jan. 1, 2019 (Jan. 1, 2019), XP55672111, retrieved from the Internet: URL: https://mfprac.com/web2019/07literature/literature/ Neurology/ParkinsonPARPI\_Olsen.pclf [retrieved on Feb. 27, 2020] \*the whole document\*.

PCT: International Search Report dated Nov. 7, 2016 in Application No. PCT/US2016/036519.

PCT: Written Opinion dated Nov. 7, 2016 in Application No. PCT/US2016/036519.

PCT: International Search Report dated Oct. 19, 2016 in Application No. PCT/US2016/041456.

PCT: Written Opinion dated Oct. 19, 2016 in Application No. PCT/US2016/041456.

PCT: International Search Report dated Jul. 20, 2017 in Application No. PCT/US2017/043157.

PCT: Written Opinion dated Jul. 20, 2017 in application No. PCT/US2017/043157.

PCT: International Search Report dated Jun. 9, 2017 in Application No. PCT/US2016/066185.

PCT: Written Opinion dated Jun. 9, 2017 in Application No. PCT/US2016/066185.

PCT: International Search Report dated Jul. 17, 2017 in Application No. PCT/US2017/013019.

PCT: Written Opinion dated Jul. 17, 2017 in Application No. PCT/US2017/013019.

PCT: International Search Report dated May 26, 2017 in Application No. PCT/US2017/013399.

PCT: Written Opinion dated May 26, 2017 in Application No. PCT/US2017/013399.

PCT: International Search report dated Aug. 25, 2017 in Application No. PCT/US2017/021639.

PCT: Written Opinion dated Aug. 25, 2017 Application No. PCT/ US2017/021639.

PCT: International Search Report dated Nov. 8, 2017 Application No. PCT/US2017/041168.

PCT: Written Opinion dated Nov. 8, 2017 in Application No. PCT/US2017/041168.

PCT: International Search Report dated Dec. 15, 2017 in Application No. PCT/US2017/36433.

PCT: Written Opinion dated Dec. 15, 2017 in Application No. PCT/US2017/36433.

PCT: International Search Report date Jul. 14, 2017 in Application No. PCT/US2017/013024.

PCT: Written Opinion dated Jul. 14, 2017 in application No. PCT/US2017/013024.

PCT: International Search Report dated May 29, 2018 in Application No. PCT/US2018/012998.

PCT: Written Opinion dated May 29, 2018 in Application No. PCT/US2018/012998.

PCT; International Search Report dated Sep. 24, 2018 in Application No. PCT/US2018/025733.

PCT; Written Opinion dated Sep. 24, 2018 in Application No. PCT/US2018/025733.

PCT; International Preliminary Report on Patentability dated Oct. 8, 2019 in the Application No. PCT/US2018/025733.

PCT; International Search Report dated Nov. 9, 2018 in Application No. PCT/US2018/037924.

PCT; Written Opinion dated Nov. 9, 2018 in Application No. PCT/US2018/037924.

PCT; Invitation to Pay Additional Fees in Application No. PCT/ US2018/053919 dated Feb. 22, 2019.

PCT; Written Opinion dated Apr. 12, 2019 in Application No. PCT/US2018/053919.

PCT; International Search Report dated Apr. 12, 2019 in Application No. PCT/ US2018/053919.

PCT; International Search Report dated Jul. 22, 2019 in the Application No. PCT/US2019/24410.

PCT; Written Opinion of the International Search Report dated Jul. 22, 2019 in the Application No. PCT/US2019/24410.

#### OTHER PUBLICATIONS

PCT; International Preliminary Report on Patentability dated Jul. 9, 2019 in the Application No. PCT/US2018/012998.

USPTO; Notice of Allowance dated Oct. 13, 2017 in U.S. Appl. No. 14/706.481.

USPTO; Requirement for Restriction dated Oct. 23, 2017 in U.S. Appl. No. 15/668,223.

USPTO; Notice of Allowance dated Nov. 2, 2017 in U.S. Appl. No. 15/652,080.

USPTO; Non-Final Office Action dated Feb. 22, 2018 in U.S. Appl. No. 15/850.937.

USPTO; Non-Final Office Action dated Feb. 22, 2018 in U.S. Appl. No. 15/849,062.

USPTO; Non-Final Office Action dated Feb. 22, 2018 in U.S. Appl. No. 13/333,882.

USPTO; Notice of Allowance dated Mar. 26, 2018 in U.S. Appl. No. 15/668,223.

USPTO; Notice of Allowance dated Apr. 23, 2018 in U.S. Appl. No. 15/850,937.

USPTO; Notice Allowance dated Apr. 26, 2018 in U.S. Appl. No. 15/849,062.

USPTO; Non-Final Office Action dated Jun. 15, 2018 in U.S. Appl. No. 15/904,131.

USPTO; Requirement for Restriction dated Jul. 12, 2018 in U.S. Appl. No. 15/736,284.

USPTO; Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Jul. 17, 2018 in Application No. PCT/US2018/ 25733.

USPTO; Requirement for Restriction dated Aug. 3, 2018 in U.S. Appl. No. 16/011,550.

USPTO; Notice of Allowance dated Aug. 10, 2018 in U.S. Appl. No. 15/904,131.

USPTO; Final Office Action dated Aug. 27, 2018 in U.S. Appl. No. 13/333,882.

USPTO; Non-Final Office Action dated Sep. 17, 2018 in U.S. Appl. No. 16/011,550.

USPTO; Invitation to Pay Additional Fees and, Where Applicable, Protest Fee dated Sep. 11, 2018 in Application No. PCT/US2018/ 37924.

USPTO; Non-Final Office Action dated Oct. 19, 2018 in U.S. Appl. No. 15/736,284.

USPTO; Notice of Allowance dated Oct. 31, 2018 in U.S. Appl. No. 16/011,550.

USPTO; Advisory Action dated Nov. 16, 2018 in U.S. Appl. No. 13/333,882.

USPTO; Non-Final Office Action dated Dec. 31, 2018 in U.S. Appl. No. 16/182,443.

USPTO; Non-Final Office Action dated Apr. 18, 2019 in U.S. Appl. No. 13/333,882.

USPTO; Final Office Action dated May 2, 2019 in U.S. Appl. No. 15/736,284.

USPTO; Final Office Action dated May 2, 2019 in U.S. Appl. No. 16/182,443.

USPTO; Non-Final Office Action dated May 7, 2019 in U.S. Appl. No. 16/008.991.

USPTO; Non-Final Office Action dated May 16, 2019 in U.S. Appl. No. 16/132,247.

USPTO; Non-Final Office Action dated May 24, 2019 in U.S. Appl. No. 16/218,010.

USPTO; Notice of Allowance dated Jun. 18, 2019 in the U.S. Appl. No. 16/182,443.

USPTO; Notice of Allowance dated Jul. 3, 2019 in U.S. Appl. No. 16/182,443.

USPTO; Advisory Action dated Jul. 23, 2019 in the U.S. Appl. No. 15/736,284.

USPTO; Notice of Allowance dated Aug. 14, 2019 in the U.S. Appl. No. 16/008.991.

USPTO; Notice of Allowance dated Sep. 25, 2019 in the U.S. Appl. No. 16/218,010.

USPTO; Final Office Action dated Jul. 1, 2019 in the U.S. Appl. No. 16/132,247.

USPTO; Notice of Allowance dated Jul. 19, 2019 in the U.S. Appl. No. 16/132,247.

USPTO; Restriction Requirement dated Oct. 22, 2019 in the U.S. Appl. No. 15/580,661.

USPTO; Restriction Requirement dated Nov. 4, 2019 in the U.S. Appl. No. 16/076,655.

USPTO; Notice of Allowance dated Oct. 29, 2019 in the U.S. Appl. No. 13/333,882.

USPTO; Restriction Requirement dated Nov. 7, 2019 in the U.S. Appl. No. 16/083,384.

USPTO; Notice of Allowance dated Nov. 27, 2019 in the U.S. Appl. No. 13/333,882.

USPTO; Non-Final Office Action dated Jan. 13, 2020 in the U.S. Appl. No. 15/580,661.

USPTO; Restriction Requirement dated Jan. 29, 2020 in the U.S. Appl. No. 16/312,056.

USPTO; Non-Final Office Action dated Feb. 21, 2020 in the U.S. Appl. No. 16/076,655.

USPTO; Non-Final Office Action dated Mar. 16, 2020 in the U.S. Appl. No. 16/083,384.

EPO; Extended Search Report dated Dec. 12, 2018 in EP Application No. 16808223.8.

EPO; Extended Search Report dated Dec. 11, 2018 in EP Application No. 16822021.8.

EPO; Extended Search Report dated Jun. 6, 2019 in EP Application No. 17739028.3.

EPO; European Search Report dated Aug. 12, 2019 in the EP Application No. 17764128.9.

EPO; Supplementary European Search Report dated Sep. 6, 2019 in the Application No. 17750547.6.

EPO; Supplementary European Search Report dated Dec. 19, 2019 in the Application No. 16904834.5.

EPO; Supplementary European Search Report dated Dec. 19, 2019 in the Application No. 17810976.5.

EPO; Extended European Supplementary Search Report dated Feb. 6, 2020 in the Application No. 17825011.4.

EPO; Extended European Supplementary Search Report dated Feb. 6, 2020 in the Application No. 17824652.6.

EPO; Extended European Supplemental Search Report dated Mar. 11, 2020 in the Application No. 17831904.2.

Cronin et al., "Altering the Tropism of Lentiviral Vectors through Pseudotyping", Curr Gene Ther, Aug. 2005, vol. 5(4), pp. 687-398. Cannon et al., "Pseudotype-Dependent Lentiviral Transduction of Astrocytes or Neurons in the Rat Substantia Nigra", Experimental Neurology, vol. 228, (Year: 2011), pp. 41-52, doi:10.1016/J.expneurol. 2010.10.016.

USPTO; Non-Final Office Action dated Nov. 18, 2020 in the U.S. Appl. No. 16/318,345.

USPTO; Non-Final Office Action dated Nov. 25, 2020 in the U.S. Appl. No. 16/943,800.

USPTO; Notice of Allowance dated Dec. 2, 2020 in the U.S. Appl. No. 16/076,655.

USPTO; Restriction Requirement dated Dec. 8, 2020 in the U.S. Appl. No. 16/563,738.

PCT; International Search Report and Written Opinion in the PCT Application No. PCT/US2019/059828 dated Feb. 14, 2020.

Wang et al., "HIV Vaccine Research: The Challenge and the Way Forward," Journal of Immunology Research, vol. 2015, Article ID 503978, 5 pages.

Bourguigon et al., "Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients," Journal of Immunological Methods, vol. 414, p. 1-10 (2014).

Briz et al., "Validation of Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1," Current Medical Chemistry, vol. 19, p. 5044-5051, (2012).

Anderson et al., "Preintegration HIV-1 Inhibition by a Combination Lentiviral Vector Containing a. Chimeric TRIM5a Protein, a CCR5 shRNA, and TAR Decoy," Molecular Therapy, vol. 17, No. 12, p. 2103-2114, Dec. 2009.

#### OTHER PUBLICATIONS

JP; Japanese Office Action in the Application No. 2017-567175 dated Jun. 15, 2020.

EPO; Extended European Search Report in the Application No. 18736295.9 dated Aug. 20, 2020.

Richard Lu et al., "Siman Virus 40-Based Replication of Catalytically Inactive Human Immunodeficiency Virus Type 1 Integrase Mutants in Nonpermissive T Cells and Monocyte-Derived Macrophages", Journal of Virology, Jan. 2004, p. 658-668. DOI: 10.1128/JVI.78.2658-668.2004.

FM Sverdrup et al., "Development of human papillomavirus plasmids capable of episomal replication in human cell lines", Gene Therapy, Mar. 26, 1999, p. 1317-1321, Retrieved from the Internet: URL: http://www.stockton-pressco.uk/gt.

Kathleen Van Craenenbroeck et al., "Episomal vectors for gene expression in mammalian cells", Eur J. Biochem, vol. 267, p. 5665-5678, Jul. 14, 2000.

JP; Japanese Office Action in the Application No. 2017-564550 dated Mar. 18, 2020.

Bergvall et al. "The E1 proteins", Virology 445; p. 35-56, (Year:2013). McBride, A., "The Papillomavirus E2 proteins", Virology 445: p. 57-79, (Year: 2013).

Chiang C-m et al., "Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins." PNAS 89: p. 5799-5803, (Year: 1992).

Krajinovic et al., "Sequencing data on the long control region of human papillomavirus type 16." Journal of General Virology 72:2573-2576, (Year: 1991).

Seedorg et al., "Human Papillomavirus type 16 DNA sequence." Virology 145: p. 181-185, (Year: 1985). Jaalouk, et al. "A Self-inactivating retrovector incorporating the

Jaalouk, et al. "A Self-inactivating retrovector incorporating the IL-2 promoter for activation-induced transgene expression engineered t-cells," Virology Journal: p. 1-12, (Year: 2006).

USPTO; Non-Final Office Action dated Sep. 22, 2020 in the U.S. Appl. No. 16/308,373.

USPTO; Notice of Allowance dated Jul. 10, 2020 in the U.S. Appl. No. 16/530.908.

USPTO; Final Office Action dated Jul. 27, 2020 in the U.S. Appl. No. 16/076,655.

JP; Japanese Office Action in the Application No. 2018-536892 dated Jun. 26, 2020.

Lee et al., "Lentiviral delivery of short hairpin RNAs protects CD4 cells from multiple clades and primary isolates of HIV." Blood, 2005, vol. 106(3):818-826. (Year: 2005).

Choi et al., "Multiplexing Seven miRNA-Based shRNAs to Suppress HIV Replication." Molecular Therapy, 2015, vol. 23(2):310-320. Supplementary materials.

Spartevello et al., Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach, Molecular Therapy— Nucleic Acids, 2016, vol. 5:1-12.

USPTO; Restriction Requirement dated Jun. 15, 2020 in the U.S. Appl. No. 16/308,373.

USPTO; Restriction Requirement dated Jun. 26, 2020 in the U.S. Appl. No. 16/318,345.

USPTO; Office Action dated Jul. 6, 2020 in the U.S. Appl. No. 16/312,056.

JP; Japanese Office Action in the Application No. 2019-500475 dated Jun. 12, 2020.

USPTO; Non-Final Office Action dated Oct. 29, 2020 in the U.S. Appl. No. 15/736,284.

JP; Japanese Office Action in the JP Application No. 2018-563892 dated Oct. 14, 2020.

Brites, C., M. Abrahao, P. Bozza, E M. Netto, A. Lyra and F. Bahia (2018). "Infection by HTLV-1 Is Associated with High Levels of Proinflammatory Cytokines in HIV-HCV-Coinfected Patients." J Acquir Immune Defic Syndr 77(2): 230-234.

Douek, D. C., J. M. Brenchley, M. R. Betts, D. R. Ambrozak, B. J. Hill, et al. (2002). "HIV preferentially infects HIV-specific CD4+ T cells." Nature 417(6884): 95-98.

Eguchi, K., N. Matsuoka, H. Ida, M. Nakashima, M. Sakai, et al. (1992). "Primary Sjogren's syndrome with antibodies to HTLV-I: clinical and laboratory features." Ann Rheum Dis 51(6): 769-776. Futsch, N., R. Mahieux and H. Dutartre (2017). "HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment." Viruses, 10, 1; doi:10.3390/v10010001.

Gessain, A., F. Barin, J. C. Vernant, O. Gout, L. Maurs, A. Calender and G. de The (1985). "Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis." Lancet 2(8452): 407-410.

Gessain, A. and O. Cassar (2012). "Epidemiological Aspects and World Distribution of HTLV-1 Infection." Front Microbiol 3: 388. Goncalves, D. U., F. A. Proietti, J. G. Ribas, M. G. Araujo, S. R. Pinheiro, A. C. Guedes and A. B. Carneiro-Proietti (2010). "Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases." Clin Microbiol Rev 23(3): 577-589.

Kagdi, H., M. A. Demontis, J. C. Ramos and G. P. Taylor (2018). "Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T-lymphotropic virus type 1 infection." PLoS Pathog 14(2): e1006861.

Kagdi, H. H., M. A. Demontis, P. A. Fields, J. C. Ramos, C. R. Bangham and G. P. Taylor (2017). "Risk stratification of adult T-cell leukemia/lymphoma using immunophenotyping." Cancer Med 6(1): 298-309.

Macnamara, A., A. Rowan, S. Hilburn, U. Kadolsky, H. Fujiwara, et al. (2010). "HLA class I binding of HBZ determines outcome in HTLV-1 infection." PLoS Pathog 6(9): e1001117.

Manel, N., F. J. Kim, S. Kinet, N. Taylor, M. Sitbon and J. L. Battini (2003). "The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV." Cell 115(4): 449-459.

Martinez, M. P., J. Al-Saleem and P. L. Green (2019). "Comparative virology of HTLV-1 and HTLV-2." Retrovirology 16(1): 21.

Mochizuki, M., T. Watanabe, K. Yamaguchi, K. Takatsuki, K. Yoshimura, et al. (1992). "HTLV-I uveitis: a distinct clinical entity caused by HTLV-I." Jpn J Cancer Res 83(3): 236-239.

Mosley, A. J., B. Asquith and C. R. Bangham (2005). "Cellmediated immune response to human T-lymphotropic virus type I." Viral Immunol 18(2): 293-305.

Nagai, M. and M. Osame (2003). "Human T-cell lymphotropic virus type I and neurological diseases." J Neurovirol 9(2): 228-235.

Yamano, Y. and T. Sato (2012). "Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis." Front Microbiol 3: 389.

Nishioka, K., I. Maruyama, K. Sato, I. Kitajima, Y. Nakajima and M. Osame (1989). "Chronic inflammatory arthropathy associated with HTLV-L." Lancet 1(8635): 441.

Osame, M., K. Usuku, S. Izumo, N. Ijichi, H. Amitani, et al. (1986). "HTLV-I associated myelopathy, a new clinical entity." Lancet 1(8488): 1031-1032.

Poiesz, B. J., F. W. Ruscetti, A. F. Gazdar, P. A. Bunn, J. D. Minna and R. C. Gallo (1980). "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma." Proc Natl Acad Sci U S A 77(12): 7415-7419.

Poiesz, B. J., F. W. Ruscetti, J. W. Mier, A. M. Woods and R. C. Gallo (1980). "T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor." Proc. Natl Acad Sci U S A 77(11): 6815-6819.

Roc, L., C. de Mendoza, M. Fernandez-Alonso, G. Reina, V. Soriano and H. N. Spanish (2019). "Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals." Ther Adv Infect Dis 6: 2049936119868028.

Soker, S., S. Takashima, H Q. Miao, G. Neufeld and M. Klagsbrun (1998). "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor." Cell 92(6): 735-745.

Uchiyama, T., J. Yodoi, K. Sagawa, K. Takatsuki and H. Uchino (1977). "Adult T-cell leukemia: clinical and hematologic features of 16 cases." Blood 50(3): 481-492.

#### OTHER PUBLICATIONS

Dickler, H. B., et al. (1973). "Lymphocyte binding of aggregated IgG and surface Ig staining in chronic lymphocytic leukaemia." Clin Exp Immunol 14(1): 97-106.

USPTO; Notice of Allowance dated May 18, 2020 in the U.S. Appl. No. 16/083,384.

USPTO; Final Office Action dated Jun. 2, 2020 in the U.S. Appl. No. 15/580,661.

USPTO; Non-Final Office Action dated Jun. 1, 2020 in the U.S. Appl. No. 16/530,908.

CN; 1st Office Action in the CN Application No. 20170017712.6 dated May 8, 2020.

EPO; Office Action in the EPO Application No. 16808223.8 dated May 11, 2020.

Yang et al., "Construction of PARP-1 gene silencing cell lines by lentiviral-mediated RNA interference," School of Public Health, Guangdong Medical College, ABSTRACT (2006).

Zhaobing Ding et al., "Liver -Directed, AAV-and Lentivirus-Mediated Gene Therapy in the Phenylketonuria Mouse Model Pah-enu2", Molecular Therapy, vol. 11, Supp. 1. (May 2005) XP055751452.

Ledley et al., "Retroviral-mediated gene transfer of human phenylalanine hydroxylase into Nih 3T3 and hepatoma cells", Proceedings of the National Academy of Sciences, vol. 83, No. 2. (Jan. 1, 1986), pp. 409-413, XP002583115.

Ledley et al., "Molecular biology of phenylalanine hydroxylase and phenylketonurina", Trends in Genetics, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 1. (Jan. 1, 1985), pp. 309-313, XP025943064. USPTO; Notice of Allowance dated Jan. 13, 2021 in the U.S. Appl. No. 16/687,525.

EP; Supplementary Search Report in the EPApplication No. 18781288.8 dated Dec. 8, 2020

JP; Final Office Action in the JP Application No. 2018-536892 dated Nov. 16, 2020.

Nada et al., "Enhancing adoptive cancer immunotherapy with V $\gamma$ 2V $\delta$ 2 T cells through pulse zoledronate stimulation", Journal for Immunotherapy of Cancer, vol. 5, No. 1, (Feb. 21, 2017), pp. 1-23, (2017) DOI 10.1186/s40425-017-0209-6 \*the whole document\*.

Benyamine et al., "BTN3A molecules considerably improve  $V\gamma 9V\delta 2T$  cells-based immunotherapy in acute myeloid leukemia," Oncolmmunology, vol. 5, No. 10, 10 pages, (Oct. 2, 2016), E1146843 \*the whole document\*.

Harly et al., "Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human  $\gamma\delta$  T-cell subset," American Society of Hematology , vol. 120, No. 11, (Sep. 13, 2012), pp. 2269-2279, XP055081172, ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-430470 \*the whole document\*.

Wang et al., "Intravenous Delivery of SiRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis", Molecular Therapy, pp. 1919-1929, vol. 21, No. 10, Oct. 2013. USPTO; Notice of Allowance dated Feb. 10, 2021 in the U.S. Appl. No. 16/943,800.

USPTO; Non-Final Office Action dated Feb. 19, 2021 in the U.S. Appl. No. 15/580,661.

USPTO; Final Office Action dated Feb. 26, 2021 in the U.S. Appl. No. 16/312,056.

USPTO; Corrected Notice of Allowance dated Mar. 3, 2021 in the U.S. Appl. No. 16/687,525.

USPTO; Non-Final Office Action dated Mar. 12, 2021 in the U.S. Appl. No. 16/563,738.

CN; 1st Office Action in the CN Application No. 202010396594.8 dated Jan. 15, 2021.

EP; Supplementary Search Report in the EP Application No. 18817253 dated Feb. 10, 2021.

JP; Office Action in the JP Application No. 2018-547354 dated Feb. 16, 2021.

JP; Office Action in the JP Application No. 2018-541270 dated Jan. 8, 2021.



Enrich (vaccine) and protect (AGT-LV) the HIV-specific CD4 T cells.

Sheet 1 of 40







Envelope Plasmid



с С С



FIC. 4A









FG. &C



FIG. 5A





П С В



П 0. 20



П 0. 20

# Elongation Factor-1 alpha (EF1-alpha) promoter

CCGGTGCCTAGAGAAGGTGGCGCGGGGGAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACGCCCCTGGCTGCAGTACGTGATTCTTGATCC CGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCT*TTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTG* GGGCCGCGGGCGACGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCCGGGGCCTGCGA CGCGCCGCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGGAGCGGGGGGGGGGGGGCACACACACACAGGAAAAGGGCCCTTTCCGTCCTCAGCCGTCGCTTCATG TGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGT GAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATC*TTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA* GTACA

# miR30 CCR5

AGGTATATTGCTGTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCCACAGATG GGTAGAGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGACTTCAAGGGGGCTT

## miR21 Vif

## miR185 Tat

Vector 1									
Long Terminal Repeat	H1 H	shCCR5	H	VPRE -	Ĺo	ng Termi Repeat	na		
Vector 2									
Long Terminal Repeat	H1 H	shRev/Tat	$\mathbb{H}_{\mathbb{Z}}$	81	$\mathbb{H}$	shCCR5	Н	WPRE	Long Terminal Repeat
Vector 3									
Long Terminal Repeat	H1	shGag	$\mathbb{H}_{\mathbb{Z}}^{\mathbb{Z}}$	H1	$\mathbb{H}$	shCCR5	Н	WPRE	Long Terminal Repeat
Vector 4									
Long Terminal Repeat	75К	shRev/Tat	Ю	H1	Н	shCCR5	Н	WPRE	Long Terminal Repeat
Vector 5									
Long Terminal Repeat	EF1	miR30 CCR5	Н	miR21 Vif	Н	miR185 Tat	Н	WPRE	Long Terminal Repeat
Vector 6									
Long Terminal Repeat	EF1	miR30 CCR5	H	miR21 Vif	Н	miR155 Tat	Н	WPRE	Long Terminal Repeat
Vector 7									
Long Terminal Repeat	EF1	miR30 CCR5	H	miR21 Vif	Н	miR185 Tat	Н	WPRE short	Long Terminal Repeat
Vector 8									
Long Terminal Repeat	EF1	miR30 CCR5	H	miR21 Vif	Н	miR185 Tat	Η	Long Te Rep	rminal eat
Vector 9									
Long Terminal Repeat	CD4	miR30 CCR5	Н	miR21 Vif	Н	miR185 Tat	μ	WPRE	Long Terminal Repeat



ПG. 82

HIV Bal-mCherry VIH ON 104 С о́ 0.83 103 AGT103-GFP 105 õ 8 0 82 00 Ô **10**<sup>4</sup> 0 48 Control LV <u>°</u>3 FIG. 88 102 GFP **1**0\_ R M n o on N 100 **10**<sup>4</sup> 1.**8** · · · · · · **\$**223**8** · · · 00.0 000 0.00 0.00 103 No No 102 8 õ 0.0 Ś ° O 100  $10^4$  $10^{3}$  $10^{2}$  $10^4$  $10^{3}$ 10°  $10^{2}$ 101 <u>10</u> тслету







FIG. 9B































Saquinavir (100 nM) is added every other day to prevent possible viral outgrowth.

FIG. 184



ПС. 188 102



FIG. 18C












FIG. 19A





# Т С З С





















FIG. 23A



**Т** С. 23 В



FIG. 23C



**Т**С. 230

# HIV PRE-IMMUNIZATION AND **IMMUNOTHERAPY**

# CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/218,010 filed on Dec. 12, 2018, entitled IMMUNO-"HIV PRE-IMMUNIZATION AND THERAPY," which is a continuation of U.S. patent appli-<sup>10</sup> cation Ser. No. 16/011,550 filed on Jun. 18, 2018, entitled "HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY" which is a continuation of U.S. patent application Ser. No. 15/668,223 filed on Aug. 3, 2017, entitled "HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY" which is a continuation of International Application No. PCT/US17/ 13019 filed on Jan. 11, 2017, entitled "HIV PRE-IMMU-NIZATION AND IMMUNOTHERAPY" which claims priority to: U.S. Provisional Patent Application No. 62/360,185 filed on Jul. 8, 2016 entitled "HIV PRE-IMMUNIZATION <sup>20</sup> AND IMMUNOTHERAPY", U.S. Provisional Patent Application No. 62/385,864 filed on Sep. 9, 2016 entitled "HIV PRE-IMMUNIZATION AND IMMUNO-THERAPY", and U.S. Provisional Patent Application No. 62/409,270 filed on Oct. 17, 2016 entitled "HIV PRE- 25 IMMUNIZATION AND IMMUNOTHERAPY," the disclosures of which are incorporated herein by reference.

# FIELD OF THE INVENTION

The present invention relates generally to the field of immunization and immunotherapy for the treatment and prevention of HIV. In particular, the disclosed methods of treatment and prevention relate to the administration of viral vectors and systems for the delivery of genes and other 35 therapeutic, diagnostic, or research uses.

# BACKGROUND OF THE INVENTION

Combination antiretroviral therapy (cART) (also known 40 as Highly Active Antiretroviral Therapy or HAART) limits HIV-1 replication and retards disease progression, but drug toxicities and the emergence of drug-resistant viruses are challenges for long-term control in HIV-infected persons. Additionally, traditional antiretroviral therapy, while suc- 45 cessful at delaying the onset of AIDS or death, has yet to provide a functional cure. Alternative treatment strategies are needed.

Intense interest in immunotherapy for HIV infection has been precipitated by emerging data indicating that the 50 immune system has a major, albeit usually insufficient, role in limiting HIV replication. Virus-specific T-helper cells, which are critical to maintenance of cytolytic T cell (CTL) function, likely play a role. Viremia is also influenced by neutralizing antibodies, but they are generally low in mag- 55 improved treatments of HIV. nitude in HIV infection and do not keep up with evolving viral variants in vivo.

Together this data indicates that increasing the strength and breadth of HIV-specific cellular immune responses might have a clinical benefit through so-called HIV immu- 60 is notherapy. Some studies have tested vaccines against HIV, but success has been limited to date. Additionally, there has been interest in augmenting HIV immunotherapy by utilizing gene therapy techniques, but as with other immunotherapy approaches, success has been limited.

Viral vectors can be used to transduce genes into target cells owing to specific virus envelope-host cell receptor

65

interactions and viral mechanisms for gene expression. As a result, viral vectors have been used as vehicles for the transfer of genes into many different cell types including whole T cells or other immune cells as well as embryos, fertilized eggs, isolated tissue samples, tissue targets in situ and cultured cells. The ability to introduce and express foreign or altered genes in a cell is useful for therapeutic interventions such as gene therapy, somatic cell reprogramming of induced pluripotent stem cells, and various types of immunotherapy.

Gene therapy is one of the ripest areas of biomedical research with the potential to create new therapeutics that may involve the use of viral vectors. In view of the wide variety of potential genes available for therapy, an efficient means of delivering these genes is needed to fulfill the promise of gene therapy as a means of treating infectious and non-infectious diseases. Several viral systems including murine retrovirus, adenovirus, parvovirus (adeno-associated virus), vaccinia virus, and herpes virus have been proposed as therapeutic gene transfer vectors.

There are many factors that must be considered when developing viral vectors, including tissue tropism, stability of virus preparations, stability and control of expression, genome packaging capacity, and construct-dependent vector stability. In addition, in vivo application of viral vectors is often limited by host immune responses against viral structural proteins and/or transduced gene products.

Thus, toxicity and safety are key hurdles that must be overcome for viral vectors to be used in vivo for the treatment of subjects. There are numerous historical examples of gene therapy applications in humans that have met with problems associated with the host immune responses against the gene delivery vehicles or the therapeutic gene products. Viral vectors (e.g., adenovirus) which co-transduce several viral genes together with one or more therapeutic gene(s) are particularly problematic.

Although lentiviral vectors do not generally induce cytotoxicity and do not elicit strong host immune responses, some lentiviral vectors such as HIV-1, which carry several immunostimulatory gene products, have the potential to cause cytotoxicity and induce strong immune responses in vivo. However, this may not be a concern for lentiviral derived transducing vectors that do not encode multiple viral genes after transduction. Of course, this may not always be the case, as sometimes the purpose of the vector is to encode a protein that will provoke a clinically useful immune response.

Another important issue related to the use of lentiviral vectors is that of possible cytopathogenicity upon exposure to some cytotoxic viral proteins. Exposure to certain HIV-1 proteins may induce cell death or functional unresponsiveness in T cells. Likewise, the possibility of generating replication-competent, virulent virus by recombination is often a concern. Accordingly, there remains a need for

#### SUMMARY OF THE INVENTION

In one aspect, a method of treating cells infected with HIV provided. The method variously includes contacting peripheral blood mononuclear cells (PBMC) isolated from a subject infected with HIV with a therapeutically effective amount of a stimulatory agent, wherein the contacting is carried out ex vivo; transducing the PBMC ex vivo with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for a sufficient period of time to ensure adequate transduction. In embodiments, the

transduced PBMC may be cultured from about 1 to about 35 days. The method may further include infusing the transduced PBMC into a subject. The subject may be a human. The stimulatory agent may include any agent suitable for stimulating a T cell response in a subject. In embodiments, 5 the stimulatory agent is a peptide or mixture of peptides, and in embodiments includes a gag peptide. The stimulatory agent may also include a vaccine. The vaccine may be a HIV vaccine, and in embodiments, the HIV vaccine is a MVA/ HIV62B vaccine or a variant thereof. In embodiments, the viral delivery system includes a lentiviral particle. In embodiments, the at least one genetic element includes a small RNA capable of inhibiting production of chemokine receptor CCR5. In further embodiments, the at least one genetic element includes at least one small RNA capable of 15 targeting an HIV RNA sequence. In further embodiments, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence includes any 20 HIV sequence suitable for targeting by a viral delivery system. In embodiments, the HIV RNA sequence includes one or more of a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one genetic element includes any genetic element capable of being expressed by a viral 25 delivery system. In embodiments, the at least one genetic element includes a microRNA or a shRNA. In further embodiments, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes 30 a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with AGGTATAT-TGCTGTTGACAGTGAGCGACTGTAAACTGAGCTT-GCTCTACTGTGAAGCCACAGATGGGTAGAGCAA-GCACAGTTTACCGCTGCCTACTGCCTCGGACTTC-35 AAGGGG CTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises: AGGTAT-ATTGCTGTTGACAGTGAGCGACTGTAAACTGAGC-TTGCTCTACTGTGAAGCC ACAGATGGGTAGAGCA-AGCACAGTTTACCGCTGCCTACTGCCTCGGACTT-40 CAAGGGG CTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with CATCTC-CATGGCTGTACCACCTTGTCGGGGGGATGTGTACTT-45 CTGAACTTGTGTTGAAT CTCATGGAGTTCAGAAG-AACACATCCGCACTGACATTTTGGTATCTTTCATC-TGACCA (SEQ ID NO: 2); or at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with GGGCCTGGCTCGAGCAGGGGGGGGGGGGGGATTCCG-50 CTTCTTCCTGCCATAGCGTGG TCCCCTCCCTATG-GCAGGCAGAAGCGGCACCTTCCCTCCCAATGACC-GCGTCTTCGT CG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTACCACCTTGTCGGGGGGATGT-55 GTACTTCTGAACTTGTGTGGAAT CTCATGGAGTTC-AGAAGAACACATCCGCACTGACATTTTGGTATCT-TTCATCTGACCA (SEQ ID NO: 2); or GGGCCTG-TGCCATAGCGTGGTCCCCTCCCCTATGGCAGGCA-GAAGCGGCACCTTCCCTCCCAATGACCGCGTCTT-CGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with AGGTATAT- 65 TGCTGTTGACAGTGAGCGACTGTAAACTGAGCTT-GCTCTACTGTGAAGCCACAGATGGGTAGAGCAA-

GCACAGTTTACCGCTGCCTACTGCCTCGGACTTC-AAGGGG CTTCCCGGGCATCTCCATGGCTGTACCA-CCTTGTCGGGGGGATGTGTACTTCTGAACTT GTGTT-GAATCTCATGGAGTTCAGAAGAACACATCCGCAC-TGACATTTTGGTATCTTTC ATCTGACCAGCTAGCG-GGCCTGGCTCGAGCAGGGGGGGGGGGGGGGGGATTCCGCT-GCCATAGCGTGGTCCCCTCCCCTATGG-TCTTCCT CAGGCAGAAGCGGCACCTTCCCTCCCAATGA CC-GCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the microRNA cluster includes: AGGTATATTG-CTGTTGACAGTGAGCGACTGTAAACTGAGCTTG-CTCT ACTGTGAAGCCACAGATGGGTAGAGCAAG-CACAGTTTACCGCTGCCTACTGCCTCGGACTTCA-AGGGGCTTCCCGGGCATCTCCATGGCTGTACCA-CCTTGTCGGGGGGATGTGTA CTTCTGAACTTGTGTT-GAATCTCATGGAGTTCAGAAGAACACATCCGCAC-TGACATTT TGGTATCTTTCATCTGACCAGCTAGCG-GGCCTGGCTCGAGCAGGGGGGGGGGGGGGGGATTCCGC-TTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGG-CAGGCAGAAGCGGCACCTTC CCTCCCAATGACC-GCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a method of treating HIV infection in a subject is disclosed. The method variously includes immunizing the subject with an effective amount of a first stimulatory agent; removing leukocytes from the subject and obtaining peripheral blood mononuclear cells (PBMC). The method further includes contacting the PBMC ex vivo with a therapeutically effective amount of a second stimulatory agent; transducing the PBMC ex vivo with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for a sufficient period of time to ensure adequate transduction. In embodiments, the transduced PBMC may be cultured from about 1 to about 35 days. In embodiments, the method further involves infusing the transduced PBMC into a subject. The subject may be a human. The first and second stimulatory agents may be the same or different. The first and second stimulatory agents may include one or more of a peptide or mixture of peptides. In embodiments, at least one of the first and second stimulatory agents includes a gag peptide. The at least one of the first and second stimulatory agents may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/HIV62B vaccine or a variant thereof. In a preferred embodiment, the viral delivery system includes a lentiviral particle. In embodiments, the at least one genetic element includes a small RNA capable of inhibiting production of chemokine receptor CCR5. In embodiments, the at least one genetic element includes at least one small RNA capable of targeting an HIV RNA sequence. In embodiments, the at least one genetic element includes a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one genetic element may include a microRNA or a shRNA. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with AGGTATAT-TGCTGTTGACAGTGAGCGACTGTAAACTGAGCT-TGCTCTACTGTGAAGCCACAGATGGGTAGAGCA-AGCACAGTTTACCGCTGCCTACTGCCTCGGACTT-5 CAAGGGG CTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises: AGGTAT-ATTGCTGTTGACAGTGAGCGACTGTAAACTGAG-

65

CTTGCTCTACTGTGAAGCC ACAGATGGGTAGAGC-AAGCACAGTTTACCGCTGCCTACTGCCTCGGACTT-CAAGGGG CTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 5 90%, or at least 95% percent identity with CATCTC-CATGGCTGTACCACCTTGTCGGGGGGATGTGTACT TCTGAACTTGTGTTGAATCTCATGGAGTTCAGAA-GAACACATCCGCACTGACATTTTGGTATCTTTCA-TCTGACCA (SEQ ID NO: 2); or at least 80%, or at least 10 85%, or at least 90%, or at least 95% percent identity with GGGCCTGGCTCGAGCAGGGGGGGGGGGGGGGATTCCGC-TTCTTCCTGCCATAGCGTGG TCCCCTCCCCTATGG-CAGGCAGAAGCGGCACCTTCCCTCCCAATGACCG-CGTCTTCGT CG (SEQ ID NO: 3). In a preferred embodi- 15 ment, the at least one genetic element includes CATCTC-CATGGCTGTACCACCTTGTCGGGGGGATGTGTACTT-CTGAACTTGTGTTGAATCTCATGGAGTTCAGAAGA-ACACATCCGCACTGACATTTTGGTATCTTTCATCT-GACCA (SEQ ID NO: 2); or GGGCCTGGCTCGAGC- 20 AGGGGGGGGGGGGGGGTTCCCGCTTCTTCCTGCCATAG-CGTGGTCCCCTCCCCTATGGCAGGCAGAAGCGG-CACCTTCCCTCCCAAT GACCGCGTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a 25 sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with AGGTATAT-TGCTGTTGACAGTGAGCGACTGTAAACTGAGCTT-GCTCTACTGTGAAGCCACAGATGGGTAGAGCAAG-CACAGTTTACCGCTGCCTACTGCCTCGGACTTCA-AGGGGCTTCCCGGGCATCTCCATGGCTGTACCAC-CTTGTCGGGGGGATGTGTACTTCTGAACTTGTGTTG-AATCTCATGGAGTTCAGAAGAACACATCCGCACT-GACATTTTGGTATCTTTCATCTGACCAGCTAGCGG-GCCTGGCTCGAGCAGGGGGGGGGGGGGGGGGATTCCGC-TTCTTCCTGCCATAGCGTGGTCCCCTCCCCTATGG-CAGGCAGAAGCGGCACCTTCCCTCCCAATGACCG-CGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the microRNA cluster includes: AGGTATATTGCT-GTTGACAGTGAGCGACTGTAAACTGAGCTTGCTCT 40 ACTGTGAAGCCACAGATGGGTAGAGCAAGCACA-GTTTACCGCTGCCTACTGCCTCGGACTTCAAGGG-GCTTCCCGGGCATCTCCATGGCTGTACCACCTTG-TCGGGGGATGTGTACTTCTGAACTTGTGTTGAAT-CTCATGGAGTTCAGAAGAACACATCCGCACTGA-CATTTTGGTATCTTTCATCTGACCAGCTAGCGGG-CCTGGCTCGAGCAGGGGGGGGGGGGGGGGGGATTCCGCTT-CTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGC-AGGCAGAAGCGGCACCTTCCCTCCCAATGACCGC-GTCTTCGTC (SEQ ID NO: 31).

In another aspect, a lentiviral vector is disclosed. The lentiviral vector includes at least one encoded genetic element, wherein the at least one encoded genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5. The at least one encoded genetic 55 element may also comprise at least one small RNA capable of targeting an HIV RNA sequence. In another aspect, the at least one encoded genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an 60 HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at least one encoded genetic element may include a microRNA or a shRNA. The at least one encoded genetic element may include a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least

90%, or at least 95% percent identity with AGGTATAT-TGCTGTTGACAGTGAGCGACTGTAAACTGAGCTT-GCTCTACTGTGAAGCC ACAGATGGGTAGAGCAA-GCACAGTTTACCGCTGCCTACTGCCTCGGACTT-CAAGGGG CTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises: AGGTAT-ATTGCTGTTGACAGTGAGCGACTGTAAACTGAGC-TTGCTCTACTGTGAAGCC ACAGATGGGTAGAGC-AAGCACAGTTTACCGCTGCCTACTGCCTCGGACTT-CAAGGGG CTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with CATCTC-CATGGCTGTACCACCTTGTCGGGGGGATGTGTACT-TCTGAACTTGTGTTGAAT CTCATGGAGTTCAGAA-GAACACATCCGCACTGACATTTTGGTATCTTTCA-TCTGACCA (SEQ ID NO: 2); or at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with GGGCCTGGCTCGAGCAGGGGGGGGGGGGGGGGATTCCG-CTTCTTCCTGCCATAGCGTGG TCCCCTCCCTAT-GGCAGGCAGAAGCGGCACCTTCCCTCCCAATGA-CCGCGTCTTCGT CG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTACCACCTTGTCGGGGGGATGT-GTACTTCTGAACTTGTGTTGAAT CTCATGGAGTT-CAGAAGAACACATCCGCACTGACATTTTGGTATC-TTTCATCTGACCA (SEQ ID NO: 2); or GGGCC-TGGCTCGAGCAGGGGGGGGGGGGGGGGGGTTCCTTC CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGC-AGAAGCGGCACCTTCCCTCCCAAT GACCGCGTCT-TCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with AGGTATAT-35 TGCTGTTGACAGTGAGCGACTGTAAACTGAGCT-TGCTCTACTGTGAAGCCACAGATGGGTAGAGCA-AGCACAGTTTACCGCTGCCTACTGCCTCGGACTT-CAAGGGGCTTCCCGGGCATCTCCATGGCTGTACC ACCTTGTCGGGGGGATGTGTACTTCTGAACTT GTGT-TGAATCTCATGGAGTTCAGAAGAACACATCCGCA-CTGACATTTTGGTATCTTTCATCTGACCAGCTAGC-GGGCCTGGCTCGAGCAGGGGGGGGGGGGGGGGATTCCG-CTTCTTCCTGCCATAGCGTGGTCCCCCTCCCCTATG-GCAGGCAGAAGCGGCACCTTCCCTCCCAATGA 45 CCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the microRNA cluster includes: AGGTATAT-TGCTGTTGACAGTGAGCGACTGTAAACTGAGCT-ACTGTGAAGCCACAGATGGGTAGAGCA-TGCTCT AGCACAGTTTACCGCTGCCTACTGCCTCGG ACTT-CAAGGGGCTTCCCGGGCATCTCCATGGCTGTACC-50 ACCTTGTCGGGGGGGATGTGTACTTCTGAACTTGTG-TTGAATCTCATGGAGTTCAGAAGAACACATCCGC-ACTGACATTT TGGTATCTTTCATCTGACCAGCTAG-CGGGCCTGGCTCGAGCAGGGGGGGGGGGGGGATTCC-GCTTCTTCCTGCCATAGCGTGGTCCCCTCCCCTAT-GGCAGGCAGAAGCGGCACCTTCCCTCCCAATGA-CCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a lentiviral vector system for expressing a lentiviral particle is disclosed. The system includes a lentiviral vector as described herein; an envelope plasmid for expressing an envelope protein preferably optimized for infecting a cell; and at least one helper plasmid for expressing genes of interest. In embodiments, the genes of interest include one or more of gag, pol, and rev genes. In embodiments, the lentiviral vector, the envelope plasmid, and the at least one helper plasmid are transfected into a packaging cell line. In further embodiments, a lentiviral particle is produced

by the packaging cell line. In embodiments, the lentiviral particle is capable of modulating production of a target of interest. In embodiments, the target of interest is any of chemokine receptor CCR5 or an HIV RNA sequence. The system may further include a first helper plasmid and a 5 second helper plasmid. In embodiments, a first helper plasmid expresses the gag and pol genes, and a second helper plasmid expresses the rev gene.

In another aspect, a lentiviral particle capable of infecting a cell is provided. The lentiviral particle includes an envelope protein preferably optimized for infecting a cell, and a lentiviral vector as described herein. In embodiments, the envelope protein may be optimized for infecting a T cell. In a preferred embodiment, the envelope protein is optimized 15 for infecting a CD4+ T cell.

In another aspect, a modified cell is provided. The modified cell includes any cell capable of being infected with a lentiviral vector system for use in accordance with present aspects and embodiments. In embodiments, the cell is a 20 CD4+ T cell that is infected with a lentiviral particle. In embodiments, the CD4+ T cell also has been selected to recognize an HIV antigen. In embodiments, the HIV antigen includes a gag antigen. In embodiments, the CD4+ T cell expresses a decreased level of CCR5 following infection 25 with the lentiviral particle.

In another aspect, a method of selecting a subject for a therapeutic treatment regimen is provided. The method variously includes immunizing the subject with an effective amount of a first stimulatory agent; removing leukocytes 30 from the subject and purifying peripheral blood mononuclear cells (PBMC) and determining a first quantifiable measurement associated with at least one factor associated with the PBMC; contacting the PBMC ex vivo with a therapeutically effective amount of a second stimulatory 35 agent, and determining a second measurement associated with the at least one factor associated with the PBMC, whereby when the second quantifiable measurement is higher than the first quantifiable measurement, the subject is selected for the treatment regimen. The at least one factor 40 expression by synthetic microRNA sequences in a lentiviral may include any of T cell proliferation or IFN gamma production.

The foregoing general description and following brief description of the drawings and detailed description are exemplary and explanatory and are intended to provide 45 further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following brief description of the drawings and detailed description of the invention. 50

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a flow diagram of an ex vivo treatment method of the present disclosure.

FIG. 2 depicts CD4+ T cell alteration and prevention of new infection in accordance with the present disclosure.

FIG. 3 depicts an exemplary lentiviral vector system comprised of a therapeutic vector, a helper plasmid, and an envelope plasmid. The therapeutic vector shown here is a 60 preferred therapeutic vector, which is also referred to herein as AGT103, and contains miR30CCR5-miR21Vif-miR185-Tat.

FIGS. 4A-4C depict an exemplary 3-vector lentiviral vector system in a circularized form. 65

FIGS. 5A-5D depict an exemplary 4-vector lentiviral vector system in a circularized form.

FIG. 6 depicts exemplary vector sequences. Positive (i.e., genomic) strand sequences of the promoter and miR cluster were developed for inhibiting the spread of CCR5-tropic HIV strains. Sequences that are not underlined comprise the EF-1alpha promoter of transcription that was selected as being a preferable promoter for this miR cluster. Sequences that are underlined show the miR cluster consisting of miR30 CCR5, miR21 Vif, and miR185 Tat (as shown collectively in SEQ ID NO: 33).

FIG. 7 depicts exemplary lentiviral vector constructs according to various aspects of this disclosure.

FIGS. 8A-8B show knockdown of CCR5 by an experimental vector and corresponding prevention of R5-tropic HIV infection in AGTc120 cells. FIG. 8A shows CCR5 expression in AGTc120 cells with or without AGT103 lentivirus vector. FIG. 8B shows the sensitivity of transduced AGTc120 cells to infection with a HIV BaL virus stock that was expressing green fluorescent protein (GFP) fused to the Nef gene of HIV.

FIGS. 9A-9B depict data demonstrating regulation of CCR5 expression by shRNA inhibitor sequences in a lentiviral vector of the present disclosure. FIG. 9A shows screening data for potential candidates. FIG. 9B shows CCR5 knock-down data following transduction with CCR5 shRNA-1 (SEQ ID NO: 16).

FIGS. 10A-10B depict data demonstrating regulation of HIV components by shRNA inhibitor sequences in a lentiviral vector of the present disclosure. FIG. 10A shows knock-down data for the rev/tat target gene. FIG. 10B shows knock-down data for the gag target gene.

FIG. 11 depicts data demonstrating that AGT103 reduces expression of Tat protein expression in cells transfected with an HIV expression plasmid, as described herein.

FIGS. 12A-12B depict data demonstrating regulation of HIV components by synthetic microRNA sequences in a lentiviral vector of the present disclosure. In FIG. 12A, tat knock-down data is shown. In FIG. 12B, vif knock-down data is shown.

FIG. 13 depicts data demonstrating regulation of CCR5 vector of the present disclosure.

FIG. 14 depicts data demonstrating regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector of the present disclosure containing either a long or short WPRE sequence.

FIG. 15 depicts data demonstrating regulation of CCR5 expression by synthetic microRNA sequences in a lentiviral vector of the present disclosure with or without a WPRE sequence.

FIG. 16 depicts data demonstrating regulation of CCR5 expression by a CD4 promoter regulating synthetic microRNA sequences in a lentiviral vector of the present disclosure.

FIG. 17 depicts data demonstrating detection of HIV 55 Gag-specific CD4 T cells.

FIGS. 18A-18E depict data demonstrating HIV-specific CD4 T cell expansion and lentivirus transduction. FIG. 18A shows an exemplary schedule of treatment. FIG. 18B shows IFN-gamma production in CD4-gated T cells, as described herein. FIG. 18C shows IFN-gamma production and GFP expression in CD4-gated T cells, as described herein. FIG. 18D shows frequency of HIV-specific CD4+ T cells, as described herein. FIG. 18E shows IFN-gamma production from PBMCs post-vaccination, as described herein.

FIGS. 19A-19C depict data demonstrating a functional assay for a dose response of increasing AGT103-GFP and inhibition of CCR5 expression. FIG. 19A shows dose response data for increasing amounts of AGT103-GFP. FIG. **19**B shows normally distributed populations in terms of CCR5 expression. FIG. **19**C shows percentage inhibition of CCR5 expression with increasing doses of AGT103-GFP.

FIGS. **20**A-**20**B depict data demonstrating AGT103 trans- <sup>5</sup> duction efficiency for primary human CD4+ T cells. FIG. **20**A shows frequency of transduced cells (GFP-positive) by FACS, as described herein. FIG. **20**B shows number of vector copies per cell, as described herein.

FIG. **21** depicts data demonstrating AGT103 inhibition of <sup>10</sup> HIV replication in primary CD4+ T cells, as described herein.

FIG. **22** depicts data demonstrating AGT103 protection of primary human CD4+ T cells from HIV-induced depletion.

FIGS. **23**A-D depict data demonstrating generation of a <sup>15</sup> CD4+ T cell population that is highly enriched for HIVspecific, AGT103-transduced CD4 T cells. FIG. **23**A shows CD4 and CD8 expression profiles for cell populations, as described herein. FIG. **23**B shows CD4 and CD8 expression profiles for cell populations, as described herein. FIG. **23**C <sup>20</sup> shows IFN-gamma and CD4 expression profiles for cell populations, as described herein. FIG. **23**D shows IFNgamma and GFP expression profiles for cell populations, as described herein.

#### DETAILED DESCRIPTION

Overview

Disclosed herein are methods and compositions for treating and/or preventing human immunodeficiency virus (HIV) 30 disease to achieve a functional cure. The methods and compositions include integrating lentivirus, non-integrating lentivirus, and related viral vector technology as described below.

Disclosed herein are therapeutic viral vectors (e.g., len- 35 tiviral vectors), immunotherapies, and methods for their use for treating HIV infection. In embodiments, methods and compositions for achieving a functional cure for HIV infection are provided. As depicted in FIG. 1 herein, the various aspects and embodiments include a first stimulation event, 40 for example a first therapeutic immunization with vaccines intended to produce strong immune responses against HIV in HIV-infected patients, for example with stable suppression of viremia due to daily administration of HAART. In embodiments, the first stimulation event enriches the frac- 45 tion of HIV-specific CD4 T cells. This is followed by (1) isolating peripheral leukocytes by leukapheresis or purifying PBMC from venous blood, (2) a second stimulating event, for example re-stimulating CD4 T cells ex vivo with a suitable stimulatory agent, such as any vaccine or protein, 50 for example, HIV or HIV-related peptides, (3) performing therapeutic lentivirus transduction, ex vivo T cell culture, and (4) re-infusion back into the original patient.

The various methods and compositions can be used to prevent new cells, such as CD4+ T cells, from becoming 55 infected with HIV. For example as illustrated in FIG. **2**, to prevent new cells from becoming infected, CCR5 expression can be targeted to prevent virus attachment. Further, destruction of any residual infecting viral RNA can also be targeted. In respect of the foregoing, and in reference to FIG. 60 **2** herein, compositions and methods are provided to stop the HIV viral cycle in cells that have already become infected with HIV. To stop the HIV viral cycle, viral RNA produced by latently-infected cells, such as latently-infected CD4+ T cells, is targeted. 65

Previous efforts to achieve a cure for HIV have fallen short due to, among others, the failure to obtain sufficient 10

numbers of HIV-specific CD4 T cells with protective genetic modifications. When this number is below a critical threshold, a functional cure as described herein is not achieved. For example, upon termination of antiretroviral therapy HIV re-emergence generally follows. Thereafter, patients often experience rapid destruction of HIV-specific CD4 T cells, and also followed by return to progression of disease despite prior genetic therapy. By employing therapeutic immunization in accordance with the compositions and methods described herein, a new HIV treatment regimen has been developed including, in various embodiments, a functional cure.

Definitions and Interpretation

Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclature used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and com-25 monly used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g.: Sambrook J. & Russell D. Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2000); Ausubel et al., Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, John & Sons, Inc. (2002); Harlow and Lane Using Antibodies: A Laboratory Manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1998); and Coligan et al., Short Protocols in Protein Science, Wiley, John & Sons, Inc. (2003). Any enzymatic reactions or purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art.

As used herein, the term "about" will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, "about" will mean up to plus or minus 10% of the particular term.

As used herein, the terms "administration of" or "administering" an active agent means providing an active agent of the invention to the subject in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically effective amount.

As used herein, the term "AGT103" refers to a particular embodiment of a lentiviral vector that contains a miR30-CCR5/miR21-Vif/miR185-Tat microRNA cluster sequence, as detailed herein.

As used herein, the term "AGT103T" refers to a cell that has been transduced with a lentivirus that contains the AGT103 lentiviral vector. Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. Further, as used herein, the term 5 "includes" means includes without limitation.

As used herein, the term "engraftment" refers to the ability for one skilled in the art to determine a quantitative level of sustained engraftment in a subject following infusion of a cellular source (see for e.g.: Rosenberg et al., *N.* 10 *Engl. J. Med.* 323:570-578 (1990); Dudley et al., *J. Immunother.* 24:363-373 (2001); Yee et al., *Curr. Opin. Immunol.* 13:141-146 (2001); Rooney et al., *Blood* 92:1549-1555 (1998)).

The terms, "expression," "expressed," or "encodes" refer 15 to the process by which polynucleotides are transcribed into mRNA and/or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. Expression may include splicing of the mRNA in a eukaryotic cell or other forms of post-transcriptional 20 modification or post-translational modification.

The term "functional cure", as referenced above, and further defined herein, refers to a state or condition wherein HIV+individuals who previously required ongoing HIV therapies such as cART or HAART, may survive with low or 25 undetectable virus replication using lower doses, intermittent doses, or discontinued dosing of such HIV therapies. An individual may be said to have been "functionally cured" while still requiring adjunct therapy to maintain low level virus replication and slow or eliminate disease progression. 30 A possible outcome of a functional cure is the eventual eradication of all or virtually all HIV such that no recurrence is detected within a specified time frame, for example, 1 month, 3 months, 6 months, 1 year, 3 years, and 5 years, and all other time frames as may be defined.

The term "HIV vaccine" encompasses immunogens plus vehicle plus adjuvant intended to elicit HIV-specific immune responses. The term "HIV vaccine" is within the meaning of the term "stimulatory agent" as described herein. A "HIV vaccine" may include purified or whole inactivated virus particles that may be HIV or a recombinant virus vectors capable of expressing HIV proteins, protein fragments or peptides, glycoprotein fragments or glycopeptides, in addition to recombinant bacterial vectors, plasmid DNA or RNA capable of directing cells to producing HIV proteins, glycoproteins or protein fragments able to elicit specific immunity. Alternately, specific methods for immune stimulation including anti-CD3/CD28 beads, T cell receptor-specific antibodies, mitogens, superantigens and other chemical or biological stimuli may be used to activate dendritic, T or B cells for the purposes of enriching HIV-specific CD4 T cells prior to transduction or for in vitro assay of lentivirustransduced CD4 T cells. Activating substances may be soluble, polymeric assemblies, liposome or endosome-based or linked to beads. Cytokines including interleukin-2, 6, 7, 12, 15, 23 or others may be added to improve cellular responses to stimuli and/or improve the survival of CD4 T cells throughout the culture and transduction intervals. Alternately, and without limiting any of the foregoing, the term "HIV vaccine" encompasses the MVA/HIV62B vaccine and variants thereof. The MVA/HIV62B vaccine is a known highly attenuated double recombinant MVA vaccine. The MVA/HIV62B vaccine was constructed through the insertion of HIV-1 gag-pol and env sequences into the known MVA vector (see: for e.g.: Goepfert et al. (2014) J. Infect. Dis. 210(1): 99-110, and see WO2006026667, both of which are incorporated herein by reference). The term "HIV vaccine" also includes any one or more vaccines provided in Table 1, below.

TABLE 1

IAVI Clinical Trial ID*	Prime**
HVTN 704 AMP	VRC-HIVMAB060-00-AB
VAC89220HPX2004	Ad26.Mos.HIV Trivalent
01-I-0079	VRC4302
04/400-003-04	APL 400-003 GENEVAX-HIV
10-1074	10-1074
87 I-114	gp160 Vaccine (Immuno-AG)
96-I-0050	APL 400-003 GENEVAX-HIV
ACTG 326; PACTG 326	ALVAC vCP1452
Ad26.ENVA.01	Ad26.EnvA-01
Ad26.ENVA.01 Mucosal/IPCAVD003	Ad26.EnvA-01
Ad5HVR48.ENVA.01	Ad5HVR48.ENVA.01
ANRS VAC 01	ALVAC vCP125
ANRS VAC 02	rgp 160 + peptide V3 ANRS VAC 02
ANRS VAC 03	ALVAC-HIV MN120TMG strain (vCP205)
ANRS VAC 04	LIPO-6
ANRS VAC 04 bis	LIPO-6
ANRS VAC 05	ALVAC vCP125
ANRS VAC 06	ALVAC vCP125
ANRS VAC 07	ALVAC vCP300
ANRS VAC 08	ALVAC-HIV MN120TMG strain (vCP205)
ANRS VAC 09	ALVAC-HIV MN120TMG strain (vCP205)
ANRS VAC 09 bis	LIPO-6
ANRS VAC 10	ALVAC vCP1452
ANRS VAC 12	LPHIV1
ANRS VAC 14	gp160 MN/LAI
ANRS VAC 16	LPHIV1
ANRS VAC 17	LIPO-6
ANRS VAC 18	LIPO-5
APL 400-003RX101	APL 400-003 GENEVAX-HIV
AVEG 002	HIVAC-1e
AVEG 002A	HIVAC-1e
AVEG 002B	HIVAC-1e
AVEG 003	VaxSyn gp160 Vaccine (MicroGeneSys)

TABLE	1-continued
	1

IAVI Clinical Trial ID*	Prime**
AVEG 003A	VaxSyn gp160 Vaccine (MicroGeneSys)
AVEG 003B	VaxSyn gp160 Vaccine (MicroGeneSys)
AVEG 004	gp160 Vaccine (Immuno-AG)
AVEG 004A	gp160 Vaccine (Immuno-AG)
AVEG 004B	gp160 Vaccine (Immuno-AG)
AVEG 005A/B	Env 2-3
AVEG 005C	Ellv 2-5 MN rm120
AVEG 007A/B	rgp120/HIV-1 SF-2
AVEG 007C	rgp120/HIV-1 SF-2
AVEG 008	HIVAC-1e
AVEG 009	MN rgp120
AVEG 010	HIVAC-1e
AVEG 011	UBI HIV-1 Peptide Immunogen, Multivalent
AVEG 012A/B	ALVAC vCP125
AVEG 013A	gp160 Vaccine (Immuno-AG)
AVEG 013B	gp160 Vaccine (Immuno-AG)
AVEG 014A/B	TBC-3B
AVEG 014C	TBC-3B
AVEG 015	rgp120/HIV-1 SF-2
AVEG 016	MN rgp120 MN rem120
AVEG 016A	MN rep120
AVEG 010B	MIN 1gp120 UPL HIV 1 Partida Vaccina, Microparticulata
AVEG 017	Monovalent
AVEG 018	LIBI HIV-1 Pentide Vaccine Micronarticulate
IN EG OTO	Monovalent
AVEG 019	p17/p24:Tv-VLP
AVEG 020	gp120 C4-V3
AVEG 021	P3C541b Lipopeptide
AVEG 022	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 022A	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 023	UBI HIV-1 Peptide Immunogen, Multivalent
AVEG 024	rgp120/HIV-1 SF-2
AVEG 026	ALVAC vCP300
AVEG 027	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 028	Salmonella typhi CVD 908-HIV-1 LAI gp 120
AVEG 029	ALVAC-HIV MN1201MG strain (vCP205)
AVEG 031	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 033	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 034/034A	ALVAC vCP1433
AVEG 036	MN rgp120
AVEG 038	ALVAC-HIV MN120TMG strain (vCP205)
AVEG 201	rgp120/HIV-1 SF-2
AVEG 202/HIVNET 014	ALVAC-HIV MN120TMG strain (vCP205)
C060301	GTU-MultiHIV
C86P1	HIV gp140 ZM96
Cervico-vaginal CN54gp140-hsp70	CN54gp140
Conjugate Vaccine (TL01)	
CM235 and SF2gp120	CM235 (ThaiE) gp120 plus SF2(B) gp120
CM235gp120 and SF2gp120	CM235 (ThatE) gp120 plus SF2(B) gp120
CDC282	CombiHIV vac
CRO2020 CRO2040/CUT*HIVAC001	r 2012 GTUL-MultiHIV
CUTHIVAC002	DNA-C CN54ENV
DCVax-001	DCVax-001
DNA-4	DNA-4
DP6?001	DP6?001DNA
DVP-1	EnvDNA
EN41-UGR7C	EN41-UGR7C
EnvDNA	EnvDNA
EnvPro	EnvPro
EuroNeut41	EN41-FPA2
EV01	NYVAC-C
EV02 (EuroVace 02)	DNA-C
EV03/ANRSVAC20	DNA-C
Extention HVTN 073E/SAAVI 102	Sub C gp140
F4/ASU1 EIT Distash	F4/AS01 GTU Nof
FIT BIOTECH	GIU-NEI Chinese DNA
HGP-30 memory responses	HGP-30
HIV-COR F002	ChAdV63 HIVconsy
HIV-POL-001	MVA-mBN32
HIVIS 01	HIVIS-DNA
HIVIS 02	MVA-CMDR
HIVIS 03	HIVIS-DNA
HIVIS 05	HIVIS-DNA

TABLE 1-continued

IAVI Clinical Trial ID*	Prime**
HIVIS06	HIVIS-DNA
HIVIS07	HIVIS-DNA
HIVNET 007	ALVAC-HIV MN120TMG strain (vCP205)
HIVNEI 026 HPTN 027	ALVAC VCP1452 ALVAC-HIV vCP1521
HVRF-380-131004	Vichrepol
HVTN 039	ALVAC vCP1452
HVTN 040	AVX101
HVTN 042 HVTN 042/ANDS VAC 19	rgp120w61d
HVTN 044	VRC-HIVDNA009-00-VP
HVTN 045	pGA2/JS7 DNA
HVTN 048	EP HIV-1090
HVIN 049 HVTN 050/Merck 018	Gag and Env DNA/PLG microparticles
HVTN 052	VRC-HIVDNA009-00-VP
HVTN 054	VRC-HIVADV014-00-VP
HVTN 055	TBC-M335
HVIN 056 HVIN 057	MEP VRC-HIVDNA009-00-VP
HVTN 059	AVX101
HVTN 060	HIV-1 gag DNA
HVTN 063	HIV-1 gag DNA
HVIN 065	nGA2/IS7 DNA
HVTN 067	EP-1233
HVTN 068	VRC-HIVADV014-00-VP
HVTN 069	VRC-HIVDNA009-00-VP
HVIN 070 HVIN 071	MRKAd5 HIV-1 989
HVTN 072	VRC-HIVDNA044-00-VP
HVTN 073	SAAVI DNA-C2
HVTN 076	VRC-HIVDNA016-00-VP
HVTN 078	NYVAC-B
HVTN 080	PENNVAX-B
HVTN 082	VRC-HIVDNA016-00-VP
HVIN 083 HVIN 084	VRC-HIVADV038-00-VP VRC-HIVADV054-00-VP
HVTN 085	VRC-HIVADV014-00-VP
HVTN 086, SAAVI 103	SAAVI MVA-C
HVTN 087 HVTN 088	HIV-MAG Oligomeric gp140/ME59
HVIN 088 HVIN 090	VSV-Indiana HIV gag vaccine
HVTN 092	DNA-HIV-PT123
HVTN 094	GEO-D03
HVIN 096 HVIN 097	AIVAC-HIV vCP1521
HVTN 098	PENNVAX-GP
HVTN 100	ALVAC-HIV-C (vCP2438)
HVTN 101 HVTN 102	DNA-HIV-PT123 DNA-HIV-PT123
HVTN 102	VRC-HIVMAB060-00-AB
HVTN 105	AIDSVAX B/E
HVTN 106	DNA Nat-B env
HVIN 110 HVIN 112	Ad4-mgag HIV-1 nef/tat/vif_env nDNA vaccine
HVTN 114; GOVX-B11	AIDSVAX B/E
HVTN 116	VRC-HIVMAB060-00-AB
HVTN 203 HVTN 204	ALVAC VCP1452 VPC HIVDNA016 00 VP
HVTN 204 HVTN 205	pGA2/JS7 DNA
HVTN 502/Merck 023 (Step Study)	MRKAd5 HIV-1 gag/pol/nef
HVTN 503 (Phambili)	MRKAd5 HIV-1 gag/pol/nef
HVIN 505 HVIN 702	VRC-HIVDNA016-00-VP ALVAC-HIV-C (vCP2438)
HVTN 703 AMP	VRC-HIVMAB060-00-AB
HVTN 908	pGA2/J57 DNA
IAVI 001	DNA.HIVA
IAVI 002 IAVI 003	DINA.HIVA MVA HIVA
IAVI 004	MVA.HIVA
IAVI 005	DNA.HIVA
LAV1 006	DNA.HIVA MVA HIVA
IAVI 000	DNA.HIVA
IAVI 010	DNA.HIVA
IAVI 011	MVA.HIVA

TABLE	1-continued
-------	-------------

IAVI Clinical Trial ID*	Prime**
IAVI 016	MVA.HIVA
IAVI A001	tgAAC09
IAVI A002	tgAAC09
IAVI A003	AAV1-P G9
IAVI B001	Ad35-GRIN/ENV
IAVI B002	Adjuvanted GSK investigational HIV vaccine
	formulation 1
IAVI B003	Ad26.EnvA-01
IAVI B004	
LAVI C002	ADWVA ADMVA
IAVI C003	ADMVA
IAVI C004/DHO-614	ADVAX
IAVI D001	TBC-M4
IAVI N004 HIV-CORE 004	Ad35-GRIN
IAVI P001	ADVAX
IAVI P002	ADVAX
IAVI R001	rcAd26.MOS1.HIVEnv
IAVI S001	SeV-G
IAVI V001	VRC-HIVDNA016-00-VP
IDEA EV06	VKC-HIVDINAUI0-00-VP DNIA UIV PT122
IHV01	Full-Lenoth Single Chain (FLSC)
IMPAACT P1112	VRC-HIVMAB060-00-AB
IPCAVD006	MVA mosaic
IPCAVD008	Trimeric gp140
IPCAVD009	Ad26.Mos.HIV Trivalent
IPCAVD010	Ad26.Mos.HIV Trivalent
ISS P-001	Tat vaccine
ISS P-002	Tat vaccine
LFn-p24 vaccine	LFn-p24
MCA-0835 Manala V520, 007	3BNC117 Ad 5 HIV 1 coc (Morely)
MRC V001	ran120w61d
MRK Ad5	Ad-5 HIV-1 gag (Merck)
MRKAd5 + ALVAC	MRKAd5 HIV-1 gag
Mucovac2	CN54gp140
MV1-F4	Measles Vector - GSK
MYM-V101	Virosome-Gp41
NCHECR-AE1	pHIS-HIV-AE
PACTG 230	AIDSVAX B/E
PAVE100	VRC-HIVDNA016-00-VP
PEACHI-04 PedVecc001 & PedVecc002	ChAdV63.HIVconsv
PolyEnv1	MVA.HIVA PolyEny1
PXVX-HIV-100-001	Ad4-mgag
RISVAC02	MVA-B
RisVac02 boost	MVA-B
RV 124	ALVAC-HIV MN120TMG strain (vCP205)
RV 132	ALVAC-HIV vCP1521
RV 135	ALVAC-HIV vCP1521
RV 138; B011	ALVAC-HIV MN120TMG strain (vCP205)
KV 144	ALVAC-HIV VCP1521
KV 151/WKAIK 984 DV 156	LFR-p24 VRC HIVDNA000 00 VP
RV 1564	VRC-HIVDNA009-00-VP
RV 158	MVA-CMDR
RV 172	VRC-HIVDNA016-00-VP
RV 305	ALVAC-HIV vCP1521
RV 306	ALVAC-HIV vCP1521
RV 328	AIDSVAX B/E
RV 365	MVA-CMDR
RV262	Pennvax-G
SGU6KSU2	HIV gp140 ZM96
ГАВУ Тамаура II	IABY UIVIS DNA
TAMOVAC-01-MZ	HIVIS-DNA
Tiantan vaccinia HIV Vaccine	Chinese DNA
Tiantan vaccinia HIV Vaccine and DNA	Chinese DNA
TMB-108	Ibalizumab
UBI HIV-1 MN China	UBI HIV-1 Peptide Immunogen, Multivalent
UBI HIV-1MN octameric-Australia study	UBI HIV-1 Peptide Immunogen, Multivalent
UBI V106	UBI HIV-1 Peptide Vaccine, Microparticulate
	Monovalent
UCLA MIG-001	TBC-3B
UCLA MIG-003	ALVAC-HIV MN1201MG strain (vCP205)
UNDADI	DINA - UN34EINV AllQ ZMI90GMN UIV p24/ME50 Vaccine
Y 271 1	m p24/mm37 vaccine

TABLE 1-continued

IAVI Clinical Trial ID*	Prime**
V3-MAPS	V3-MAPS
V520-016	MRKAd5 HIV-1 gag/pol/nef
V520-027	MRKAd5 HIV-1 gag/pol/nef
V526-001 MRKAd5 and MRKAd6 HIV-1	MRKAd5 HIV-1 gag/pol/nef
Trigene Vaccines	0.01
VAX 002	AID SVAX B/B
VAX 003	AID SVAX B/E
VAX 004	AID SVAX B/B
VRC 004 (03-I-0022)	VRC-HIVDNA009-00-VP
VRC 006 (04-I-0172)	VRC-HIVADV014-00-VP
VRC 007 (04-I-0254)	VRC-HIVDNA016-00-VP
VRC 008 (05-I-0148)	VRC-HIVDNA016-00-VP
VRC 009 (05-I-0081)	VRC-HIVDNA009-00-VP
VRC 010 (05-I-0140)	VRC-HIVADV014-00-VP
VRC 011 (06-I-0149)	VRC-HIVDNA016-00-VP
VRC 012 (07-I-0167)	VRC-HIVADV027-00-VP
VRC 015 (08-I-0171)	VRC-HIVADV014-00-VP
VRC 016	VRC-HIVDNA016-00-VP
VRC 602	VRC-HIVMAB060-00-AB
VRC 607	VRCHIVMAB080-00-AB
VRC01LS	VRCHIVMAB080-00-AB
VRI01	MVA-B
X001	CN54gp140

\*IAVI is the International AIDS Vaccine Initiative, whose clinical trials database is publicly available at

http://www.iavi.org/rinals-database/trials.
 \*\*As used herein, the term "Prime" refers to the composition initially used as an immunological inoculant in a given clinical trial as referenced in Table 1 herein.

The term "in vivo" refers to processes that occur in a living organism. The term "ex vivo" refers to processes that occur outside of a living organism. For example, in vivo 30 treatment refers to treatment that occurs within a patient's body, while ex vivo treatment is one that occurs outside of a patient's body, but still uses or accesses or interacts with tissues from that patient. Thereafter, an ex vivo treatment step may include a subsequent in vivo treatment step.

The term "miRNA" refers to a microRNA, and also may be referred to herein as "miR". The term "microRNA cluster" refers to at least two microRNAs that are situate on a vector in close proximity to each other and are coexpressed.

The term "packaging cell line" refers to any cell line that can be used to express a lentiviral particle.

The term "percent identity," in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage 45 of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence. as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to persons of ordinary skill in the 50 art) or by visual inspection. Depending on the application, the "percent identity" can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared. For sequence comparison, typically one sequence 55 acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The 60 sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optimal alignment of sequences for comparison can be 65 conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homol-

ogy alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual 35 inspection (see generally Ausubel et al., infra).

One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing 40 BLAST analyses is publicly available through the National Center for Biotechnology Information website.

The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (I Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http:// www.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

The nucleic acid and protein sequences of the present disclosure can further be used as a "query sequence" to perform a search against public databases to, for example, identify related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, word length=12 to obtain nucleotide

sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http:// www.ncbi.nlm.nih.gov.

As used herein, "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues, organs, and/or bodily fluids of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.

As used herein, a "pharmaceutically acceptable carrier" refers to, and includes, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The compositions can include a phar-25 maceutically acceptable salt, e.g., an acid addition salt or a base addition salt (see, e.g., Berge et al. (1977) *J Pharm Sci* 66:1-19).

As used herein, the term "SEQ ID NO" is synonymous with the term "Sequence ID No."

As used herein, "small RNA" refers to non-coding RNA that are generally less than about 200 nucleotides or less in length and possess a silencing or interference function. In other embodiments, the small RNA is about 175 nucleotides or less, about 150 nucleotides or less, about 125 nucleotides 35 or less, about 100 nucleotides or less, or about 75 nucleotides or less in length. Such RNAs include microRNA (miRNA), small interfering RNA (siRNA), double stranded RNA (dsRNA), and short hairpin RNA (shRNA). "Small RNA" of the disclosure should be capable of inhibiting or 40 knocking-down gene expression of a target gene, for example through pathways that result in the destruction of the target gene mRNA.

As used herein, the term "stimulatory agent" refers to any exogenous agent that can stimulate an immune response, 45 and includes, without limitation, a vaccine, a HIV vaccine, and HIV or HIV-related peptides. A stimulatory agent can preferably stimulate a T cell response.

As used herein, the term "subject" includes a human patient but also includes other mammals. The terms "subject," "individual," "host," and "patient" may be used interchangeably herein.

The term "therapeutically effective amount" refers to a sufficient quantity of the active agents of the present invention, in a suitable composition, and in a suitable dosage form 55 to treat or prevent the symptoms, progression, or onset of the complications seen in patients suffering from a given ailment, injury, disease, or condition. The therapeutically effective amount will vary depending on the state of the patient's condition or its severity, and the age, weight, etc., 60 of the subject to be treated. A therapeutically effective amount can vary, depending on any of a number of factors, including, e.g., the route of administration, the condition of the subject, as well as other factors understood by those in the art.

As used herein, the term "therapeutic vector" is synonymous with a lentiviral vector such as the AGT103 vector. 22

The term "treatment" or "treating" generally refers to an intervention in an attempt to alter the natural course of the subject being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects include, but are not limited to, preventing occurrence or recurrence of disease, alleviating symptoms, suppressing, diminishing or inhibiting any direct or indirect pathological consequences of the disease, ameliorating or palliating the disease state, and causing remission or improved prognosis.

The term "vaccine", which is used interchangeably with the term "therapeutic vaccine" refers to an exogenous agent that can elicit an immune response in an individual and includes, without limitation, purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, peptides or peptide fragments, or virus-like particles (VLPs).

Description of Aspects of the Disclosure

As detailed herein, in one aspect, a method of treating 20 cells infected with HIV is provided. The method generally includes contacting peripheral blood mononuclear cells (PBMC) isolated from a subject infected with HIV with a therapeutically effective amount of a stimulatory agent, wherein the contacting step is carried out ex vivo; transducing the PBMC ex vivo with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for a period of time sufficient to achieve such transduction. In embodiments, the transduced PBMC are cultured from about 1 to about 35 days. The method may further include infusing the transduced PBMC into a subject. The subject may be a human. The stimulatory agent may include a peptide or mixture of peptides, and in a preferred embodiment includes a gag peptide. The stimulatory agent may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/HIV62B vaccine or a variant thereof. In a preferred embodiment, the viral delivery system includes a lentiviral particle. In embodiments, the at least one genetic element may include a small RNA capable of inhibiting production of chemokine receptor CCR5. In embodiments, the at least one genetic element includes at least one small RNA capable of targeting an HIV RNA sequence. In other embodiments, the at least one genetic element includes a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or variants thereof. The at least one genetic element may include at least one of a microRNA or a shRNA. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with AGGTATATTGCTGTTGACAGT-GAGCGACTGTAAACTGAGCTTGCTCTACTGTGAA-GCC ACAGATGGGTAGAGCAAGCAAGCACAGTTTACCGC-TGCCTACTGCCTCGGACTTCAAGGGG CTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises: AGGTATATTGCTGTTGACAGTGA-GCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCC ACAGATGGGTAGAGCAAGCACAGTTTACCGCTG-CCTACTGCCTCGGACTTCAAGGGG CTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with CATCTCCATGGCTGTACCAC-CTTGTCGGGGGGATGTGTACTTCTGAACTTGTGTTG--5 AAT CTCATGGAGTTCAGAAGAACACATCCGC- ACT-GACATTTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, 10 at least 93%, at least 94%, at least 95% or more percent identity with GGGCCTGGCTCGAGCAGGGGGGGGGAGG-GATTCCGCTTCTTCCTGCCATAGCGTGG TCCCC-TCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC-CAATGACCGCGTCTTCGT CG (SEQ ID NO: 3). In a 15 preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTACCACCTTGTCGGGG-GATGTGTACTTCTGAACTTGTGTTGAAT CTCATGG-AGTTCAGAAGAACACATCCGCACTGACATTTTGGT-ATCTTTCATCTGACCA (SEQ ID NO: 2); or GGG- 20 CCTGGCTCGAGCAGGGGGGGGGGGGGGGGGGGGGTTCCGCTTC-TTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCAG-GCAGAAGCGGCACCTTCCCTCCCAATGACCG CGT-CTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a 25 sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with AGGTATATTGCTGTTGACAGT- 30 GAGCGACTGTAAACTGAGCTTGCTCTACTGTGAA-GCCACAGATGGGTAGAGCAAGCACAGTTTACCGC-TGCCTACTGCCTCGGACTTCAAGGGG CTTCCCGG-GCATCTCCATGGCTGTACCACCTTGTCGGGGGGAT-GTGTACTTCTGAACTTGTGTGTGAATCTCATGGAG-TTCAGAAGAACACATCCGCACTGACATTTTGGTA-TCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGA-GC- AGGGGGGGGGGGGGGGATTCCGCTTCTTCCT GCCAT-AGCGTGGTCCCCTCCCCTATGGCAGGCAGAGCG-GCACCTTCCCTCCCAATGA CCGCGTCTTCGTC (SEQ 40 ID NO: 31). In a preferred embodiment, the microRNA cluster includes: AGGTATATTGCTGTTGACAGTGAGC-GACTGTAAACTGAGCTTGCTCT ACTGTGAAGCCA-CAGATGGGTAGAGCAAGCACAGTTTACCGCTGCC-TACTGCCTCGG ACTTCAAGGGGGCTTCCCGGGCAT- 45 CTCCATGGCTGTACCACCTTGTCGGGGGGATGTGTA CTTCTGAACTTGTGTGTGAATCTCATGGAGTTCAG-AAGAACACATCCGCACTGACATTT TGGTATCTTTC-ATCTGACCAGCTAGCGGGGCCTGGCTCGAGCAGG-GGGCGAGGGATTCCGCTTCTTCCTGCCATAGCGTG-50 GTCCCCTCCCCTATGGCAGGCAGAAGCGGCAC CT-TC CCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a method of treating HIV infection in a subject is disclosed. The method generally includes immunizing the subject with an effective amount of a first stimulatory agent; removing leukocytes from the subject and purifying peripheral blood mononuclear cells (PBMC). The method further includes contacting the PBMC ex vivo with a therapeutically effective amount of a second stimulatory 60 agent; transducing the PBMC ex vivo with a viral delivery system encoding at least one genetic element; and culturing the transduced PBMC for a period of time sufficient to achieve transduction. The method may further include further enrichment of the PBMC, for example, by preferably 65 enriching the PBMC for CD4+ T cells. In embodiments, the transduced PBMC are cultured from about 1 to about 35

days. The method may further involve infusing the transduced PBMC into a subject. The subject may be a human. The first and second stimulatory agents may be the same or different from each other. The at least one of the first and second stimulatory agents may include a peptide or mixture of peptides. In embodiments, at least one of the first and second stimulatory agents includes a gag peptide. The at least one of the first and second stimulatory agents may include a vaccine. The vaccine may be a HIV vaccine, and in a preferred embodiment, the HIV vaccine is a MVA/ HIV62B vaccine or a variant thereof. In embodiments, the first stimulatory agent is a HIV vaccine and the second stimulatory agent is a gag peptide.

In embodiments, the viral delivery system includes a lentiviral particle. In embodiments, the at least one genetic element includes a small RNA capable of inhibiting production of chemokine receptor CCR5. In embodiments, the at least one genetic element includes at least one small RNA capable of targeting an HIV RNA sequence. In embodiments, the at least one genetic element includes a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence may include a HIV RNA sequence. The HIV RNA sequence may include a HIV vif sequence, a HIV Tat sequence, or variants thereof. The at least one genetic element may include a microRNA or a shRNA, or a cluster thereof. In a preferred embodiment, the at least one genetic element comprises a microRNA cluster.

 In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more
 percent identity with AGGTATATTGCTGTTGACAGTGA-GCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCC ACAGATGGGTAGAGCAAGCACAGTTTACCGCTG-CCTACTGCCTCGGACTTCAAGGGG CTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic
 element comprises: AGGTATATTGCTGTTGACAGTGA-GCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCC ACAGATGGGTAGAGCAAGCACAGTTTACCGCTGC-CTACTGCCTCGGACTTCAAGGGG CTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, or at least 85%, or at least 90%, or at least 95% percent identity with CATCTC-CATGGCTGTACCACCTTGTCGGGGGGATGTGTACT-TCTGAACTTGTGTTGAAT CTCATGGAGTTCAGAA-GAACACATCCGCACTGACATTTTGGTATCTTTCAT-CTGACCA (SEQ ID NO: 2); or at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with GGGCCTGGCT-CATAGCGTGG TCCCCTCCCCTATGGCAGGCAGAA-GCGGCACCTTCCCTCCCAATGACCGCGTCTTCGT-CG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTAC-CACCTTGTCGGGGGGATGTGTACTTCTGAACTTGT-GTTGAAT CTCATGGAGTTCAGAAGAACACATCCG-CACTGACATTTTGGTATCTTTCATCTGACCA (SEQ ID NO: 2); or GGGCCTGGCTCGAGCAGGGGGGGGGGGGG GATTCCGCTTCTTCCTGCCATAGCGTGGTCCCCT- C-CCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC-CAAT GACCGCGTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more 5 percent identity with AGGTATATTGCTGTTGACAGT-GAGCGACTGTAAACTGAGCTTGCTCTACTGTGAA-GCCACAGATGGGTAGAGCAAGCACAGTTTACCGC-TGCCTACTGCCTCGGACTTCAAGGGGGCTTCCCGG-GCATCTCCATGGCTGTACCACCTTGTCGGGGGGATG-10 TGTACTTCTGAACTT GTGTTGAATCTCATGGAGTT-CAGAAGAACACATCCGCACTGACATTITGGTATCT-TTCATCTGACCAGCTAGCGGGCCTGGCTCGAGCA-GGGGGCGAGGGATTCCGCTTCTTCCTGCCATAGC-GTGGTCCCCTCCCCTATGGCAGGCAGAAGCGGCA-15 CCTTCCCTCCCAATGA CCGCGTCTTCGTC (SEQ ID NO: 31). In a preferred embodiment, the microRNA cluster includes: AGGTATATTGCTGTTGACAGTGAGCGACT-GTAAACTGAGCTTGCTCT ACTGTGAAGCCACAGA-TGGGTAGAGCAAGCACAGTTTACCGCTGCCTACT-GCCTCGG ACTTCAAGGGGGCTTCCCGGGCATCTCC-ATGGCTGTACCACCTTGTCGGGGGGATGTGTACTTC-TGAACTTGTGTTGAATCTCATGGAGTTCAGAAGA-ACACATCCGCACTGACATTT TGGTATCTTTCATCT-GACCAGCTAGCGGGCCTGGCTCGAGCAGGGGGC-25 GAGGGATTC CGCTTCTTCCTGCCATAGCGTGGTC-CCCTCCCCTATGGCAGGCAGAAGCGGCACCTTC-CCTCCCAATGACCGCGTCTTCGTC (SEQ ID NO: 31).

In another aspect, a lentiviral vector is disclosed. The lentiviral vector includes at least one encoded genetic ele-30 ment, wherein the at least one encoded genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 or at least one small RNA capable of targeting an HIV RNA sequence. In another aspect a lentiviral vector is disclosed in the at least one second genetic element comprises a small RNA capable of inhibiting production of chemokine receptor CCR5 and at least one small RNA capable of targeting an HIV RNA sequence. The HIV RNA sequence may include a HIV Vif sequence, a HIV Tat sequence, or a variant thereof. The at 40 least one encoded genetic element may include a microRNA or a shRNA. The at least one encoded genetic element may include a microRNA cluster.

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, 45 at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with AGGTATATTGCTGTTGACAGT-GAGCGACTGTAAACTGAGCTTGCTCTACTGTGAA-50 GCC ACAGATGGGTAGAGCAAGCACAGTTTACCG-CTGCCTACTGCCTCGGACTTCAAGGGG CTT (SEQ ID NO: 1). In a preferred embodiment, the at least one genetic element comprises: AGGTATATTGCTGTTGACAGTGA-GCGACTGTAAACTGAGCTTGCTCTACTGTGAAGCC 55 ACAGATGGGTAGAGCAAGCACAGTTTACCGCTGC-CTACTGCCTCGGACTTCAAGGGG CTT (SEQ ID NO: 1).

In another aspect, the at least one genetic element includes a microRNA having at least 80%, at least 81%, at least 82%, 60 at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with CATCTCCATGGCTGTACCACC-TTGTCGGGGGATGTGTACTTCTGAACTTGTGTTG-65 AAT CTCATGGAGTTCAGAAGAACACATCCGCA-CTGACATTTTGGTATCTTTCATCTGACCA (SEQ ID

NO: 2); or at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with GGGCCTGGCTCGAGCAGGGGGGGGGGGGGGG GATTCCGCTTCTTCCTGCCATAGCGTGG TCCCC-TCCCCTATGGCAGGCAGAAGCGGCACCTTCCCTCC-CAATGACCGCGTCTTCGT CG (SEQ ID NO: 3). In a preferred embodiment, the at least one genetic element includes CATCTCCATGGCTGTACCACCTTGTCGGGG-GATGTGTACTTCTGAACTTGTGTTGAAT CTCATGG-AGTTCAGAAGAACACATCCGCACTGACATTTTGG-TATCTTTCATCTGACCA (SEQ ID NO: 2); or GGG-CCTGGCTCGAGCAGGGGGGGGGGGGGGGGGGATTCCGCTT-CTTCCTGCCATAGCGTGGTCCCCTCCCCTATGGCA-GGCAGAAGCGGCACCTTCCCTCCCAATGACCGC-GTCTTCGTCG (SEQ ID NO: 3).

In another aspect, the microRNA cluster includes a 20 sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% or more percent identity with AGGTATATTGCTGTTGACAGT-GAGCGACTGTAAACTGAGCTTGCTCTACTGTGAA-GCC ACAGATGGGTAGAGCAAGCACAGTTTACCGC-TGCCTACTGCCTCGGACTTCAAGGGG CTTCCCGG-GCATCTCCATGGCTGTACCACCTTGTCGGGGGGAT-GTGTACTTCTGAACTTGTGTTGAATCTCATGGAG-TTCAGAAGAACACATCCGCACTGACATTTTGGTA-TCTTTCATCTGACCAGCTAGCGGGCCTGGCTCGA-AGCGTGGTCCCCTCCCCTATGGCAGGCAGAAGC-GGCACCTTCCCTCCCAATGACCGCGTCTTCGTC-(SEQ ID NO: 31). In a preferred embodiment, the microRNA cluster includes: AGGTATATTGCTGTTG-ACAGTGAGCGACTGTAAACTGAGCTTGCTCTACT-GTGAAGCCACAGATGGGTAGAGCAAGCACAGTT-TACCGCTGCCTACTGCCTCGG ACTTCAAGGGG-CTTCCCGGGCATCTCCATGGCTGTACCACCTTTGT-CGGGGGATGTGTA CTTCTGAACTTGTGTTGAATCT-CATGGAGTTCAGAAGAACACATCCGCACTGACA-TTTTGGTATCTTTCATCTGACCAGCTAGCGGGCCT-GGCTCGAGCAGGGGGGGGGGGGGGGGGATTCCGCTTCTTC-CTGCCATAGCGTGGTCCCCTCCCCTATGGCAGGC-AGAAGCGGCACCTTC CCTCCCAATGACCGCGTCT-TCGTC (SEO ID NO: 31).

In another aspect, a lentiviral vector system for expressing a lentiviral particle is provided. The system includes a lentiviral vector as described herein; at least one envelope plasmid for expressing an envelope protein preferably optimized for infecting a cell; and at least one helper plasmid for expressing a gene of interest, for example any of gag, pol, and rev genes, wherein when the lentiviral vector, the at least one envelope plasmid, and the at least one helper plasmid are transfected into a packaging cell, wherein a lentiviral particle is produced by the packaging cell, wherein the lentiviral particle is capable of modulating a target sequence of interest, for example inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA sequence.

In another aspect, a lentiviral particle capable of infecting a cell is disclosed. The lentiviral particle includes at least one envelope protein preferably optimized for infecting a cell, and a lentiviral vector as described herein. The envelope protein may be optimized for infecting a T cell. In a preferred embodiment, the envelope protein is optimized for infecting a CD4+ T cell.

In another aspect, a modified cell is disclosed. In embodiments, the modified cell is a CD4+ T cell. In embodiments, the CD4+ T cell is infected with a lentiviral particle as described herein. In embodiments, the CD4+ T cell also has been selected to recognize an HIV antigen based on the prior 5 immunization with a stimulatory agent. In a further preferred embodiment, the HIV antigen that is recognized by the CD4+ T cell includes a gag antigen. In a further preferred embodiment, the CD4+ T cell expresses a decreased level of CCR5 following infection with the lentiviral particle.

In another aspect, a method of selecting a subject for a therapeutic treatment regimen is disclosed. The method generally includes immunizing the subject with an effective amount of a first stimulatory agent; removing leukocytes from the subject and purifying peripheral blood mononu- 15 clear cells (PBMC) and determining a first quantifiable measurement associated with at least one factor associated with the PBMC; contacting the PBMC ex vivo with a therapeutically effective amount of a second stimulatory agent, and determining a second measurement associated 20 with the at least one factor associated with the PBMC, whereby when the second quantifiable measurement is different (e.g., higher) than the first quantifiable measurement, the subject is selected for the treatment regimen. The at least one factor may be T cell proliferation or IFN gamma 25 production.

Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus, which is also commonly referred to as "HIV", is a retrovirus that causes acquired immunodeficiency syndrome (AIDS) in humans. 30 AIDS is a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending upon the HIV subtype. Infection with 35 HIV occurs by the transfer of bodily fluids, including but not limited to blood, semen, vaginal fluid, pre-ejaculate, saliva, tears, lymph or cerebro-spinal fluid, or breast milk. HIV may be present in an infected individual as both free virus particles and within infected immune cells.

HIV infects vital cells in the human immune system such as helper T cells, although tropism can vary among HIV subtypes. Immune cells that may be specifically susceptible to HIV infection include but are not limited to CD4+ T cells, macrophages, and dendritic cells. HIV infection leads to low 45 levels of CD4+ T cells through a number of mechanisms, including but not limited to apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell 50 numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections and cancer.

Structurally, HIV is distinct from many other retroviruses. The RNA genome consists of at least seven structural 55 landmarks (LTR, TAR, RRE, PE, SLIP, CRS, and INS), and at least nine genes (gag, pol, env, tat, rev, nef, vif, vpr, vpu, and sometimes a tenth tev, which is a fusion of tat, env and rev), encoding 19 proteins. Three of these genes, gag, pol, and env, contain information needed to make the structural 60 proteins for new virus particles.

HIV replicates primarily in CD4 T cells, and causes cellular destruction or dysregulation to reduce host immunity. Because HIV establishes infection as an integrated provirus and may enter a state of latency wherein virus 65 expression in a particular cell decreases below the level for cytopathology affecting that cell or detection by the host

immune system, HIV is difficult to treat and has not been eradicated even after prolonged intervals of highly active antiretroviral therapy (HAART). In the vast majority of cases, HIV infection causes fatal disease although survival may be prolonged by HAART.

A major goal in the fight against HIV is to develop strategies for curing disease. Prolonged HAART has not accomplished this goal, so investigators have turned to alternative procedures. Early efforts to improve host immunity by therapeutic immunization (using a vaccine after infection has occurred) had marginal or no impact. Likewise, treatment intensification had moderate or no impact.

Some progress has been made using genetic therapy, but positive results are sporadic and found only among rare human beings carrying defects in one or both alleles of the gene encoding CCR5 (chemokine receptor), which plays a critical role in viral penetration of host cells. However, many investigators are optimistic that genetic therapy holds the best promise for eventually achieving an HIV cure.

As disclosed herein, the methods and compositions of the invention are able to achieve a functional cure that may or may not include complete eradication of all HIV from the body. As mentioned above, a functional cure is defined as a state or condition wherein HIV+individuals who previously required HAART, may survive with low or undetectable virus replication and using lower or intermittent doses of HAART, or are potentially able to discontinue HAART altogether. As used herein, a functional cure may still possibly require adjunct therapy to maintain low level virus replication and slow or eliminate disease progression. A possible outcome of a functional cure is the eventual eradication of HIV to prevent all possibility of recurrence.

The primary obstacles to achieving a functional cure lie in the basic biology of HIV itself. Virus infection deletes CD4 T cells that are critical for nearly all immune functions. Most importantly, HIV infection and depletion of CD4 T cells requires activation of individual cells. Activation is a specific mechanism for individual CD4 T cell clones that 40 recognize pathogens or other molecules, using a rearranged T cell receptor.

In the case of HIV, infection activates a population of HIV-specific T cells that become infected and are consequently depleted before other T cells that are less specific for the virus, which effectively cripples the immune system's defense against the virus. The capacity for HIV-specific T cell responses is rebuilt during prolonged HAART; however, when HAART is interrupted the rebounding virus infection repeats the process and again deletes the virus-specific cells, resetting the clock on disease progression.

Clearly, a functional cure is only possible if enough HIV-specific CD4 T cells are protected to allow for a host's native immunity to confront and control HIV once HAART is interrupted. In one embodiment, the present invention provides methods and compositions for improving the effectiveness of genetic therapy to provide a functional cure of HIV disease. In another embodiment, the present invention provides methods and compositions for enhancing host immunity against HIV to provide a functional cure. In yet another embodiment, the present invention provides methods and compositions for enriching HIV-specific CD4 T cells in a patient to achieve a functional cure.

In one embodiment of the invention, treatment results in enriching a subject's HIV-specific CD4 T cells by about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, about 700%, about 800%, about 900%, or about 1000%.

Gene Therapy Viral vectors are used to deliver genetic constructs to host cells for the purposes of disease therapy or prevention.

Genetic constructs can include, but are not limited to, functional genes or portions of genes to correct or comple- 5 ment existing defects, DNA sequences encoding regulatory proteins, DNA sequences encoding regulatory RNA molecules including antisense, short homology RNA, long noncoding RNA, small interfering RNA or others, and decoy sequences encoding either RNA or proteins designed to 10 compete for critical cellular factors to alter a disease state. Gene therapy involves delivering these therapeutic genetic constructs to target cells to provide treatment or alleviation of a particular disease.

There are multiple ongoing efforts to utilize genetic 15 therapy in the treatment of HIV disease, but thus far, the results have been poor. A small number of treatment successes were obtained in rare HIV patients carrying a spontaneous deletion of the CCR5 gene (an allele known as CCR5delta32).

Lentivirus-delivered nucleases or other mechanisms for gene deletion/modification may be used to lower the overall expression of CCR5 and/or help to lower HIV replication. At least one study has reported having success in treating the disease when lentivirus was administered in patients with a 25 genetic background of CCR5delta32. However, this was only one example of success, and many other patients without the CCR5delta32 genotype have not been treated as successfully. Consequently, there is a substantial need to improve the performance of viral genetic therapy against 30 HIV, both in terms of performance for the individual viral vector construct and for improved use of the vector through a strategy for achieving functional HIV cure.

For example, some existing therapies rely on zinc finger nucleases to delete a portion of CCR5 in an attempt to render 35 tein with protein sequences representing the predominant cells resistant to HIV infection. However, even after optimal treatment, only 30% of T cells had been modified by the nuclease at all, and of those that were modified, only 10% of the total CD4 T cell population had been modified in a way that would prevent HIV infection. In contrast, the disclosed 40 methods result in virtually every cell carrying a lentivirus transgene having a reduction in CCR5 expression below the level needed to allow HIV infection.

For the purposes of the disclosed methods, gene therapy can include, but is not limited to, affinity-enhanced T cell 45 receptors, chimeric antigen receptors on CD4 T cells (or alternatively on CD8 T cells), modification of signal transduction pathways to avoid cell death cause by viral proteins, increased expression of HIV restriction elements including TREX, SAMHD1, MxA or MxB proteins, APOBEC com- 50 plexes, TRIMS-alpha complexes, tetherin (BST2), and similar proteins identified as being capable of reducing HIV replication in mammalian cells.

Immunotherapy

Historically, vaccines have been a go-to weapon against 55 deadly infectious diseases, including smallpox, polio, measles, and yellow fever. Unfortunately, there is no currently approved vaccine for HIV. The HIV virus has unique ways of evading the immune system, and the human body seems incapable of mounting an effective immune response 60 against it. As a result, scientists do not have a clear picture of what is needed to provide protection against HIV.

However, immunotherapy may provide a solution that was previously unaddressed by conventional vaccine approaches. Immunotherapy, also called biologic therapy, is 65 a type of treatment designed to boost the body's natural defenses to fight infections or cancer. It uses materials either

made by the body or in a laboratory to improve, target, or restore immune system function.

In some embodiments of the disclosed invention, immunotherapeutic approaches may be used to enrich a population of HIV-specific CD4 T cells for the purpose of increasing the host's anti-HIV immunity. In some embodiments of the disclosed invention, integrating or non-integrating lentivirus vectors may be used to transduce a host's immune cells for the purposes of increasing the host's anti-HIV immunity. In yet another embodiment of the invention, a vaccine comprising HIV proteins including but not limited to a killed particle, a virus-like particle, HIV peptides or peptide fragments, a recombinant viral vector, a recombinant bacterial vector, a purified subunit or plasmid DNA combined with a suitable vehicle and/or biological or chemical adjuvants to increase a host's immune responses may be used to enrich the population of virus-specific T cells or antibodies, and these methods may be further enhanced through the use of HIV-targeted genetic therapy using len-20 tivirus or other viral vector.

Methods

In one aspect, the disclosure provides methods for using viral vectors to achieve a functional cure for HIV disease. The methods generally include immunotherapy to enrich the proportion of HIV-specific CD4 T cells, followed by lentivirus transduction to deliver inhibitors of HIV and CCR5 and CXCR4 as required.

In one embodiment, the methods include a first stimulation event to enrich a proportion of HIV-specific CD4 T cells. The first stimulation can include administration of one or more of any agent suitable for enriching a patient's HIV-specific CD4+ T cells including but not limited to a vaccine.

Therapeutic vaccines can include one or more HIV proviral types of the geographic region where treatment is occurring. Therapeutic vaccines will include purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, peptides or peptide fragments, viruslike particles (VLPs), biological or chemical adjuvants including cytokines and/or chemokines, vehicles, and methods for immunization. Vaccinations may be administered according to standard methods known in the art and HIV patients may continue antiretroviral therapy during the interval of immunization and subsequent ex vivo lymphocyte culture including lentivirus transduction.

In some embodiments, HIV+ patients are immunized with an HIV vaccine, increasing the frequency of HIV-specific CD4 T cells by about 2, about 25, about 250, about 500, about 750, about 1000, about 1250, or about 1500-fold (or any amount in between these values). The vaccine may be any clinically utilized or experimental HIV vaccine, including the disclosed lentiviral, other viral vectors or other bacterial vectors used as vaccine delivery systems. In another embodiment, the vectors encode virus-like particles (VLPs) to induce higher titers of neutralizing antibodies. In another embodiment, the vectors encode peptides or peptide fragments associated with HIV including but not limited to gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and tev, as well as LTR, TAR, RRE, PE, SLIP, CRS, and INS. Alternatively, the HIV vaccine used in the disclosed methods may comprise purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, peptides or peptide fragments, virus-like particles (VLPs), or biological or chemical adjuvants including cytokines and/or chemokines.

In one embodiment, the methods include ex vivo restimulation of CD4 T cells from persons or patients previ-

ously immunized by therapeutic vaccination, using purified proteins, inactivated viruses, virally vectored proteins, bacterially vectored proteins, biological or chemical adjuvants including cytokines and/or chemokines, vehicles, and methods for re-stimulation. Ex vivo re-stimulation may be performed using the same vaccine or immune stimulating compound used for in vivo immunization, or it may be performed using a different vaccine or immune stimulating compound than those used for in vivo immunization. Moreover, in some embodiments, the patient does not require prior therapeutic vaccination or re-stimulation of CD4 T cells if the individual has sufficiently high antigen-specific CD4 T cell responses to HIV proteins. In these embodiments, such a patient may only require administration of the 15 disclosed viral vectors to achieve a functional cure.

In embodiments, peripheral blood mononuclear cells (PBMCs) are obtained by leukapheresis and treated ex vivo to obtain about  $1 \times 10^{10}$  CD4 T cells of which about 0.1%, about 1%, about 5% or about 10% or about 30% are both 20 HIV-specific in terms of antigen responses, and HIV-resistant by virtue of carrying the therapeutic transgene delivered by the disclosed lentivirus vector. Alternatively, about  $1\times10^7$ , about  $1\times10^8$ , about  $1\times10^9$ , about  $1\times10^{10}$ , about  $1\times10^{11}$ , or about  $1\times10^{12}$  CD4 T cells may be isolated for 25 re-stimulation. Any suitable amount of CD4 T cells are isolated for ex vivo re-stimulation.

The isolated CD4 T cells can be cultured in appropriate medium throughout re-stimulation with HIV vaccine antigens, which may include antigens present in the prior 30 therapeutic vaccination. Antiretroviral therapeutic drugs including inhibitors of reverse transcriptase, protease or integrase may be added to prevent virus re-emergence during prolonged ex vivo culture. CD4 T cell re-stimulation is used to enrich the proportion of HIV-specific CD4 T cells 35 in culture. The same procedure may also be used for analytical objectives wherein smaller blood volumes with peripheral blood mononuclear cells obtained by purification, are used to identify HIV-specific T cells and measure the frequency of this sub-population.

The PBMC fraction may be enriched for HIV-specific CD4 T cells by contacting the cells with HIV proteins matching or complementary to the components of the vaccine previously used for in vivo immunization. Ex vivo re-stimulation can increase the relative frequency of HIV- 45 specific CD4 T cells by about 5, about 10, 25, about 50, about 75, about 100, about 125, about 150, about 175, or about 200-fold.

The methods additionally include combining in vivo therapeutic immunization and ex vivo re-stimulation of CD4 50 T cells with ex vivo lentiviral transduction and culturing.

Thus, in one embodiment, the re-stimulated PBMC fraction that has been enriched for HIV-specific CD4 T cells can be transduced with therapeutic anti-HIV lentivirus or other vectors and maintained in culture for a sufficient period of 55 time for such transduction, for example from about 1 to about 21 days, including up to about 35 days. Alternatively, the cells may be cultured for about 1-about 18 days, about 1-about 15 days, about 1-about 12 days, about 1-about 9 days, or about 3-about 7 days. Thus, the transduced cells 60 may be cultured for about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, 65 about 30, about 31, about 32, about 33, about 34, or about 35 days.

In further embodiments, once the transduced cells have been cultured for a sufficient period of time, transduced CD4 T cells are infused back into the original patient. Infusion can be performed using various devices and methods known in the art. In some embodiments, infusion may be accompanied by pre-treatment with cyclophosphamide or similar compounds to increase the efficiency of re-engraftment.

In some embodiments, a CCR5-targeted therapy may be added to a subject's antiretroviral therapy regimen, which was continued throughout the treatment process. Examples of CCR5-targeted therapies include but are not limited to Maraviroc (a CCR5 antagonist) or Rapamycin (immunosuppressive agent that lowers CCR5). In some embodiments, the antiretroviral therapy may be ceased and the subject can be tested for virus rebound. If no rebound occurs, adjuvant therapy can also be removed and the subject can be tested again for virus rebound.

In various embodiments, continued virus suppression with reduced or no antiretroviral therapy including cART or HAART, and reduced or no adjuvant therapy for about 26 weeks can be considered a functional cure for HIV. Other definitions of a functional cure are described herein.

The lentiviral and other vectors used in the disclosed methods may encode at least one, at least two, at least three, at least four, or at least five genes, or at least six genes, or at least seven genes, or at least eight genes, or at least nine genes, or at least ten genes, or at least eleven genes, or at least twelve genes of interest. Given the versatility and therapeutic potential of HIV-targeted gene therapy, a viral vector of the invention may encode genes or nucleic acid sequences that include but are not limited to (i) an antibody directed to an antigen associated with an infectious disease or a toxin produced by the infectious pathogen, (ii) cytokines including interleukins that are required for immune cell growth or function and may be therapeutic for immune dysregulation encountered in HIV and other chronic or acute human viral or bacterial pathogens, (iii) factors that suppress the growth of HIV in vivo including CD8 suppressor factors, (iv) mutations or deletions of chemokine receptor CCR5, 40 mutations or deletions of chemokine receptor CXCR4, or mutations or deletions of chemokine receptor CXCR5, (v) antisense DNA or RNA against specific receptors or peptides associated with HIV or host protein associated with HIV, (vi) small interfering RNA against specific receptors or peptides associated with HIV or host protein associated with HIV, or (vii) a variety of other therapeutically useful sequences that may be used to treat HIV or AIDS.

Additional examples of HIV-targeted gene therapy that can be used in the disclosed methods include, but are not limited to, affinity-enhanced T cell receptors, chimeric antigen receptors on CD4 T cells (or alternatively on CD8 T cells), modification of signal transduction pathways to avoid cell death cause by viral proteins, increased expression of HIV restriction elements including TREX, SAMHD1, MxA or MxB proteins, APOBEC complexes, TRIMS-alpha complexes, tetherin (BST2), and similar proteins identified as being capable of reducing HIV replication in mammalian cells.

In some embodiments, a patient may be undergoing cART or HAART concurrently while being treated according to the methods of the invention. In other embodiments, a patient may undergo cART or HAART before or after being treated according to the methods of the invention. In some embodiments, cART or HAART is maintained throughout treatment according to the methods of the invention and the patient may be monitored for HIV viral burden in blood and frequency of lentivirus-transduced CD4 T cells in blood.

25

Preferably, a patient receiving cART or HAART prior to being treated according to the methods of the invention is able to discontinue or reduce cART or HAART following treatment according to the methods of the invention.

For efficacy purposes, the frequency of transduced, HIV-5 specific CD4 T cells, which is a novel surrogate marker for gene therapy effects, may be determined, as discussed in more detail herein.

Compositions

In various aspects, the disclosure provides lentiviral vectors capable of delivering genetic constructs to inhibit HIV penetration of susceptible cells. For instance, one mechanism of action in accordance herein is to reduce mRNA levels for CCR5 and/or CXCR4 chemokine receptors for 15 reducing the rates for viral entry into susceptible cells.

Alternatively, the disclosed lentiviral vectors are capable of inhibiting the formation of HIV-infected cells by reducing the stability of incoming HIV genomic RNA. And in yet another embodiment, the disclosed lentivirus vectors are 20 capable of preventing HIV production from a latently infected cell, wherein the mechanism of action is to cause instability of viral RNA sequences through the action of inhibitory RNA including short-homology, small-interfering or other regulatory RNA species.

The therapeutic lentiviruses disclosed generally comprise at least one of two types of genetic cargo. First, the lentiviruses may encode genetic elements that direct expression of small RNA capable of inhibiting the production of chemokine receptors CCR5 and/or CXCR4 that are impor- 30 tant for HIV penetration of susceptible cells. The second type of genetic cargo includes constructs capable of expressing small RNA molecules targeting HIV RNA sequences for the purpose of preventing reverse transcription, RNA splicing, RNA translation to produce proteins, or packaging of 35 viral genomic RNA for particle production and spreading infection. An exemplary structure is diagrammed in FIG. 3.

As shown in FIG. 3 (top panel), an exemplary construct may comprise numerous sections or components. For example, in one embodiment, an exemplary LV construct 40 may comprise the following sections or components:

RSV-a Rous Sarcoma virus long terminal repeat;

- 5'LTR-a portion of an HIV long terminal repeat that can be truncated to prevent replication of the vector after chromosomal integration; 45
- Psi-a packaging signal that allows for incorporation of the vector RNA genome into viral particles during packaging;
- RRE-a Rev Responsive element can be added to improve expression from the transgene by mobilizing 50 RNA out of the nucleus and into the cytoplasm of cells;
- cPPT—a Poly purine tract that facilitates second strand DNA synthesis prior to integration of the transgene into the host cell chromosome;
- Promoter-a promoter initiates RNA transcription from 55 the integrated transgene to express micro-RNA clusters (or other genetic elements of the construct), and in some embodiments, the vectors may use an EF-1 promoter;
- Anti-CCR5-a micro RNA targeting messenger RNA for 60 the host cell factor CCR5 to reduce its expression on the cell surface;
- Anti-Rev/Tat-a micro RNA targeting HIV genomic or messenger RNA at the junction between HIV Rev and Tat coding regions, which is sometimes designated 65 miRNA Tat or given a similar description in this application;

Anti-Vif-a micro RNA targeting HIV genomic or messenger RNA within the Vif coding region;

- WPRE-a woodchuck hepatitis virus post-transcriptional regulatory element is an additional vector component that can be used to facilitate RNA transport of the nucleus; and
- deltaU3 3'LTR-a modified version of a HIV 3' long terminal repeat where a portion of the U3 region has been deleted to improve safety of the vector.

One of ordinary skill in the art will recognize that the above components are merely examples, and that such components may be reorganized, substituted with other elements, or otherwise changed, so long as the construct is able to prevent expression of HIV genes and decrease the spread of infection.

Vectors of the invention may include either or both of the types of genetic cargo discussed above (i.e., genetic elements that direct expression of a gene or small RNAs, such as siRNA, shRNA, or miRNA that can prevent translation or transcription), and the vectors of the invention may also encode additionally useful products for the purpose of treatment or diagnosis of HIV. For instance, in some embodiments, these vectors may also encode green fluorescent protein (GFP) for the purpose of tracking the vectors or antibiotic resistance genes for the purposes of selectively maintaining genetically-modified cells in vivo.

The combination of genetic elements incorporated into the disclosed vectors is not particularly limited. For example, a vector herein may encode a single small RNA, two small RNAs, three small RNA, four small RNAs, five small RNAs, six small RNAs, seven small RNAs, eight small RNAs, nine small RNAs, or ten small RNAs, or eleven small RNAs, or twelve small RNAs. Such vectors may additionally encode other genetic elements to function in concert with the small RNAs to prevent expression and infection of HIV.

Those of ordinary skill in the art will understand that the therapeutic lentivirus may substitute alternate sequences for the promoter region, targeting of regulatory RNA, and types of regulatory RNA. Further, the therapeutic lentivirus of the disclosure may comprise changes in the plasmids used for packaging the lentivirus particles; these changes are required to increase levels of production in vitro.

Lentiviral Vector System

A lentiviral virion (particle) in accordance with various aspects and embodiments herein is expressed by a vector system encoding the necessary viral proteins to produce a virion (viral particle). In various embodiments, one vector containing a nucleic acid sequence encoding the lentiviral pol proteins is provided for reverse transcription and integration, operably linked to a promoter. In another embodiment, the pol proteins are expressed by multiple vectors. In other embodiments, vectors containing a nucleic acid sequence encoding the lentiviral Gag proteins for forming a viral capsid, operably linked to a promoter, are provided. In embodiments, this gag nucleic acid sequence is on a separate vector than at least some of the pol nucleic acid sequence. In other embodiments, the gag nucleic acid is on a separate vector from all the pol nucleic acid sequences that encode pol proteins.

Numerous modifications can be made to the vectors herein, which are used to create the particles to further minimize the chance of obtaining wild type revertants. These include, but are not limited to deletions of the U3 region of the LTR, tat deletions and matrix (MA) deletions. In embodiments, the gag, pol and env vector(s) do not

contain nucleotides from the lentiviral genome that package lentiviral RNA, referred to as the lentiviral packaging sequence.

The vector(s) forming the particle preferably do not contain a nucleic acid sequence from the lentiviral genome <sup>5</sup> that expresses an envelope protein. Preferably, a separate vector that contains a nucleic acid sequence encoding an envelope protein operably linked to a promoter is used. This env vector also does not contain a lentiviral packaging sequence. In one embodiment the env nucleic acid sequence <sup>10</sup> encodes a lentiviral envelope protein.

In another embodiment the envelope protein is not from the lentivirus, but from a different virus. The resultant particle is referred to as a pseudotyped particle. By appropriate selection of envelopes one can "infect" virtually any cell. For example, one can use an env gene that encodes an envelope protein that targets an endocytic compartment such as that of the influenza virus, VSV-G, alpha viruses (Semliki forest virus, Sindbis virus), arenaviruses (lymphocytic cho- 20 riomeningitis virus), flaviviruses (tick-borne encephalitis virus, Dengue virus, hepatitis C virus, GB virus), rhabdoviruses (vesicular stomatitis virus, rabies virus), paramyxoviruses (mumps or measles) and orthomyxoviruses (influenza virus). Other envelopes that can preferably be used include 25 those from Moloney Leukemia Virus such as MLV-E, MLV-A and GALV. These latter envelopes are particularly preferred where the host cell is a primary cell. Other envelope proteins can be selected depending upon the desired host cell. For example, targeting specific receptors 30 such as a dopamine receptor can be used for brain delivery. Another target can be vascular endothelium. These cells can be targeted using a filovirus envelope. For example, the GP of Ebola, which by post-transcriptional modification become the GP, and GP2 glycoproteins. In another embodiment, one 35 can use different lentiviral capsids with a pseudotyped envelope (for example, FIV or SHIV [U.S. Pat. No. 5,654, 195]). A SHIV pseudotyped vector can readily be used in animal models such as monkeys.

Lentiviral vector systems as provided herein typically 40 include at least one helper plasmid comprising at least one of a gag, pol, or rev gene. Each of the gag, pol and rev genes may be provided on individual plasmids, or one or more genes may be provided together on the same plasmid. In one embodiment, the gag, pol, and rev genes are provided on the 45 same plasmid (e.g., FIGS. 4A-4B). In another embodiment, the gag and pol genes are provided on a first plasmid and the rev gene is provided on a second plasmid (e.g., FIGS. 5A-5B). Accordingly, both 3-vector and 4-vector systems can be used to produce a lentivirus as described herein. In 50 embodiments, the therapeutic vector, at least one envelope plasmid and at least one helper plasmid are transfected into a packaging cell, for example a packaging cell line. A non-limiting example of a packaging cell line is the 293T/17 HEK cell line. When the therapeutic vector, the envelope 55 plasmid, and at least one helper plasmid are transfected into the packaging cell line, a lentiviral particle is ultimately produced.

In another aspect, a lentiviral vector system for expressing a lentiviral particle is disclosed. The system includes a 60 lentiviral vector as described herein; an envelope plasmid for expressing an envelope protein optimized for infecting a cell; and at least one helper plasmid for expressing gag, pol, and rev genes, wherein when the lentiviral vector, the envelope plasmid, and the at least one helper plasmid are 65 transfected into a packaging cell line, a lentiviral particle is produced by the packaging cell line, wherein the lentiviral

particle is capable of inhibiting production of chemokine receptor CCR5 or targeting an HIV RNA sequence.

In another aspect, the lentiviral vector, which is also referred to herein as a therapeutic vector, includes the following elements: hybrid 5' long terminal repeat (RSV/5' LTR) (SEQ ID NOS: 34-35), Psi sequence (RNA packaging site) (SEQ ID NO: 36), RRE (Rev-response element) (SEQ ID NO: 37), cPPT (polypurine tract) (SEQ ID NO: 38), EF-la promoter (SEQ ID NO: 4), miR30CCR5 (SEQ ID NO: 1), miR21Vif (SEQ ID NO: 2), miR185Tat (SEQ ID NO: 3), Woodchuck Post-Transcriptional Regulatory Element (WPRE) (SEQ ID NOS: 32 or 80), and  $\Delta$ U3 3' LTR (SEQ ID NO: 39). In another aspect, sequence variation, by way of substitution, deletion, addition, or mutation can be used to modify the sequences references herein.

In another aspect, a helper plasmid includes the following elements: CAG promoter (SEQ ID NO: 41); HIV component gag (SEQ ID NO: 43); HIV component pol (SEQ ID NO: 44); HIV Int (SEQ ID NO: 45); HIV RRE (SEQ ID NO: 46); and HIV Rev (SEQ ID NO: 47). In another aspect, the helper plasmid may be modified to include a first helper plasmid for expressing the gag and pol genes, and a second and separate plasmid for expressing the rev gene. In another aspect, sequence variation, by way of substitution, deletion, addition, or mutation can be used to modify the sequences references herein.

In another aspect, an envelope plasmid includes the following elements: RNA polymerase II promoter (CMV) (SEQ ID NO: 60) and vesicular stomatitis virus G glycoprotein (VSV-G) (SEQ ID NO: 62). In another aspect, sequence variation, by way of substitution, deletion, addition, or mutation can be used to modify the sequences references herein.

In various aspects, the plasmids used for lentiviral packaging are modified by substitution, addition, subtraction or mutation of various elements without loss of vector function. For example, and without limitation, the following elements can replace similar elements in the plasmids that comprise the packaging system: Elongation Factor-1 (EF-1), phosphoglycerate kinase (PGK), and ubiquitin C (UbC) promoters can replace the CMV or CAG promoter. SV40 poly A and bGH poly A can replace the rabbit beta globin poly A. The HIV sequences in the helper plasmid can be constructed from different HIV strains or clades. The VSV-G glycoprotein can be substituted with membrane glycoproteins from feline endogenous virus (RD114), gibbon ape leukemia virus (GALV), Rabies (FUG), lymphocytic choriomeningitis virus (LCMV), influenza A fowl plague virus (FPV), Ross River alphavirus (RRV), murine leukemia virus 10A1 (MLV), or Ebola virus (EboV).

Various lentiviral packaging systems can be acquired commercially (e.g., Lenti-vpak packaging kit from OriGene Technologies, Inc., Rockville, Md.), and can also be designed as described herein. Moreover, it is within the skill of a person ordinarily skilled in the art to substitute or modify aspects of a lentiviral packaging system to improve any number of relevant factors, including the production efficiency of a lentiviral particle.

Bioassays

In various aspects, the present invention includes bioassays for determining the success of HIV treatment for achieving a functional cure. These assays provide a method for measuring the efficacy of the disclosed methods of immunization and treatment by measuring the frequency of transduced, HIV specific CD4 T cells in a patient. HIVspecific CD4 T cells are recognizable because, among others, they proliferate, change the composition of cell surface markers, induce signaling pathways including phosphorylation, and/or express specific marker proteins that may be cytokines, chemokines, caspases, phosphorylated signaling molecules or other cytoplasmic and/or nuclear components. Specific responding CD4 T cells are recognized for example, using labeled monoclonal antibodies or specific in situ amplification of mRNA sequences, that allow sorting of HIV-specific cells using flow cytometry sorting, magnetic bead separation or other recognized methods for antigen-specific CD4 T cell isolation. The isolated CD4 T 10 cells are tested to determine the frequency of cells carrying integrated therapeutic lentivirus. Single cell testing methods may also be used including microfluidic separation of individual cells that are coupled with mass spectrometry, PCR, ELISA or antibody staining to confirm responsiveness to 15 HIV and presence of integrated therapeutic lentivirus.

Thus, in various embodiments, following application of a treatment according to the invention (e.g., (a) immunization, (b) ex vivo leukocyte/lymphocyte culture; (c) re-stimulation with purified proteins, inactivated viruses, virally vectored 20 proteins, bacterially vectored proteins, biological or chemical adjuvants including cytokines and/or chemokines, vehicles; and (d) infusion of the enriched, transduced T cells), a patient may be subsequently assayed to determine the efficacy of the treatment. A threshold value of target T cells in the body may be established to measure a functional cure at a determined value, for example, at about  $1 \times 10^8$ HIV-specific CD4 T cells bearing genetic modification from therapeutic lentivirus. Alternatively, the threshold value may be about  $1 \times 10^5$ , about  $1 \times 10^6$ , about  $1 \times 10^7$ , about  $1 \times 10^8$ , 30 about  $1 \times 10^9$ , or about  $1 \times 10^{10}$  CD4 T cells in the body of the patient.

HIV-specific CD4 T cells bearing genetic modification from therapeutic lentivirus can be determined using any suitable method, such as but not limited to flow cytometry, 35 cell sorting, FACS analysis, DNA cloning, PCR, RT-PCR or Q-PCR, ELISA, FISH, western blotting, southern blotting, high throughput sequencing, RNA sequencing, oligonucleotide primer extension, or other methods known in the art.

While methods for defining antigen specific T cells with 40 genetic modifications are known in the art, utilizing such methods to combine identifying HIV-specific T cells with integrated or non-integrated gene therapy constructs as a standard measure for efficacy is a novel concept in the field of HIV treatment, as described variously herein. 45 Doses and Dosage Forms

The disclosed methods and compositions can be used for treating HIV+patients during various stages of their disease. Accordingly, dosing regimens may vary based upon the condition of the patient and the method of administration. 50

In various embodiments, HIV-specific vaccines for the initial in vivo immunization are administered to a subject in need in varying doses. In general, vaccines delivered by intramuscular injection include about 10 µg to about 300 µg, about 25  $\mu$ g to about 275  $\mu$ g, about 50  $\mu$ g to about 250  $\mu$ g, 55 about 75 µg to about 225, or about 100 µg to about 200 µg of HIV protein, either total virus protein prepared from inactivated virus particles, virus-like particles or purified virus protein from recombinant systems or purified from virus preparations. Recombinant viral or bacterial vectors 60 may be administered by any and all of the routes described. Intramuscular vaccines will include about 1 µg to about 100 μg, about 10 μg to about 90 μs, about 20 μg to about 80 μg, about 30 µg to about 70 µg, about 40 µg to about 60 µg, or about 50 µg of suitable adjuvant molecules and be sus- 65 pended in oil, saline, buffer or water in volumes of 0.1 to 5 ml per injection dose, and may be soluble or emulsion

preparations. Vaccines delivered orally, rectally, bucally, at genital mucosal or intranasally, including some virallyvectored or bacterially-vectored vaccines, fusion proteins, liposome formulations or similar preparations, may contain higher amounts of virus protein and adjuvant. Dermal, sub-dermal or subcutaneous vaccines utilize protein and adjuvant amounts more similar to oral, rectal or intranasaldelivered vaccines. Depending on responses to the initial immunization, vaccination may be repeated 1-5 times using the same or alternate routes for delivery. Intervals may be of 2-24 weeks between immunizations. Immune responses to vaccination are measured by testing HIV-specific antibodies in serum, plasma, vaginal secretions, rectal secretions, saliva or bronchoalveolar lavage fluids, using ELISA or similar methodology. Cellular immune responses are tested by in vitro stimulation with vaccine antigens followed by staining for intracellular cytokine accumulation followed by flow cytometry or similar methods including lymphoproliferation, expression of phosphorylated signaling proteins or changes in cell surface activation markers. Upper limits of dosing may be determined based on the individual patient and will depend on toxicity/safety profiles for each individual product or product lot.

Immunization may occur once, twice, three times, or 25 repeatedly. For instance, an agent for HIV immunization may be administered to a subject in need once a week, once every other week, once every three weeks, once a month, every other month, every three months, every six months, every nine months, once a year, every eighteen months, 30 every two years, every 36 months, or every three years.

Immunization will generally occur at least once before ex vivo expansion and enrichment of CD4 T cells, and immunization may occur once, twice, three times, or more after ex vivo leukocyte/lymphocyte culture/re-stimulation and infusion.

In one embodiment, HIV-vaccines for immunization are administered as a pharmaceutical composition. In one embodiment, the pharmaceutical composition comprising an HIV vaccines formulated in a wide variety of nasal, pulmo-40 nary, oral, topical, or parenteral dosage forms for clinical application. Each of the dosage forms can comprise various disintegrating agents, surfactants, fillers, thickeners, binders, diluents such as wetting agents or other pharmaceutically acceptable excipients. The pharmaceutical composition 45 comprising an HIV vaccine can also be formulated for injection.

HIV vaccine compositions for the purpose of immunization can be administered using any pharmaceutically acceptable method, such as intranasal, buccal, sublingual, oral, rectal, ocular, parenteral (intravenously, intradermally, intramuscularly, subcutaneously, intracisternally, intraperitoneally), pulmonary, intravaginal, locally administered, topically administered, topically administered after scarification, mucosally administered, via an aerosol, or via a buccal or nasal spray formulation.

Further, the HIV vaccine compositions can be formulated into any pharmaceutically acceptable dosage form, such as a solid dosage form, tablet, pill, lozenge, capsule, liquid dispersion, gel, aerosol, pulmonary aerosol, nasal aerosol, ointment, cream, semi-solid dosage form, and a suspension. Further, the composition may be a controlled release formulation, sustained release formulation, immediate release formulation, or any combination thereof. Further, the composition may be a transdermal delivery system.

In another embodiment, the pharmaceutical composition comprising an HIV vaccine is formulated in a solid dosage form for oral administration, and the solid dosage form can be powders, granules, capsules, tablets or pills. In yet another embodiment, the solid dosage form includes one or more excipients such as calcium carbonate, starch, sucrose, lactose, microcrystalline cellulose or gelatin. In addition, the solid dosage form can include, in addition to the excipients, a lubricant such as talc or magnesium stearate. In some embodiments, the oral dosage form is in immediate release or a modified release form. Modified release dosage forms include controlled or extended release, enteric release, and the like. The excipients used in the modified release dosage forms are commonly known to a person of ordinary skill in the art.

In a further embodiment, the pharmaceutical composition comprising a HIV vaccine is formulated as a sublingual or buccal dosage form. Such dosage forms comprise sublingual tablets or solution compositions that are administered under the tongue and buccal tablets that are placed between the cheek and gum.

In yet a further embodiment, the pharmaceutical compo-<sub>20</sub> sition comprising an HIV vaccine is formulated as a nasal dosage form. Such dosage forms of the present invention comprise solution, suspension, and gel compositions for nasal delivery.

In one embodiment, the pharmaceutical composition is 25 formulated in a liquid dosage form for oral administration, such as suspensions, emulsions or syrups. In other embodiments, the liquid dosage form can include, in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as humectants, sweeteners, 30 aromatics or preservatives. In particular embodiments, the composition comprising HIV vaccine or a pharmaceutically acceptable salt thereof is formulated to be suitable for administration to a pediatric patient.

In one embodiment, the pharmaceutical composition is 35 formulated in a dosage form for parenteral administration, such as sterile aqueous solutions, suspensions, emulsions, non-aqueous solutions or suppositories. In other embodiments, the non-aqueous solutions or suspensions includes propyleneglycol, polyethyleneglycol, vegetable oils such as 40 olive oil or injectable esters such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao oil, laurin oil or glycerinated gelatin can be used.

The dosage of the pharmaceutical composition can vary depending on the patient's weight, age, gender, administra- 45 tion time and mode, excretion rate, and the severity of disease.

For the purposes of re-stimulation, lymphocytes, PBMCs, and/or CD4 T cells are generally removed from a patient and isolated for re-stimulation and culturing. The isolated cells 50 may be contacted with the same HIV vaccine or activating agent used for immunization or a different HIV vaccine or activating agent. In one embodiment, the isolated cells are contacted with about 10 ng to 5  $\mu$ g of an HIV vaccine or activating agent per about 10<sup>6</sup> cells in culture (or any other 55 suitable amount). More specifically, the isolated cells may be contacted with about 50 ng, about 100 ng, about 200 ng, about 300 ng, about 400 ng, about 500 ng, about 600 ng, about 700 ng, about 200 ng, about 500 ng, about 3  $\mu$ g, about 2  $\mu$ g, about 2.5  $\mu$ g, or about 3  $\mu$ g, about 3.5  $\mu$ g, 60 about 4  $\mu$ g, about 4.5  $\mu$ g, or about 5  $\mu$ g of an HIV vaccine or activating agent per about 10<sup>6</sup> cells in culture.

Activating agents or vaccines are generally used once for each in vitro cell culture but may be repeated after intervals of about 15 to about 35 days. For example, a repeat dosing could occur at about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about

65

25, about 26, about 27, about 28, about 29, about 30, about 31, about 32, about 33, about 34, or about 35 days.

For transduction of the enriched, re-stimulated cells, the cells may be transduced with lentiviral vectors or with other known vector systems as disclosed, for example, in FIGS. **4A-4**C. The cells being transduced may be contacted with about 1-1,000 viral genomes (measured by RT-PCR assay of culture fluids containing lentivirus vector) per target cell in culture (or any other suitable amount). Lentivirus transduc-tion may be repeated 1-5 times using the same range of 1-1,000 Viral genomes per target cell in culture.

Cellular Enrichment

In various embodiments, cells such as T cells are obtained from an HIV infected patient and cultured. Culturing can occur in multiwell plates in a culture medium comprising conditioned media ("CM"). The levels of supernatant p24gag ("p24") and viral RNA levels may be assessed by standard means. Those patients whose CM-cultured cells have peak p24 supernatant levels of less than 1 ng/ml may be suitable patients for large-scale T-cell expansion in CM with or without the use of additional anti-viral agents. Additionally, different drugs or drug combinations of interest may be added to different wells and the impact on virus levels in the sample may be assessed by standard means. Those drug combinations providing adequate viral suppression are therapeutically useful combinations. It is within the capacity of a competent technician to determine what constitutes adequate viral suppression in relation to a particular subject. In order to test the effectiveness of drugs of interest in limiting viral expansion, additional factors such as anti-CD3 antibodies may be added to the culture to stimulate viral production. Unlike culture methods for HIV infected cell samples known in the art, CM allows the culture of T cells for periods of over two months, thereby providing an effective system in which to assay long term drug effective-

This approach allows the inhibition of gene expression driven by the HIV LTR promoter region in a cell population by the culture of cells in a medium comprising the CM. Culture in CM4 likely inhibits HIV LTR driven gene expression by altering one or more interactions between transcription mediating proteins and HIV gene expression regulatory elements. Transcription-mediating proteins of interest include host cell encoded proteins such as AP-1, NFkappaB, NF-AT, IRF, LEF-1 and Sp1, and the HIV encoded protein Tat. HIV gene expression regulatory elements of interest include binding sites for AP-1, NFkappaB, NF-AT, IRF, LEF-1 and Sp1, as well as the transacting responsive element ("TAR") which interacts with Tat.

In a preferred embodiment, the HIV infected cells are obtained from a subject with susceptible transcription mediating protein sequences and susceptible HIV regulatory element sequences. In a more preferred embodiment, the HIV infected cells are obtained from a subject having wild-type transcription-mediating protein sequences and wild-type HIV regulatory sequences.

Another method of enriching T Cells utilizes immunoaffinity-based selection. This method includes the simultaneous enrichment or selection of a first and second population of cells, such as a CD4+ and CD8+ cell population. Cells containing primary human T cells are contacted with a first immunoaffinity reagent that specifically binds to CD4 and a second immunoaffinity reagent that specifically binds to CD8 in an incubation composition, under conditions whereby the immunoaffinity reagents specifically bind to CD4 and CD8 molecules, respectively, on the surface of cells in the sample. Cells bound to the first and/or the second immunoaffinity reagent are recovered, thereby generating an enriched composition comprising CD4+ cells and CD8+ cells. This approach may include incubation of the composition with a concentration of the first and/or second immunoaffinity reagent that is at a sub-optimal yield concentration. Notably, in some embodiments, transduced cells are a mixed T cell population, and in other embodiments transduced cells are not a mixed T cell population.

In some embodiments, immunoaffinity-based selection is used where the solid support is a sphere, such as a bead, such <sup>10</sup> as a microbead or nanobead. In other embodiments, the bead can be a magnetic bead. In another embodiment, the antibody contains one or more binding partners capable of forming a reversible bond with a binding reagent immobilized on the solid surface, such as a sphere or chromatography matrix, wherein the antibody is reversibly mobilized to the solid surface. In some embodiments, cells expressing a cell surface marker bound by the antibody on said solid surface are capable of being recovered from the matrix by disruption of the reversible binding between the binding <sup>20</sup> reagent and binding partner. In some embodiments, the binding reagent is streptavidin or is a streptavidin analog or mutant.

Stable transduction of primary cells of the hematopoietic system and/or hematopoietic stem cells may be obtained by 25 contacting, in vitro or ex vivo, the surface of the cells with both a lentiviral vector and at least one molecule which binds the cell surface. The cells may be cultured in a ventilated vessel comprising two or more layers under conditions conducive to growth and/or proliferation. In <sup>30</sup> some embodiments, this approach may be used in conjunction with non-CD4+ T cell depletion and/or broad polyclonal expansion.

In another approach to T cell enrichment, PBMCs are stimulated with a peptide and enriched for cells secreting a 35 cytokine, such as interferon-gamma. This approach generally involves stimulating a mixture of cells containing T cells with antigen, and effecting a separation of antigenstimulated cells according to the degree to which they are labeled with the product. Antigen stimulation is achieved by 40 exposing the cells to at least one antigen under conditions effective to elicit antigen-specific stimulation of at least one T cell. Labeling with the product is achieved by modifying the surface of the cells to contain at least one capture moiety, culturing the cells under conditions in which the product is 45 secreted, released and specifically bound ("captured" or "entrapped") to said capture moiety; and labeling the captured product with a label moiety, where the labeled cells are not lysed as part of the labeling procedure or as part of the separation procedure. The capture moiety may incorporate 50 detection of cell surface glycoproteins CD3 or CD4 to refine the enrichment step and increase the proportion of antigenspecific T cells in general, of CD4+ T cells in specific.

The following examples are given to illustrate aspects of the present invention. It should be understood, however, that <sup>55</sup> the invention is not to be limited to the specific conditions or details described in these examples. All printed publications referenced herein are specifically incorporated by reference.

### EXAMPLES

# Example 1: Development of a Lentiviral Vector System

A lentiviral vector system was developed as summarized in FIG. 3 (linear form) and FIGS. 4A-C (circularized form). Referring first to the top portion of FIG. **3**, a representative therapeutic vector has been designed and produced with the following elements being from left to right: hybrid 5' long terminal repeat (RSV/5' LTR) (SEQ ID NOS: 34-35), Psi sequence (RNA packaging site) (SEQ ID NO: 36), RRE (Rev-response element) (SEQ ID NO: 37), cPPT (polypurine tract) (SEQ ID NO: 38), EF-la promoter (SEQ ID NO: 4), miR30CCR5 (SEQ ID NO: 1), miR21Vif (SEQ ID NO: 2), miR185Tat (SEQ ID NO: 3), Woodchuck Post-Transcriptional Regulatory Element (WPRE) (SEQ ID NOS: 32 or 80), and  $\Delta$ U3 3' LTR (SEQ ID NO: 39). The therapeutic vector detailed in FIG. **3** is also referred to herein as AGT103.

Referring next to the middle portion of FIG. **3**, a helper plasmid has been designed and produced with the following elements being from left to right: CAG promoter (SEQ ID NO: 41); HIV component gag (SEQ ID NO: 43); HIV component pol (SEQ ID NO: 44); HIV Int (SEQ ID NO: 45); HIV RRE (SEQ ID NO: 46); and HIV Rev (SEQ ID NO: 47).

Referring next to the lower portion of FIG. **3**, an envelope plasmid has been designed and produced with the following elements being from left to right: RNA polymerase II promoter (CMV) (SEQ ID NO: 60) and vesicular stomatitis virus G glycoprotein (VSV-G) (SEQ ID NO: 62).

Lentiviral particles were produced in 293T/17 HEK cells (purchased from American Type Culture Collection, Manassas, Va.) following transfection with the therapeutic vector, the envelope plasmid, and the helper plasmid (as shown in FIG. 3). The transfection of 293T/17 HEK cells, which produced functional viral particles, employed the reagent Poly(ethylenimine) (PEI) to increase the efficiency of plasmid DNA uptake. The plasmids and DNA were initially added separately in culture medium without serum in a ratio of 3:1 (mass ratio of PEI to DNA). After 2-3 days, cell medium was collected and lentiviral particles were purified by high-speed centrifugation and/or filtration followed by anion-exchange chromatography. The concentration of lentiviral particles can be expressed in terms of transducing units/ml (TU/ml). The determination of TU was accomplished by measuring HIV p24 levels in culture fluids (p24 protein is incorporated into lentiviral particles), measuring the number of viral DNA copies per cell by quantitative PCR, or by infecting cells and using light (if the vectors encode luciferase or fluorescent protein markers).

As mentioned above, a 3-vector system (i.e., a 2-vector lentiviral packaging system) was designed for the production of lentiviral particles. A schematic of the 3-vector system is shown in FIGS. **4A-4C**. The schematic of FIGS. **4A-4C** is a circularized version of the linear system previously described in FIG. **3**. Briefly, and with reference to FIGS. **4A-4C**, FIG. **4A** depicts a helper plasmid, which, in this case, includes Rev. The vector appearing in FIG. **4B** is the envelope plasmid. The vector appearing in FIG. **4C** is the previously described therapeutic vector.

Referring more specifically to FIG. 4A, the Helper plus Rev plasmid includes a CAG enhancer (SEQ ID NO: 40); a CAG promoter (SEQ ID NO: 41); a chicken beta actin intron
(SEQ ID NO: 42); a HIV gag (SEQ ID NO: 43); a HIV Pol (SEQ ID NO: 44); a HIV Int (SEQ ID NO: 45); a HIV RRE (SEQ ID NO: 46); a HIV Rev (SEQ ID NO: 47); and a rabbit beta globin poly A (SEQ ID NO: 48).

The Envelope plasmid of FIG. 4B includes a CMV promoter (SEQ ID NO: 60); a beta globin intron (SEQ ID NO: 61); a VSV-G (SEQ ID NO: 62); and a rabbit beta globin poly A (SEQ ID NO: 63).

65

Synthesis of a 2-Vector Lentiviral Packaging System Including Helper (Plus Rev) and Envelope Plasmids.

Materials and Methods:

Construction of the helper plasmid: The helper plasmid was constructed by initial PCR amplification of a DNA 5 fragment from the pNL4-3 HIV plasmid (NIH Aids Reagent Program) containing Gag, Pol, and Integrase genes. Primers were designed to amplify the fragment with EcoRI and NotI restriction sites which could be used to insert at the same sites in the pCDNA3 plasmid (Invitrogen). The forward 10 primer was (5'-TAAGCAGAATTC ATGAATTTGCCAG-GAAGAT-3') (SEQ ID NO: 81) and reverse primer was (5% CCATACAAT-

GAATGGACACTAGGCGGCCGCACGAAT-3') (SEQ ID NO: 82). The sequence for the Gag, Pol, Integrase fragment 15 was as follows:

(SEQ ID NO: 83) GAATTCATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGGAAT TGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCT GCGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAAC ATAATTGGAAGAAATCTGTTGACTCAGATTGGCTGCACTTTAAATTTTCC CATTAGTCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATG GCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTA GTAGAAATTTGTACAGAAATGGAAAAGGAAGGAAAAATTTCAAAAATTGG GCCTGAAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGACA GTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACT CAAGATTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAAA ACAGAAAAAATCAGTAACAGTACTGGATGTGGGCGATGCATATTTTTCAG TTCCCTTAGATAAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGT ATAAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACA GGGATGGAAAGGATCACCAGCAATATTCCAGTGTAGCATGACAAAAATCT TAGAGCCTTTTAGAAAAACAAAATCCAGACATAGTCATCTATCAATACATG GATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAA AATAGAGGAACTGAGACAACATCTGTTGAGGTGGGGATTTACCACACCAG ACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACTC CATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAGGACAG  ${\tt CTGGACTGTCAATGACATACAGAAATTAGTGGGAAAATTGAATTGGGCAA}$ GTCAGATTTATGCAGGGATTAAAGTAAGGCAATTATGTAAACTTCTTAGG GGAACCAAAGCACTAACAGAAGTAGTACCACTAACAGAAGAAGCAGAGCT AGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCGGTACATGGAGTGT ATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAA GGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAAC AGGAAAGTATGCAAGAATGAAGGGTGCCCACACTAATGATGTGAAACAAT TAACAGAGGCAGTACAAAAAATAGCCACAGAAAGCATAGTAATATGGGGA AAGACTCCTAAATTTAAATTACCCATACAAAAGGAAACATGGGAAGCATG GTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTCA 

#### -continued

ATAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCCAATAGGGAAACTAA ATTAGGAAAAGCAGGATATGTAACTGACAGAGGAAGACAAAAAGTTGTCC CCCTAACGGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCATCTA GCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTGACAGACTCACAATA TGCATTGGGAATCATTCAAGCACAACCAGATAAGAGTGAATCAGAGTTAG TCAGTCAAATAATAGAGCAGTTAATAAAAAAGGAAAAAGTCTACCTGGCA TGGGTACCAGCACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATT GGTCAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAGATAAGG CCCAAGAAGAACATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAGT GATTTTAACCTACCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGA TAAATGTCAGCTAAAAGGGGAAGCCATGCATGGACAAGTAGACTGTAGCC 20 CAGGAATATGGCAGCTAGATTGTACACATTTAGAAGGAAAAGTTATCTTG GTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTAATTCCAGC AGAGACAGGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCAGGAAGAT 25 ggccagtaaaaacagtacatacagacaatggcagcaatttcaccagtact ACAGTTAAGGCCGCCTGTTGGTGGGCGGGGGATCAAGCAGGAATTTGGCAT TCCCTACAATCCCCAAAGTCAAGGAGTAATAGAATCTATGAATAAAGAAT 30 TAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACA GCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGGAT TGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACA TACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTCGG 35 GTTTATTACAGGGACAGCAGAGATCCAGTTTGGAAAGGACCAGCAAAGCT CCTCTGGAAAGGTGAAGGGGGCAGTAGTAATACAAGATAATAGTGACATAA AAGTAGTGCCAAGAAGAAAAGCAAAGATCATCAGGGATTATGGAAAACAG 40 ATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAA

Next, a DNA fragment containing the Rev, RRE, and rabbit beta globin poly A sequence with XbaI and XmaI 45 flanking restriction sites was synthesized by MWG Operon. The DNA fragment was then inserted into the plasmid at the XbaI and XmaI restriction sites The DNA sequence was as follows:

#### -continued

AGCATCTGTTGCAACTCACAGTCTGGGGGCATCAAGCAGCTCCAGGCAAGA ATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTAGATCTTT TCCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGA CTTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAAT TTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAA ACATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCATATGCT GGCTGCCATGAACAAAGGTGGCTATAAAGAGGTCATCAGTATATGAAACA GCCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTT AAATTTTCCTTACATGTTTTACTAGCCAGATTTTTCCTCCTCCTGACT AGCCCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTG TTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTA AAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGC TCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCGGATCCGCAT CTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCC CCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTT TTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAG AAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTAAC TTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAA TTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCA AACTCATCAATGTATCTTATCAGCGGCCGCCCCGGG

Finally, the CMV promoter of pCDNA3.1 was replaced with the CAG enhancer/promoter plus a chicken beta actin intron sequence. A DNA fragment containing the CAG 40 enhancer/promoter/intron sequence with MluI and EcoRI flanking restriction sites was synthesized by MWG Operon. The DNA fragment was then inserted into the plasmid at the MluI and EcoRI restriction sites. The DNA sequence was as follows:

(SEQ ID NO: 85) ACGCGTTAGTTATTAATAGTAATCAATTACGGGGGTCATTAGTTCATAGCC CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGC TGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCC CATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATT TACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGT ACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGC CCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTAT TAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCAC CGGCGGCAGCCAATCAGAGCGGCGCGCCCCCGAAAGTTTCCTTTTATGGCG

# 46

#### -continued

5 GACGGCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCT CGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTAAAGGGCTCCGGGAGGGCC 10 GGGGAGCGCCGCGTGCGGCCCGCGCTGCCGGCGGCTGTGAGCGCTGCGG GCGCGGCGCGGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGG CGGGGGCGGTGCCCCGCGGTGCGGGGGGGGCTGCGAGGGGAACAAAGGCTG TCGGGCTGTAACCCCCCCTGCACCCCCCCCCCGAGTTGCTGAGCACGG 20 CCCGGCTTCGGGTGCGGGGGCTCCGTGCGGGGGCGTGGCGCGGGGCTCGCCG CCTCGGGCCGGGGAGGGCTCGGGGGGGGGGGCGCGCGCCCCGGAGCGCC 25 GGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATC GTGCGAGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGGCGGAGCCGAA 30 CGGCGCCGGCAGGAAGGAAATGGGCGGGGGGGGGCCTTCGTGCGTCGCCGC GCCGCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACG GCTGCCTTCGGGGGGGGGCGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTG 35 ACCGGCGGGAATTC

Construction of the VSV-G Envelope Plasmid:

The vesicular stomatitis Indiana virus glycoprotein (VSV-G) sequence was synthesized by MWG Operon with flanking EcoRI restriction sites. The DNA fragment was then inserted into the pCDNA3.1 plasmid (Invitrogen) at the EcoRI restriction site and the correct orientation was determined by sequencing using a CMV specific primer. The DNA sequence was as follows:

(SEO ID NO: 86) GAATTCATGAAGTGCCTTTTGTACTTAGCCTTTTTATTCATTGGGGTGAA TTGCAAGTTCACCATAGTTTTTCCACACAAAAAAAGGAAACTGGAAAA  $50 \ \ {\tt ATGTTCCTTCTAATTACCATTATTGCCCGTCAAGCTCAGATTTAAATTGG}$ CATAATGACTTAATAGGCACAGCCTTACAAGTCAAAATGCCCAAGAGTCA CAAGGCTATTCAAGCAGACGGTTGGATGTGTCATGCTTCCAAATGGGTCA CTACTTGTGATTTCCGCTGGTATGGACCGAAGTATATAACACATTCCATC 55 CGATCCTTCACTCCATCTGTAGAACAATGCAAGGAAAGCATTGAACAAAC GAAACAAGGAACTTGGCTGAATCCAGGCTTCCCTCCTCAAAGTTGTGGAT ATGCAACTGTGACGGATGCCGAAGCAGTGATTGTCCAGGTGACTCCTCAC 60 CATGTGCTGGTTGATGAATACACAGGAGAATGGGTTGATTCACAGTTCAT CAACGGAAAATGCAGCAATTACATATGCCCCACTGTCCATAACTCTACAA CCTGGCATTCTGACTATAAGGTCAAAGGGCTATGTGATTCTAACCTCATT 65 TCCATGGACATCACCTTCTTCTCAGAGGACGGAGAGCTATCATCCCTGGG

#### -continued

AAAGGAGGGCACAGGGTTCAGAAGTAACTACTTTGCTTATGAAACTGGAG GCAAGGCCTGCAAAATGCAATACTGCAAGCATTGGGGAGTCAGACTCCCA TCAGGTGTCTGGTTCGAGATGGCTGATAAGGATCTCTTTGCTGCAGCCAG ATTCCCTGAATGCCCAGAAGGGTCAAGTATCTCTGCTCCATCTCAGACCT CAGTGGATGTAAGTCTAATTCAGGACGTTGAGAGGATCTTGGATTATTCC CTCTGCCAAGAAACCTGGAGCAAAATCAGAGCGGGTCTTCCAATCTCTCC AGTGGATCTCAGCTATCTTGCTCCTAAAAACCCAGGAACCGGTCCTGCTT TCACCATAATCAATGGTACCCTAAAATACTTTGAGACCAGATACATCAGA GTCGATATTGCTGCTCCAATCCTCTCAAGAATGGTCGGAATGATCAGTGG AACTACCACAGAAAGGGAACTGTGGGATGACTGGGCACCATATGAAGACG TGGAAATTGGACCCAATGGAGTTCTGAGGACCAGTTCAGGATATAAGTTT CCTTTATACATGATTGGACATGGTATGTTGGACTCCGATCTTCATCTTAG CTCAAAGGCTCAGGTGTTCGAACATCCTCACATTCAAGACGCTGCTTCGC AACTTCCTGATGATGAGAGTTTATTTTTTTGGTGATACTGGGCTATCCAAA AATCCAATCGAGCTTGTAGAAGGTTGGTTCAGTAGTTGGAAAAGCTCTAT TGCCTCTTTTTTCTTTATCATAGGGTTAATCATTGGACTATTCTTGGTTC TCCGAGTTGGTATCCATCTTTGCATTAAATTAAAGCACACCAAGAAAAGA CAGATTTATACAGACATAGAGATGAGAATTC

A 4-vector system (i.e., a 3-vector lentiviral packaging system) has also been designed and produced using the methods and materials described herein. A schematic of the 4-vector system is shown in FIGS. 5A-5D. Briefly, and with 35 reference to FIG. 5, the vector of FIG. 5A is a helper plasmid, which, in this case, does not include Rev. The vector depicted in FIG. 5B is a separate Rev plasmid. The vector depicted in FIG. 5C is the envelope plasmid. The vector depicted in FIG. 5D is the previously described 40 therapeutic vector.

Referring, in part, to FIG. 5A, the Helper plasmid includes a CAG enhancer (SEQ ID NO: 49); a CAG promoter (SEQ ID NO: 50); a chicken beta actin intron (SEQ ID NO: 51); a HIV gag (SEQ ID NO: 52); a HIV Pol $^{-45}$ (SEQ ID NO: 53); a HIV Int (SEQ ID NO: 54); a HIV RRE (SEQ ID NO: 55); and a rabbit beta globin poly A (SEQ ID NO: 56).

The Rev plasmid depicted in FIG. 5B includes a RSV promoter (SEQ ID NO: 57); a HIV Rev (SEQ ID NO: 58); <sup>50</sup> and a rabbit beta globin poly A (SEQ ID NO: 59).

The Envelope plasmid depicted in FIG. 5C includes a CMV promoter (SEQ ID NO: 60); a beta globin intron (SEQ ID NO: 61); a VSV-G (SEQ ID NO: 62); and a rabbit beta 55 TGTTTAGGCGAAAAGCGGGGGCTTCGGTTGTACGCGGTTAGGAGTCCCCTC globin poly A (SEQ ID NO: 63).

Synthesis of a 3-Vector Lentiviral Packaging System Including Helper, Rev, and Envelope Plasmids.

Materials and Methods:

Construction of the Helper Plasmid without Rev:

The Helper plasmid without Rev was constructed by inserting a DNA fragment containing the RRE and rabbit beta globin poly A sequence. This sequence was synthesized by MWG Operon with flanking XbaI and XmaI restriction sites. The RRE/rabbit poly A beta globin sequence was then 65 inserted into the Helper plasmid at the XbaI and XmaI restriction sites. The DNA sequence is as follows:

**48** 

(SEQ ID NO: 87)

TCTAGAAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTA TGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCT GGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACA GCATCTGTTGCAACTCACAGTCTGGGGGCATCAAGCAGCTCCAGGCAAGAA TCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTAGATCTTTT 10 CCCTCTGCCAAAAATTATGGGGACATCATGAAGCCCCTTGAGCATCTGAC TTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATT TTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTAAAA CATCAGAATGAGTATTTGGTTTAGAGTTTGGCAACATATGCCATATGCTG GCTGCCATGAACAAAGGTGGCTATAAAGAGGTCATCAGTATATGAAACAG CCCCCTGCTGTCCATTCCTTATTCCATAGAAAAGCCTTGACTTGAGGTTA AATTTTTCCTTACATGTTTTACTAGCCAGATTTTTTCCTCCTCCTCCTGACTA CTCCCAGTCATAGCTGTCCCTCTTTCTCTTTATGAAGATCCCTCGACCTGCA 25 GCCCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGT TATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAA AGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCT 30 CACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCGGATCCGCATC TCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCC CTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTT TTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGA AGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTAACT TGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAAT TTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAA ACTCATCAATGTATCTTATCACCCGGG

Construction of the Rev Plasmid:

The RSV promoter and HIV Rev sequence was synthesized as a single DNA fragment by MWG Operon with flanking MfeI and XbaI restriction sites. The DNA fragment was then inserted into the pCDNA3.1 plasmid (Invitrogen) at the MfeI and XbaI restriction sites in which the CMV promoter is replaced with the RSV promoter. The DNA sequence was as follows:

(SEQ ID NO: 88) CAATTGCGATGTACGGGCCAGATATACGCGTATCTGAGGGGGACTAGGGTG AGGATATAGTAGTTTCGCTTTTGCATAGGGAGGGGGAAATGTAGTCTTAT GCAATACACTTGTAGTCTTGCAACATGGTAACGATGAGTTAGCAACATGC CTTACAAGGAGAGAAAAAGCACCGTGCATGCCGATTGGTGGAAGTAAGGT 60 GGTACGATCGTGCCTTATTAGGAAGGCAACAGACAGGTCTGACATGGATT GGACGAACCACTGAATTCCGCATTGCAGAGATAATTGTATTTAAGTGCCT AGCTCGATACAATAAACGCCATTTGACCATTCACCACATTGGTGTGCACC TCCAAGCTCGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCAT
-continued

CCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCC CTCGAAGCTAGCGATTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAG CGACGAAGAACTCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATCAAA GCAACCCACCTCCCAATCCCGAGGGGGACCCGACAGGCCCGAAGGAATAGA AGAAGAAGGTGGAGAGAGAGAGAGAGAGAGACAGATCCATTCGATTAGTGAACG GATCCTTAGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGC TACCACCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACT TCTGGGACGCAGGGGGGGGGGAAGCCCTCAAATATTGGTGGAATCTCCTAC

### AATATTGGAGTCAGGAGCTAAAGAATAGTCTAGA

The plasmids for the 2-vector and 3-vector packaging systems could be modified with similar elements and the intron sequences could potentially be removed without loss of vector function. For example, the following elements 20 could replace similar elements in the 2-vector and 3-vector packaging system:

Promoters: Elongation Factor-1 (EF-1) (SEQ ID NO: 64), phosphoglycerate kinase (PGK) (SEQ ID NO: 65), and 25 ubiquitin C (UbC) (SEQ ID NO: 66) can replace the CMV (SEQ ID NO: 60) or CAG promoter (SEQ ID NO: 100). These sequences can also be further varied by addition, substitution, deletion or mutation.

Poly A sequences: SV40 poly A (SEQ ID NO: 67) and  $_{30}$ bGH poly A (SEQ ID NO: 68) can replace the rabbit beta globin poly A (SEQ ID NO: 48). These sequences can also be further varied by addition, substitution, deletion or mutation.

HIV Gag, Pol, and Integrase sequences: The HIV 35 sequences in the Helper plasmid can be constructed from different HIV strains or clades. For example, HIV Gag (SEQ ID NO: 69); HIV Pol (SEQ ID NO: 70); and HIV Int (SEQ ID NO: 71) from the Bal strain can be interchanged with the gag, pol, and int sequences contained in the helper/helper 40 plus Rev plasmids as outlined herein. These sequences can also be further varied by addition, substitution, deletion or mutation.

Envelope: The VSV-G glycoprotein can be substituted with membrane glycoproteins from feline endogenous virus 45 (RD114) (SEQ ID NO: 72), gibbon ape leukemia virus (GALV) (SEO ID NO: 73), Rabies (FUG) (SEO ID NO: 74), lymphocytic choriomeningitis virus (LCMV) (SEQ ID NO: 75), influenza A fowl plague virus (FPV) (SEQ ID NO: 76), Ross River alphavirus (RRV) (SEQ ID NO: 77), murine 50 leukemia virus 10A1 (MLV) (SEQ ID NO: 78), or Ebola virus (EboV) (SEQ ID NO: 79). Sequences for these envelopes are identified in the sequence portion herein. Further, these sequences can also be further varied by addition, substitution, deletion or mutation.

In summary, the 3-vector versus 4-vector systems can be compared and contrasted, in part, as follows. The 3-vector lentiviral vector system contains: 1. Helper plasmid: HIV Gag, Pol, Integrase, and Rev/Tat; 2. Envelope plasmid: VSV-G/FUG envelope; and 3. Therapeutic vector: RSV 60 oligonucleotide sequences containing BamHI and EcoRI 5'LTR, Psi Packaging Signal, Gag fragment, RRE, Env fragment, cPPT, WPRE, and 3'delta LTR. The 4-vector lentiviral vector system contains: 1. Helper plasmid: HIV Gag, Pol, and Integrase; 2. Rev plasmid: Rev; 3. Envelope plasmid: VSV-G/FUG envelope; and 4. Therapeutic vector: 65 RSV 5'LTR, Psi Packaging Signal, Gag fragment, RRE, Env fragment, cPPT, WPRE, and 3'delta LTR. Sequences corre-

sponding with the above elements are identified in the sequence listings portion herein.

### Example 2: Development of an Anti-HIV Lentivirus Vector

The purpose of this example was to develop an anti-HIV lentivirus vector.

Inhibitory RNA Designs. The sequence of Homo sapiens 10 chemokine C-C motif receptor 5 (CCR5) (GC03P046377) mRNA was used to search for potential siRNA or shRNA candidates to knockdown CCR5 levels in human cells. Potential RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs 15 such as from the Broad Institute or the BLOCK-iT RNAi Designer from Thermo Scientific. Individual selected shRNA sequences were inserted into lentiviral vectors immediately 3' to a RNA polymerase III promoter such as H1, U6, or 7SK to regulate shRNA expression. These lentivirus-shRNA constructs were used to transduce cells and measure the change in specific mRNA levels. The shRNA most potent for reducing mRNA levels were embedded individually within a microRNA backbone to allow for expression by either the CMV or EF-1alpha RNA polymerase II promoters. The microRNA backbone was selected from mirbase.org. RNA sequences were also synthesized as synthetic siRNA oligonucleotides and introduced directly into cells without using a lentiviral vector.

The genomic sequence of Bal strain of human immunodeficiency virus type 1 (HIV-1 85US\_BaL, accession number AY713409) was used to search for potential siRNA or shRNA candidates to knockdown HIV replication levels in human cells. Based on sequence homology and experience, the search focused on regions of the Tat and Vif genes of HIV although an individual of skill in the art will understand that use of these regions is non-limiting and other potential targets might be selected. Importantly, highly conserved regions of gag or pol genes could not be targeted by shRNA because these same sequences were present in the packaging system complementation plasmids needed for vector manufacturing. As with the CCR5 (NM 000579.3, NM 001100168.1-specific) RNAs, potential HIV-specific RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Gene-E Software Suite hosted by the Broad Institute (broadinstitute.org/mai/public) or the BLOCK-iT RNAi Designer from Thermo Scientific (rnadesigner.thermofi sher.com/rnaiexpress/

setOption.do?designOption=shrna&pid=67126273607

06061801). Individual selected shRNA sequences were inserted into lentiviral vectors immediately 3' to a RNA polymerase III promoter such as H1, U6, or 7SK to regulate shRNA expression. These lentivirus-shRNA constructs were used to transduce cells and measure the change in specific 55 mRNA levels. The shRNA most potent for reducing mRNA levels were embedded individually within a microRNA backbone to allow for expression by either the CMV or EF-1alpha RNA polymerase II promoters

Vector Constructions. For CCR5, Tat or Vif shRNA, restriction sites were synthesized by Eurofins MWG Operon, LLC. Overlapping sense and antisense oligonucleotide sequences were mixed and annealed during cooling from 70 degrees Celsius to room temperature. The lentiviral vector was digested with the restriction enzymes BamHI and EcoRI for one hour at 37 degrees Celsius. The digested lentiviral vector was purified by agarose gel electrophoresis and extracted from the gel using a DNA gel extraction kit from Invitrogen. The DNA concentrations were determined and vector to oligo (3:1 ratio) were mixed, allowed to anneal, and ligated. The ligation reaction was performed with T4 DNA ligase for 30 minutes at room temperature. 2.5 5 microliters of the ligation mix were added to 25 microliters of STBL3 competent bacterial cells. Transformation was achieved after heat-shock at 42 degrees Celsius. Bacterial cells were spread on agar plates containing ampicillin and drug-resistant colonies (indicating the presence of ampicil-10 lin-resistance plasmids) were recovered, purified and expanded in LB broth. To check for insertion of the oligo sequences, plasmid DNA were extracted from harvested bacteria cultures with the Invitrogen DNA mini prep kit. Insertion of the shRNA sequence in the lentiviral vector was 15 verified by DNA sequencing using a specific primer for the promoter used to regulate shRNA expression. Exemplary vector sequences that were determined to restrict HIV replication can be found in FIG. 6. For example, the shRNA sequences with the highest activity against CCR5. Tat or Vif 20 gene expression were then assembled into a microRNA (miR) cluster under control of the EF-1alpha promoter. The promoter and miR sequences are depicted in FIG. 6.

Further, and using standard molecular biology techniques (e.g., Sambrook; Molecular Cloning: A Laboratory Manual, 25 4<sup>th</sup> Ed.) as well as the techniques described herein, a series of lentiviral vectors have been developed as depicted in FIG. 7 herein.

Vector 1 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a H1 30 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24-Y); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102). 35

Vector 2 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a H1 element (SEQ ID NO: 101); a shRev/Tat (SEQ ID NO: 10); a H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24); a posttranscriptional regulatory 40 element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 3 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a H1 45 element (SEQ ID NO: 101); a shGag (SEQ ID NO: 12); a H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102). 50

Vector 4 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a 7SK element (SEQ ID NO: 103); a shRev/Tat (SEQ ID NO: 10); a H1 element (SEQ ID NO: 101); a shCCR5 (SEQ ID NOS: 16, 18, 20, 22, or 24); a posttranscriptional regulatory 55 element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 5 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a 60 EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102). 65

Vector 6 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR155Tat (SEQ ID NO: 104); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 7 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 8 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a EF1 element (SEQ ID NO: 4); miR30CCR5 (SEQ ID NO: 1); MiR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); and a long terminal repeat portion (SEQ ID NO: 102).

Vector 9 was developed and contains, from left to right: a long terminal repeat (LTR) portion (SEQ ID NO: 35); a CD4 element (SEQ ID NO: 30); miR30CCR5 (SEQ ID NO: 1); miR21Vif (SEQ ID NO: 2); miR185Tat (SEQ ID NO: 3); a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) (SEQ ID NOS: 32, 80); and a long terminal repeat portion (SEQ ID NO: 102).

Development of Vectors

It should be noted that not all vectors developed for these experiments necessarily worked as might be predicted. More specifically, a lentivirus vector against HIV might include three main components: 1) inhibitory RNA to reduce the level of HIV binding proteins (receptors) on the target cell surface to block initial virus attachment and penetration; 2) overexpression of the HIV TAR sequence that will sequester viral Tat protein and decrease its ability to transactivate viral gene expression; and 3) inhibitory RNA that attack impor-35 tant and conserved sequences within the HIV genome.

With respect to the first point above, a key cell surface HIV binding protein is the chemokine receptor CCR5. HIV particles attach to susceptible T cells by binding to the CD4 and CCR5 cell surface proteins. Because CD4 is an essential glycoprotein on the cell surface that is important for the immunological function of T cells, this was not chosen as a target to manipulate its expression levels. However, people born homozygous for null mutations in the CCR5 gene and completely lacking receptor expression, live normal lives save for enhanced susceptibility to a few infectious diseases and the possibility of developing rare autoimmunity. Thus, modulating CCR5 was determined to be a relatively safe approach and was a primary target in the development of anti-HIV lentivirus vectors.

With respect to the second point above, the viral TAR sequence is a highly structured region of HIV genomic RNA that binds tightly to viral Tat protein. The Tat:TAR complex is important for efficient generation of viral RNA. Overexpression of the TAR region was envisioned as a decoy molecule that would sequester Tat protein and decrease the levels of viral RNA. However, TAR proved toxic to most mammalian cells including cells used for manufacturing lentivirus particles. Further, TAR was inefficient for inhibiting viral gene expression in other laboratories and has been discarded as a viable component in HIV gene therapy.

In various embodiments, viral gene sequences have been identified that meet 3 criteria: i) Sequences that are reasonably conserved across a range of HIV isolates representative of the epidemic in a geographic region of interest; ii) reduction in RNA levels due to the activity of an inhibitory RNA in a viral vector will reduce the corresponding protein levels by an amount sufficient to meaningfully reduce HIV

replication; and iii) the viral gene sequence(s) targeted by inhibitory RNA are not present in the genes required for packaging and assembling viral vector particles during manufacturing. In various embodiments, a sequence at the junction of HIV Tat and Rev genes and a second sequence within the HIV Vif gene have been targeted by inhibitory RNA. The Tat/Rev targeting has an additional benefit of reducing HIV envelope glycoprotein expression because this region overlaps with the envelope gene in the HIV <sup>10</sup> genome.

Various methods for vector development and testing relies first on identifying suitable targets (as described herein) followed by constructing plasmid DNAs expressing indi- 15 vidual or multiple inhibitory RNA species for testing in cell models, and finally constructing lentivirus vectors containing inhibitory RNA with proven anti-HIV function. The lentivirus vectors are tested for toxicity, yield during in vitro  $_{20}$ production, and effectiveness against HIV in terms of reducing CCR5 expression levels or lowering viral gene products to inhibit virus replication.

Table 2 below demonstrates progression through multiple  $_{25}$ versions of inhibitory constructs until arriving at a clinical candidate. Initially, shRNA (short homology RNA) molecules were designed and expressed from plasmid DNA constructs.

Plasmids 1-4, as detailed in Table 2 below, tested shRNA sequences against Gag, Pol and RT genes of HIV. While each shRNA was active for suppressing viral protein expression in a cell model, there were two important problems that prevented further development. First, the sequences were 35 targeted to a laboratory isolate of HIV that was not representative of Clade B HIV strains currently circulating in North America and Europe. Second, these shRNA targeted critical components in the lentivirus vector packaging system and would severely reduce vector yield during manu- 40 facturing. Plasmid 5, as detailed in Table 2, was selected to target CCR5 and provided a lead candidate sequence. Plasmids 6, 7, 8, 9, 10, and 11, as detailed in Table 2, incorporated the TAR sequence and it was found they produced unacceptable toxicity for mammalian cells including cells used for lentivirus vector manufacturing. Plasmid 2, as detailed in Table 2, identified a lead shRNA sequence capable of reducing Tat RNA expression. Plasmid 12, as detailed in Table 2, demonstrated the effectiveness of shCCR5 expressed as a microRNA (miR) in a lentiviral vector and confirmed it should be in the final product. Plasmid 13, as detailed in Table 2, demonstrated the effectiveness of a shVif expressed as a microRNA (miR) in a lentiviral vector and confirmed it should be in the final 55 product. Plasmid 14, as detailed in Table 2, demonstrated the effectiveness of shTat expressed as a microRNA (miR) in a lentiviral vector and confirmed it should be in the final product. Plasmid 15, as detailed in Table 2, contained the miR CCR5, miR Tat and miR Vif in the form of a miR 60 cluster expressed from a single promoter. These miR do not target critical components in the lentivirus vector packaging system and proved to have negligible toxicity for mammalian cells. The miR within the cluster were equally effective to individual miR that were tested previously, and the overall 65 impact was a substantial reduction in replication of a CCR5tropic HIV BaL strain.

54	
TADIE	2

_			IADLE 4	<u> </u>	
		De	velopment of HIV	V Vectors	
	Internal Code	Material	Description	Remarks	Decision
1	SIH-H1- shRT-1,3	Lentiviral vector	shRNA construct for RT of LAI strain	Wrong target, lab virus, no virus test	Abandon
2	SIH-H1- shRT43 (Tat/Rev NL4-3)	Lentiviral vector	H1 promoter shRNA Tat/Rev overlap	Tat protein knock- down >90%	Lead

Vector Construction: For Rev/Tat (RT) shRNA, oligonucleotide sequences containing BamHI and EcoRI restriction sites were synthesized by MWG Operon. Two different Rev/Tat target sequences were tested for their ability to decrease Tat mRNA expression. The RT1.3 target sequence is (5'-ATGGCAGGAAGAAGCGGAG-3') (SEO ID NO: 89) and shRNA sequence is (5'-ATGGCAGGAAGAAGCG-GAGTTCAAGAGACTCCGCTTCTTCCTGCCATTTT-TT-3') (SEQ ID NO: 90). The RT43 sequence is (5'-GCG-GAGACAGCGACGAAGAGC-3') (SEQ ID NO: 9) and shRNA sequence is (5'-GCGGAGACAGCGACGA-AGAGCTTCAAGAGAGCTCTTCGTCGCTGTCTCCG-CTTTTT-3') (SEQ ID NO: 10). Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences).

Functional test for shRNA against Rev/Tat: The ability of the vector to reduce Tat expression was tested using a luciferase reporter plasmid which contained the Rev/Tat target sequences inserted into the 3'-UTR (untranslated region of the mRNA). Either the shRT1,3 or shRT43 plasmid was co-transfected with the plasmid containing luciferase and the Rev/Tar target sequence. There was a 90% reduction in light emission indicating strong function of the shRT43 shRNA sequence but less than 10% with the shRT1,3 plasmid.

Conclusion: The SIH-H1-shRT43 was superior to SIH-H1-shRT-1,3 in terms of reducing mRNA levels in the Luciferase assay system. This indicates potent inhibitory activity of the shRT43 sequence and it was selected as a lead candidate for further development.

3 SIH-H1- Lentiviral shRNA In construct for ex LAI Gag inl	hibits Gag Abandon xpression but will hibit packaging
--	---

Vector Construction: For Gag shRNA, oligonucleotide sequences containing BamHI and EcoRI restriction sites were synthesized by MWG Operon. A Gag target sequence was tested for their ability to decrease Gag mRNA expression. The Gag target sequence is (5'-GAAGAAAT-GATGACAGCAT-3') (SEQ ID NO: 11) and shRNA sequence (5'-GAAGAAATGATGACAGCATTTis CAAGAGAATGCTGTCATCATTTCTTCTTTTT-3') (SEQ ID NO: 12). Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences).

Functional test for shRNA against Gag: The ability of the vector to reduce Gag expression was tested using a luciferase reporter plasmid which contained the Gag target sequences inserted into the 3'-UTR (untranslated region of the mRNA). The Gag plasmid was co-transfected with the plasmid containing luciferase and the Gag target sequence.

There was nearly a 90% reduction in light emission indicating a strong effect of the shGag shRNA sequence.

Conclusion: This shRNA sequence is potent against HIV Gag expression but was abandoned. The lentivirus packaging system requires production of Gag from the helper 5 plasmid and shRNA inhibition of Gag will reduce lentivirus vector vield. This shRNA sequence could be used as an oligonucleotide inhibitor of HIV or incorporated into an alternate viral vector packaging system that uses a different vector genome or is modified to resist inhibition by this shRNA.

4	SIH-H1- shPol-1	Lentiviral vector	shRNA construct for	Inhibits Pol expression but will	Abandon
			Pol	inhibit packaging	

Vector Construction: A Pol shRNA was constructed with oligonucleotide sequences containing BamHI and EcoRI restriction sites that were synthesized by MWG Operon. A Pol target sequence was tested for its ability to decrease Pol mRNA expression. The Pol target sequence is (5'-CAG-GAGCAGATGATACAG-3') (SEQ ID NO: 13) and shRNA (5'-CAGGAGATGATACAGTTCAAGAsequence is 25 GACTGTATCATCTGCTCCTGTTTTT-3') (SEQ ID NO: 14). Oligonucleotide sequences were inserted into the pSIH lentiviral vector (System Biosciences).

Functional tests for shRNA against HIV Pol: The ability of the vector to reduce Pol expression was tested using a  $_{30}$ luciferase reporter plasmid which contained the Pol target sequences inserted into the 3'-UTR (untranslated region of the mRNA). The Pol plasmid was co-transfected with the plasmid containing luciferase and the Pol target sequence. There was a 60% reduction in light emission indicating a 35 strong effect of the shPol shRNA sequence.

Conclusion: This shRNA sequence is potent against HIV Pol expression but was abandoned. The lentivirus packaging system requires production of Pol from the helper plasmid and shRNA inhibition of Pol will reduce lentivirus vector  $_{40}$ yield. This shRNA sequence could be used as an oligonucleotide inhibitor of HIV or incorporated into an alternate viral vector packaging system that uses a different vector genome or is modified to resist inhibition by this shRNA.

5	SIH-H1- shCCR5-1	Lentiviral vector	shRNA construct for CCR5	Best of 5 candidates, Extracellular CCR5 protein reduction >90%	Lead
---	---------------------	----------------------	--------------------------------	---	------

Vector Construction: A CCR5 shRNA was constructed with oligonucleotide sequences containing BamHI and EcoRI restriction sites that were synthesized by MWG Operon. Oligonucleotide sequences were inserted into the 55 pSIH lentiviral vector (System Biosciences). The CCR5 target sequence #1, which focuses on CCR5 gene sequence 1 (SEQ ID NO: 25), is (5'-GTGTCAAGTCCAATCTATG-3') (SEQ ID NO: 15) and the shRNA sequence is (5'-GTGTCAAGTCCAATCTATGTTCAAGAGACATAGAT-60 TGGACTTGACACTTTTT-3') (SEQ ID NO: 16). The CCR5 target sequence #2, which focuses on CCR5 gene sequence 2 (SEQ ID NO: 26), is (5'-GAGCATGACTGA-CATCTAC-3') (SEQ ID NO: 17) and the shRNA sequence is (5'-GAGCATGACTGACATCTACTTCAAGAGAGTA-65 GATGTCAGTCATGCTCTTTTT-3') (SEQ ID NO: 18). The CCR5 target sequence #3, which focuses on CCR5 gene

sequence 3 (SEQ ID NO: 27), is (5'-GTAGCTC TAACAGGTTGGA-3') (SEQ ID NO: 19) and the shRNA sequence is (5'-GTAGCTCTAACAGGTTGGATTCAAG AGATCCAACCTGTTAGAGCTACTTTTT-3') (SEQ ID NO: 20). The CCR5 target sequence #4, which focuses on CCR5 gene sequence 4 (SEQ ID NO: 28, is (5'-GTTCAGAAACTACCTCTTA-3') (SEQ ID NO: 21) and the shRNA sequence is (5'-GTTCAGAAACTACCTCTTAT-TCAAGAGATAAGAGGTAGTTTCTGAACTTTTT-3')

(SEQ ID NO: 22). The CCR5 target sequence #5, which focuses on CCR5 gene sequence 5 (SEQ ID NO: 29), is (5'-GAGCAAGCTCAGTTTACACC-3') (SEQ ID NO: 23) and the shRNA sequence is (5'-GAGCAAGCTCAGTTTA-CACCTTCAAGAGAGGTGTAAACTGAGCTTGC TCTT <sup>15</sup> TTT-3') (SEQ ID NO: 24).

Functional test for shRNA against CCR5: The ability of a CCR5 shRNA sequence to knock-down CCR5 RNA expression was initially tested by co-transfecting each of the lentiviral plasmids, in separate experiments for each plasmid, containing one of the five CCR5 target sequences with a plasmid expressing the human CCR5 gene. CCR5 mRNA expression was then assessed by qPCR analysis using CCR5-specific primers.

Conclusion: Based on the reduction in CCR5 mRNA levels the shRNACCR5-1 was most potent for reducing CCR5 gene expression. This shRNA was selected as a lead candidate.

6	SIH-U6- TAR	Lentiviral vector	U6 promoter- TAR	Toxic to cells	Abandon
7	SIH-U6- TAR-H1- shCCR5	Lentiviral vector	U6 promoter- TAR-H1- shCCR5	Toxic to cells	Abandon
8	U6-TAR- H1-shRT	Lentiviral vector	U6 promoter- TAR-H1-RT	Suppress HIV, toxic to cells, poor packaging	Abandon
9	U6-TAR- 7SK-shRT	Lentiviral vector	Change shRNA promoter to 7SK	Toxic, poor packaging	Abandon
10	U6-TAR- H1-shRT- H1-shCCR5	Lentiviral vector	U6 promoter- TAR-H1-RT- H1-shCCR5	Toxic, poor packaging, H1 repeats	Abandon
11	U6-TAR- 7SK-shRT- H1-CCR5	Lentiviral vector	Change shRNA promoter to 7SK	Toxic, poor packaging	Abandon
	6 7 8 9 10 11	<ul> <li>6 SIH-U6- TAR</li> <li>7 SIH-U6- TAR-H1- shCCR5</li> <li>8 U6-TAR- H1-shRT</li> <li>9 U6-TAR- 7SK-shRT</li> <li>10 U6-TAR- H1-shCCR5</li> <li>11 U6-TAR- 7SK-shRT- H1-CCR5</li> </ul>	<ul> <li>6 SIH-U6- Lentiviral TAR vector</li> <li>7 SIH-U6- Lentiviral TAR-H1- vector shCCR5</li> <li>8 U6-TAR- Lentiviral H1-shRT vector</li> <li>9 U6-TAR- Lentiviral 7SK-shRT Lentiviral H1-shCR5</li> <li>11 U6-TAR- Lentiviral 7SK-shRT vector H1-shCCR5</li> <li>12 U6-TAR- Lentiviral 7SK-shRT vector H1-shCCR5</li> </ul>	<ul> <li>6 SIH-U6- Lentiviral U6 promoter- TAR vector TAR</li> <li>7 SIH-U6- Lentiviral U6 promoter- TAR-H1- vector TAR-H1- shCCR5</li> <li>8 U6-TAR- Lentiviral U6 promoter- H1-shRT vector TAR-H1-RT</li> <li>9 U6-TAR- Lentiviral Vector VAR-H1-RT</li> <li>9 U6-TAR- Lentiviral U6 promoter- TAR-H1-RT</li> <li>9 U6-TAR- Lentiviral U6 promoter- TAR-H1-RT</li> <li>9 U6-TAR- Lentiviral U6 promoter- H1-shRT vector TAR-H1-RT- H1-shCR5 H1-shCCR5</li> <li>11 U6-TAR- Lentiviral Change shRNA 7SK-shRT vector promoter to H1-cCR5</li> </ul>	6     SIH-U6- TAR     Lentiviral     U6 promoter- TAR     Toxic to cells       7     SIH-U6- TAR-H1- shCCR5     Lentiviral     U6 promoter- TAR-H1- shCCR5     Toxic to cells       8     U6-TAR- H1-shRT     Lentiviral     U6 promoter- to cells, poor packaging     Suppress HIV, to cells, poor packaging       9     U6-TAR- TSK-shRT     Lentiviral     Change shRNA Vector     Toxic, poor packaging       10     U6-TAR- H1-shCR5     Lentiviral     U6 promoter- promoter to TAR-H1-RT     Toxic, poor       11     U6-TAR- H1-shCR5     Lentiviral     U6 promoter- packaging     Toxic, poor Toxic, poor TAR-H1-RT       11     U6-TAR- H1-shCR5     Lentiviral     Change shRNA Toxic, poor TSK-shRT     Toxic, poor packaging       11     U6-TAR- TAR-     Lentiviral     Change shRNA Toxic, poor TSK-shRT     Toxic, poor packaging       11     U6-TAR- TAR-     Lentiviral     Change shRNA Toxic, poor TSK-shRT     Toxic, poor       11     U6-TAR- TAR-     Lentiviral     Change shRNA Toxic, poor     Toxic, poor       11     U6-TAR- TAR-     Lentiviral     Change shRNA Toxic, poor     Toxic, poor       11     U6-TAR- TAR-     Lentiviral     Change shRNA Toxic, poor     Toxic, poor

Vector Construction: A TAR decoy sequence containing flanking KpnI restriction sites was synthesized by MWG operon and inserted into the pSIH lentiviral vector (System Biosciences) at the KpnI site. In this vector, TAR expression 50 is regulated by the U6 promoter. The TAR decoy sequence is (5'-CTTGCAATGATGTCGTAATTTGCGTCTTACCT C GTTCTCGACAGCGACCAGATCTGAGCCTGGGAGC T CTCTGGCTGTCAGTAAGCTGGTACAGAAGGTT G ACGAAAAATTCTT ACTGAGCAAGAAA-3') (SEQ ID NO: 8). Expression of the TAR decoy sequence was determined by qPCR analysis using specific primers for the TAR sequence. Additional vectors were constructed also containing the TAR sequence. The H1 promoter and shRT sequence was inserted in this vector in the XhoI site. The H1 shRT sequence is (5'-GAACGCTGACGTCATCAACCCGCTC-CAAGGAATCGCGGGCCCAGTGTCACTAGGCG GGA ACACCCAGCGCGCGTGCGCCCTGGCAGGAAGAT GGCTGTGAGGGACAGGGGA GTGGCGCCCTGCAAT-ATTTGCATGTCGCTATGTGTTCTGGGAAATCACCAT-AAACGT GAAATGTCTTTGGATTTGGGAATCTTATAA GTTCTGTATGAGACCACTTGGATCCGC GGAGAC AG CGACGAAGAGCTTCAAGAGAGCTCTTCGTCGCT-

GTCTCCGCTTTTT-3') (SEQ ID NO: 91). This vector could express TAR and knockdown RT. The 7SK promoter was also substituted for the H1 promoter to regulate shRT expression. Another vector was constructed containing U6 TAR, H1 shRT, and H1 shCCR5. The H1 shCCR5 sequence 5 was inserted into the SpeI site of the plasmid containing U6 TAR and H1 shRT. The 1-11 CCR5 sequence is (5'-GAACGCTGACGTCATCAACCCGCTCCAAGGAA TC GCGGGCCCAGTGTCACTAGGCG GGAACACCC AG CGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAG GGACAGGGGA GTGGCGCCCTGCAATATTTGCAT GT CGCTATGTGTTCTGGGAAATCACCATAAACGT GAA ATGTCTTTGGATTTGGGAATCTTATAAGTTCTGTAT-GAGACCACTTGGATCCGTGTCAAGTCCAATCTAT G 15 TTCAAGAGACATAGATTGGACTTGACACTTTT-3') (SEQ ID NO: 92). The 7SK promoter was also substituted for the H1 promoter to regulate shRT expression.

Functional test for TAR decoy activity: We tested the effect of SIH-U6-TAR on packaging efficiency. When TAR  $_{20}$  sequence was included, the yield of vector in the SIH packaging system was reduced substantially.

Conclusion: Lentivirus vectors expressing the TAR decoy sequence are unsuitable for commercial development due to low vector yields. These constructs were abandoned.

12	shCCR5	Lentiviral vector	microRNA sequence	Extracellular CCR5 protein reduction >90%	Lead
				2010	

Vector Construction: A CCR5 microRNA was constructed with oligonucleotide sequences containing BsrGI and NotI restriction sites that were synthesized by MWG Operon. Oligonucleotide sequences were inserted into the pCDH 35 lentiviral vector (System Biosciences). The EF-1 promoter was substituted for a CMV promoter that was used in the plasmid construct Test Material 5. The EF-1 promoter was synthesized by MWG Operon containing flanking ClaI and BsrGI restriction sites and inserted into the pCDH vector containing shCCR5-1. The EF-1 promoter sequence is (5'- 40 CCGGTĞCCTAGAGAAGGTGĠCGCGGGĠŤAAACT GGGAAAGTGATGTCGTGTACTG GCTCCGCC TTTTT CCCGAGGGTGGGGGGGGAGAACCGTATATAA GTGCAG TAGTCGCCG TGAACGTTCTTTTTCGCAACGGGTTT GCCG CCAGAACACAGGTAAGTGCCGTGTGTG GT 45 TCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCC TTGCGTGCCTTGAATTACTT CCACGCCC CTGGC TG CAGTACGTGATTCTTGATCCCGAGCTTC GGGT TGG AAGTGG GTGGGAGAGTTCGAGGCCTTGCGCTTAA GGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTG 50 GCCTGGGCGCTGGGGGCCGCCGCGTGCGAATCTG GTGGCACCTTCGCGCC TGTCTCGCTGC TTTCGATA AGTCTCTAGCCATTTAAAATTTTTGATGACCTG CT G CGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAAT GCGGGCCAAGATCTGCACACTGGTATTTCGGTTTT TGGGGCCGCGGGCGGCGACGG GGCCCGTGCGT CC 55 CAGCGCACATGTTCGGCGAGGCGGGGGCCTGC GAG CGCGGCCACCGAGAA TCGGA CGGGGGTAGTCT C AAGCTGGCCGGCCTGCTCTGGT GCCT GGCCTCGC GCCGCCGTGTATCGCCCCGCCC TGGGCGGCAA GG CTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAA 60 GATGGCCGC TTCCCGGCCCT GCTGCAGGGAGCTC AAAATGGAGGACGCGG CGC TCGGGAGAGCG GGC GGGTGAGTCACCCACACAAAGGAAAAGGGCCT TT CCGTCCTCAGCCGTCGCTT CATGTGACTCCACGGA GTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCT CGAGC TTTTGGAGTACGTCGTCTTTAGGTTGGGG G 65 GAGGGGTTTTATGCGATGGAGTTTCCC CACACTGA GTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACT

TGATGTAATTCTC CTTGGAATTTGCCCTTTTTGAGT TTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTG GTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA-3') (SEQ ID NO: 4).

Functional test for lentivirus CDH-shCCR5-1: The ability of the miR CCR5 sequences to knock-down CCR5 expression was determined by transducing CEM-CCR5 T cells and measuring cell surface CCR5 expression after staining with a fluorescently-labeled monoclonal antibody against CCR5 and measuring the intensity of staining, that is directly proportional to the number of cell surface CCR5 molecules, by analytical flow cytometry. The most effective shRNA sequence for targeting CCR5 was CCR5 shRNA sequence #1. However, the most effective CCR5 targeting sequence for constructing the synthetic microRNA sequence was overlapping with CCR5 sequence #5; this conclusion was based on sequence alignments and experience with miRNA construction. Finally, the miR30 hairpin sequence was used to construct the synthetic miR30 CCR5 sequence which is (5'-AGGTATATTGCTGTTGACAGTGAGCGACTGTAA ACTGAGCTTGCTCTACTGTGAAG CCACAGATGGG TAGAGCAAGCACAGTTTACCGCTGCCTACTGCCT C GGACTTCAAG GGGCTT-3') (SEQ ID NO: 1). The miR CCR5 target sequence is (5'-GAGCAAGCTCAGTTTACA-3') (SEQ ID NO: 5). At multiplicity of infection equal to 5, generating on average 1.25 genome copies of integrated lentivirus per cell, CCR5 expression levels were reduce by ≥90% indicating potent inhibition of CCR5 mRNA by the miR30CCR5 micro RNA construct in a lentivirus vector.

Conclusion: The miR30CCR5 construct is potent for reducing CCR5 cell surface expression and is a lead candidate for a therapeutic lentivirus for HIV.

13	shVif	Lentiviral	microRNA	Vif protein	Lead
		vector	sequence	reduction >80%	

Vector Construction: A Vif microRNA was constructed with oligonucleotide sequences containing BsrGI and NotI restriction sites that were synthesized by MWG Operon. Oligonucleotide sequences were inserted into the pCDH lentiviral vector (System Biosciences) containing an EF-1 promoter. Based on sequence alignments and experience with constructing synthetic miRNA, the miR21 hairpin sequence was used to construct the synthetic miR21 Vif sequence which is (5'-CATCTCCATGGCTGTACCACC TTGTCGGGGGGATGTGTACTTCTGAACTTGTGTTGA A TCTCATGGAGTTCAGAAGAACACATCCGCACTG ACATTTTGGTATCTTTCATCTGAC CA-3') (SEQ ID NO: 2). The miR Vif target sequence is (5'-GGGATGTGT ACTTCTGAACTT-3') (SEQ ID NO: 6).

Functional test for potency of miR21Vif The ability of the miR Vif sequence to knock-down Vif expression was determined by measuring Vif protein expression by immunoblot analysis using an anti-Vif monoclonal antibody to identify the Vif protein.

Conclusion: the miR21Vif reduced Vif protein expression by ≥10-fold as determined by quantitative image analysis of immunoblot data. This was sufficient to justify miR21Vif as a lead candidate for our therapeutic lentivirus.

14	shTat	Lentiviral	microRNA	Tat RNA	Lead
		vector	sequence	reduction >80%	

Vector Construction: A Tat microRNA was constructed with oligonucleotide sequences containing BsrGI and NotI

15

restriction sites that were synthesized by MWG Operon. The microRNA cluster was inserted into the pCDH lentiviral vector (System Biosciences) containing an EF-1 promoter. Based on sequence alignments and experience in the construction of synthetic miRNA, the miR185 hairpin sequence was selected for constructing a synthetic miR185 Tat sequence which is (5'-GGGCCTGGCTCGAGC AGGGGGG CGAGGGATTCCGCTTCTTCCTGCCATAGCGTGGTC CCCTCCCCTATGGCAGGCAGGCAGAAGCGGCA CCTTC CC TCCCAATGACCGCGTCTTCGTC G-3'). The miR Tat target sequence is (5'-TCCGCTTCTTCCTGCCATAG-3') (SEQ ID NO: 3).

Functional test for potency of miR185Tat: The ability of miR Tat to knock-down Tat expression was determined by measuring Tat mRNA expression by RT-PCR analysis using Tat specific primers. We compared the miR185Tat with a similar miR155Tat on the basis of reducing the relative levels of Tat mRNA.

Conclusion: The miR185Tat was approximately twice as potent for reducing Tat mRNA compared to miR155Tat, and <sup>20</sup> was selected as the lead candidate for our therapeutic lentivirus.

15 shCCR5- Lentiviral microRNA shVif-shTat vector cluster sequence	CCR5 Candidate reduction >90%, Vif protein reduction >80%, Tat RNA reduction >80%, >95% inhibition of HIV replication	25 30
--	---	----------

Vector Construction: A miR30CCR5 miR21Vif miR185Tat microRNA cluster sequence was constructed 35 with a synthetic DNA fragment containing BsrGI and NotI restriction sites that was synthesized by MWG Operon. The DNA fragment was inserted into the pCDH lentiviral vector (System Biosciences) containing the EF-1 promoter. The miR cluster sequence is (5'-AGGTATATTGCTGTTGAC 40 Table 3 below: AGTGAGCGACTGTAAACTGAGCTTGCTCTACTGT-GAAG CCACAGATGGGTAGAGCAAGCACAGTTTAC CGCTGCCTACTGCCTCGGACTTCAAG GGGCTT CCC GGGCATCTCCATGGCTGTACCACCTTGTCGGGGG ATGTGTACTTCTGAACTTGTGTTGAATCTCATGGA 45 GTTCAGAAGAACACATCCGCACTGACATTTTGGTA T CTTTCATCTGACCAGCTAGCGGGCCTGGCTCG A GC AGGGGGGGGGGGGGGGGGTTCCGCTT CTTCCTGCCAT-AGCGTGGTCCCCTCCCCTATGGCAGGCAGA AGCG GCACCTTCCCTC CCAATGACCGCGTCTTCGTC-3') 50 (SEQ ID NO: 31) and incorporates Test Material 12, Test Material 13 and Test Material 14 into a single cluster that can be expressed under control of the EF-1 promoter.

Functional test for potency of the Lentivirus Vector AGT103 containing the microRNA cluster of miR30CCR5, 55 miR21Vif and miR185Tat: The AGT103 vector was tested for potency against CCR5 using the assay for reduction in cell surface CCR5 expression (Test Material 12). The AGT103 vector was tested for potency against Vif using the assay for reduction in cell surface Vif expression (Test 60 Material 13). The AGT103 vector was tested for potency against Tat using the assay for reduction in cell surface Tat expression (Test Material 14).

Conclusion: Potency for reducing CCR5 expression by the miRNA cluster was similar to potency observed for the 65 miR30CCR5 alone. Potency for reducing Vif expression by the miRNA cluster was similar to potency observed for the

miR21Vif alone. Potency for reducing Tat expression by the miRNA cluster was similar to potency observed for the miR185Tat alone. The miRNA cluster is potent for reducing cell surface CCR5 levels and for inhibiting two HIV genes. Thus, AGT103 containing this miRNA cluster was selected as the therapeutic vector construct for our HIV functional cure program.

Functional Assays. Individual lentivirus vectors containing CCR5, Tat or Vif shRNA sequences and, for experimental purposes, expressing green fluorescent protein (GFP) under control of the CMV Immediate Early Promoter, and designated AGT103/CMV-GFP were tested for their ability to knockdown CCR5, Tat or Vif expression. Mammalian cells were transduced with lentiviral particles either in the presence or absence of polybrene. Cells were collected after 2-4 days; protein and RNA were analyzed for CCR5, Tat or Vif expression. Protein levels were tested by Western blot assay or by labeling cells with specific fluorescent antibodies (CCR5 assay), followed by analytical flow cytometry comparing modified and unmodified cell fluorescence using either the CCR5-specific or isotype control antibodies.

Starting Testing of Lentivirus. T cell culture medium was made using RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin. Cytokine stocks of IL2 10,000 units/ml, IL-12 1 µg/ml, IL-7 1 µg/ml, IL-15 1 µg/ml were also prepared in advance.

Prior to transduction with the lentivirus, an infectious viral titer was determined and used to calculate the amount of virus to add for the proper multiplicity of infection (MOI).

Day 0-12: Antigen-specific enrichment. On day 0, cryopreserved PBMC were thawed, washed with 10 ml 37° C. medium at 1200 rpm for 10 minutes and resuspended at a concentration of  $2\times10^6$ /ml in 37° C. medium. The cells were cultured at 0.5 ml/well in a 24-well plate at 37° C. in 5% CO2. To define the optimal stimulation conditions, cells were stimulated with combinations of reagents as listed in Table 3 below:

TABLE 3

1	2	3	4	5	6
IL-2 + IL-12	IL-7 + IL-15	Peptides + IL-2 + IL-12	Peptides + IL-7 + IL-15	MVA + IL-2 + IL-12	MVA + IL-7 + IL-15

Final concentrations: IL-2=20 units/ml, IL-12=10 ng/ml, IL-7=10 ng/ml, IL-15=10 ng/ml, peptides=5 µg/ml individual peptide, MVA MOI=1.

On days 4 and 8, 0.5 ml fresh medium and cytokine at listed concentrations (all concentrations indicate the final concentration in the culture) were added to the stimulated cells.

Day 12-24: non-specific expansion and lentivirus transduction. On day 12, the stimulated cells were removed from the plate by pipetting and resuspended in fresh T cell culture medium at a concentration of  $1 \times 106$ /ml. The resuspended cells were transferred to T25 culture flasks and stimulated with DYNABEADS® Human T-Activator CD3/CD28 following the manufacturer's instruction plus cytokine as listed above; flasks were incubated in the vertical position.

On day 14, AGT103/CMV-GFP was added at MOI 20 and cultures were returned to the incubator for 2 days. At this

time, cells were recovered by pipetting, collected by centrifugation at 1300 rpm for 10 minutes, resuspended in the same volume of fresh medium, and centrifuged again to form a loose cell pellet. That cell pellet was resuspended in fresh medium with the same cytokines used in previous 5 steps, with cells at  $0.5 \times 10^6$  viable cells per ml.

From days 14 to 23, the number of the cells was evaluated every 2 days and the cells were diluted to  $0.5 \times 10^6$ /ml with fresh media. Cytokines were added every time.

On day 24, the cells were collected and the beads were 10 removed from the cells. To remove the beads, cells were transferred to a suitable tube that was placed in the sorting magnet for 2 minutes. Supernatant containing the cells was transferred to a new tube. Cells were then cultured for 1 day in fresh medium at 1×10<sup>6</sup>/ml. Assays were performed to 15 determine the frequencies of antigen-specific T cells and lentivirus transduced cells.

To prevent possible viral outgrowth, amprenavir (0.5 ng/ml) was added to the cultures on the first day of stimulation and every other day during the culture.

Examine antigen-specific T cells by intracellular cytokine staining for IFN-gamma. Cultured cells after peptide stimulation or after lentivirus transduction at  $1 \times 10^6$  cells/ml were stimulated with medium alone (negative control), Gag peptides (5 µg/ml individual peptide), or PHA (5 µg/ml, positive 25 control). After 4 hours, BD GolgiPlug™ (1:1000, BD Biosciences) was added to block Golgi transport. After 8 hours, cells were washed and stained with extracellular (CD3, CD4 or CD8; BD Biosciences) and intracellular (IFN-gamma; BD Biosciences) antibodies with BD Cytofix/Cytoperm<sup>TM</sup> 30 kit following the manufacturer's instruction. Samples were analyzed on a BD FACSCalibur™ Flow Cytometer. Control samples labeled with appropriate isotype-matched antibodies were included in each experiment. Data were analyzed using Flowjo software. 35

Lentivirus transduction rate was determined by the frequency of GFP+ cells. The transduced antigen-specific T cells are determined by the frequency of CD3+CD4+GFP+ IFN gamma+cells; tests for CD3+CD8+GFP+IFN gamma+ cells are included as a control.

These results indicate that CD4 T cells, the target T cell population, can be transduced with lentiviruses that are designed to specifically knock down the expression of HIV-specific proteins, thus producing an expandable population of T cells that are immune to the virus. This example 45 serves as a proof of concept indicating that the disclosed lentiviral constructs can be used in combination with vaccination to produce a functional cure in HIV patients.

### Example 4: CCR5 Knockdown with Experimental Vectors

AGTc120 is a Hela cell line that stably expresses large amounts of CD4 and CCR5. AGTc120 was transduced with or without LV-CMV-mCherry (the red fluorescent protein 55 mCherry expressed under control of the CMV Immediate Early Promoter) or AGT103/CMV-mCherry. Gene expression of the mCherry fluorescent protein was controlled by a CMV (cytomegalovirus immediate early promoter) expression cassette. The LV-CMV-mCherry vector lacked a 60 AGT103/CMV-mCherry microRNA cluster, while expressed therapeutic miRNA against CCR5, Vif, and Tat.

As shown in FIG. 8A, transduction efficiency was >90%. After 7 days, cells were collected and stained with fluorescent monoclonal antibody against CCR5 and subjected to 65 analytical flow cytometry. Isotype controls are shown in gray on these histograms plotting Mean Fluorescence Inten-

sity of CCR5 APC (x axis) versus cell number normalized to mode (y axis). After staining for cell surface CCR5, cells treated with no lentivirus or control lentivirus (expressing only the mCherry marker) showed no changes in CCR5 density while AGT103 (right section) reduced CCR5 staining intensity to nearly the levels of isotype control. After 7 days, cells were infected with or without R5-tropic HIV reporter virus Bal-GFP. 3 days later, cells were collected and analyzed by flow cytometry. More than 90% of cells were transduced. AGT103-CMV/CMVmCherry reduced CCR5 expression in transduced AGTc120 cells and blocked R5-tropic HIV infection compared with cells treated with the Control vector.

FIG. 8B shows the relative insensitivity of transfected AGTc120 cells to infection with HIV. As above, the lentivirus vectors express mCherry protein and a transduced cell that was also infected with HIV (expressing GFP) would appear as a double positive cell in the upper right quadrant of the false color flow cytometry dot plots. In the absence of <sup>20</sup> HIV (upper panels), there were no GFP+ cells under any condition. After HIV infection (lower panels), 56% of cells were infected in the absence of lentivirus transduction and 53.6% of cells became infected in AGTc120 cells transduced with the LV-CMV-mCherry. When cells were transduced with the therapeutic AGT103/CMV-mCherry vector, only 0.83% of cells appeared in the double positive quadrant indicating they were transduced and infected.

Dividing 53.62 (proportion of double positive cells with control vector) by 0.83 (the proportion of double positive cells with the therapeutic vector) shows that AGT103 provided greater than 65-fold protection against HIV in this experimental system.

Example 5: Regulation of CCR5 Expression by shRNA Inhibitor Sequences in a Lentiviral Vector

Inhibitory RNA Design. The sequence of Homo sapiens chemokine receptor CCR5 (CCR5, NC 000003.12) was used to search for potential siRNA or shRNA candidates to knockdown CCR5 levels in human cells. Potential RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Broad Institute or the BLOCK-IT RNA iDesigner from Thermo Scientific. A shRNA sequence may be inserted into a plasmid immediately after a RNA polymerase III promoter such as H1, U6, or 7SK to regulate shRNA expression. The shRNA sequence may also be inserted into a lentiviral vector using similar promoters or embedded within a microRNA backbone to allow for expression by an RNA polymerase II 50 promoter such as CMV or EF-1 alpha. The RNA sequence may also be synthesized as a siRNA oligonucleotide and utilized independently of a plasmid or lentiviral vector.

Plasmid Construction. For CCR5 shRNA, oligonucleotide sequences containing BamHI and EcoRI restriction sites were synthesized by MWG Operon. Oligonucleotide sequences were annealed by incubating at 70° C. then cooled to room temperature. Annealed oligonucleotides were digested with the restriction enzymes BamHI and EcoRI for one hour at 37° C., then the enzymes were inactivated at 70° C. for 20 minutes. In parallel, plasmid DNA was digested with the restriction enzymes BamHI and EcoRI for one hour at 37° C. The digested plasmid DNA was purified by agarose gel electrophoresis and extracted from the gel using a DNA gel extraction kit from Invitrogen. The DNA concentration was determined and the plasma to oligonucleotide sequence was ligated in the ratio 3:1 insert to vector. The ligation reaction was done with T4 DNA ligase for 30 minutes at

room temperature.  $2.5 \,\mu$ L, of the ligation mix were added to  $25 \,\mu$ L of STBL3 competent bacterial cells. Transformation required heat shock at 42° C. Bacterial cells were spread on agar plates containing ampicillin and colonies were expanded in L broth. To check for insertion of the oligo sequences, plasmid DNA was extracted from harvested bacterial cultures using the Invitrogen DNA Miniprep kit and tested by restriction enzyme digestion. Insertion of the shRNA sequence into the plasmid was verified by DNA sequencing using a primer specific for the promoter used to regulate shRNA expression.

Functional Assay for CCR5 mRNA Reduction: The assay for inhibition of CCR5 expression required co-transfection of two plasmids. The first plasmid contains one of five 15 different shRNA sequences directed against CCR5 mRNA. The second plasmid contains the cDNA sequence for human CCR5 gene. Plasmids were co-transfected into 293T cells. After 48 hours, cells were lysed and RNA was extracted using the RNeasy kit from Qiagen. cDNA was synthesized 20 from RNA using a Super Script Kit from Invitrogen. The samples were then analyzed by quantitative RT-PCR using an Applied Biosystems Step One PCR machine. CCR5 expression was detected with SYBR Green from Invitrogen using the forward primer (5'-AGGAATTGATGGCGAG 25 AAGG-3') (SEQ ID NO: 93) and reverse primer (5'-CCC-CAAAGAAGGTCAAGGTAATCA-3') (SEQ ID NO: 94) with standard conditions for polymerase chain reaction analysis. The samples were normalized to the mRNA for beta actin gene expression using the forward primer (5'- 30 AGCGCGGCTACAGCTTCA-3') (SEQ ID NO: 95) and reverse primer (5'-GGCGACGTAGCACAGCTTCP-3') (SEQ ID NO: 96) with standard conditions for polymerase chain reaction analysis. The relative expression of CCR5 mRNA was determined by its Ct value normalized to the 35 level of actin messenger RNA for each sample. The results are shown in FIGS. 9A-9B.

As shown in FIG. **9**A, CCR5 knock-down was tested in 293T cells by co-transfection of the CCR5 shRNA construct and a CCR5-expressing plasmid. Control samples were <sup>40</sup> transfected with a scrambled shRNA sequence that did not target any human gene and the CCR5-expressing plasmid. After 60 hours post-transfection, samples were harvested and CCR5 mRNA levels were measured by quantitative PCR. Further, as shown in FIG. **9**B, CCR5 knock-down after <sup>45</sup> transduction with lentivirus expressing CCR5 shRNA-1 (SEQ ID NO: 16).

Example 6: Regulation of HIV Components by shRNA Inhibitor Sequences in a Lentiviral Vector

Inhibitory RNA Design.

The sequences of HIV type 1 Rev/Tat (5'-GCGGA-GACAGCGACGAAGAGC-3') (SEQ ID NO: 9) and Gag (5'-GAAGAAATGATGACAGCAT-3') (SEQ ID NO: 11) 55 were used to design: Rev/Tat: (5'GCGGAGACAGCGACG AAGAGCTTCAAGAGAGCTCTTCGTCGCTGTCTC CGCTTTTT-3') (SEQ ID NO: 10) and Gag: (5'GAAG AAATGATGACAGCATTTCAAGAGAATGCTGTCAT-CATTTCTTCTTTTT-3') (SEQ ID NO: 12) shRNA that 60 were synthesized and cloned into plasmids as described above.

Plasmid Construction. The Rev/Tat or Gag target sequences were inserted into the 3'UTR (untranslated region) of the firefly luciferase gene used commonly as a 65 reporter of gene expression in cells or tissues. Additionally, one plasmid was constructed to express the Rev/Tat shRNA 64

and a second plasmid was constructed to express the Gag shRNA. Plasmid constructions were as described above.

Functional assay for shRNA targeting of Rev/Tat or Gag mRNA: Using plasmid co-transfection we tested whether a shRNA plasmid was capable of degrading luciferase messenger RNA and decreasing the intensity of light emission in co-transfected cells. A shRNA control (scrambled sequence) was used to establish the maximum yield of light from luciferase transfected cells. When the luciferase construct containing a Rev/Tat target sequence inserted into the 3'-UTR (untranslated region of the mRNA) was co-transfected with the Rev/Tat shRNA sequence there was nearly a 90% reduction in light emission indicating strong function of the shRNA sequence. A similar result was obtained when a luciferase construct containing a Gag target sequence in the 3'-UTR was co-transfected with the Gag shRNA sequence. These results indicate potent activity of the shRNA sequences.

As shown in FIG. **10**A, knock-down of the Rev/Tat target gene was measured by a reduction of luciferase activity, which was fused with the target mRNA sequence in the 3'UTR, by transient transfection in 293T cells. As shown in FIG. **10**B, knock-down of the Gag target gene sequence fused with the luciferase gene. The results are displayed as the mean±SD of three independent transfection experiments, each in triplicate.

# Example 7: AGT103 Decreases Expression of Tat and Vif

Cells were transfected with exemplary vector AGT103/ CMV-GFP. AGT103 and other exemplary vectors are defined in Table 3 below.

TABLE 3

Composition
EF1-miR30CCR5-miR21Vif-miR185-Tat-WPRE
CMV-mCherry
CMV-mCherry-EF1-miR30CCR5-miR21Vif-miR185-
Tat-WPRE-
CMV-mCherry
CMV-GFP-EF1-miR30CCR5-miR21Vif-miR185-Tat-
WPRE-

Abbreviations:

50

EF-1: elongation factor 1 transcriptional promoter

miR30CCR5 - synthetic microRNA capable of reducing CCR5 protein on cell surfaces miR21Vif - synthetic microRNA capable of reducing levels of HIV RNA and Vif protein expression

expression miR18STat - synthetic micro RNA capable of reducing levels of HIV RNA and Tat protein expression CMV - Immediate early transcriptional promoter from human cytomegalovirus

mCherry - coding region for the mCherry red fluorescent protein

GFP - coding region for the green fluorescent protein

WPRE - Woodchuck hepatitis virus post transcriptional regulatory element

A T lymphoblastoid cell line (CEM; CCRF-CEM; American Type Culture Collection Catalogue number CCL119) was transduced with AGT103/CMV-GFP. 48 hours later the cells were transfected with an HIV expression plasmid encoding the entire viral sequence. After 24 hours, RNA was extracted from cells and tested for levels of intact Tat sequences using reverse transcriptase polymerase chain reaction. Relative expression levels for intact Tat RNA were reduced from approximately 850 in the presence of control lentivirus vector, to approximately 200 in the presence of AGT103/CMV-GFP for a total reduction of >4 fold, as shown in FIG. **11**.

### Example 8: Regulation of HIV Components by Synthetic MicroRNA Sequences in a Lentiviral Vector

Inhibitory RNA Design. The sequence of HIV-1 Tat and 5 Vif genes were used to search for potential siRNA or shRNA candidates to knockdown Tat or Vif levels in human cells. Potential RNA interference sequences were chosen from candidates selected by siRNA or shRNA design programs such as from the Broad Institute or the BLOCK-IT RNA 10 iDesigner from Thermo Scientific. The selected shRNA sequences most potent for Tat or Vif knockdown were embedded within a microRNA backbone to allow for expression by an RNA polymerase II promoter such as CMV or EF-I alpha. The RNA sequence may also be synthesized 15 as a siRNA oligonucleotide and used independently of a plasmid or lentiviral vector.

Plasmid Construction. The Tat target sequence (5'-TCCGCTTCTTCCTGCCATAG-3') (SEQ ID NO: 7) was incorporated into the miR185 backbone to create a Tat 20 miRNA (5'-GGGCCTGGCTCGAGCAGGGGGGGGGGGGGGGGG ATTCCGCTTCTTCCTGCCATAGCGTGGTCCC CTCC CCTATGGCAGGCAGAAGCGGCACCTTCCCTCC-CAATGACCGCGTCTTCGTCG-3 ') (SEQ ID NO: 3) that was inserted into a lentivirus vector and expressed under 25 control of the EF-1 alpha promoter. Similarly, the Vif target sequence (5'-GGGATGTGTACTTCTGAACTT-3') (SEQ ID NO: 6) was incorporated into the miR21 backbone to create a Vif miRNA (5'-CATCTCCATGGCTGTACCAC CTTGTCGGGGGGATGTGTACTTCTGAACTTGTGTT-GAAT CTCATGGAGTTCAGAAGAACACATCCGCA CTGACATTTTGGTATCTTTC ATCTGACCA-3') (SEQ ID NO: 2) that was inserted into a lentivirus vector and expressed under control of the EF-1 alpha promoter. The resulting Vif/Tat miRNA-expressing lentivirus vectors were 35 produced in 293T cells using a lentiviral vector packaging system. The Vif and Tat miRNA were embedded into a microRNA cluster consisting of miR CCR5, miR Vif, and miR Tat all expressed under control of the EF-1 promoter.

Functional assay for miR185Tat inhibition of Tat mRNA 40 accumulation. A lentivirus vector expressing miR185 Tat (LV-EF1-miR-CCR5-Vif-Tat) was used at a multiplicity of infection equal to 5 for transducing 293T cells. 24 hours after transduction the cells were transfected with a plasmid expressing HIV strain NL4-3 (pNL4-3) using Lipo-45 fectamine2000 under standard conditions. 24 hours later RNA was extracted and levels of Tat messenger RNA were tested by RT-PCR using Tat-specific primers and compared to actin mRNA levels for a control.

Functional assay for miR21 Vif inhibition of Vif protein 50 accumulation. A lentivirus vector expressing miR21 Vif (LV-EF1-miR-CCR5-Vif-Tat) was used at a multiplicity of infection equal to 5 for transducing 293T cells. 24 hours after transduction, the cells were transfected with a plasmid expressing HIV strain NL4-3 (pNL4-3) using Lipo-55 fectamine2000. 24 hours later cells were lysed and total soluble protein was tested to measure the content of Vif protein. Cell lysates were separated by SDS-PAGE according to established techniques. The separated proteins were transferred to nylon membranes and probed with a Vif-60 specific monoclonal antibody or actin control antibody.

As shown in FIG. **12**A, Tat knock-down was tested in 293T cells transduced with either a control lentiviral vector or a lentiviral vector expressing either synthetic miR185 Tat or miR155 Tat microRNA. After 24 hours, the HIV vector 65 pNL4-3 was transfected with Lipofectamine2000 for 24 hours and then RNA was extracted for qPCR analysis with

primers for Tat. As shown in FIG. **12**B, Vif knock-down was tested in 293T cells transduced with either a control lentiviral vector or a lentiviral vector expressing a synthetic miR21 Vif microRNA. After 24 hours, the HIV vector pNL4-3 was transfected with Lipofectamine2000 for 24 hours and then protein was extracted for immunoblot analysis with an antibody for HIV Vif.

### Example 9: Regulation of CCR5 Expression by Synthetic microRNA Sequences in a Lentiviral Vector

CEM-CCR5 cells were transduced with a lentiviral vector containing a synthetic miR30 sequence for CCR5 (AGT103: TGTAAACTGAGCTTGCTCTA (SEQ ID NO: 97), AGT103-R5-1: TGTAAACTGAGCTTGCTCGC (SEQ ID NO: 98), or AGT103-R5-2: CATAGATTGGACTTGACAC (SEQ ID NO: 99). After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody and quantified by mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. The target sequence of AGT103 and AGT103-R5-1 is in the same region as CCR5 target sequence #5. The target sequence of AGT103-R5-2 is the same as CCR5 target sequence #1. AGT103 (2% of total CCR5) is most effective at reducing CCR5 levels as compared with AGT103-R5-1 (39% of total CCR5) and AGT103-R5-2 which does not reduce CCR5 levels. The data is demonstrated in FIG. 13 herein.

### Example 10: Regulation of CCR5 Expression by Synthetic microRNA Sequences in a Lentiviral Vector Containing Either a Long or Short WPRE Sequence

Vector Construction. Lentivirus vectors often require an RNA regulatory element for optimal expression of therapeutic genes or genetic constructs. A common choice is to use the Woodchuck hepatitis virus post transcriptional regulatory element (WPRE). We compared AGT103 that contains a full-length WPRE:

10

15

with a modified AGT103 vector containing a shortened WPRE element

(SEO ID NO: 80) (5 'AATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGATATTCT TAACTATGTTGCTCCTTTTACGCTGTGTGGGATATGCTGCTTTAATGCCTC TGTATCATGCTATTGCTTCCCGTACGGCTTTCGTTTTCTCCCCCTTGTAT AAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCCGTCA GCATTGCCACCACCTGTCAACTCCTTTCTGGGACTTTCGCTTTCCCCCTC CCGATCGCCACGGCAGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGAC AGGGGCTAGGTTGCTGGGCACTGATAATTCCGTGGTGTTGTC-3').

Functional assay for modulating cell surface CCR5 expression as a function of long versus short WPRE element in the vector sequence. AGT103 containing long or short WPRE elements were used for transducing CEM-CCR5 T cells a multiplicity of infection equal to 5. Six days after transduction cells were collected and stained with a monoclonal antibody capable of detecting cell surface CCR5 25 protein. The antibody was conjugated to a fluorescent marker and the intensity of staining is directly proportional to the level of CCR5 on the cell surface. A control lentivirus had no effect on cell surface CCR5 levels resulting in a single population with a mean fluorescence intensity of 73.6 30 units. The conventional AGT103 with a long WPRE element reduced CCR5 expression to a mean fluorescence intensity level of 11 units. AGT103 modified to incorporate a short WPRE element resulted in a single population of cells with mean fluorescence intensity of 13 units. Accordingly, sub- 35 stituting a short WPRE element had little or no effect on the capacity for AGT103 to reduce cell surface CCR5 expression.

As shown in FIG. 14, CEM-CCR5 cells were transduced with AGT103 containing either a long or short WPRE 40 sequence. After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody and quantified as mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. The reduction in CCR5 levels was similar for 45 ggggctctggaaaaaaagacagccagggtggaggtagattggtctttgact AGT103 with either the short (5.5% of total CCR5) or long (2.3% of total CCR5) WPRE sequence.

### Example 11: Regulation of CCR5 Expression by Synthetic microRNA Sequences in a Lentiviral Vector with or without a WPRE Sequence

Vector construction. In order to test whether WPRE was required for AGT103 down regulation of CCR5 expression we constructed a modified vector without WPRE element 55 sequences.

Functional assay for modulating cell surface CCR5 expression as a function of including or not including a long WPRE element in the AGT103 vector. In order to test whether WPRE was required for AGT103 modulation of 60 CCR5 expression levels we transduced CEM-CCR5 T cells with AGT103 or a modified vector lacking WPRE using a multiplicity of infection equal to 5. Six days after transduction cells were collected and stained with a monoclonal antibody capable of recognizing cell surface CCR5 protein. 65 The monoclonal antibody was directly conjugated to a fluorescent marker and the intensity of staining is directly

proportional to the number of CCR5 molecules per cell surface. A lentivirus control vector had no effect on cell surface CCR5 levels resulting in a uniform population with mean fluorescence intensity of 164. The lentivirus vector (AGT103 with a long WPRE and also expressing GFP marker protein), AGT103 lacking GFP but containing a long WPRE element, or AGT103 lacking both GFP and WPRE all were similarly effective for modulating cell surface CCR5 expression. After removing GFP, AGT103 with or without WPRE elements were indistinguishable in terms of their capacity for modulating cell surface CCR5 expression. CEM-CCR5 cells were transduced with AGT103 with or without GFP and WPRE. After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody and quantified as mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. The reduction in CCR5 levels was similar for AGT103 with (0% of total CCR5) or without (0% 20 of total CCR5) the WPRE sequence. This data is demonstrated in FIG. 15.

### Example 12: Regulation of CCR5 Expression by a CD4 Promoter Regulating Synthetic microRNA Sequences in a Lentiviral Vector

Vector Construction. A modified version of AGT103 was constructed to test the effect of substituting alternate promoters for expressing the microRNA cluster that suppresses CCR5, Vif and Tat gene expression. In place of the normal EF-1 promoter we substituted the T cell-specific promoter for CD4 glycoprotein expression using the sequence:

(SEO TD NO: 30) (5 ' TGTTGGGGTTCAAATTTGAGCCCCAGCTGTTAGCCCTCTGCAAAGAA AAAAAAAAAAAAAAAAAAAAAAAAGGGCCTAGATTTCCCTTCTGAGCCCCA CCCTAAGATGAAGCCTCTTCTTTCAAGGGAGTGGGGTTGGGGTGGAGGCG GATCCTGTCAGCTTTGCTCTCTCTGTGGCTGGCAGTTTCTCCAAAGGGTA ACAGGTGTCAGCTGGGCTGAGCCTAGGCTGAACCCTGAGACATGCTACCTC TGTCTTCTCATGGCTGGAGGCAGCCTTTGTAAGTCACAGAAAGTAGCTGA CCTGATTTAAGCCTGATTCTGCTTAACTTTTTCCCTTGACTTTGGCATTT 50 GCTGGTGACGTTTGGGGCCGGCCCAGGCCTAGGGTGTGGAGGAGCCTTGC CATCGGGCTTCCTGTCTCTCTTCATTTAAGCACGACTCTGCAGA-3') .

Functional assay comparing EF-1 and CD4 gene promoters in terms of potency for reducing cell surface CCR5 protein expression. AGT103 modified by substituting the CD4 gene promoter for the normal EF-1 promoter was used for transducing CEM-CCR5 T cells. Six days after transduction cells were collected and stained with a monoclonal antibody capable of recognizing cell surface CCR5 protein. The monoclonal antibody was conjugated to a fluorescent marker and staining intensity is directly proportional to the level of cell surface CCR5 protein. A control lentivirus transduction resulted in a population of CEM-CCR5 T cells that were stained with a CCR5-specific monoclonal antibody and produced a mean fluorescence intensity of 81.7 units. The modified AGT103 using a CD4 gene promoter in place of the EF-1 promoter for expressing microRNA showed a broad distribution of staining with a mean fluorescence intensity roughly equal to 17.3 units. Based on this result, the EF-1 promoter is at least similar and likely superior to the CD4 gene promoter for microRNA expression. Depending on the desired target cell population, the EF-1 promoter <sup>5</sup> is universally active in all cell types and the CD4 promoter is only active in T-lymphocytes.

CEM-CCR5 cells were transduced with a lentiviral vector containing a CD4 promoter regulating a synthetic microRNA sequence for CCR5, Vif, and Tat (AGT103). <sup>10</sup> After 6 days, CCR5 expression was determined by FACS analysis with an APC-conjugated CCR5 antibody and quantified as mean fluorescence intensity (MFI). CCR5 levels were expressed as % CCR5 with LV-Control set at 100%. In cells transduced with LV-CD4-AGT103, CCR5 levels were <sup>15</sup> 11% of total CCR5. This is comparable to that observed for LV-AGT103 which contains the EF1 promoter. This data is demonstrated in FIG. **16**.

### Example 13: Detecting HIV Gag-Specific CD4 T Cells

Cells and reagents. Viable frozen peripheral blood mononuclear cells (PBMC) were obtained from a vaccine company. Data were obtained with a representative specimen 25 from an HIV+individual who was enrolled into an early stage clinical trial (TRIAL REGISTRATION: clinicaltrials-.gov NCT01378156) testing a candidate HIV therapeutic vaccine. Two specimens were obtained for the "Before vaccination" and "After vaccination" studies. Cell culture 30 products, supplements and cytokines were from commercial suppliers. Cells were tested for responses to recombinant Modified Vaccinia Ankara 62B from Geovax Corporation as described in Thompson, M., S. L. Heath, B. Sweeton, K. Williams, P. Cunningham, B. F. Keele, S. Sen, B. E. Palmer, 35 N. Chomont, Y. Xu, R. Basu, M. S. Hellerstein, S. Kwa and H. L. Robinson (2016). "DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent 40 Virus." PLoS One 11(10): e0163164. Synthetic peptides representing the entire HIV-1 Gag polyprotein were obtained from GeoVax the HIV (GAG) Ultra peptide sets were obtained from JPT Peptide Technologies GmbH (www.jpt.com), Berlin, Germany. HIV (GAG) Ultra con- 45 tains 150 peptides each being 15 amino acids in length and overlapping by 11 amino acids. They were chemically synthesized then purified and analyzed by liquid chromatography-mass spectrometry. Collectively these peptides represent major immunogenic regions of the HIV Gag 50 polyprotein and are designed for average coverage of 57.8% among known HIV strains. Peptide sequences are based on the HIV sequence database from the Los Alamos National (http://www.hiv.lanl.gov/content/sequence/ Laboratory NEWALIGN/align.html). Peptides are provided as dried 55 trifluoroacetate salts, 25 micrograms per peptide, and are dissolved in approximately 40 microliters of DMSO then diluted with PBS to final concentration. Monoclonal antibodies for detecting CD4 and cytoplasmic IFN-gamma were obtained from commercial sources and intracellular staining 60 was done with the BD Pharmingen Intracellular Staining Kit for interferon-gamma. Peptides were resuspended in DMSO and we include a DMSO only control condition. Functional assay for detecting HIV-specific CD4+ T cells. Frozen PBMC were thawed, washed and resuspended in RPMI 65 medium containing 10% fetal bovine serum, supplements and cytokines. Cultured PBMC collected before or after

70

vaccination were treated with DMSO control, MVA GeoVax (multiplicity of infection equal to 1 plaque forming unit per cell), Peptides GeoVax (1 microgram/ml) or HIV (GAG) Ultra peptide mixture (1 microgram/ml) for 20 hours in the presence of Golgi Stop reagent. Cells were collected, washed, fixed, permeabilized and stained with monoclonal antibodies specific for cell surface CD4 or intracellular interferon-gamma. Stained cells were analyzed with a FACSCalibur analytical flow cytometer and data were gated on the CD4+ T cell subset. Cells highlighted within boxed regions are double-positive and designated HIV-specific CD4 T cells on the basis of interferon-gamma expression after MVA or peptide stimulation. Numbers within the boxed regions show the percentage of total CD4 that were identified as HIV-specific. We did not detect strong responses to DMSO or MVA. Peptides from GeoVax elicited fewer responding cells compared to HIV (GAG) Ultra peptide mixture from JPT but differences were small and not sig-20 nificant.

As shown in FIG. **17**, PBMCs from a HIV-positive patient before or after vaccination were stimulated with DMSO (control), recombinant MVA expressing HIV Gag from GeoVax (MVA GeoVax), Gag peptide from GeoVax (Pep GeoVax, also referred to herein as Gag peptide pool 1) or Gag peptides from JPT (HIV (GAG) Ultra, also referred to herein as Gag peptide pool 2) for 20 hours. IFNg production was detected by intracellular staining and flow cytometry using standard protocols. Flow cytometry data were gated on CD4 T cells. Numbers captured in boxes are the percentage of total CD4 T cells designated "HIV-specific" on the basis of cytokine response to antigen-specific stimulation.

### Example 14: HIV-Specific CD4 T Cell Expansion and Lentivirus Transduction

Designing and testing methods for enriching PBMC to increase the proportion of HIV-specific CD4 T cells and transducing these cells with AGT103 to produce the cellular product AGT103T.

The protocol was designed for ex vivo culture of PBMC (peripheral blood mononuclear cells) from HIV-positive patients who had received a therapeutic HIV vaccine. In this example, the therapeutic vaccine consisted of three doses of plasmid DNA expressing HIV Gag, Pol and Env genes followed by two doses of MVA 62-B (modified vaccinia Ankara number 62-B) expressing the same HIV Gag, Pol, and Env genes. The protocol is not specific for a vaccine product and only requires a sufficient level of HIV-specific CD4+ T cells after immunization. Venous blood was collected and PBMC were purified by Ficoll-Paque density gradient centrifugation. Alternately, PBMC or defined cellular tractions can be prepared by positive or negative selection methods using antibody cocktails and fluorescence activated or magnetic bead sorting. The purified PBMC are washed and cultured in standard medium containing supplements, antibiotics and fetal bovine serum. To these cultures, a pool of synthetic peptides was added representing possible T cell epitopes within the HIV Gag polyprotein. Cultures are supplemented by adding cytokines interleukin-2 and interleukin-12 that were selected after testing combinations of interleukin-2 and interleukin-12, interleukin 2 and interleukin-7, interleukin 2 and interleukin-15. Peptide stimulation is followed by a culture interval of approximately 12 days. During the 12 days culture, fresh medium and fresh cytokine supplements were added approximately once every four days.

The peptide stimulation interval is designed to increase the frequency of HIV-specific CD4 T cells in the PBMC culture. These HIV-specific CD4 T cells were activated by prior therapeutic immunization and can be re-stimulated and caused to proliferate by synthetic peptide exposure. Our goal is to achieve greater than or equal to 1% of total CD4 T cells being HIV-specific by end of the peptide stimulation culture period.

On approximately day 12 of culture cells are washed to remove residual materials then stimulated with synthetic <sup>10</sup> beads decorated with antibodies against CD4 T cell surface proteins CD3 and CD28. This well-established method for polyclonal stimulation of T cells will reactivate the cells and make them more susceptible for AGT103 lentivirus transduction. The lentivirus transduction is performed on approximately day 13 of culture and uses a multiplicity of infection between 1 and 5. After transduction cells are washed to remove residual lentivirus vector and cultured in media containing interleukin-2 and interleukin-12 with fresh medium and cytokines added approximately once every four days until approximately day 24 of culture.

Throughout the culture interval the antiretroviral drug Saquinavir is added at a concentration of approximately 100 nM to suppress any possible outgrowth of HIV.

On approximately day 24 of culture cells are harvested, washed, a sample is set aside for potency and release assay, then the remaining cells are suspended in cryopreservation medium before freezing in single aliquots of approximately  $1 \times 10^{10}$  cells per dose that will contain approximately  $1 \times 10^{8}$  HIV-specific CD4 T cells that are transduced with AGT103.

Potency of the cell product (AGT103T) is tested in one of two alternate potency assays. Potency assay 1 tests for the average number of genome copies (integrated AGT103 vector sequences) per CD4 T cell. The minimum potency is 35 approximately 0.5 genome copies per CD4 T cell in order to release the product. The assay is performed by positive selection of CD3 positive/CD4 positive T cells using magnetic bead labeled monoclonal antibodies, extracting total cellular DNA and using a quantitative PCR reaction to detect 40 sequences unique to the AGT103 vector. Potency assay 2 tests for the average number of genome copies of integrated AGT103 within the subpopulation of HIV-specific CD4 T cells. This essay is accomplished by first stimulating the PBMC with the pool of synthetic peptides representing HIV 45 Gag protein. Cells are then stained with a specific antibody reagent capable of binding to the CD4 T cell and also capturing secreted interferon-gamma cytokine. The CD4 positive/interferon-gamma positive cells are captured by magnetic bead selection, total cellular DNA is prepared, and 50 the number of genome copies of AGT103 per cell is determined with a quantitative PCR reaction. Release criterion based on potency using Assay 2 require that greater than or equal to 0.5 genome copies per HIV-specific CD4 T-cell are present in the AGT103 cell product.

Functional test for enriching and transducing HIV-specific CD4 T cells from PBMC of HIV-positive patients that received a therapeutic HIV vaccine. The impact of therapeutic vaccination on the frequency of HIV-specific CD4 T cells was tested by a peptide stimulation assay (FIG. **14** 60 panel B). Before vaccination the frequency of HIV-specific CD4 T cells was 0.036% in this representative individual. After vaccination, the frequency of HIV-specific CD4 T cells was increased approximately 2-fold to the value of 0.076%. Responding cells (HIV-specific) identified by accumulation 65 of cytoplasmic interferon-gamma, were only detected after specific peptide stimulation.

We also tested whether peptide stimulation to enrich for HIV-specific CD4 T cells followed by AGT103 transduction would reach our goal of generating approximately 1% of total CD4 T cells in culture that were both HIV-specific and transduced by AGT103. In this case, we used an experimental version of AGT103 that expresses green fluorescence protein (see GFP). In FIG. **14**, panel C the post-vaccination culture after peptide stimulation (HIV (GAG) Ultra) and AGT103 transduction demonstrated that 1.11% of total CD4 T cells were both HIV-specific (based on expressing interferon-gamma in response to peptide stimulation) and AGT103 transduced (based on expression of GFP).

Several patients from a therapeutic HIV vaccine study were tested to assess the range of responses to peptide stimulation and to begin defining eligibility criteria for entering a gene therapy arm in a future human clinical trial. FIG. 18D shows the frequency of HIV-specific CD4 T cells in 4 vaccine trial participants comparing their pre- and post-vaccination specimens. In three cases the post-vaccination specimens show a value of HIV-specific CD4 T cells that was greater than or equal to 0.076% of total CD4 T cells. The ability to reach this value was not predicted by the pre-vaccination specimens as patient 001-004 and patient 001-006 both started with pre-vaccination values of 0.02% 25 HIV-specific CD4 T cells but one reached an eventual post-vaccination value of 0.12% HIV-specific CD4 T cells while the other individual fail to increase this value after vaccination. The same three patients that responded well to vaccine, in terms of increasing the frequency of HIV-specific CD4 T cells, also showed substantial enrichment of HIVspecific CD4 T cells after peptide stimulation and culture. In the three cases shown in FIG. 18E, peptide stimulation and subsequent culture generated samples where 2.07%, 0.72% or 1.54% respectively of total CD4 T cells were HIVspecific. These values indicate that a majority of individuals responding to a therapeutic HIV vaccine will have a sufficiently large ex vivo response to peptide stimulation in order to enable our goal of achieving approximately 1% of total CD4 T cells that are HIV-specific and transduced with AGT103 in the final cell product.

FIG. 18A describes the schedule of treatment. FIG. 18B demonstrates that PBMCs were stimulated with Gag peptide or DMSO control for 20 hours. IFN gamma production was detected by intracellular staining by FACS. CD4<sup>+</sup> T cells were gated for analysis. FIG. 18C demonstrates CD4+ T cells were expanded and transduced with AGT103-GFP using the method as shown in FIG. 18A. Expanded CD4<sup>+</sup> T cells were rested in fresh medium without any cytokine for 2 days and re-stimulated with Gag peptide or DMSO control for 20 hours. IFN gamma production and GFP expression was detected by FACS. CD4+ T cells were gated for analysis. FIG. 18D demonstrates frequency of HIV-specific CD4+ T cells (IFN gamma positive, pre- and post-vaccination) were detected from 4 patients. Panel E demonstrates Post-55 vaccination PBMCs from 4 patients were expanded and HIV-specific CD4<sup>+</sup> T cells were examined.

#### Example 15: Dose Response

Vector Construction. A modified version of AGT103 was constructed to test the dose response for increasing AGT103 and its effects on cell surface CCR5 levels. The AGT103 was modified to include a green fluorescent protein (GFP) expression cassette under control of the CMV promoter. Transduced cells expression the miR30CCR5 miR21Vif miR185Tat micro RNA cluster and emit green light due to expressing GFP.

30

Functional assay for dose response of increasing AGT103-GFP and inhibition of CCR5 expression. CEM-CCR5 T cells were transduced with AGT103-GFP using multiplicity of infection per cell from 0 to 5. Transduced cells were stained with a fluorescently conjugated (APC) 5 monoclonal antibody specific for cell surface CCR5. The intensity of staining is proportional to the number of CCR5 molecules per cell surface. The intensity of green fluorescence is proportional to the number of integrated AGT103-GFP copies per cell.

FIG. 19A demonstrates the dose response for increasing AGT103-GFP and its effects on cell surface CCR5 expression. At multiplicity of infection equal to 0.4 only 1.04% of cells are both green (indicating transduction) and showing significantly reduced CCR5 expression. At multiplicity of infection equal to 1 the number of CCR5low, GFP+ cells increases to 68.1%/At multiplicity of infection equal to 5 the number of CCR5low, GFP+ cells increased to 95.7%. These data are presented in histogram form in FIG. 19B that shows a normally distribution population in terms of CCR5 stain- 20 ing, moving toward lower mean fluorescence intensity with increasing doses of AGT103-GFP. The potency of AGT103-GFP is presented in graphical form in FIG. 19C showing the percentage inhibition of CCR5 expression with increasing doses of AGT103-GFP. At multiplicity of infection equal to 25 5, there was greater than 99% reduction in CCR5 expression levels.

### Example 16: AGT103 Efficiently Transduces Primary Human CD4<sup>+</sup> T Cells

Transducing primary CD4 T cells with AGT103 lentivirus vector. A modified AGT103 vector containing the green fluorescence protein marker (GFP) was used at multiplicities of infection between 0.2 and 5 for transducing purified, 35 primary human CD4 T cells.

Functional assay for transduction efficiency of AGT103 in primary human CD4 T cells. CD4 T cells were isolated from human PBMC (HIV-negative donor) using magnetic bead labeled antibodies and standard procedures. The purified 40 CD4 T cells were stimulated ex vivo with CD3/CD28 beads and cultured in media containing interleukin-2 for 1 day before AGT103 transduction. The relationship between lentivirus vector dose (the multiplicity of infection) and transduction efficiency is demonstrated in FIG. 20A showing that 45 multiplicity of infection equal to 0.2 resulted in 9.27% of CD4 positive T cells being transduced by AGT103 and that value was increased to 63.1% of CD4 positive T cells being transduced by AGT103 with a multiplicity of infection equal to 5. In addition to achieving efficient transduction of 50 primary CD4 positive T cells it is also necessary to quantify the number of genome copies per cell. In FIG. 20B total cellular DNA from primary human CD4 T cells transduced at several multiplicities of infection were tested by quantitative PCR to determine the number of genome copies per 55 cell. In a multiplicity of infection equal to 0.2 we measured 0.096 genome copies per cell that was in good agreement with 9.27% GFP positive CD4 T cells in FIG. 20A. Multiplicity of infection equal to 1 generated 0.691 genome copies per cell and multiplicity of infection equal to 5 60 generated 1.245 genome copies per cell.

As shown in FIGS. 20A-20B, CD4<sup>+</sup> T cells isolated from PBMC were stimulated with CD3/CD28 beads plus IL-2 for 1 day and transduced with AGT103 at various concentrations. After 2 days, beads were removed and CD4<sup>+</sup> T cells 65 were collected. As shown in FIG. 20A, frequency of transduced cells (GFP positive) were detected by FACS. As

shown in FIG. 20B, the number of vector copies per cell was determined by qPCR. At a multiplicity of infection (MOI) of 5, 63% of CD4<sup>+</sup> T cells were transduced with an average of 1 vector copy per cell.

### Example 17: AGT103 Inhibits HIV Replication in Primary CD4+ T Cells

Protecting primary human CD4 positive T cells from HIV infection by transducing cells with AGT103. Therapeutic lentivirus AGT103 was used for transducing primary human CD4 positive T cells at multiplicities of infection between 0.2 and 5 per cell. The transduced cells were then challenged with a CXCR4-tropic HIV strain NL4.3 that does not require cell surface CCR5 for penetration. This assay tests the potency of microRNA against Vif and Tat genes of HIV in terms of preventing productive infection in primary CD4 positive T cells, but uses an indirect method to detect the amount of HIV released from infected, primary human CD4 T cells

Functional assay for AGT103 protection against CXCR4tropic HIV infection of primary human CD4 positive T cells. CD4 T cells were isolated from human PBMC (HIV-negative donor) using magnetic bead labeled antibodies and standard procedures. The purified CD4 T cells were stimulated ex vivo with CD3/CD28 beads and cultured in media containing interleukin-2 for 1 day before AGT103 transduction using multiplicities of infection between 0.2 and 5. Two days after transduction the CD4 positive T cell cultures were challenged with HIV strain NL4.3 that was engineered to express the green fluorescent protein (GFP). The transduced and HIV-exposed primary CD4 T cell cultures were maintained for 7 days before collecting cell-free culture fluids containing HIV. The cell-free culture fluids were used to infect a highly permissive T cell line C8166 for 2 days. The proportion of HIV-infected C8166 cells was determined by flow cytometry detecting GFP fluorescence. With a mock lentivirus infection, the dose of 0.1 multiplicity of infection for NL4.3 HIV resulted in an amount of HIV being released into culture fluids that was capable of establishing productive infection in 15.4% of C8166 T cells. With the dose 0.2 multiplicity of infection for AGT103, this value for HIV infection of C8166 cells is reduced to 5.3% and multiplicity of infection equal to 1 for AGT103 resulted in only 3.19% of C8166 T cells being infected by HIV. C8166 infection was reduced further to 0.62% after AGT103 transduction using a multiplicity of infection equal to 5. There is a clear dose response relationship between the amount of AGT103 used for transduction and the amount of HIV released into the culture medium.

As shown in FIG. 21, CD4<sup>+</sup> T cells isolated from PBMC were stimulated with CD3/CD28 beads plus IL-2 for 1 day and transduced with AGT103 at various concentrations (MOI). After 2 days, beads were removed and CD4<sup>+</sup> T cells were infected with 0.1 MOI of HIV NL4.3-GFP. 24 hours later, cells were washed 3 times with PBS and cultured with IL-2 (30U/ml) for 7 days. At the end of the culture, supernatant was collected to infect the HIV permissive cell line C8166 for 2 days. HIV-infected C8166 cells (GFP positive) were detected by FACS. There was a reduction in viable HIV with an increase in the multiplicity of infection of AGT103 as observed by less infection of C8166 cells MOI 0.2=65.6%, MOI 1=79.3%, and MOI 5=96%).

Example 18: AGT103 Protects Primary Human CD4+ T Cells from HIV-Induced Depletion

AGT103 transduction of primary human CD4 T cells to protect against HIV-mediated cytopathology and cell depletion. PBMC were obtained from healthy, HIV-negative donors and stimulated with CD3/CD28 beads then cultured for 1 day in medium containing interleukin-2 before AGT103 transduction using multiplicities of infection between 0.2 and 5.

Functional assay for AGT103 protection of primary human CD4 T cells against HIV-mediated cytopathology. AGT103-transduced primary human CD4 T cells were infected with HIV NL 4.3 strain (CXCR4-tropic) that does not require CCR5 for cellular entry. When using the 10 CXCR4-tropic NL 4.3, only the effect of Vif and Tat microRNA on HIV replication is being tested. The dose of HIV NL 4.3 was 0.1 multiplicity of infection. One day after HIV infection, cells were washed to remove residual virus and cultured in medium plus interleukin-2. Cells were collected every three days during a 14-day culture then stained with a monoclonal antibody that was specific for CD4 and directly conjugated to a fluorescent marker to allow measurement of the proportion of CD4 positive T cells in PBMC. Untreated CD4 T cells or CD4 T cells transduced 20 with the control lentivirus vector were highly susceptible to HIV challenge and the proportion of CD4 positive T cells in PBMC fell below 10% by day 14 culture. In contrast, there was a dose-dependent effect of AGT103 on preventing cell depletion by HIV challenge. With a AGT103 dose of 0.2 25 multiplicity of infection more than 20% of PBMC were CD4 T cells by day 14 of culture and this value increased to more than 50% of PBMC being CD4 positive T cells by day 14 of culture with a AGT103 dose of multiplicity of infection equal to 5. Again, there is a clear dose response effect of 30 AGT103 on HIV cytopathogenicity in human PBMC.

As shown in FIG. **22**, PBMCs were stimulated with CD3/CD28 beads plus IL-2 for 1 day and transduced with AGT103 at various concentrations (MOI). After 2 days, beads were removed and cells were infected with 0.1 MOI <sup>35</sup> of HIV NL4.3. 24 hours later, cells were washed 3 times with PBS and cultured with IL-2 (30U/ml). Cells were collected every 3 days and the frequency of CD4+ T cells were analyzed by FACS. After 14 days of exposure to HIV, there was an 87% reduction in CD4+ T cells transduced with <sup>40</sup> LV-Control, a 60% reduction with AGT103 MOI 0.2, a 37% reduction with AGT103 MOI 1, and a 17% reduction with AGT103 MOI 5.

### Example 19: Generating a Population of CD4+ T Cells Enriched for HIV-Specificity and Transduced with AGT103/CMV-GFP

Therapeutic vaccination against HIV had minimal effect on the distribution of CD4+, CD8+ and CD4+/CD8+ T cells. <sup>50</sup> As shown in FIG. **23**A, the CD4 T cell population is shown in the upper left quadrant of the analytical flow cytometry dot plots, and changes from 52% to 57% of total T cells after the vaccination series. These are representative data.

Peripheral blood mononuclear cells from a participant in 55 an HIV therapeutic vaccine trial were cultured for 12 days in medium+/-interleukin-2/interleukin-12 or +/-interleukin-7/interleukin-15. Some cultures were stimulated with overlapping peptides representing the entire p55 Gag protein of HIV-1 (HIV (GAG) Ultra peptide mixture) as a source of 60 epitope peptides for T cell stimulation. These peptides are 10-20 amino acids in length and overlap by 20-50% of their length to represent the entire Gag precursor protein (p55) from HIV-1 BaL strain. The composition and sequence of individual peptides can be adjusted to compensate for 65 regional variations in the predominant circulating HIV sequences or when detailed sequence information is avail-

able for an individual patient receiving this therapy. At culture end, cells were recovered and stained with anti-CD4 or anti-CD8 monoclonal antibodies and the CD3+ population was gated and displayed here.

The HIV (GAG) Ultra peptide mixture stimulation for either pre- or post-vaccination samples was similar to the medium control indicating that HIV (GAG) Ultra peptide mixture was not toxic to cells and was not acting as a polyclonal mitogen. The results of this analysis can be found in FIG. **23**B.

HIV (GAG) Ultra peptide mixture and interleukin-2/ interleukin-12 provided for optimal expansion of antigenspecific CD4 T cells. As shown in the upper panels of FIG. **23**C, there was an increase in cytokine (interferon-gamma) secreting cells in post-vaccination specimens exposed to HIV (GAG) Ultra peptide mixture. In the pre-vaccination sample, cytokine secreting cells increased from 0.43 to 0.69% as a result of exposure to antigenic peptides. In contrast, the post-vaccination samples showed an increase of cytokine secreting cells from 0.62 to 1.76% of total CD4 T cells as a result of peptide stimulation. These data demonstrate the strong impact of vaccination on the CD4 T cell responses to HIV antigen.

Finally, AGT103/CMV-GFP transduction of antigen-expanded CD4 T cells produced HIV-specific and HIV-resistant helper CD4 T cells that are needed for infusion into patients as part of a functional cure for HIV (in accordance with other various aspects and embodiments, AGT103 alone is used; for example, clinical embodiments may not include the CMV-GFP segment). The upper panels of FIG. 23C show the results of analyzing the CD4+ T cell population in culture. The x axis of FIG. 23C shows Green Fluorescent Protein (GFP) emission indicating that individual cells were transduced with the AGT103/CMV-GFP. In the post-vaccination samples 1.11% of total CD4 T cells that were both cytokine secreting was recovered, indicating that the cells are responding specifically to HIV antigen, and transduced with AGT103/CMV-GFP. This is the target cell population and the clinical product intended for infusion and functional cure of HIV. With the efficiency of cell expansion during the antigen stimulation and subsequent polyclonal expansion phases of ex vivo culture,  $4 \times 10^8$  antigen-specific, lentivirus transduced CD4 T cells can be produced. This exceeds the target for cell production by 4-fold and will allow achievement of a count of antigen-specific and HIV-resistant CD4 45 T cells of approximately 40 cells/microliter of blood or around 5.7% of total circulating CD4 T cells.

Table 4 below shows the results of the ex vivo production of HIV-specific and HIV-resistant CD4 T cells using the disclosed vectors and methods.

TABLE 4

Material/manipulation	Total CD4 T cells	Percentage HIV- specific	Percentage HIV- specific and HIV-resistant
Leukapheresis pack from HIV+ patient	$\sim 7 \times 10^{8}$	~0.12	N/A
Peptide expansion ex	$\sim 8 \times 10^8$	~2.4	N/A
Mitogen expansion Lentivirus transduction	$\sim 1.5 \times 10^{10}$ $\sim 1.5 \times 10^{10}$	~2.4 ~2.4	N/A ~1.6

Example 20: Clinical Study for Treatment of HIV

AGT103T is a genetically modified autologous PBMC containing  $>5\times10'$  HIV-specific CD4 T cells that are also transduced with AGT103 lentivirus vector.

A Phase I clinical trial will test the safety and feasibility of infusing ex vivo modified autologous CD4 T cells (AGT103T) in adult research participants with confirmed HIV infection, CD4+ T-cell counts >600 cells per mm<sup>3</sup> of blood and stable virus suppression below 200 copies per ml 5 of plasma while on cART. All study participants will continue receiving their standard antiretroviral medications through the Phase I clinical trial. Up to 40 study participants receive two doses by intramuscular injection 8 weeks apart, of recombinant modified vaccinia Ankara (rMVA) express- 10 ing HIV Gag, Pol and Env proteins. Seven to 10 days after the second immunization a blood sample is collected for in vitro testing to measure the frequency of CD4+ T-cells that respond to stimulation with a pool of overlapping, synthetic peptides representing the HIV-1 Gag polyprotein. Subjects 15 in the upper half of vaccine responders, based on measuring the frequency of Gag-specific CD4 T cells are enrolled in the gene therapy arm and subjects in the lower half of responders do not continue in the study. We anticipate that the cut-off for higher responders is a HIV-specific CD4+ T cell fre- 20 quency ≥0.065% of total CD4 T cells. Subjects enrolled into the gene therapy arm of our trial undergo leukapheresis followed by purification of PBMC (using Ficoll density gradient centrifugation or negative selection with antibodies) that are cultured ex vivo and stimulated with HIV Gag 25 peptides plus interleukin-2 and interleukin-12 for 12 days, then stimulated again with beads decorated with CD3/CD28 bispecific antibody. The antiretroviral drug Saquinavir is included at 100 nM to prevent emergence of autologous HIV during ex vivo culture. One day after CD3/CD28 stimulation 30 cells are transduced with AGT103 at multiplicity of infection between 1 and 10. The transduced cells are cultured for an additional 7-14 days during which time they expand by polyclonal proliferation. The culture period is ended by harvesting and washing cells, setting aside aliquots for 35 potency and safety release assays, and resuspending the remaining cells in cryopreservation medium. A single dose is  $\leq 1 \times 10^{10}$  autologous PBMC. The potency assay measures the frequency of CD4 T cells that respond to peptide stimulation by expressing interferon-gamma. Other release 40 criteria include the product must include  $>0.5 \times 10^7$  HIVspecific CD4 T cells that are also transduced with AGT103. Another release criterion is that the number of AGT103 genome copies per cell must not exceed 3. Five days before infusion with AGT103T subjects receive one dose of busul- 45 furam (or Cytoxan) conditioning regimen followed by infusion of  $\leq 1 \times 10^{10}$  PBMC containing genetically modified CD4 T cells.

A Phase II study will evaluate efficacy of AGT103T cell therapy. Phase II study participants include individuals 50 enrolled previously in our Phase I study who were judged to have successful and stable engraftment of genetically modified, autologous, HIV-specific CD4 T cells and clinical responses defined as positive changes in parameters monitored as described in efficacy assessments (1.3.). Study 55 participants will be asked to add Maraviroc to their existing regimen of antiretroviral medication. Maraviroc is a CCR5 antagonist that will enhance the effectiveness of genetic therapy directed at reducing CCR5 levels. Once the Maraviroc regimen is in place subjects will be asked to discon- 60 tinue the previous antiretroviral drug regimen and only maintain Maraviroc monotherapy for 28 days or until plasma viral RNA levels exceed 10,000 per ml on 2 sequential weekly blood draws. Persistently high viremia requires participants to return to their original antiretroviral drug 65 regimen with or without Maraviroc according to recommendations of their HIV care physician.

78

If participants remain HIV suppressed (below 2,000 vRNA copies per ml of plasma) for >28 days on Maraviroc monotherapy, they will be asked to gradually reduce Maraviroc dosing over a period of 4 weeks followed by intensive monitoring for an additional 28 days. Subjects who maintained HIV suppression with Maraviroc monotherapy are considered to have a functional cure. Subjects who maintain HIV suppression even after Maraviroc withdrawal also have a functional cure. Monthly monitoring for 6 months followed by less intensive monitoring will establish the dura-

bility of functional cure.

Patient Selection

Inclusion Criteria:

- Aged between 18 and 60 years.
- Documented HIV infection prior to study entry.
- Must be willing to comply with study-mandated evaluations; including not changing their antiretroviral regimen (unless medically indicated) during the study period.
- CD4+ T-cell count >600 cell per millimeter cubed (cells/ mm3)
- CD4+ T-cell nadir of >400 cells/mm3
- HIV viral load <1,000 copies per milliliter (mL)

Exclusion Criteria:

Any viral hepatitis

- Acute HIV infection
- HIV viral load >1,000 copies/mL
- Active or recent (prior 6 months) AIDS defining complication
- Any change in HIV medications within 12 weeks of entering the study
- Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin
- Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled angina or arrhythmias
- History of bleeding problems
- Use of chronic steroids in past 30 days
- Pregnant or breast feeding
- Active drug or alcohol abuse
- Serious illness in past 30 days
- Currently participating in another clinical trial or any prior gene therapy

Safety Assessments

- Acute infusion reaction
- Post-infusion safety follow-up
- Efficacy Assessments—Phase I
  - Number and frequency of modified CD4 T cells.
  - Durability of modified CD4 T cells.
  - In vitro response to Gag peptide restimulation (ICS assay) as a measure of memory T cell function.
  - Polyfunctional anti-HIV CD8 T cell responses compare to pre- and post-vaccination time points.
  - Frequency of CD4 T cells making doubly spliced HIV mRNA after in vitro stimulation.
- Efficacy Assessments—Phase II
- Number and frequency of genetically modified CD4 T cells.
- Maintenance of viral suppression (<2,000 vRNA copies per ml but 2 consecutive weekly draws not exceeding  $5 \times 10^4$  vRNA copies per ml are permitted) with Maraviroc monotherapy.
- Continued virus suppression during and after Maraviroc withdrawal.
- Stable CD4 T cell count.

CD4 T cells that are also transduced with AGT103 lentivirus vector. A Phase I clinical trial will test the safety and feasibility of infusing ex vivo modified autologous CD4 T cells (AGT103T) in adult research participants with confirmed HIV infection, CD4+ T-cell counts >600 cells per 5 mm<sup>3</sup> of blood and stable virus suppression below 200 copies per ml of plasma while on cART. Up to 40 study participants receive two doses by intramuscular injection 8 weeks apart, of recombinant modified vaccinia Ankara (rMVA) expressing HIV Gag, Pol and Env proteins. Seven to 10 days after 10 the second immunization a blood sample is collected for in vitro testing to measure the frequency of CD4+ T-cells that respond to stimulation with a pool of overlapping, synthetic peptides representing the HIV-1 Gag polyprotein. Subjects in the upper half of vaccine responders, based on measuring the frequency of Gag-specific CD4 T cells are enrolled in the gene therapy arm and subjects in the lower half of responders do not continue in the study. We anticipate that the cut-off for higher responders is a HIV-specific CD4+ T cell frequency  $\ge 0.065\%$  of total CD4 T cells. Subjects enrolled into 20 the gene therapy arm of our trial undergo leukapheresis and the CD4+ T cells are enriched by negative selection. The enriched CD4 subset is admixed with 10% the number of cells from the CD4-negative subset to provide a source and antigen-presenting cells. The enriched CD4 T cells are 25 stimulated with HIV Gag peptides plus interleukin-2 and interleukin-12 for 12 days, then stimulated again with beads decorated with CD3/CD28 bispecific antibody. The antiretroviral drug Saquinavir is included at 100 nM to prevent emergence of autologous HIV during ex vivo culture. One 30 day after CD3/CD28 stimulation cells are transduced with AGT103 at multiplicity of infection between 1 and 10. The transduced cells are cultured for an additional 7-14 days during which time they expand by polyclonal proliferation. The culture period is ended by harvesting and washing cells, 35 setting aside aliquots for potency and safety release assays, and resuspending the remaining cells in cryopreservation medium. A single dose is  $\leq 1 \times 10^{10}$  autologous cells enriched for the CD4+ T cell subset. The potency assay measures the frequency of CD4 T cells that respond to peptide stimulation

80

by expressing interferon-gamma. Other release criteria include that the product must include  $\ge 0.5 \times 10^7$  HIV-specific CD4 T cells that are also transduced with AGT103. Another release criterion is that the number of AGT103 genome copies per cell must not exceed 3. Five days before infusion with AGT103T subjects receive one dose of busulfuram (or Cytoxan) conditioning regimen followed by infusion of  $\le 1 \times 10^{10}$  enriched and genetically modified CD4 T cell.

A Phase II study will evaluate efficacy of AGT103T cell therapy. Phase II study participants include individuals enrolled previously in our Phase I study who were judged to have successful and stable engraftment of genetically modified, autologous, HIV-specific CD4 T cells and clinical responses defined as positive changes in parameters monitored as described in efficacy assessments (1.3.). Study participants will be asked to add Maraviroc to their existing regimen of antiretroviral medication. Maraviroc is a CCR5 antagonist that will enhance the effectiveness of genetic therapy directed at reducing CCR5 levels. Once the Maraviroc regimen is in place subjects will be asked to discontinue the previous antiretroviral drug regimen and only maintain Maraviroc monotherapy for 28 days or until plasma viral RNA levels exceed 10,000 per ml on 2 sequential weekly blood draws. Persistently high viremia requires participants to return to their original antiretroviral drug regimen with or without Maraviroc according to recommendations of their HIV care physician.

If participants remain HIV suppressed (below 2,000 vRNA copies per ml of plasma) for >28 days on Maraviroc monotherapy, they will be asked to gradually reduce Maraviroc dosing over a period of 4 weeks followed by intensive monitoring for an additional 28 days. Subjects who maintained HIV suppression with Maraviroc monotherapy are considered to have a functional cure. Subjects who maintain HIV suppression even after Maraviroc withdrawal also have a functional cure. Monthly monitoring for 6 months followed by less intensive monitoring will establish the durability of functional cure.

Sequences

The following sequences are referred to herein:

SEQ ID NO:	Description	Sequence
1	miR30 CCR5	AGGTATATTGCTGTTGACAGTGAGCGACTGTAAAC TGAGCTTGCTCTACTGTGAAGCCACAGATGGGTAG AGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGA CTTCAAGGGGCTT
2	miR21 Vif	CATCTCCATGGCTGTACCACCTTGTCGGGGGATGT GTACTTCTGAACTTGTGTTGAATCTCATGGAGTTCA GAAGAACACATCCGCACTGACATTTTGGTATCTTT CATCTGACCA
3	miR185 Tat	GGGCCTGGCTCGAGCAGGGGGCGAGGGATTCCGCT TCTTCCTGCCATAGCGTGG TCCCCTCCCC
4	Elongation Factor-1 alpha (EF1-alpha) promoter	CCGGTGCCTAGAGAAGGTGGCGCGGGGGTAAACTG GGAAAGTGATGTCGTGTGTACTGGCTCCGCCTTTTTCC CGAGGGTGGGGGGAGAACCGTATATAAGTGCAGTA GTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC GCCAGAACACAGGTAAGTGCCGTGTGTGTGTCCCG CGGGCCTGGCCT

81

SEQ ID NO:	Description	Sequence
		CATTTAAAATTTTTGATGACCTGCTGCGACGCTTTT TTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAG ATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGG GCGGCAACGGGGCCCGTGCGTCCAAGCCAATGT TCGGCGAACGGGGGCAGCCTGGCGCCGGCCCGGC
5	CCR5 target sequence	GAGCAAGCTCAGTTTACA
6	Vif target sequence	GGGATGTGTACTTCTGAACTT
7	Tat target sequence	TCCGCTTCTTCCTGCCATAG
8	TAR decoy sequence	CTTGCAATGATGTCGTAATTTGCGTCTTACCTCGTT CTCGACAGCGACCAGATCTGAGCCTGGGAGCTCTC TGGCTGTCAGTAAGCTGGTACAGAAGGTTGACGAA AATTCTTACTGAGCAAGAAA
9	Rev/Tat target sequence	GCGGAGACAGCGACGAAGAGC
10	Rev/Tat shRNA sequence	GCGGAGACAGCGACGAAGAGCTTCAAGAGAGCTC TTCGTCGCTGTCTCCGCTTTTT
11	Gag target sequence	GAAGAAATGATGACAGCAT
12	Gag shRNA sequence	GAAGAAATGATGACAGCATTTCAAGAGAATGCTGT CATCATTTCTTCTTTT
13	Pol target sequence	CAGGAGCAGATGATACAG
14	Pol shRNA sequence	CAGGAGATGATACAGTTCAAGAGACTGTATCATCT GCTCCTGTTTTT
15	CCR5 target sequence #1	GTGTCAAGTCCAATCTATG
16	CCR5 shRNA sequence #1	GTGTCAAGTCCAATCTATGTTCAAGAGACATAGAT TGGACTTGACACTTTT
17	CCR5 target sequence #2	GAGCATGACTGACATCTAC
18	CCR5 shRNA sequence #2	GAGCATGACTGACATCTACTTCAAGAGAGTAGATG TCAGTCATGCTCTTTT
19	CCR5 target sequence #3	GTAGCTCTAACAGGTTGGA
20	CCR5 shRNA sequence #3	GTAGCTCTAACAGGTTGGATTCAAGAGATCCAACC TGTTAGAGCTACTTTTT
21	CCR5 target sequence #4	GTTCAGAAACTACCTCTTA
22	CCR5 shRNA sequence #4	GTTCAGAAACTACCTCTTATTCAAGAGATAAGAGG TAGTTTCTGAACTTTTT

-continued

SEQ II NO:	Description	Sequence
23	CCR5 target	GAGCAAGCTCAGTTTACACC
24	CCR5 shRNA	GAGCAAGCTCAGTTTACACCTTCAAGAGAGGGTGTA
25	Homo sapiens CCR5 gene, sequence 1	ATCIGACITIGICITITI ATGGATTATCAAGTGTCAAGTCCAATCTATGACAT CAATTATTATACATCGGAGCCCTGCCAAAAAATCA ATGTGAAGCAAATCGCAGCCCGCCTCCTGCCTCCG CTCTACTCACTGGTGTTCATCTTTGGTTTTTGTGGGC
26	<i>Homo sapiens</i> CCR5 gene, sequence 2	AACATGCTGGTCATCCTCATCCTGATAAACTGCAA AAGGCTGAAGAGCATGACTGACATCTACCTGCTCA ACCTGGCCATCTCTGACCTGTTTTTCCTTCTTACTG TCCCCTTCTGGGCTCACTATGCTGCCGCCCAGTGGG ACTTTGGAAATACAATGTGTCAACTCTTGACAGGG CTCTATTTTATAGGCTTCTTCTCTGGAATCTTCTCA TCATCCTCCTGACAATCGATAGGTACCTGGCTGTC GTCCATGGTGGTGTTGCTTTAAAAGCCAGGACCATGGG TGGTGGCTGTGTTTGCGTCTCTCCCCGAGAATCATCT TTACCAGATCTCAAAAAGAAGTCTTCATTACACC TGGAGGCTGTGTTTCCATACAGTAGTACATCT GGGCTGGTCTCCCCAGGAATCATCT TGGGAGAATTCCCAACATTAAAGATAGTCATCT GGGGCTGGTCTCCCCAGGAATCCATCT CGGAGGATCCTCAAAAAGAAGATCGTCTCG CTACTCGGGAATCCTCAAAAACTGGTCATGGTC GAATGAGAAAGAAGAGGCCAGGGCTGTGAGGCT TATCTCACCATCATGATTGTTTATTTTCCTTCTGG GCTCCCTACAACATTGTCCTTCCCTGAAC
27	<i>Homo sapiens</i> CCR5 gene, sequence 3	ACCTTCCAGGAATTCTTTGGCCTGAATAATTGCAGT AGCTCTAACAGGTTGGACCAAGCTATGCAGGTGA
28	<i>Homo sapiens</i> CCR5 gene, sequence 4	CAGAGACTCTTGGGATGACGCACTGCTGCATCAAC CCCATCATCTATGCCTTTGTCGGGGAGAAGTTCAG AAACTACCTCTTAGTCTTCTTCCAAAAGCACATTGC CAAACGCTTCTGCAAATGCTGTTCTATTTTCCAG
29	<i>Homo sapiens</i> CCR5 gene, sequence 5	CAAGAGGCTCCCGAGCGAGCAAGCTCAGTTTACAC CCGATCCACTGGGGAGCAGGAAATATCTGTGGGCT TGTGA
30	CD4 promoter sequence	TGTTGGGGTTCAAATTTGAGCCCCAGCTGTTAGCC CTCTGCAAAGAAAAAAAAAA
31	miR30- CCR5/miR21- Vif/miR185 Tat microRNA cluster sequence	AGGTATATTGCTGTTGACAGTGAGCGACTGTAAAC TGAGCTTGCTCTACTGTGAAGCCACAGATGGGTAG AGCAAGCACAGTTTACCGCTGCCTACTGCCTCGGA CTTCAAGGGGCTTCCCGGGCATCTCCATGGCTGTA CCACCTTGTCGGGGGATGTGTACTTCTGAACTTGTG TTGAATCTCATGAGAGTCAGAAGAACACATCCGCA CTGACATTTTGGTATCTTCATCTGACCAGCTAGCG GGCCTGGCTCGAGCAGGGGGCGGAGGATTCCGCTT CTTCCTGCCATAGCGTGGTCCCCTCCCC

TTCGTC

.,.,.

84

SEQ II NO:	Description	Sequence
32	Long WPRE sequence	AATCAACCTCTGATTACAAAATTTGTGAAAGATTG ACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTA TGTGGATACGCTGCTTTAATGCCTTTGTATCATGCT ATTGCTTCCCGGTGTGGCGTGTCCTTTTATGAGAGTTGT GGCCCGTTGTCAGCAACCGTGGCGTGG
33	Elongation Factor-1 alpha (EF1-alpha) promoter; miR30CCR5; miR21Vif; miR185 Tat	CCGGTGCCTAGAGAAGGTGGCGGGGGGTAAACTG GGAAAGTGATGTGTGTGTGTGTGGCCGCCTTTTTCC CAAGGGTGGGGAGAACCGTATATAAGTGCAGTA GTCGCCGTGAACGTTCTTTTTCGCAACGGGTTGCC GCCAGAACACAGGTAAGTGCCGTGTGGTGTG
34	Rous Sarcoma virus (RSV) promoter	GTAGTCTTATGCAATACTCTTGTAGTCTTGCAACAT GGTAACGATGAGTTAGCAACATGCCTTACAAGGAG AGAAAAAGCACCGTGCATGCCGATTGGTGGAAGT AAGGTGGTACGATCGTGCCTTATTAGGAAGGCAAC AGACGGGTCTGACATGGATTGGACGAACCACTGAA TTGCCGCATTGCAGAGATATTGTATTTAAGTGCCTA GCTCGATACAATAAACG
35	5' Long terminal repeat (LTR)	GGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAG CTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCC TCAATAAAGCTTGCCTTGAGTGGTTCAAGTAGTGT GTGCCCGTCTGTTGTGTGGACTCTGGTAACTAGAGA TCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCT AGCA

SEQ ID NO:	Description	Sequence
36	Psi Packaging signal	TACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGG AGAGAG
37	Rev response element (RRE)	AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAG GAAGCACTATGGGCGCAGCCTCAATGACGCTGACG GTACAGGCCAGACAATTATTGTCTGGTATAGTGCA GCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGC AACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AACCAGCTCCAGGCAAGAATCCTGGCTGTGGAAA GATACCTAAAGGATCAACAGCTCC
38	Central polypurine tract (cPPT)	TTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGT GCAGGGGAAAGAATAGTAGACATAATAGCAACAG ACATACAAACTAAAGAATTACAAAAACAAATTAC AAAATTCAAAATTTTA
39	3' delta LTR	TGGAAGGGCTAATTCACTCCCAACGAAGATAAGAT CTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGAC CAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGG GAACCCACTGCTTAAGCCTCCAATAAAGCTTGCCTT GAGTGCTTCAAGTAGTGTGGCCCGTCTGTTGTGTG ACTCTGGTAACTAGAGATCCCTCCAGACCCTTTTAGT CAGTGTGGAAAATCTCTAGCAGTAGTAGTTCATGT CA
40	Helper/Rev; CMV early (CAG) enhancer; Enhance Transcription	TAGTTATTAATAGTAATCAATTACGGGGTCATTAG TTCATAGCCCATATATGGAGTTCCGCGTTACATAA CTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA CGACCCCCGCCCATTGACGTCAATAATGACGTATG TTCCCATAGTAACGCCAATAGGGACTTTCCATTGA CGTCAATGGGTGGACTATTACGGTAAACTGCCA CTTGGCAGTACATCAAGTGTATCATATGCCAAGTA CGCCCCCTTATTGACGTCAATGACGTAAATGGCCC GCCTGGCATTATGCCCAGTACATGACCTTATGGGA CTTTCCTACTTGGCAGTACATCTACGTATTAGTCAT C
41	Helper/Rev; Chicken beta actin (CAG) promoter; Transcription	GCTATTACCATGGGTCGAGGTGAGCCCCACGTTCT GCTTCACTCTCCCCATCTCCCCCCCCCC
42	Helper/Rev; Chicken beta actin intron; Enhance gene expression	GGAGTCGCTGCGTTGCCTTCGCCCGTGCCCGGCTC GGCGCCCCTCGCGCCCCGCCCCGGCTCTGACT GACCGCGTTACTCCCACAGGTGAGCGGGCGGGACG GCCTTCTCCTCCGGGCTGTAATTAGCGCTGGTGTT AATGACGGCTCGTTCTTTTCTGTGCGGGCGGGG GGGAGCGGCTCGGGGGGGCCCTTTGTGCGGG GCGTGTGAGCGCTCGGGGGGCGCGGGGCCCGGGCCCG GCGGCTGTGAGCGCTGCGGGGCGCGGGGCCCGGGCCCG GGGGGCGTGCCCCCCGCGTGCGGGGGGGCCCGGGGCCGGGGCCGGGGCCCGGGGGG

89

-continued

SEQ ID NO:	Description	Sequence
43	Helper/Rev; HIV Gag; Viral capsid	ATGGTGCGAGAGCGTCAGTATTAAGCGGGGGAG AATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA GGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTT AATCCTGGGCTGTTAGAACATCAGAAGGCTGTAG ACAAATACTGGGACAGCTACAACCATCCCTTCAGA GAGAATCGGACAGCTAGAACATCACCATCCCTTCAGA GAGAACCCCTCTATTGTGTGCATCAAAGGATAG GATAAAAGACACCAAGGAAGCTTTAGACAAGGATA GAGGAAGAGCAAAACAAGGAAGCTTTAGACAAGATA GAGGAAGAGCAAAACAAGGAAGCATTAGACAAGAACACC AGCAAGCAGCGCGACAAGGAAGCTTTAGACAAGAACACC AGCAAGCAGCAGCGGACACAGGAACACGCAATCC GGTCAGCCAAAATTACCCTATAGGCAGAACATCC AGGGGCAAATGGTACATCAGGCCATATCACCTAGA ACTTTAAATGCATGGGTAAAAGTAGTAGAAGAAGA ACTTTAAATGCACGAGGAGCATCCAGGACACCACGCATTCAG GCATGCTAAACACACTGGGGGAGACATCCAGGA GCCATGCTAAACACACTGGGGGGGACATCCAGGA GCCATGCTAAACACACTGGGGGGGACATCCAGGA GCCATGCCAAAATGTAAAAGAGACCACCAATGAGG AAGCTCCAGAATGTGTAAAAGAGACCACCAATGAGG AAGCTCCAGGATGGAATAGCAGGACCACCCAGATGAGGA CAAGGGGAAGTGACATAGCAGGACCACCCAGTGCAT GCAGGGCCTATTGCACCAGGCCAGATGAGAGAAC CAAGGGAACGATAGGAAGACTACTAGTAC CCTTCCGGGATTAAAAGAGATGGAACACAAGAG ATAATCCTGGGAATAGGAGGACATCAAGACGATC CACTACCCAGCATTGTGAGCAGATGA CAAGGAACCCTTTAGAGACAATGAGAAGAAGGA CAAAGGAACCCTTTAGAGACAATGAGAGACGACCCAAGA GGTAAAAATTGGATGACACACTAGTAGAGCGATC TATAAAACTTAAGAGCGCACCATGAGACAAGGA CAAAGGAACCCCTAGGAGAGCACTAGAGACAAGGA CAAAGGAACCCCTAGGAGACACTAGAGACAAGGA CAAAGCAAGCCAGGAGCACCTAGAAGAAATGA TGACGCACCAAGGAGTGGTAGAGACATGATGAAGAAGA TAACAAATCCAGCAACACAAGAAGACTGTTAGAGCCAA TAACAAATCCAGCTACCAATGAACACTGGTAAGGCCAAG TAACAAATCCAGCACCAAAGAAAGACTGTTAAGGCCAAG TAACAAATCCAGCTACCAAAGAAGACTGTTAAGGCCAAG TAACAAATCCAGCTACCAAAGAAGACTGTTAGGACCAAAG TAACAAATCCAGCTACCAAATGAACAACTGGC AATTTTAGGAACCAAAGAAGACCCCAAATGAACAACTGGC CTCCACAAGGACCCCAAATGAAAGATTGTAC TGAGAGCAGGACACCAAAAAAGATTGTAC TGAGAGACAGGCCCAAAGGACACCAAACACTCCCTCT CAGAAGCAGGACCCCAAAGAACACCCCCCCACAAGAGAACACTGCCTT CAAGAGCCAGGCCGAACACCACCACAACACCTCCCTCT CAGAAGCAGGACCGAACACCACCCACCAGAAGAACCTCCCTC
44	Helper/Rev; HIV Pol; Protease and reverse transcriptase	ATGAATTTGCCAGGAAGATGGAAACCAAAAATGA TAGGGGGAATTGGAGGTTTTATCAAAGTAGGACAG TATGATCAGATACTCATAGAAATCTGCGGACATAA AGCTATAGGTACAGTATTAGTAGGACCTACACCTG TCAACATAATTGGAAGAATCTGTTGACACACCTG GCTGCACTTTAAATTTTCCCATTAGTCCTAATGAG ACTGTACCAGTAAAATTGACAGAAATTGGCCATATGAG ACTGTACCAGTAAAATTAGTAGCAGAAATGGG CCCAAAAGTTAAACAATGGCCATTGACAGAAAT GGAAAGGAAGAAAAATTTCAAAAATTGGCCATAAA GAAAAAGGAAGAAAAATTCCAGTATTGTACAGAAAT GAAAAAGGAAGAAAAATTCCAGTATTGGCCT GAAAATCCATACAATACTCCAGTATTGGCCT GAAAATCCATACAATACTCCAGTATTGCCATAAA GAAAAAGACAGTACTAAATGGGGAAAATTAGTA GATTCCAGGAACTTAATAGGAGAAATTAGTA GATTCCAGGAACTTAATAGGAGAAACTCCAGGA TGTGGGCGATGCATATTATGCAATACCGCATCCTGCAG GGTTAAAACAGAAAAAATCAGTAACAGTACTGGA TGTGGGCGATGCATATTTTCCAGTCCCTTAGATAA AGACTTCCAGGAGTATAATGGGGATTACCACATCCTA GTATAAACAATGAGACACCAGGGATTAGCATCCTA GTATAAACAATGAGACACCAGGGATTAGCATCCTA GTATAAACAATGGAGCACCAGGGATTAGCACC AGCATATTCCAGTGTGAGCATGGAAAGATCTTAG AGCCTTTTAGAAAACAAAATCCAGACAAAAATCTTAG AGACTGCAGACAACATCTGTGAGGGATTTAC CACACCAGACAACATCTGTGAGGGGATTAC CACACCAGACAACATCTGTGAGAGGAGCACCCA TTCCTTTGGATGGCTACCATAGTCATCC TTCCTTTGGAAGGCAACATCGTGAGAAAAATCCAG GAACTGAGACAACATCTGAGAGCACAAAAATCGCA CTTAGAAATAGGGCAACATCGTGAGAACAAAAATAGAG GAACTGAGCCAACATCTGTGAGAGAACCTCCA TTCCTTTGGATGGGTTATGAACTCCAGAAAAAAGAG CAGCCAGACAACATCGGCAAGAACCTCCA TTCCTTTGGATGGGTATGAACTCCAGAAAAAGAGA CAGCTGGACCTGCAATAGCACCACAGAAATTAGTGG GAAAATTGAATTG

NO :	Description	Sequence
		GAAGAAGCAGAGCTAGAACTGGCAGAAAACAGGG AGATTCTAAAAGAACCGGTACATGGAGTGTATTAT GACCCATCAAAAGACTTAATAGCAGAGATGTATTAT CAAGGGCCAAGGCCAATGGACATATCAAATTAT CAAGACCAATTAAAATCTGAAAACAGGAAAAT ATGCAAGAATGAAGGGTGCCCACACTAATGATGTG AAACAATTAACAGAGGGTGCCCACACTAATGATGTG AAACAATTAACAGAGGCAGTACAAAAAATAGCCA CAGAAAGCATAGTAATATGGGGAAAGACTCCTAA ATTTAAATTACCCATCAAAAGGAAAACATGGGAAG CATGGTGGACAGAGTATTGGCAAGCCACCTGGATT CCTGAGTGGGACATGTGTCAATACCCCTCCCTTAGTG AAGTTATGGTACCAGTTAGGAAAGACCCCTAGT AGGACCAGAAACTTTCTATGTAATGGGGACGCCA ATGGGAGAAACTTTCTATGTAAAGGAAAGCCCATAAT AGGAGCAGAAACTTACGAGAAAGACCCCATAAT AGGACCAGAACAAATTAGGAAAGACCGCATAAT AGGACACAACAAATCAGAAAAACTGGCCCCCTA ACTGACAGAGGAGAGACAAAAAGTGGTCCCCCTA ACGGACACAACAAATCAGGAACAGAGTTAACAAG CAATTCATCTACGTAGCATCGGGATTAGAA GTAAACATAGTGACCAGACTAACAAGTAGTCATCAG AGTTAGTCAGTCAAACAACAACAAGTAGTCATCAG AGTTAGTCAGTCACAACAACAGGAGTAAAAA AAGGAAAAAGTCTACCTGGCATGGGTACCAGCAC ACAAAGGAATTGGAGAGAAATGAACAAGTAGTGG GTTGGTCAGTGGCAGGACTCACAATAGGGTACCACCAC
45	Helper Rev; HIV Integrase; Integration of viral RNA	TTTTTAGATGGAATAGATAAGGCCCAAGAAGAACA TGAGAAATATCACAGTAATTGGGAGCCAAGAAGAACA TGAGAATATCACAGATAGTTGGAGAGCAATGGCTA GTGATTTTAACCTACCACCTGTAGTAGCAAAAGAA ATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGG GGAAGCCATGCATGGACAAGTAGACTGTAGCCCA GGAATATGGCAGCTAGGACAGTAGACTGTAGCCCAG GGAATATCTTGGTAGCAGTTCAACTATTAGAAGG AAAAGTTATCTTGGTAGCAGTTCAATGTAGCCAGTG GATATATAGAAGCAGAAGTAATTCCAGCAAGAGA AGGGCAAGAAACAGCATACTTCCTCTTAAAATTAG CAGGAAGATGGCCAGTAAAACAGTACATACAGA CAATGGCAGCAATTCCACCAGTACTACAGTACAAG CAATGGCAGCAATTCCACCAGTACTACAGCAGGAATTT GGCATTCCCTACAATCCCCAAAGTCAAGCAGGAATTT GGCATTCCCTACAATCCCCAAAGTCAAGCAGGAATTA AGAATCTATGAATAAAGAATTAAAGAAATTATAG GACAGGTACAAATGGCAGTAATCAGGCAGGACATCTTAAAGA AGCAGTACAAATGGCAGTATTCACACAACTCCACAGT AGCAGTACAAATGGCAGTATTCACAGACACACACAGC GGAAAGAATAGTAGACATAATAGCAACAGACACAA TTCAAAATATTTCGAGAATTACAAAAATTACAAAAA TTCCAAAATTTCGAAAGGCGCAGTAGTAATACAAGAATAAT AGTGCCATAAAAGAGTAGTGCCCAAGAAGACACACAA AGTCCACTAAAAGGGGGCATTATGGAAAACAGAATACCAGACAGA
6	Helper/Rev; HIV RRE; Binds Rev element	AG AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAG GAAGCACTATGGGCGCAGCGTCAATGACGCTGACG GTACAGGCCAGACAATTATTGTCTGGTATAGTGCA GCAGCAGAACAATTTGCTGAGGGCTATTGAGGGCGC AACAGCATCTGTTGCAACTCACAGCTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAA GATACCTAAAGGATCAACAGCTCCT
47	Helper/Rev; HIV Rev; Nuclear export and stabilize viral mRNA	ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAAC TCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATC AAAGCAACCCACCTCCCAATCCCGAGGGGACCCG ACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGA GAGAGACAGAGACAGATCCATTCGGTAGAAC GGATCCTTAGCACTTATCTGGGACGATCTGCGGAG CCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTT ACTCTTGATTGTAACGAGGATTGTGGAACTTCTGG GACGCAGGGGGTGGGAAGCCCTCAAATATTGGTG GAATCTCCCTACAATATTGGAGTCAGGAGCTAAAGA ATAG
48	Helper/Rev; Rabbit beta globin poly A; RNA stability	AGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAAT AAAGGAAATTTATTTCATTGCAATAGTGTGTGG AATTTTTTGGTCTCTCACTCGGAAGGACATATGGG AGGGCAAATCATTTAAAACATCAGAATGAGTATTT

-continued

SEO TO		
NO:	Description	Sequence
		GGTTTAGAGTTTGGCAACATATGCCATATGCTGGC TGCCATGAACAAAGGTGGCTATAAAGAGGTCATCA GTATATGAAACAGCCCCCTGCTGTCCATTCCTTATT CCATAGAAAAGCCTTGACTTGA
49	Helper; CMV early (CAG) enhancer; Enhance transcription	TAGTTATTAATAGTAATCAATTACGGGGTCATTAG TTCATAGCCCATATATGGAGTTCCGCGTTACATAA CTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA CGACCCCCGCCCATTGACGTCAATAATGACGTATG TTCCCATAGTAACGCCAATAGGGACTTTCCATTGA CGTCAATGGGTGGACTATTACGGTAAACTGCCCA CTTGGCAGTACATCAAGTGTATATCATATGCCAAGTA CGCCCCCTATTGACGTCAATGACGGTAAATGGCCC GCCTGGCATTATGCCCAGTACATGACCTTATGGGA CTTTCCTACTTGGCAGTACATCACGTATTAGTCAT C
50	Helper; Chicken beta actin (CAG) promoter; Transcription	GCTATTACCATGGGTCGAGGTGAGCCCCACGTTCT GCTTCACTCTCCCCATCTCCCCCCCCCC
51	Helper; Chicken beta actin intron; Enhance gene expression	GGAGTCGCTGCGTGCCTTCGCCCGTGCCCCGCTC GCCGCCCCCGCCGCCCGC
52	Helper; HIV Gag; Viral capsid	ATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAG AATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA GGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTT AATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAG ACAAATACTGGGACAGCTACAACCATCCCTCAGA CAGGATCAGAAGAACTTAGATCATATATAATACA GTAGCAACCCTCTATTGTGCATCAAAGGATAGA GATAAAAGACACCAAGAAAGTATAGAACAAAGACA AGCAAGCAGCCAACAAAAGTAAGAAAAAAGCAC AGCAAGCAGCCGACACAGGACACAGCAATCA GGTCAGCCAAAATTACCATCAGGCAATACAC GGTCAGCCAAAATTACCATCAGGCAAAACAACACA AGCTATCAGGAACACAGGACACAGCAATCC AGGGCAAATGGTACACAGGACACAGCAATCCA CAGGGCAAATGGTACATCAGGCCATATCCACCTAGA ACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGA AGCTTTCAACCCCAGAAGTGATACCCATGTTTTCA

GCATTATCAGAAGGAGCCACCCCACAAGATTTAAA

95

10 :	Description	Sequence
		CACCATGCTAAACACAGTGGGGGGACATCAAGCA GCCATGCAAATGTTAAAAGAGACCATCAATGAGG AAGCTGCAGAATGGGATAGAGTGCATCCAGTGCAT GCAGGGCCTATTGCACCAGGCCAGATGAGAGAAA CCAGGGGAAGTGACATAGCAGGAACTACTAGTAC CCTTCAGGAACAAATAGGATGGATGACACATAATC CACCTATCCCCAGTAGGAGAAATCTATAAAAGATGG
		ATAATCCTGGGATTAAATAAAAAGTAAGAAAGAA TAGCCCTACCAGCATTCTGGACAATAAGACAAGGAC CAAAGGAACCCTTTAGAGACATATGTAGACCGATTC TATAAAACCTTAGAGACCGAGCAACCTTCACAAGA
		GGTAAAAAATTGGATGACAGAAACCTTGTTGGTC AAAATGCGAACCAGATGTAAGACTATTTTAAA GCATTGGGACCAGGAGCGACACTAGAAGAAAATGA
		TGACAGCATGTCAGGGAGTGGGGGGACCCGGCCA TAAAGCAAGAGTTTTGGCTGAAGCAATGAGCCAAG TAACAAATCCAGCTACCATAATGATACAGAAAGGC
		AATTTTAGGAACCAAAGAAGACTGTTAAGTGTTT CAATTGTGGCAAAGAAGGGCACATAGCCAAAAAT TGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAAT
		GTGGAAAGGAAGGACACCAAATGAAAGATGTAC TGAGAGACAGGCTAATTTTTAGGGAAGATCTGGC CTTCCCACAAGGAAGGCCAGGGAATTTTCTCAG AGCAGACCAGAGGCAACAGCCCCACCAGAAGAGA
		GCTTCAGGTTTGGGGAAGAGAGACAACAACTCCCTCT CAGAAGCAGGAGCCGATAGACAAGGAACTGTATC CTTTAGCTTCCCTCAGATCACTCTTTGGCAGCGACC CCTCGCACATA
3	Helper; HIV Pol; Protease and	ATGAATTTGCCAGGAAGATGGAAACCAAAAATGA TAGGGGGAATTGGAGGTTTTATCAAAGTAGGACAG
	reverse transcriptase	TATGATCAGATACTCATAGAAATCTGCGGACATAA AGCTATAGGTACAGTATTAGTAGGACCTACACCTG TCAACATAATTGGAAGAAATCTGTTGACTCAGATT
		GGCTGCACTTTAAATTTTCCCATTAGTCCTATTGAG ACTGTACCAGTAAAATTAAAGCCAGGAATGGATGG CCCAAAAGTTAAACAATGGCCATTGACAGAAGAA
		AAAATAAAAGCATTAGTAGAAATTTGTACAGAAAT GGAAAAGGAAGGAAAAATTTCAAAAATTGGGCCT GAAAATCCATACAATACTCCAGTATTTGCCATAAA
		GAAAAAAGACAGTACTAAATGGAGAAAATTAGTA GATTTCAGAGAACTTAATAAGAGAACTCAAGATTT CTGGGAAGTTCAATTAGGAATACCACATCCTGCAG
		GGTTAAAACAGAAAAAATCAGTAACAGTACTGGA TGTGGGGCGATGCATATTTTCAGTTACCCTTAGATAA AGACTTCAGGAAGTATACTGCATTTACCATACCTA
		GTATAAACAATGAGACACCAGGGATTAGATATCAG TACAATGTGCTTCCACAGGGATGGAAAGGATCACC AGCAATATTCCAGTGAGAAGGATGACAAAAATCTTAG
		AGCUTTITAGAAAACGAAAATCUAGACATAGTCATC TATCAATACATGGATGATTGTATGTAGGATCTGA CTTAGAAATAGGGCAGCATAGAACAAAAATAGAG CAATGACAAAAAAGAGAACAAAAATAGAG
		CACACCAGACAACACTCIGIIGAGAGACCTCCA CACACCAGACAAAAAACATCAGAAAGAACCTCCA TTCCTTTGGATGGGTTATGAACTCCATCCTGATAAA TGGACAGTACCAGCCTATAGTGCTGCCCAGAAAAGGA
		CAGCTGGACTGTCAATGACATACAGAAATTAGTGG GAAAATTGAATTG
	AACCAAAGCACTAACAGAAGTAGTACCACTAACA GAAGAAGCAGAGCTAGAACTGGCAGAAAACAGGG AGATTCTAAAAGAACCGGTACATGGAGTGTATTAT	
	GACCCATCAAAAGACTTAATAGCAGAAATACAGA AGCAGGGGCAAGGCCAATGGACATATCAAATTTAT CAAGAGCCATTTAAAAATCTGAAAAACAGGAAAAT	
		ATGCAAGAATGAAGGGTGCCCACACTAATGATGTG AAACAATTAACAGAGGCAGTACAAAAAATAGCCA CAGAAAGCATAGTAATATGGGGAAAGACTCCTAA
		ATTTAAATTACCCATACAAAAGGAAACATGGGAAG CATGGTGGACAGAGTATTGGCAAGCCACCTGGATT CCTGAGTGGGAGTTTGTCAATACCCCTCCCTTAGTG
		AAGTTATGGTACCAGTTAGAGAAAGAACCCATAAT AGGAGCAGAAACTTTCTATGTAGATGGGGCAGCCA ATAGGGAAACTAAATTAGGAAAAGCAGGATATGT
		AACTGACAGAGGAAGACAAAAAGTTGTCCCCCTA ACGGACACAACAAATCAGAAGACTGAGTTACAAG

SEQ ID NO:	Description	Sequence
		CAATTCATCTAGCTTTGCAGGATTCGGGATTAGAA GTAAACATAGTGACAGACTCACAATATGCATTGGG AATCATTCAAGCACAACCAGATAAGAGTGAATCAG AGTTAGTCAGTCAAATAATAAGAGCAGTTAATAAAA AAGGAAAAAGTCTACCTGGCATGGGTACCAGCAC ACAAAGGAATTGGAGGAAATGAACAAGTAGATGG GTTGGTCAGTGCTGGAATCAGGAAAGTACTA
54	Helper; HIV Integrase; Integration of viral RNA	TTTTTAGATGGAATAGATAAGGCCCAAGAAGAACA TGAGAAATATCACAGTAATTGGAGAGCAATGGCTA GTGATTTTAACCTACCACTGTAGTAGGAGCAATGGCTA ATAGTAGCCAGGCATGTGATAAATGTCAGCTAAAAGA GGAAGCCATGCATGGACAAGTAGACTGTAGCCAGT GGAATATGGCAGCAGAAGTAGTACACATTTAGAAGG AAAAGTTATCTTGGTAGCAGTTCATGTAGCCAGTG GATATATAGAAGCAGAAGTAATTCCAGCAGAGAC AGGGCAAGAAACAGCATACTTCCTCTTAAAATTAG CAGGAAGATGGCCAGGTAACTACCAGTTAAAGG CAGGCAGCAAGAAACAGCATACTACCAGTTAAAGG CCGCCTGTTGGTGGGCGGGGGATCAAGCAGGAATTT GGCATTCCTACAATTCCACCAGTACTAAGG AGAACGATAGCAGAATTAAAGAACATTAAAG GACAGGTAAGAAATGAGCATTAAAGGAACTTTAAAG GACAGGTAAGAAGATTAGGGGGGTACAGCAGCAG GAAAGAATAGTAGCAGTAATAGCAACAGACATTA CAAACTAAAGGGGGGATTGGGGGGGTACAGTGCAGG GGAAAGAATAGTAGACATAATAGCAACGACATA CAAACTAAAGAATACAAAACAAA
55	Helper; HIV RRE; Binds Rev element	AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAG GAAGCACTATGGGCGCAGCGTCAATGACGCTGACG GTACAGGCCAGACAATTATTGTCTGGTATAGTGCA GCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGC AACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAA GATACCTAAAGGATCAACAGCTCCT
56	Helper; Rabbit beta globin poly A; RNA stability	AGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAAT AAAGGAAATTTATTTTCATTGCAATAGTGTGTTGG AATTTTTTGTGTCTCTCACTCGGAAGGACATATGGG AGGCAAAATCATTTAAAACATCAGAATGAGGTATTT GGTTTAGAGTTTGGCAACATATGCCATAGCTGC TGCCATGAACAAAGGTGGCTATAAAGAGGTCATCA GTATATGAAACAGCCCCTGCTGTCCATTCCTTATT CCATAGAAAAGCTTGACTTAGAGTTAGATTTTTT TATATTTGTTTTGT
57	Rev; RSV promoter; Transcription	ATGGCAGGAAGAAGCGGAGGAGACAGCGACGAAGAAC TCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATC AAAGCAACCCACCTCCCAATCCCGAGGGGACCCG ACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGA GAGAGACAGAGACAGATCCATTCGATTAGTGAAC GGATCCTTAGCACTTATCTGGGACGATCTGCGGAG CCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTT ACTCTTGATTGTAACGAGGATTGTGGAACTTTCGG GACGCAGGGGGGGGGAAGCCCTCAAATATTGGTG GAATCTCCTACAATATTGGAGTCAGGAGCTAAAGA ATAG
58	Rev; HIV Rev; Nuclear export and stabilize viral mRNA	ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAAC TCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATC AAAGCAACCCACCTCCCAATCCCGAGGGGACCCG ACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGA GAGAGACAGAGACAGATCCATTCGATTAGTGAAC GGATCCTTAGCACTTATCTGGGACGATCTGCGGAG CCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTT

## 99

-continued

SEO TO		
NO:	Description	Sequence
		ACTCTTGATTGTAACGAGGATTGTGGAACTTCTGG GACGCAGGGGGTGGGAAGCCCTCAAATATTGGTG GAATCTCCTACAATATTGGAGTCAGGAGCTAAAGA ATAG
59	Rev; Rabbit beta globin poly A; RNA stability	AGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAAT AAAGGAAATTATTTTCATTGCAATAGTGTGTTGG AATTTTTTGGTCTCTCACTCGGAAGGACATATGGG AGGCAAATCATTTAAAACATCAGAATGAGATATT GGTTTAGAGTTTGGCAACATATGCCCATATGCTGG CTGCCATGAACAAAGGTTGGCTATAAAGAGGTCAT CAGTATATGAAACAGCCCCCTGCTGTCCATTCCTTA TTCCATAGAAAAGCCTTGACTTGA
60	Envelope; CMV promoter; Transcription	ACATTGATTATTGACTAGTTATTAATAGTAATCAAT TACGGGGTCATTAGTTCATAGCCCATATATGGAGT TCCGCGTTACATAACTTACGGTAAATGGCCCGCCT GGCTGACCGCCAACGACCCCCGCCATTGACGTC AATAATGACGTATGTTCCCATAGTAACGCCCAATAG GGACTTTCCATTGACGTCAATGGGTGGAGTATTTA CGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA TCATATGCCAAGTACGCCCCCTATTGACGTCAATG ACGGTAAATGGCCCGCCTGGCATTATGCCCAGTAC ATGACCTTATGGGACTTTCCTACTTGGCAGTACATC TACGTATAGTCATCGCTATTACCATGGTGATGCG GTTTTGGCAGTACATCAATGGGCGTGGATAGCGGT TTGACTCCACGGGGATTTCCAAGTCTCCACCCCCATTG ACGTCAATGGGCGTTTTCGACGCCCCCATTG ACGTCAATGGGAGTTTCCAAGTCTCCCACCCCCATTG ACGTCAATGGGAGTTGTTTGGCACCAAAATCAA CGGGACTTTCCAAAATGTCCTAACAACTCCGCCC ATTGACGCAAATGGGCGTAGGGGGGGACGGGGGGGGGG
61	Envelope; Beta globin intron; Enhance gene expression	GTGAGTTTGGGGACCCTTGATTGTTCTTTCTTTTC GCTATTGTAAAATTCATGTTATATGGAGGGGGGCAA AGTTTTCAGGGTGTTGTTTAGAATGGGAAGATGTC CCTTGTATCACCATGGACCCTCATGATAATTTTGTT TCTTTCACTTTCTGTTACATTGTGACCATTGTCTC CTCTTATTTCTTTTCATTGCAGACCATTGTTTCAGT AAACTTTAGCTTGCATTGTAACGAATTTTTAAATT CACTTTTGTTTATTGTCAGGCAATCGAGATATTT TTTTGACTTCACCACAGTTTTAGAGAACATTG TTATAATAAATGATAAGGTAGAATATTCTTATGGT AGAAACAACTACACCCGGGTGGAAATATTCTTATTGGT GAGAACAACTACACCCGGTCGACATATCCTTCT CTCTTTATGGTACATCTGGTAGATATCCTGCTT GAGGATAAAATACTCTGGAGTCATCACCGGGCCCT CTGCTAACCATGTTCAGGCCTTCTCTCTCTCTCTCTAGGTAACCTGTTCGAGAT GAGGATAAAATACTCTGAGTCCAACCGGGCCCT CTGCTAACCATGTCATGCCTTCTCTCTCTCTCTACGAG
62	Envelope; VSV- G; Glycoprotein envelope-cell entry	ATGAAGTGCCTTTTGTACTTAGCCTTTTTATTCATT GGGGTGAATTGCAAGTTCACCATAGTTTTTCCACA CAACCAAAAAGGAAACTGGAAAAATGTTCCTTCTA ATTACCATTATTGCCCGCCAAGCTCAGATTTAAATT GGCATAATGACTTAATAGGCACAGCCTTACAAGTC AAAATGCCCAAGAGTCATAGGCACAGGCCATTACAAGCA ACGGTTGGATGTGTCATGCTTCCAAATGGGTCACT ACTTGTGGATTCCCGCTGGTATGGACCGAAGTATAT AACACATTCCATCCGGTCTTCACCACTGTAGA ACAATGCCAAGGAAAGCATTGAACAAAGGAAACAA GGAACTTGGCTGAATCCATCACCACTCTCCACATGTGA TGTGGATATGCAACTGTGACGGATGCCGAAGCAG TGTGGATATGCAACTGTGACGGATGCCGAAGCAG TGATTGTCCAGGGAAACTCCTCCACCATGTGCTGGTTG ATGAATACACAGGAGAATCCCTCCACCATGTGCTGGTTG ATGAATACACAGGAGAATGCATTACATATGCCCCAC TGTCCATAACTCTACACCTGGCATTCTGACTATAA GGTCAAAGGGCTATGTGATTCTAACTCATTCCAT GGACATCACCTTCTTCCCAGGGAGCGAGAGCTAT CATCCCTGGGAAAGGAGGCCACAGGGTTCAGAAG TAACTACTTTGCTTATGAAACTGGAGGCCACAGGCTCAGAG TAACTACCTTGCTTATGAAACTGGAGGCCACAGGCCT GCAAAATGCAATACTGCAGCACTGGGGAGGCCTAG

100

101

NO :	Description	Sequence
		ACTCCCATCAGGTGTCTGGTTCGAGATGGCTGATA AGGATCTCTTTGCTGCAGCCAGATTCCCTGAATGC CCAGAAGGGTCAAGTATCTTGCTCCATCTCAGAC CTCAGTGGATGTAAGTCTAATTCAGGACGTTGAGA GGATCTTGGATTATTCCCTCTGCCAAGAAACCTGG AGCAAAATCAGAGGGGGTCTTCCAATCTCTCCCAGT GGATCTCAGCTATCTTGCTCCTAAAAACCCAGGA CCGGTCCTGCTTTCACCATAATCAATGGTACCCTAA AATACTTTGGACCAGATACTCAAGAGTCGGAATGAT GCTGCTCCAATCCTCCAAGAATGGTCGGAATGAT GACTGGGACCACCAGATAGATGGTGGGAATTGGACC CAATGGAACTACCACAGAAAGGGAACTGTGGGAT GACTGGGCACCATATGAAGACGTGGGAAATTGGACC CAATGGAACTACCACAGAAAGGGACCTGTGGGAT TCCCTTTATACATGATTGGACAGGTTCGGAATGTCC CGATCTTCACTCAGAGCCAGTTCAGGATATTAAGT TTCCTTTATACATGATTGGACAGGTCGGGTTCG AACATCCTCACATCAAGACGTGGTCCGCAACTT CCTGATGATGAGAGGTTTATTTTTGGTGATACTGGG CTATCCAAAAATCCAATCGAGCTTGTGGAATTGG CTTCAGTAGATGGAAAGGCTCATTGGATACTGGG CTATCCAAAAATCCAATCGAGCTTATGCACTTTTTT CTTTATCATAGGTTAATCATTGGACTATTGCTTTTTTT CTTTATCATAGGGTTAACTTTGGGT TTCCCGACTTGGTAACCATGGACTATTCTGGT TCCCCGACTTGGTAACCATCATGGACTATTCTGGT TCCCCGACTGGTAACCATTGGACTATTGGACTATTGGT ACCACACAAAAAAGACAGATTTATACAGACATA GACACCCAAGAAAAGACAGATTTATACAGACATA GAGATGA
63	Envelope; Rabbit beta globin poly A; RNA stability	AGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAAT AAAGGAAATTATTTTCATTGCAATAGTGTGTTGG AATTTTTTGGTCTCTCACTCGGAAGGACATATGGG AGGCAAATCATTTAAAACATCAGAATGAGTATTT GGTTTAGAGTTTGGCAACATATGCCCATATGCTGG CTGCCATGAACAAAGGTTGGCTATAAAGAGGTCAT CAGTATATGAAACAGCCCCCGTGTCCATTCCTTA TTCCATAGAAAAGCCTTGACTTGA
64	Promoter; EF-1	CCCTAAAATTTTCCTTACATGTTTTACTAGCCAGAT TTTTCCTCCTCTCTGACTACTCCCAGTCATAGCTG TCCCTCTTCTCTT
		CTCGGCCTGGTGCGTGAGGCCTGGGGCCGGGCGCGCGCGC
65	Promoter; PGK	GGGGTTGGGGTTGCGCCTTTTCCAAGGCAGCCCTG GGTTTGCGCAGGGACGCGGCTGCTCTGGGCGTGGT TCCGGGAAACGCAGCGGCGCCGACCCTGGTTCTCG CACATTCTTCACGTCCGTTCGCAGCGTCACCCGGAT CTTCGCCGCTCTTGTGGGCCCCCCCGGCACGC

## 103

NO:	Description	Sequence
		TTCCTGCTCCGCCCCTAAGTCGGGAAGGTTCCTTGC GGTTCGCGCGCGTGCCGGACGTGACAAACGGAAGC CGCACGTCTCACTAGTACCCTCGCAGACGGACAGC GCCAGGGAGCAATGGCAGCGCCGCCGACGCGCATG GGCTGTGGCCAATAGCCAGCGGCGCGCGCGGA CGCGGGGGTGGGGCCGGGAGGGGCGGTGCGGGA GGCGGGGGTGTGGGGCGGTAGTGGGGCCCTGTTCC TGCCCGCCGGGTGTTCCGCATTCTGCAAGCCTCCG GAGCGCACGTCGGCAGTCGGCTCCCTCGTTGACCG AATCACCGACCTCTCCCCCAG
6	Promoter; UbC	GCGCCGGGTTTTGGCGCCTCCCGCGGGGCGCCCCCC TCCTCACGCGAGCGCTGCCACGTCAGACGAAGGG CGCAGGAGCGTTCCTGATCCTTCCGCCCGGACGCT TAGAACCCCAGTATCAGCAGAAGGACATTTTAGGA CGGGACTTGGGTGACTCTAGGGGACTGGTTTTCTT CCAGAGACGCGAACAGCGAGGAAAGTAGTCCC TTCTCGGCGATCTGCGGGGGGGGCCGGGG GGTGAACGCCGATGATTATATAAGGACCGCCCGGG GGTGACACCCGATGATTATTATAAGGACCGCCGGG GGTGACGCCGATGATTATTATAAGGACCGCCGGG GGTGACGCGCTCTGGTGGACCGGGGCTGTGAGCCGGG CTTTCGTGGGCGCCGCGGGCCGCTGGGCCGGGG CTTTCGTGGCGCCCCGGGCCGCTGGGCCGGGG CTTCGTGGGACGCCCGGGCCGCTGGGCCGGGG GGGAGCGCACAAATGGCGCCTGGGCCGGGG TCCGCGACCAAGGTCGCCAGGGCTGTGGGCCGGGG GGGAGCGCACAAAATGGCGGCTGTCCCGAGTCT GAATGGAAGACGCTTGTAAGCCGGGCTGTGAGGTC GTTGAAACAAGGTGGGGGCCTTCGGTGGCGGCA GAACCCCAGGTCTTGGAGGGCCTGTGGGGGCCCC ACCTGGGGACCGCCGGCGGGCCGGGC
7	Poly A; SV40	GTTTATTGCAGCTTATAATGGTTACAAATAAAGCA ATAGCATCACAAATTTCACAAATAAAGCATTTTTT CACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCA ATGTATCTTATCA
8	Poly A; bGH	GACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTG CCCCTCCCCGTGCCTTCCTTGACCCTGGAAGGTGC CACTCCCACTGTCCTTTCCTAATAAAATGAGGAAA TTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC TGGGGGGTGGGGT
39	HIV Gag; Bal	ATGGGTGCGAGAGAGCGTCAGTATTAAGCGGGGGAG AATTAGATAGGTGGGAAAAAATTCGGTTAAGGCCA GGGGGAAAGAAAAAATATAGATTAAAACATATAG TATGGCAAGCAGGGAACTAGAAAGATTCGCAGT CAATCCTGGCCTGTTAGAAACATCAGAAGGCTGCA GACAAATACTGGGACAGCTACAACACCATCCCTTCAG ACAGATCAGAAGAACATTGGACACCATCCCTTCAG ACAGATCAGAAGAACATTGGTACATCAAAAGATAG AGGTAAAAGACACCAAGGAAGCTTTAGACAAAAT AGAGGAAGAGCAAAACAATGTAAGAAAAAGGCA CAGCAAGCAAGCAAAACAATGTAAGAAAAAGGCA CAGCAAGCAAGCAAAACTAATGGTACAACAGCGGTC AGGTCAGCCAAAATTTCCCTATAGTGCAGAACCTC CAGGGGCAAAATGTCACGAGGAAACAAGGAG AACTTTAAATGCATGGGTAAAAGTAATAGAAGAG AAAGCTTTCAGCCAGAAGTAATACCATGTTTC AGCATTATCAGAAGAGCCACCCCCCCACAAGATTTAA

105

SEQ ID	Description	Section co
110.	Description	Sequence
		AGCCATGCAAATGTTAAAAGAACCCATCAATGAGG AAGCTGCAAGATGGGATAGATTGCATCCCGTGCAG
		GCAGGGCCTGTTGCACCAGGCCAGATAAGAGATCC
		AAGGGGAAGTGACATAGCAGGAACTACCAGTACC
		CTTCAGGAACAAATAGGATGGATGACAAGTAATCC ACCTATCCCAGTAGGAGAAATCTATAAAAGATGGA
		TAATCCTGGGATTAAATAAAATAGTAAGGATGTAT
		AGCCCTACCAGCATTTTGGACATAAGACAAGGACC
		AAAGGAACCCTTTAGAGACTATGTAGACCGGTTCT ATAAAACTCTAAGAGCCGAGCAAGCTTCACAGGA
		GGTAAAAAATTGGATGACAGAAAACCTTGTTGGTCC
		AAAATGCGAACCCAGATTGTAAGACTATTTTAAAA
		GCATTGGGACCAGCAGCTACACTAGAAGAAATGAT GACAGCATGTCAGGGAGTGGGAGGACCCAGCCAT
		AAAGCAAGAATTTTGGCAGAAGCAATGAGCCAAG
		TAACAAATTCAGCTACCATAATGATGCAGAAAGGC
		AATTTTTAGGAACCAAAGAAAGATTGTTAAATGTTT CAATTGTGGCAAAGAAGGGCACATAGCCAGAAAC
		TGCAGGGCCCCTAGGAAAAGGGGCTGTTGGAAAT
		GTGGAAAGGAAGGACACCAAATGAAAGACTGTAC
		TGAGAGACAGGCTAATTTTTTAGGGAAAATCTGGC
		AGCAGACCAGAGCCAACAGCCCCACCAGCCCCAC
		CAGAAGAGAGCTTCAGGTTTGGGGAAGAGACAAC
		AACTCCCTCTCAGAAGCAGGAGCTGATAGACAAGG
		GCAACGACCCCTCGTCACAATAA
70	HIV Pol: Bal	ATGAATTTGCCAGGAAGATGGAAACCAAAAATGA
	,	TAGGGGGAATTGGAGGTTTTATCAAAGTAAGACAG
		AGCTATAGGTACAGTATTAATAGGACCTACACCTG TCAACATAATTGGAAGAAATCTGTTGACTCAGATT
		GGTTGCACTTTAAATTTTCCCATTAGTCCTATTGAA
		ACTGTACCAGTAAAATTAAAACCAGGAATGGATGG
		CCCAAAAGTTAAACAATGGCCACTGACAGAAGAA AAAATAAAAGCATTAATGGAAATCTGTACAGAAAT
		GGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCT
		GAAAATCCATACAATACTCCAGTATTTGCCATAAA
		GAAAAAAGACAGTACTAAATGGAGAAAATTAGTA GATTTCAGAGAACTTAATAAGAAAAGACTT
		CTGGGAAGTACAATTAGGAATACACATCCCGCAGG
		GGTTAAAAAAGAAAAAATCAGTAACAGTACTGGA
		TGTGGGTGATGCATATTTTTCAGTTCCCTTAGATAA
		GTATAAACAATGAAACACCAGGGATCAGATATCA
		GTACAATGTACTTCCACAGGGATGGAAAGGATCAC
		CAGCAATATTTCAAAGTAGCATGACAAGAATCTTA GAGCCTTTTTAGAAAACAAAATCCAGAAATAGTGAT
		CTATCAATACATGGATGATTTGTATGTAGGATCTG
		ACTTAGAAATAGGGCAGCATAGAACAAAAATAGA
		GGAACTGAGACAACATCTGTTGAGGTGGGGATTTA
		ATTCCTTTGGATGGGTTATGAACTCCATCCTGATAA
		ATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAG
		ACAGCTGGACTGTCAATGACATACAGAAGTTAGTG
		AATTAAAGTAAAGCAATTATGTAGGCTCCTTAGGG
		GAACCAAGGCATTAACAGAAGTAATACCACTAAC
		AAAAGAAACAGAGCTAGAACTGGCAGAGAACAGG
		GAAATTCTAAAAGAACCAGTACATGGGGTGTATTA TGACCCATCAAAAGACTTAATAGCAGAAATACAGA
		AGCAGGGGCAAGGCCAATGGACATATCAAATTTAT
		CAAGAGCCATTTAAAAATCTGAAAACAGGAAAAT
		ATGCAAGAATGAGGGGTGCCCACACTAATGATGTA
		AAACAATTAACAGAGGCAGTGCAAAAAATAACCA Cagaaagcataatataggggaaagaggctcctaa
		ATTTAAACTACCCATACAAAAAGAAACATGGGAA
		ACATGGTGGACAGAGTATTGGCAAGCCACCTGGAT
		TCCTGAGTGGGAGTTTGTCAATACCCCTCCCTTAGT
		GAAATTATGGTACCAGTTAGAGAAAGAACCCATAA
		TAGGAGCAGAAACATTCTATGTAGATGGAGCAGCT AACCGGGAGACTAAATTAGGAAAAGCAGGATATG
		TTACTAACAGAGGAAGACAAAAAAGTTGTCTCCCTA
		ACTGACACAACAAATCAGAAGACTGAGTTACAAG
		CAATTCATCTAGCTTTACAAGATTCAGGATTAGAA

## 107

.10 :	Description	Sequence
		GTAAACATAGTAACAGACTCACAATATGCATTAGG AATCATTCAAGCACAACCAGATAAAAGTGAATCAG AGTTAGTCAGTCAAATAATAGAACAGTTAATAAAA AAGGAAAAGGTCTACCTGGCATGGGTACCAGCGC ACAAAGGAATTGGAGGAAATGAACAAGTAGATAA ATTAGTCAGTACTGGAATCAGGAAAGTACTA
71	HIV Integrase; Bal	TTTTTAGATGGAATAGATATAGCCCAAGAAGAACA TGAGAATATCACAGTAATTGGAGAGCAATGGCTA GTGATTTTAACCTGCCACCTGTGGTAGCAAAAGA ATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGG AGAAGCCATGCATGGACAAGTAGACTGTAGTCCAG GAATATGGCAACTAGGAGATGTAACACATTTAGAAGGA AAAATTATCCTGGTAGCAGTTCATGTAGCCAGTGG ATATATAGAAGCAGAAGTTATTCCAGCAGAGACAG GGCAGGAAACAGCATACTTTCTCTTAAAATTAGCA GGAAGATGGCCAGTAAAAACAATACATACAGACA ATGCCAGCAGTTCACTGTAGCAGGAGAAG CAGTAGGCGCAGTAAAAACAATACATACAGACA ATTCCTTACAATCCCCAAAGTCAGGAGATAGTAG AATCTATAAATAAAGAATTAAAGAAATTATAGGA CAGTACAAATCGCAGGCTGAACAGCAGGAGTAGTAG AATCTATAAATAAAGAATTAAAGAAAATTATAGGA CAGGTAAGAGATCGGCGGTATAGTGCAAGGGG AGTACAAATGCCAGTATTCACACACCTCTTAAAACAGC AGTACAAATGGCAGTATTCACCACAATTTAAAG AAAAGGGGGATTGGGGGGTATAGTGCAGGGGA AAGAATAGTAGACATTACAAGACAAATTACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCCA AAATTTCCGGTTTATTACAGGGACAGCAGCAGAGAAT CCACTTTGGAAAGGACCAGCAAAGCTTCCTGGAAA GGTGAAGGGCAGTAGTAATACAAAGCAAAAGAT CATTAGGAATAGTACCAACAAGCCATCCTGGAAA GGTGAAGGACGAGTAATACAAGACTACCTGGAAA GGTGAAGGACGAGAAGAACCAAAGCTACCTGGAAA GGTGAAGGACAGGAAGAAACCAAAGCAAAG
72	Envelope; RD114	ATGAAACTCCCAACAGGAATGGTCATTTTATGTAG CCTAATAATAGTTCGGGCAGGGTTGACGACCCCC GCAAGGCTATCGCATTAGTACAAAAACAACATGGT AAACCATGCCATG

-continued

NO. Dogg	rintion	Semience
MO: Desci	11201011	pequeitoe
		GGGCTTTCTTCCGTACCTCCTACCTCCTGGGACC CCTACTCACCCTCCTACTCATACTAACCATTGGGCC ATGCGTTTTCAATCGATTGGTCCAATTTGTTAAGA CAGGATCTCAGTGGTCCAGGCTCTGGTTTTGACTC AGCAATATCACCAGCTAAAACCCATAGAGTACGAG CCATGA
73 Envel GALV	Lope;	CCATGA ATGCTTCTCACCTCAAGCCCGCACCACCTTCGGCA CCAGATGAGTCCTGGGAGCTGGAAAAGACTGATCA TCCTCTTAAGCTGGCATTTCGGGAGCGGCAAAACG AGTCTGCGAGATAAGAACCCCACCACCACCGCGTGGAC CCTCACCTGGCAGATATCGTCCTGTAAAGCAGTGACCC CTGGCGGCCGGTCTTGTAACACCTGGGATATCCCGGG ATCTGGTGGCCCTCTTGAAGCAGTTACCCGGG ACTCGGGGCCGGTCTTGAAGCGCGCTTATAAGCAATC ACCTGGGGACCATAGGGTGCAGCTCCCTGGAGCTAAGCAAGC
74 Envel	Lope; FUG	ATGGTTCCGCAGGTTCTTTTGTTTGTACTCCTTCTG GGTTTTTCGTTGTGTTTCGGGAAGTTCCCCATTTAC ACGATACCAGACGAACTTGGTCCCTGGAGCCCTAT TGACATACACCATCTCAGCTGTCCAAATAACCTGG

111

SEQ II	)	
NO :	Description	Sequence
		ACTGGAAGATGGCCGGTGACCCCAGATATGAAGA
		GTCCCTACACAATCCATACCCCGACTACCACTGGC
		TTCGAACTGTAAGAACCACCAAAGAGTCCCTCATT
		ATCATATCCCCAAGTGTGACAGATTTGGACCCATA
		GAAAGTGCTCAGGAATAACGGTGTCCTCTACCTAC
		CCACCAA
		TTACCAATAGCAGAGGGAAGAGAGAGCATCCAACGG
		GAACAAGACTTGCGGCTTTGTGGATGAAAGAGGCC
		TGTATAAGTCTCTAAAAGGAGCATGCAGGCTCAAG
		TTATGTGGAGTTCTTGGACTTAGACTTATGGATGG
		AACATGGGTCGCGATGCAAACATCAGATGAGACC
		AAATGGTGCCCTCCAGATCAGTTGGTGAATTTGCA
		CGACTTTCGCTCAGACGAGATCGAGCATCTCGTTG
		GGATGCATTAGAGTCCATCATGACCACCAAGTCAG
		TAAGTTTCAGACGTCTCAGTCACCTGAGAAAACTT
		GTCCCAGGGTTTGGAAAAGCATATACCATATTCAA
		CAAAACCTTGATGGAGGCTGATGCTCACTACAAGT
		CAGTCCGGACCTGGAATGAGATCATCCCCTCAAAA
		GGGTGTTTGAAAGTTGGAGGAAGGTGCCATCCTCA
		TGTGAACGGGGTGTTTTTCAATGGTATAATATTAG
		GGCCTGACGACCATGTCCTAATCCCAGAGATGCAA
		CCCTTCTACAGTTTTCAAAGAAGGTGATGAGGCTG
		AGGATTTTGTTGAAGTTCACCTCCCCGATGTGTACA
		AACAGATCTCAGGGGTTGACCTGGGTCTCCCGAAC
		TGGGGAAAGTATGTATTGATGACTGCAGGGGCCAT
		GATTGGCCTGGTGTTGATATTTTCCCTAATGACATG
		GTGCAGAGTTGGTATCCATCTTTGCATTAAATTAA
		AGUAUUAAGAAAAGAUAGATTT'ATACAGACAT bababatabbacab cutugabbbacat
		AGAGAIGAACCGACIIGGAAAGIAA
75	Envelope:	ATGGGTCAGATTGTGACAATGTTTGAGGCTCTGCC
	LCMV	TCACATCATCGATGAGGTGATCAACATTGTCATTA
		TTGTGCTTATCGTGATCACGGGTATCAAGGCTGTCT
		ACAATTTTGCCACCTGTGGGATATTCGCATTGATCA
		GTTTCCTACTTCTGGCTGGCAGGTCCTGTGGCATGT
		ACGGTCTTAAGGGACCCGACATTTACAAAGGAGTT
		TACCAATTTAAGTCAGTGGAGTTTGATATGTCACA
		GGACTAGAATTGACCTTCACCAATGATTCCATCAT
		CAGTCACAACTTTTGCAATCTGACCTCTGCCTTCAA
		CAAAAAGACCTTTGACCACACACTCATGAGTATAG
		TTTCGAGCCTACACCTCAGTATCAGAGGGAACTCC
		AACTATAAGGCAGTATCCTGCGACTTCAACAATGG
		CATAACCATCCAATACAACTTGACATTCTCAGATC
		GACAAAGTGCTCAGAGCCAGTGTAGAACCTTCAGA
		GGIAGAGTUUTAGATATGTTTAGAACTGUUTTUGG GGGGAAATACATGAGGAGTGGGTGGGGGGGGGGAGA
		GGCTCAGATGGCAAGACCACCTGGTGTAGCCAGAC
		GAGTTACCAATACCTGATTATACAAAATAGAACCT
		GGGAAAACCACTGCACATATGCAGGTCCTTTTGGG
		ATGTCCAGGATTCTCCTTTCCCAAGAGAAGACTAA
		GTTCTTCACTAGGAGACTAGCGGGCACATTCACCT
		GGACTTTGTCAGACTCTTCAGGGGTGGAGAATCCA
		GGTGGTTATTGCCTGACCAAATGGATGATTCTTGCT
		GCAGAGCTTAAGTGTTTCGGGGAACACAGCAGTTGC
		GAAATGCAATGTAAATCATGATGCCGAATTCTGTG
		ALATGUTGUGAUTAATTGAUTACAACAAGGUTGUT TTCA CTA A CTTCA A A CA CCA CCTA CA A TCTCCCCTT
		ΤΙ GAGI AAGI I CAAAGAGGACGI AGAAI UTGUUTT GC 2 CTT 2 TTC 2 2 2 2 C 2 C 2 C 2 C 2 C
		CCACITATICAAAACAACAGIGAATICITIGATITC AGATCAACTACTGATGAGGAACCACTTGAGAGAGA
		TGATGGGGGTGCCATATTGCAATTACTCAAAGATC
		TGGTACCTAGAACATGCAAAGACCCCCCCCCAAAGIII
		GTGTCCCCAAGTGCTGGCTTGTCACCAATGGTTCTT
		ACTTAAATGAGACCCACTTCAGTGATCAAATCGAA
		CAGGAAGCCGATAACATGATTACAGAGATGTTGAG
		GAAGGATTACATAAAGAGGCAGGGGAGTACCCCC
		CTAGCATTGATGGACCTTCTGATGTTTTCCACATCT
		GCATATCTAGTCAGCATCTTCCTGCACCTTGTCAAA
		ATACCAACACAGGCACATAAAAGGTGGCTCATG
		TCCAAAGCCACACCGATTAACCAACAAAGGAATTT

## 113

SEQ ID NO:	Descriptio	n	Sequence
			GTAGTTGTGGTGCATTTAAGGTGCCTGGTGTAAAA ACCGTCTGGAAAAGACGCTGA
76	Envelope;	FPV	ATGAACACTCAAATCCTGGTTTTCGCCCTTGTGGCA GTCATCCCCACAAATGCAAATGGCACCAAAGTAAACA CACTCATGCTGTATCAAATGGCACCAAAGTAAACA CACTCACTGAGAGAGGGGACAAACATCCCCAAAA TTTGCTCAAAAGGGAAAAGAACACCCCTGATCTTGGC CAATGCGGACTGTTAGGGACCAATGCACTGTGTGC ACATGCGACCAATTCTAGGACATTGCGACCACTG CAATGCGACCAATTTCTAGGACTATGCGGA CAATGCGACCAATTCTAGAGAGGAATGCACAGGA CAATCCTCAGAGAGACGAGAAGGAAATGAGTTGCGA CAACGGAACTAGTGCATGTAGAGAATAGGACC AACGGAACAACTAGTGCATGTAGAAAAGGACCCAACGGACCACCCTGTCCA CAATGCGACCAATGCACTTCCCACAAATGACAAA AACAATGGGATTCACATATGGGAGGAGAATCAGGGT CTTCATTCTATGCAGAAATGGAGTGGCTCCTGTCA AATACAGACAACTAGTGCACTCCAGGAGGAATCAACCCAC CGAACGACCAAACCACGGAGGAGAATCACCCAC CGAACGACCAAACTATTGGGAGAGAATCACCCAC CGAACGACCAACCAACGAGGAGAATCACCCAC CGAACGACCAACCACCACCCAGCAGCAATAAA ATCATACAAGACCGGGAGTCCCAGCCGCAGATAA ATGGCCAGTCCCAGGACACCGACCGCAGATAA ATGGCCAGTCCCAGGACACCGACCGCAGATAA ATGGCCAGTCCCAGGACACGACCGCCGCAGATAA ATGGCCAGTCCCAGGAGATCCAGGGGAATCCAC CCACGGGGGAAAGTCCATGGGGAATCCACCTT CTTGAGGGGAAAGTCCATGGGGAATCCAGCTT CTTGAGGGGAAAGTCCATGGGGAATGCCTT TTCGAAGGTTAAACAGCAACGGAAGGGATGCTA CCACGGGAGAAGTCCATGGGGAACGCTTGGCCAAATGC CCAAGTATGTAAAACAGGAAAGTTTGCAAAGCC CCAAGTATGTAAAACAGGAAAGTTTGCCAAATGC CCAAGTAGGACGAACGTTCCGGAACGTCG ACTGGGATGAAGAACGTTCCGGAACGTTGGCCAAA AAAGGAAAAAAGAGGCTTTCTGGCCAATTGGCAAATGC CCAAGGAGGAACTGCCAGCACTTCGGACGAATGCCAA GGGAACAGTTAATAACAGGAAAGCTTCCAGAACCCC AACTGGGAAGAACTTCACGGAAAGCTTGGCCAAATGC CAACGGGATGAGAACGTCCAGCAACTTGGACCAA GGGAACAATTAAGGAAAACCAACCAACCAGCAATTGGACCAA AAGGAAAGAAACAGACAGCTTCCAGAAAGCCCC AATGGCAATTAATGACTACAGGAAAGCTACTAAA GGAAACAATTAAGGAAAATCCTGAACGGAAAGCCG ATTGGCAATTAAGGAAAAACCAGCCACTATTGGACTACCA GGAAACAATTAAGGAAAAACCAGCCACATATGGACTACTATG GCAACAATTAAGGAAAAGCCAACCACCACAATTGGACGAG GGAACAATTAAGGAAAAGCCGACACTATGGACGAGGA GGAACAATTAAGGAAAAGCCGACACTATGGACGATGG CACCGGTTGCTTGGAAAATCTTAGGTTCGGG GCACCAATTGACGAGAAGACCGGAACATACTTATG GCAACAATTAAGGAAAATGCTGAAGGAGGGCGG CTTGTTTCCAAAGATGGCAACTTCTGGGCC TTGTTTCCAAATGGCAATTGGTCGGGCCTTGTTTGGCAATGGGGC CTTGTTTCCAAATGGAAAGCCGGAACCAGCGAACATGCGGGCCTTGTTTGCTTCTGCTTGCT
77	Envelope;	RRV	AGTGTAACAGAGCACTTTAATGTGTATAAGGCTAC TAGACCATACCTAGCACATTGCGCCGATTGCGGGG ACGGGTACTTCGCTATAGCCCAGTTGCTATCGAG GAGATCCGAGATGAGGCGTCTGATGGCATAGCTAA GATCCAAGTCTCCGCCCAAATAGGTCTGGACAAGG CAGGCACCCACGCCCACACGAAGCTCCGATATATG GCTGGTCATGATGTTCAGGAATCTAAGAGAGATTC CTTGAGGGTGTACACGTCCGCAGCGTGCTCCATAC ATGGGACGATGGGACACTTCATCGTCGCACACTGT CCACCAGGCGACTACCTCAAGGTTCGTTCGAGGA CGCAGATTCGCACGTGAAGGCATGTAAGGTCCAAT
			ACAAGCACAATCCATTGCCGGTGGGTAGAGAGAA GTTCGTGGTTAGACCACACTTTGGCGTAGAGCTGC CATGCACCTCATACCAGCTGACAACGGCTCCCACC GACGAGGAGATTGACATGCATACACCGCCAGATAT ACCGGATCGCACCCTGCTATCACAGACGGCGGGGCA ACGTCAAAATAACAGCAGCGGCAGGACTATCAG GTACAACTGTACCTGCGGCCGTGACAACGTAGGCA CTACCAGTACTGACAAGACCATCAACACATGCAAG ATTGACCAATGCCATGCTGCCGTCACCAGGCATGA CAAATGGCAATTTACCTCTCCATTGGTTCCCAGGGC TGATCAGACAGCTAGGAAAGGCAACGATGCCCT

## 115

SEQ ID NO:	Descripti	on	Sequence
			TGGCTCGAGCGCCGGATGCCACCTATGGTAAGAAG GAGGTGACCCTGAGATTACACCCAGATCATCCGAC GCTCTTCTCCTATAGGAGTTTAGGAGCCGAACCGC ACCCGTACGAGGAATGGGTTGACAAGTTCTCTGAG CGCATCATCCCAGTGACGGAAGGAATGAGGA CCAGTGGGGCAACAACCCGCCGTCTGGCGG GCCACATGACAACACCCGCGGTCTGCCTGTGGG GCCACATGAAATCATTCAGTACTATTATGGACTAT ACCCCGCCGCCACTATTCAGGACTATTATGGACTAT ACCCCGCCGCCACTATTCTGGCGCACACG GTCTGATGGCCACCCAGGGGGAAAAGTGCCTAA CACCGTACGCCCCCGACGAGGAGAAAGTGCCTAA CACCGTACGCCCCCGAGGAGAAAGTGCCTAA CACCGTACGCCCCCGAGGAGAGAGGGTGGTCCG TTGACACTGGGGCTGCTTTGCTGCGCACCGAGGGG GAATGCA
78	Envelope; 10A1	MLV	AGTGTAACAGAGCACTTTAATGTGTATAAGGCTAC TAGACCATACCTAGCACATTGCGCCGATTGCGGGG ACGGGTACTTCTGCTATAGCCCAGTTGCTATCGAG GAGATCCGAGATGAGGCGCTCTAATGGCATGCTTAA GATCCAAGTCTCCGCCCAAATAGGTCTGGACAAGG CAGGCACCCACGCCACACGAAGCTCCGATATATG GCTGGTCATGATGTTCAGGAATCTAAGAGAGATTC CTTGAGGGTGGACACTTCATCGTCGCACACTGT CCACCAGGCGACGACGTCCTAACGATCGACACTGT CCACCAGGCGACTACCTCATCGTCGCACACTGT CCACCAGGCGACTGCACACGTGTCGAGAGA CGCAGATTCGCACGTGAAGGCATGTAAGGTCCCAAT ACAAGCACAATCCATTGCCGGTGGGTAGAGGAGA GTTCGTGGTTAGACCACCACTTTGGCGGAGAGAGA GTTCGTGGTTAGACCACCACTTTGGCGCACACTGC CACGAGAGAGATGACACCACACTTTGGCGGCGAGAGAGA GTTCGTGGTTAGACCACCACTTTGGCGCCGCAGATAT ACCAGGACAATCCATGCCGCCGCAGACATA ACCGGATCGCACCCTGCTATCACACGCCGCCAGATAT ACCGGATCGCACCCTGCTATCACAGACGGCGGGGCA ACGTCAAAATAACAGCAGGCGGCAGGACTATCAG GTACCAACTGTACCTGCGGCCGTGACACCATGACACCATGCAG CAAATGGCAATTTACCTCTCCATTGTTCCCAGGGC GGACCAGCCAGGAGGCAGGCAGGCAGACCATGA CAAATGGCAATTTACCTCTCCATTGTTCCCAGGGC TGGCTCGACTAAGACACCCCAGGCGGAGGCA GAGGTGACCCTGAGGAAGGCAAGGTACACGTTC CGTTCGCCTGACTAACGCCACCCTATGGTGAGAGA GAGGTGACCCTGAGGATTACACCCAGGCGGCG GCCCAACGACGAGGAGGACGACCGC ACCCGTACGAGGAATGGCCGCCCCACGCAACCGC GCCCTACGAGGAATGGGTTGACAAGGTACACCGT GGCTCGACCAGGAGGATGACACCCAGGCG CGCAACGACCGGAGGCCAAACCCCATGGCG CGCAACGACCACGACGGAGGACAACCCCATGGCG GCCCACGGACGACCGCGGAGGCAAACCCCATGGCG GCCACTGACGACCGAGGGCAAACCCCATGGCG GCCACTGACGACCGAGGGCAAACCCCATGGCG GCCACAGGAAATCATCCAGGCGGAGGAAAGGCCAAGGA CCCGTGGGCCACCATATGCCGCAGGATGACCCATG CCCGCCCCCCCCAGAGGACAACCCCATGGCG GCCACATGACGACCCCCCGCGGCTGCCGCACCGG CCCACAGAAACCCCCCCGCGGCCGCACCGG CCCACTGACGACCCCCCGCGGCGCCCCAAGGC CCCACGCGCCCCCCACGAGGCCAACCCCATGGCG GCCACATGACGACCCCCCCGCGGCGCACCCATG CCCGCCCCCGCGCGCCCCCAAGGCCAACCCCATGGCG ACCCGCCCCCCGCGCGCGAGGAAAGCCCCAAGGCCAACG CCGCACCGCCCCGCGCCCCCACGCGCGCCCCCAAG CCCGCCCCCGCGCGCCCCCCCC
79	Envelope;	Ebola	ATGGGTGTTACAGGAATATTGCAGTTACCTCGTGA TCGATTCAAGAGGACATCATTCTTTCTTTGGGTAAT TATCCTTTTCCAAAGAACATTTTCCATCCCACTTGG AGTCATCCACAATAGCACATTACAGGTTAGTGATG TCGACAAACTGGTTTGCCGTGACAAACTGTCATCC ACAAATCAATTGAGATCAGTTGGACTGAATCTCGA AGGGAATGGAGTGGCAACTGACGTGCATCTGCAA CTAAAAGATGGGGCTTCAGGCCGGTGGCACTCGCAA CTAAAAGATGGGGCTTCAGGCCGGTGATGGGCCGA AAGGTGGTCAATTATGAAACCGGACGGGATT CGGGGCTTCCCCGGTGCCGGTGGCCCGACGGGGATT CGGGGCTCCCCCGGTGCCGGTAGTGCACAAAGT ATCAGGAACGGGACCGTGTCCCGCGGAGCGGGATT CCCCAAAGAGGGGCCTTCTTCTCCTGTATGACCGA CTTGCTCCCACAGTTATCTACCAGCAGAACGACTTTC GCTGAAGGTGCTGTGCATTTCTGCTGATACCGCA AGCTACAGGTGCCGTGCC

117

-continued

NO :	Description	Sequence
		ACGGGAAAACTAATTTGGAAGGTCAACCCCGAAAT
		TGATACAACAATCGGGGAGTGGGCCTTCTGGGAAA
		CTAAAAAAACCTCACTAGAAAAATTCGCAGTGAAG
		AGTTGTCTTTCACAGCTGTATCAAACAGAGCCAAA
		AAAATCATGGCTTCAGAAAATTCCTCTGCAATGGT
		TCAAGTGCACAGTCAAGGAAGGGAAGCTGCAGTG
		TCGCATCTGACAACCCTTGCCACAATCTCCACGAG
		TCCTCAACCCCCACAACCAAACCAGGTCCGGACA
		ACAGCACCCACAATACACCCGTGTATAAACTTGAC
		ATCTCTGAGGCAACTCAAGTTGAACAACATCACCG
		AGAGAACACCAACACGAGCAAGGGTACCCGACCTC
		CTGGACCCCGCCACCACAACAAGTCCCCCAAAACCA
		CAGCGAGACCGCTGGCAACAACAACACTCATCACC
		AAGATACCGGAGAAGAGAGTGCCAGCAGCGGGAA
		GCTAGGCTTAATTACCAATACTATTGCTGGAGTCG
		CAGGACTGATCACAGGCGGGAGGAGAGCTCGAAG
		CIAAIIIACAIIACIGGACTACTCAGGATGAAGGT GCTGCAATCGCACTGCCCTGCATACCATATTCCCC
		GCCAGCAGCCGAGGGAATTTACATAGAGGGGGCTG
		ATGCACAATCAAGATGGTTTAATCTGTGGGTTGAG
		ACAGCTGGCCAACGAGACGACTCAAGCTCTTCAAC
		TGTTCCTGAGAGCCACAACCGAGCTACGCACCTTT
		TCAATCCTCAACCGTAAGGCAATTGATTTCTTGCTG
		ACATAACAGACAAACCACAIGAIIGGACCAAGA
		TTTGTTGATAAAACCCTTCCGGACCAGGGGGGACAA
		TGACAATTGGTGGACAGGATGGAGACAATGGATA
		CCGGCAGGTATTGGAGTTACAGGCGTTATAATTGC
		AGTTATCGCTTTATTCTGTATATGCAAATTTGTCTT
		TTAG
30	Short WPRE	ΔΑΤΓΑΑCCTCTGGΑΤΤΑCΑΔΑΑΤΤΤGTGΔΑΑGΑΤΤ
00	sequence	GACTGATATTCTTAACTATGTTGCTCCTTTTACGCT
		GTGTGGATATGCTGCTTTAATGCCTCTGTATCATGC
		TATTGCTTCCCGTACGGCTTTCGTTTTCTCCTCCTT
		TATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTG
		TGGCCCGTTGTCCGTCAACGTGGCGTGGTGTGCTCT
		GTGTTTGCTGACGCAACCCCCACTGGCTGGGGCAT
		TGCCACCACCTGTCAACTCCTTTCTGGGACTTTCGC
		CCGCCTGCCTTGCCCGCTGCTGGACAGAACICAICG
		TTGCTGGGCACTGATAATTCCGTGGTGTTGTC
31	Primer	TAAGCAGAATTC ATGAATTTGCCAGGAAGAT
0.0	Drimor	
02	FIIMEI	AT
0.2	Gag Pol	CA ATTCATCA ATTTCCCACCA ACATCCA A A CCA A A
	Integrase	AATGATAGGGGGGAATTGGAGGTTTTATCAAAGTAA
	fragment	GACAGTATGATCAGATACTCATAGAAATCTGCGGA
		CATAAAGCTATAGGTACAGTATTAGTAGGACCTAC
		ACCTGTCAACATAATTGGAAGAAATCTGTTGACTC
		AGATTGGCTGCACTTTAAATTTTCCCATTAGTCCTA
		TTGAGACTGTACCAGTAAAATTAAAGCCAGGAATG
		GAAATGGAAAACGAACGAAAAAAAAAAAAAAAAAAAAAA
		GGCCTGAAAATCCATACAATACTCCAGTATTTCCC
		ATAAAGAAAAAAGACAGTACTAAATGGAGAAAAT
		TAGTAGATTTCAGAGAACTTAATAAGAGAACTCAA
		GATTTCTGGGAAGTTCAATTAGGAATACCACATCC
		TGCAGGGTTAAAACAGAAAAAATCAGTAACAGTA
		CTGGATGTGGGCGATGCATATTTTTCAGTTCCCTTA
		GATAAAGACTTCAGGAAGTATACTGCATTTACCAT
		ACCTAGTATAAACAATGAGACACCAGGGATTAGAT
		ATCAGTACAATGTGCTTCCACAGGGATGGAAAGGA
		TCACCAGCAATATTCCAGTGTAGCATGACAAAAAT
		CTTA CACCTTTTTA CAAAAA CAAAATCCACACACATAC

118

119

-continued

: 01	Description	Sequence
		CTGACTTAGAAATAGGGCAGCATAGAACAAAAAT
		AGAGGAACTGAGACAACATCTGTTGAGGTGGGGA
		TTTACCACACCAGACAAAAAACATCAGAAAGAAC
		CTCCATTCCTTTGGATGGGTTATGAACTCCATCCTG
		ATAAATGGACAGTACAGCCTATAGTGCTGCCAGAA
		AAGGACAGCTGGACTGTCAATGACATACAGAAATT
		AGTGGGAAAATTGAATTGGGCAAGTCAGATTTATG
		CAGGGATTAAAGTAAGGCAATTATGTAAACTTCTT
		AGGGGAACCAAAGCACTAACAGAAGTAGTACCAC
		TAACAGAAGAAGCAGAGCTAGAACTGGCAGAAAA
		CAGGGAGATTCTAAAAGAACCGGTACATGGAGTGT
		ATTATGACCCATCAAAAGACTTAATAGCAGAAATA
		CAGAAGCAGGGGCAAGGCCAATGGACATATCAAA
		TTTATCAAGAGCCATTTAAAAATCTGAAAACAGGA
		AAGTATGCAAGAATGAAGGGTGCCCACACTAATG
		ATGTGAAACAATTAACAGAGGCAGTACAAAAAAT
		AGCCACAGAAAGCATAGTAATATGGGGGAAAGACT
		CCTAAATTTAAATTACCCATACAAAAGGAAACATG
		GGAAGCATGGTGGACAGAGTATTGGCAAGCCACCT
		AGUUAA IAGGGAAAU IAAA IIAGGAAAAGUAGGA TATUTA AUTUA CACA CA A A A A AUTUCTUCA
		AACCAATTCATCTACCATTCCACCATTCCCCCCATTA
		CAACTAAACATACTCACACACACTCACAATATCCATT
		GGGAATCATTCAAGCACAACCAGATAAGAGTGAA
		TCAGAGTTAGTCAGTCAAATAATAGAGCAGTTAAT
		AAAAAAGGAAAAAGTCTACCTGGCATGGGTACCA
		GCACACAAAGGAATTGGAGGAAATGAACAAGTAG
		ATAAATTGGTCAGTGCTGGAATCAGGAAAGTACTA
		TTTTTAGATGGAATAGATAAGGCCCAAGAAGAACA
		TGAGAAATATCACAGTAATTGGAGAGCAATGGCTA
		GTGATTTTAACCTACCACCTGTAGTAGCAAAAGAA
		ATAGTAGCCAGCTGTGATAAATGTCAGCTAAAAGG
		GGAAGCCATGCATGGACAAGTAGACTGTAGCCCA
		GGAATATGGCAGCTAGATTGTACACATTTAGAAGG
		AAAAGTTATCTTGGTAGCAGTTCATGTAGCCAGTG
		GATATATAGAAGCAGAAGTAATTCCAGCAGAGAC
		AGGGCAAGAAACAGCATACTTCCTCTTAAAATTAG
		CAGGAAGATGGCCAGTAAAAACAGTACATACAGA
		CAATGGCAGCAATTTCACCAGTACTACAGTTAAGG
		CCGCCTGTTGGTGGGCGGGGATCAAGCAGGAATTT
		GGCATTCCCTACAATCCCCAAAGTCAAGGAGTAAT
		AGAATCTATGAATAAAGAATTAAAGAAAATTATAG
		GACAGGTAAGAGATCAGGCTGAACATCTTAAGAC
		AGCAGTACAAATGGCAGTATTCATCCACAATTTTA
		AAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGG
		GGAAAGAATAGTAGACATAATAGCAACAGACATA
		CAAACTAAAGAATTACAAAAACAAATTACAAAAA
		TTCAAAATTTTCGGGTTTATTACAGGGACAGCAGA
		GATCCAGTTTGGAAAGGACCAGCAAAGCTCCTCTG
		GAAAGGTGAAGGGGCAGTAGTAATACAAGATAAT
		AGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAA
		AGATCATCAGGGATTATGGAAAACAGATGGCAGG
		TGATGATTGTGTGGCAAGTAGACAGGATGAGGATT AA
34	DNA Fragment	TCTAGAATGGCAGGAAGAAGCGGAGACAGCGACG
	containing Rev,	AAGAGCTCATCAGAACAGTCAGACTCATCAAGCTT
	KKE and rabbit	UTUTATCAAAGCAACCCACCTCCCAATCCCGAGGG
	beta globin poly	GACCCGACAGGCCCGAAGGAATAGAAGAAGAAGG
	A	TGGAGAGAGAGACAGAGACAGATCCATTCGATTA
		GTGAACGGATCCTTGGCACTTATCTGGGACGATCT
		GCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGA

TCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTG GCTGTGGAAAGATACCTAAAGGATCAACAGCTCCT
121

: ОИ	Description	sequence
		AGATCTTTTTCCCTCTGCCAAAAATTATGGGGACAT CATGAAGCCCCTTGAGCATCTGACTTCTGGCTAAT
		AAAGGAAATTTATTTTCATTGCAATAGTGTGTTGG AATTTTTTGTGTCTCTCACTCGGAAGGACATATGGG
		AGGGCAAATCATTTAAAACATCAGAATGAGTATTT
		TGCCATGAACAAAGGTGGCTATAAAGAGGTCATCA
		GTATATGAAACAGCCCCCTGCTGTCCATTCCTTATT
		CCATAGAAAAGCCTTGACTTGAGGTTAGATTTTTTT TATATATTTTTTTTTT
		CTAAAATTTTCCTTACATGTTTTACTAGCCAGATTT
		TTCCTCCTCTCCTGACTACTCCCAGTCATAGCTGTC
		GTGAAATTGTTATCCGCTCACAATTCCACACAACA
		TACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGG
		TGCCTAATGAGTGAGCTAACTCACATTAATTGCGT
		TCGTGCCAGCGGATCCGCATCTCAATTAGTCAGCA
		ACCATAGTCCCGCCCTAACTCCGCCCATCCCGCC
		GGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGT
		GAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAA
		AAGCTAACTTGTTTATTGCAGCTTATAATGGTTACA
		GCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCC
		AAACTCATCAATGTATCTTATCAGCGGCCGCCCCG
		GG
85	DNA fragment	ACGCGTTAGTTATTAATAGTAATCAATTACGGGGT
	containing the	CATTAGTTCATAGCCCATATATGGAGTTCCGCGTTA
	CAG	CATAACTTACGGTAAATGGCCCGCCTGGCTGACCG
	enhancer/promoter/	CCCAACGACCCCCGCCCATTGACGTCAATAATGAC GTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
	sequence	ATTGACGTCAATGGGTGGACTATTTACGGTAAACT
	-	GCCCACTTGGCAGTACATCAAGTGTATCATATGCC
		AAGTACGCCCCCTATTGACGTCAATGACGGTAAAT
		GGCCCGCCTGGCATTATGCCCAGTACATGACCTTA TGGGACTTTCCTACTTGGCAGTACATCTACGTATTA
		GTCATCGCTATTACCATGGGTCGAGGTGAGCCCCA
		CGTTCTGCTTCACTCTCCCCATCTCCCCCCCCCCCC
		CACCCCCAATTTTGTATTTATTTATTTTTTAATTATT TTCTCCACCATCCCCCCCC
		GGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCA
		ATCAGAGCGGCGCGCCCCGAAAGTTTCCTTTTATG
		GCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGC
		TCGCCCCGTGCCCCGCTCCGCGCCGCCTCCGCGCCG
		CCCGCCCCGGCTCTGACTGACCGCGTTACTCCCAC
		AGGTGAGCGGGCGGGACGGCCCTTCTCCCCGGGC
		TGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCT
		GGAGGGCCCTTTGTGCGGGGGGGGGGGGGGGGGGGGGGG
		GGGTGCGTGCGTGTGTGTGTGTGCGTGGGGAGCGCCG
		CGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCT
		GUGGGUGUGGUGUGGGGUTTTGTGUGCTCUGCGTG TGUGUGAGGGGAGUGUGUGUUGGUGUGUGUGUGU
		GCGGTGCGGGGGGGGCTGCGAGGGGGAACAAAGGCT
		GCGTGCGGGGTGTGTGCGTGGGGGGGGGGGGGGGGGGGG
		GGGTGTGGGGCGCGGCGGTCGGGCTGTAACCCCCCC
		CTGUACCCCCCCCCGAGTTGCTGAGCACGGCCC GGCTTCGGGTGCGGGGGCTCCGTGCGGGGCGTGCGCG
		CGGGGCTCGCCGTGCCGGGCGGGGGGGGGGGGGGGCGCA
		GGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGG
		GCCGGGGAGGGCTCGGGGGGGGGGGGCGCGGCGCC
		CCGGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGC
		GGCGCAGGGACTTCCTTTGTCCCAAATCTGGCGAGAG
		GCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTA
		GCGGGCGCGGGCGAAGCGGTGCGGCGGCGGCAGG
		AAGGAAATGGGCGGGGGGGGGGGCCTTCGTGCGTCGC
		GCCGAAATCTGGGAGGCGCCGCCGCCGCCCCTCTA GCGGGCGCGGGGGGAGGGGGGGGGG

# 123

NO:	Description	Sequence
		GCTGCCGCAGGGGGACGGCTGCCTTCGGGGGGGA CGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGAC CGGCGGGAATTC
86	DNA fragment containing VSV- g	GAATTCATGAAGTGCCTTTTGTACTTAGCCTTTTA TTCATTGGGGTGAATTGCAAGTTCACCATAGTTTT CCACCAACCAAAAAGGAATGGCAAAATGTTC CTTCTAATTACCATTATTGCCCGTCAAGCTCAGATT TAAATTGGCATAATGACTTAATAGGCACAGCCTTA CAAGTCAAAATGCCAAGAGTCACACAGGCTATTCA AGCAGACGTTGGATGTCCATGCTCCACACGAAGT ATATAACACATTCCATCCGATGCTTCACTCCATCTG TAGAACAATGCAAGGAAAGCATTGAACCAAACGAA ACAAGGACTTGGCTGAATCCAGGCTTCCCTCCTC AAAGTTGTGGATATGCAACTGTGACCAAGAA GCAGTGATGTCCAGGTGACTCCTCACCCATGTG GGTTGATGAATACACAGGAAGCATTACATATGC CCCACTGTCCATAACTGTACACGGATGCCGAA GCAGTGATGACAACGGAAATGCAGCAATTACATATGC CCCACTGTCCATAACTCTACAACCTGGAGGTTCAT TTCCATGGACATCACCTTCTTCTCAGAGGACGGAG AGCTATCATCCACGGAAAGCAATGCAACTGGAGGGT AGCTACCATCACCGGAAAGGAGGGCCAAGGGCT AGCTACCATCCCTGGGAAAGGAGGGCCAGGGGAG AGCTATCATCCCTGGGAAAGGAGGGCCAGGGGCA GGCTCCCAAAATGCAAGTATCTGCACGCAGTCCGA AGAGTAACTACTTTGCTTGCAGCAGATTCCGAG GCCCCCACGAGGGCCAAGGTTC CCACGGGCCACAAGGACTGCGAGGCCAGGGCT GATAAGGATCTCTTTGCTGCGCAGCAGGAGGCC GCTACAAATGCAATGC
87	Helper plasmid containing RRE and rabbit beta globin poly A	TCTAGAAGGAGCTTTGTTCCTTGGGTTCTTGGGAGC AGCAGGAAGCACTATGGGCGCAGCGTCAATGACG CTGACGGTACAGGCCAGACAATTATTGTCTGGTAT AGTGCAGCAGCAGCACAATTATTGTCTGGTAT AGTGCAGCAGCAGCACCACTGTGCAACTAGTCG GGCATCAAGCAGCTCCTGGCTGTGCACCACAGCTCTGG GGCATCAAGCAGCTCCTAGGCAAGAATCCTGGCTGT GGAAAGATACCTAAAGGATCAACAGCTCCTAGATC TTTTCCCCTCTGCCAAAAATTATGGGGACATCATGA AGCCCCTTGAGCATCTGACTTCTGGCTAATAAAGG AAATTTATTTTCATTGCAATAGTGTGTGGAATTTT TTGTGTCTCTCACTCGGAAGAACAATGGGACGCC AAATCATTTAAAACATCAGAATGAGTATTGGGTTT AGAGTTTGGCAACAATATGCCATATGGAGGGC TGAACAAAGGTGGCTATTAAGAGGTCATCAGTAT TGAAACAAGCCCCGCTGTCCATTATCCTTATTCCATA GAAAAGCCCTGACTTTAGCAATGGCAGCTACAGTAT TTGTTTTTGTTTTTTTTTT

# 125

NO:	Description	Sequence
		CCGCCCAGTTCCGCCCATTCTCCCGCCCATGGCTG ACTAATTTTTTTTATTATGCAGAGGCCGAGGCCGC CTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCAA ACTTGTTTATTGCAGGCTATAATGGTACAAAATAAA GCAATAGCATCACAAATTTCACAAATAAAGCATTT TTTTCACTGCATTCTAGTTGTGGGTTTGTCCAAACTC ATCAATGTATCTTATCACCCGGG
88	RSV promoter and HIV Rev	CAATTGCGATGTACGGGCCAGATATACGCGTATCT GAGGGGACTAGGGTGGTTTAGGCGAAAAGCGGG GCTTCGGTTGTACGCGGTTAGGAGTCCCCTCAGGA TATAGTAGTTTCGCTTTTGCATAGGAGGGGGAGAA TGTAGTCTTATGCAATACACTTGTAGTCTTGCAACA TGGTACGATGAGTTAGCAATGCCTTACAAGGA GAGAAAAGCACCGTGCATGCCGATTGGTGGAAG TAAGTGGTACGATGACATGGCCTTATAGGAGGCAA CAGACAGGTCTACAGTGGCCTTATGGAAGGCAA CAGCCGATTGCAGAGATAATTGTATTTAAGTGCCT AGCTCGATACGATCGCCTCCAAGCCCGAGCCGCATCACC ACATTGGTGTGCACCTCCAAGCTCGAGCCGCTCCACG CTGTTTGACCGACGCCCGGAGCAGCCACTCC CCAGCCGCCCCCCAAGCTCGAGCCCCCCGGA CCGCTCCCCCCCCAAGCCCCGGGACCGCAT CCAGCCTCCCCCCCAAGCCAATCCCCGGACCGCAT CCAGCCTCCCCCCCAAGCCAATCCACGGACCGAT CCAAGCCCCCCCGAAGCAACCCGGACCGAT CCAAGCCCCCCCCAAGCCAATCCACGGACCGAC CGCCCCCCCCCC
89	Target sequence	ATGGCAGGAAGAAGCGGAG
90	shRNA sequence	ATGGCAGGAAGAAGCGGAGTTCAAGAGACTCCGC TTCTTCCTGCCATTTTT
91	H1 promoter and shRT sequence	GAACGCTGACGTCATCAACCCGCTCCAAGGAATCG CGGGCCCAGTGTCACTAGGCGGGAACACCCAGCGC GCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGA CAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGC TATGTGTTCTGGGAAATCACCATAAACGTGAAATG TCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAG ACCACTTGGATCCGCGGAGACAGCGACGAAGAGC TTCAAGAGAGCTCTTCGTCGCTGTCTCCGCTTTTT
92	H1 CCR5 sequence	GAACGCTGACGTCATCAACCCGCTCCAAGGAATCG CGGGCCCAGTGTCACTAGGCGGGAACACCCAGCGC GCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGA CAGGGGAGTGGCGCCCTGCAATATTGCATGTCGC TATGTGTTCTGGGAAATCACCATAAACGTGAAATG TCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAG ACCACTTGGATCCGTGTCAAGTCCAATCTATGTTCA AGAGACATAGATTGGACTTGACACTTTTT
93	Primer	AGGAATTGATGGCGAGAAGG
94	Primer	CCCCAAAGAAGGTCAAGGTAATCA
95	Primer	AGCGCGGCTACAGCTTCA
96	Primer	GGCGACGTAGCACAGCTTCP
97	AGT103 CCR5 miR30	TGTAAACTGAGCTTGCTCTA
98	AGT103-R5-1	TGTAAACTGAGCTTGCTCGC
99	AGT103-R5-2	CATAGATTGGACTTGACAC

#### 127

-continued

SEQ ID NO:	Description	Sequence
100	CAG promoter	TAGTTATTAATAGTAATCAATTACGGGGTCATTAG TTCATAGCCCATATATGGAGTTCCGCGTTACATAA CTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAA CGACCCCCGCCCATTGACGTCAATAATGACGTATG TTCCCATAGTAACGCCAATAGGGACTTTCCATTGA CGTCAATGGGTGGACTATTACGGTAAACTGCCCA CTTGGCAGTACATCAAGTGTATCATATGCCAAGTA CGCCCCCTATTGACGTCAATGACGTAATAGGCC GCCTGGCATTATGCCCAGTACATGACCTTATGGGA CTTTCCTACTTGGCAGTACATGACGTATTAGTCAT CGCTACTACTGGGTGAGGTCAGGGAGGCCCCCCCCCC
101	Hl element	GAACGCTGACGTCATCAACCCGCTCCAAGGAATCG CGGGCCCAGTGTCACTAGGCGGGAACACCCAGCGC GCGTGCGCCCTGGCAGAAGATGGCTGTGAGGGA CAGGGGAGTGGCGCCCTGCAATATTTGCATGTCGC TATGTGTTCTGGGAAATCACCATAAACGTGAAATG TCTTTGGATTTGGGAATCTTATAAGTTCTGTATGAG ACCACTT
102	3' LTR	TGGAAGGGCTAATTCACTCCCAACGAAGATAAGAT CTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGAC CAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGG GAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTT GAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTG ACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGT CAGTGTGGAAAATCTCTAGCAGTAGTAGTTCATGT CA
103	75K promoter	CTGCAGTATTTAGCATGCCCCACCCATCTGCAAGG CATTCTGGATAGTGTCAAAACAGCCGGAAATCAAG TCCGTTTATCTCAAACTTTAGCATTTTGGGAATAAA TGATATTTGCTATGCTGGTGGTTAAATTAGATTTTAGTT AAATTTCCTGCTGAAGCTCTAGTACGATAAGCAAC TTGACCTAAGTGTAAAGTTGAGATTTCCTTCAGGTT TATATAGCTTGTGCGCCGCCTGGCTACCTC
104	miR155 Tat	CTGGAGGCTTGCTGAAGGCTGTATGCTGTCCGCTT CTTCCTGCCATAGGGTTTTGGCCACTGACTGACCCT ATGGGGAAGAAGCGGACAGGACA

While certain of the preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto  $_{50}$  without departing from the scope and spirit of the present invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 104

<210> SEQ ID NO 1
<211> LENGTH: 118
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: miR30 CCC5

<400> SEQUENCE: 1

aggtatattg ctgttgacag tgagcgactg taaactgagc ttgctctact gtgaagccac 60

tttcttccat ttcaggtgtc gtga

#### -continued

130

agatgggtag agcaagcaca gtttaccgct gcctactgcc tcggacttca aggggctt 118 <210> SEQ ID NO 2 <211> LENGTH: 116 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: miR21 Vif <400> SEQUENCE: 2 catctccatg gctgtaccac cttgtcgggg gatgtgtact tctgaacttg tgttgaatct 60 catggagttc agaagaacac atccgcactg acattttggt atctttcatc tgacca 116 <210> SEQ ID NO 3 <211> LENGTH: 114 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: miR185 Tat <400> SEQUENCE: 3 gggcetgget egageagggg gegagggatt eegettette etgecatage gtggteeeet 60 cccctatqqc aqqcaqaaqc qqcaccttcc ctcccaatqa ccqcqtcttc qtcq 114 <210> SEO ID NO 4 <211> LENGTH: 1104 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Elongation Factor-1 alpha (EF1-alpha) promoter <400> SEOUENCE: 4 ccggtgccta gagaaggtgg cgcggggtaa actgggaaag tgatgtcgtg tactggctcc 60 gcctttttcc cgagggtggg ggagaaccgt atataagtgc agtagtcgcc gtgaacgttc 120 tttttcgcaa cgggtttgcc gccagaacac aggtaagtgc cgtgtgtggt tcccgcgggc 180 ctggcctctt tacgggttat ggcccttgcg tgccttgaat tacttccacg cccctggctg 240 cagtacgtga ttcttgatcc cgagcttcgg gttggaagtg ggtgggagag ttcgaggcct 300 360 cgccgcgtgc gaatctggtg gcaccttcgc gcctgtctcg ctgctttcga taagtctcta 420 gccatttaaa atttttgatg acctgctgcg acgctttttt tctggcaaga tagtcttgta 480 aatgegggee aagatetgea caetggtatt teggtttttg gggeegeggg eggegaeggg 540 gcccgtgcgt cccagcgcac atgttcggcg aggcggggcc tgcgagcgcg gccaccgaga 600 660 atcqqacqqq qqtaqtctca aqctqqccqq cctqctctqq tqcctqqcct cqcqccqccq tgtatcgccc cgccctgggc ggcaaggctg gcccggtcgg caccagttgc gtgagcggaa 720 780 agatggccgc ttcccggccc tgctgcaggg agctcaaaat ggaggacgcg gcgctcggga gagcgggcgg gtgagtcacc cacacaaagg aaaagggcct ttccgtcctc agccgtcgct 840 tcatgtgact ccacggagta ccgggcgccg tccaggcacc tcgattagtt ctcgagcttt 900 tggagtacgt cgtctttagg ttgggggggag gggttttatg cgatggagtt tccccacact 960 gagtgggtgg agactgaagt taggccagct tggcacttga tgtaattctc cttggaattt 1020 gecetttttg agtttggate ttggtteatt etcaageete agacagtggt teaaagtttt 1080 1104

132

131

-continued

<210> SEQ ID NO 5	
<211> LENGTH: 18	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE: <223> OTHER INFORMATION: CCR5 target sequence	
<400> SEQUENCE: 5	
gagcaagctc agtttaca	18
<210> SEQ ID NO 6 <211> LENGTH: 21	
<212> TYPE: DNA	
<220> FEATURE:	
<223> OTHER INFORMATION: Vif target sequence	
<400> SEQUENCE: 6	
gggatgtgta cttctgaact t	21
<210> SEQ ID NO 7	
<211> LENGTH: 20	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<223> OTHER INFORMATION: Tat target sequence	
<400> SEQUENCE: 7	
tccgcttctt cctgccatag	20
<210> SEQ ID NO 8	
<211> LENGTH: 126	
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<pre>&lt;223&gt; OTHER INFORMATION: TAR decoy sequence </pre>	
<400> SEQUENCE: 8	
ettgeaatga tgtegtaatt tgegtettae etegtteteg acagegaeea gatetgagee	60
tgggagetet etggetgtea gtaagetggt acagaaggtt gaegaaaatt ettaetgage	120
aagaaa	126
<210> SEQ ID NO 9	
<211> LENGTH: 21	
<212> TIFE: DNA <213> ORGANISM: Artificial Sequence	
<220> FEATURE:	
<pre>&lt;223&gt; OTHER INFORMATION: Rev/Tat target sequence </pre>	
<400> SEQUENCE: 9	
gcggagacag cgacgaagag c	21
<210> SEQ ID NO 10	
<211> LENGTH: 56	
<213> ORGANISM: Artificial Sequence	
<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Rev/Tat_shRNA_sequence</pre>	
<pre>///// content of the state state sequence ///// content sequence ///////////////////////////////////</pre>	
<400> SEQUENCE: IU	
gcggagacag cgacgaagag cttcaagaga gctcttcgtc gctgtctccg ctttt	56
<210> SEO ID NO 11	

<210> SEQ 1D NO 11 <211> LENGTH: 19

134

1	22	
T	33	

<pre>&lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Gag target sequence</pre>	
<400> SEQUENCE: 11	
gaagaaatga tgacagcat	19
<210> SEQ ID NO 12 <211> LENGTH: 52 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Gag shRNA sequence	
<400> SEQUENCE: 12	
gaagaaatga tgacagcatt tcaagagaat gctgtcatca tttcttcttt tt	52
<210> SEQ ID NO 13 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Pol target sequence	
<400> SEQUENCE: 13	
caggagcaga tgatacag	18
<210> SEQ ID NO 14 <211> LENGTH: 47 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Pol shRNA sequence	
<400> SEQUENCE: 14	
caggagatga tacagttcaa gagactgtat catctgctcc tgttttt	47
<210> SEQ ID NO 15 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 target sequence #1	
<400> SEQUENCE: 15	
gtgtcaagtc caatctatg	19
<210> SEQ ID NO 16 <211> LENGTH: 52 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 shRNA sequence #1 <400> SEQUENCE: 16	
gtgtcaagtc caatctatgt tcaagagaca tagattggac ttgacacttt tt	52
<210> SEQ ID NO 17 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 target sequence #2	
<400> SEQUENCE: 17	

136

135

gagcatgact gacatctac	19
<210> SEQ ID NO 18 <211> LENGTH: 52 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 shRNA sequence #2	
<400> SEQUENCE: 18	
gagcatgact gacatctact tcaagagagt agatgtcagt catgctcttt tt	52
<210> SEQ ID NO 19 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 target sequence #3 <400> SEQUENCE: 19	
atagetetaa caggitgga	19
<pre>&lt;210&gt; SEQ ID NO 20 &lt;211&gt; LENGTH: 52 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: CCR5 shRNA sequence #3</pre>	
<400> SEQUENCE: 20	
gtagetetaa caggttggat teaagagate caacetgtta gagetaettt tt	52
<210> SEQ ID NO 21 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 target sequence #4 <400> SEQUENCE: 21	
gttcagaaac tacctctta	19
<210> SEQ ID NO 22 <211> LENGTH: 52 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 shRNA sequence #4	
<400> SEQUENCE: 22	
gttcagaaac tacctcttat tcaagagata agaggtagtt tctgaacttt tt	52
<210> SEQ ID NO 23 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 target sequence #5	
<400> SEQUENCE: 23	
gagcaagete agtttacaee	20
<210> SEQ ID NO 24 <211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence	

138

1	-2	7
1	. J	1

-continued

<pre>&lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: CCR5 shRNA sequence #5</pre>	
<400> SEQUENCE: 24	
gagcaagctc agtttacacc ttcaagagag gtgtaaactg agcttgctct tttt	54
<210> SEQ ID NO 25 <211> LENGTH: 141 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 gene, sequence 1	
<400> SEQUENCE: 25	
atggattatc aagtgtcaag tccaatctat gacatcaatt attatacatc ggagccctgc	60
caaaaaatca atgtgaagca aatcgcagcc cgcctcctgc ctccgctcta ctcactggtg	120
ttcatctttg gttttgtggg c	141
<210> SEQ ID NO 26 <211> LENGTH: 633 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 gene, sequence 2	
<400> SEQUENCE: 26	
aacatgctgg tcatcctcat cctgataaac tgcaaaaggc tgaagagcat gactgacatc	60
tacctgetca acctggecat etetgacetg ttttteette ttactgteee ettetggget	120
cactatgctg cogoccagtg ggactttgga aatacaatgt gtcaactott gacagggoto	180
tattttatag gcttcttctc tggaatcttc ttcatcatcc tcctgacaat cgataggtac	240
ctggctgtcg tccatgctgt gtttgcttta aaagccagga cggtcacctt tggggtggtg	300
acaagtgtga tcacttgggt ggtggctgtg tttgcgtctc tcccaggaat catctttacc	360
agateteaaa aagaaggtet teattaeaee tgeagetete atttteeata eagteagtat	420
caattetgga agaattteea gacattaaag atagteatet tggggetggt eetgeegetg	480
cttgtcatgg tcatctgcta ctcgggaatc ctaaaaactc tgcttcggtg tcgaaatgag	540
aagaagaggo acagggotgt gaggottato ttoaccatca tgattgttta ttttototto	600
tgggeteeet acaacattgt eetteteetg aac	633
<210> SEQ ID NO 27 <211> LENGTH: 70 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 gene, sequence 3	
<400> SEQUENCE: 27	
accttccagg aattctttgg cctgaataat tgcagtagct ctaacaggtt ggaccaagct	60
atgcaggtga	70
<210> SEQ ID NO 28 <211> LENGTH: 140 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 gene, sequence 4	

<400> SEQUENCE: 28

140

# 139

-continued			
cagagactct tgggatgacg cactgctgca tcaaccccat catctatgcc tttgtcgggg	60		
agaagttcag aaactacctc ttagtcttct tccaaaagca cattgccaaa cgcttctgca	120		
aatgetgtte tatttteeag	140		
<210> SEQ ID NO 29 <211> LENGTH: 75 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CCR5 gene, sequence 5			
<400> SEQUENCE: 29			
caagaggete eegagegage aageteagtt tacaeeegat eeactgggga geaggaaata	60		
tctgtgggct tgtga	75		
<210> SEQ ID NO 30 <211> LENGTH: 541 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CD4 promoter sequence			
<400> SEQUENCE: 30			
tgttggggtt caaatttgag ccccagctgt tagccctctg caaagaaaaa aaaaaaaaa	60		
aaagaacaaa gggcctagat ttcccttctg agccccaccc taagatgaag cctcttcttt	120		
caagggagtg gggttggggt ggaggcggat cetgteaget ttgetetete tgtggetgge	180		
agttteteea aagggtaaca ggtgteaget ggetgageet aggetgaace etgagaeatg	240		
ctacctctgt cttctcatgg ctggaggcag cctttgtaag tcacagaaag tagctgaggg	300		
gctctggaaa aaagacagcc agggtggagg tagattggtc tttgactcct gatttaagcc	360		
tgattetget taaettttte eettgaettt ggeattttea etttgaeatg tteeetgaga	420		
gcctgggggg tggggaaccc agctccagct ggtgacgttt ggggccggcc caggcctagg	480		
gtgtggagga gccttgccat cgggcttcct gtctctttc atttaagcac gactctgcag	540		
a	541		
<210> SEQ ID NO 31 <211> LENGTH: 359 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: miR30-CCR5/miR21-Vif/miR185 Tat microRNA cluster sequence			
<400> SEQUENCE: 31			
aggtatattg ctgttgacag tgagcgactg taaactgagc ttgctctact gtgaagccac	60		
agatgggtag agcaagcaca gtttaccgct gcctactgcc tcggacttca aggggcttcc	120		
cgggcatctc catggctgta ccaccttgtc ggggggatgtg tacttctgaa cttgtgttga	180		
atctcatgga gttcagaaga acacatccgc actgacattt tggtatcttt catctgacca	240		
gctageggge etggetegag eagggggega gggatteege ttetteetge eatagegtgg	300		
teccetecce tatggeagge agaageggea eetteeetee eaatgaeege gtettegte	359		
<210> SEQ ID NO 32 <211> LENGTH: 590 <212> TVDE: DND			

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:

### -continued

<223> OTHER INFORMATION: Long WPRE sequence			
<400> SEQUENCE: 32			
aatcaacctc tgattacaaa atttgtgaaa ga	attgactgg tattettaae tatgttgete 60		
cttttacgct atgtggatac gctgctttaa tg	geetttgta teatgetatt getteeegta 120		
tggctttcat tttctcctcc ttgtataaat co	ctggttgct gtctctttat gaggagttgt 180		
ggcccgttgt caggcaacgt ggcgtggtgt gc	cactgtgtt tgctgacgca acccccactg 240		
gttggggcat tgccaccacc tgtcagctcc tt	ttccgggac tttcgctttc cccctcccta 300		
ttgccacggc ggaactcatc gccgcctgcc tt	zgeeegetg etggaeaggg geteggetgt 360		
tgggcactga caatteegtg gtgttgtegg gg	gaaatcatc gtcctttcct tggctgctcg 420		
cctgtgttgc cacctggatt ctgcgcggga cg	gteettetg etacgteeet teggeeetea 480		
atccagegga eetteettee egeggeetge tg	geoggetet geggeetett eegegtette 540		
geettegeee teagaegagt eggateteee tt	tgggccgc ctccccgcct 590		
<pre>&lt;210&gt; SEQ ID NO 33 &lt;211&gt; LENGTH: 1469 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Elongation promoter - miR30CCR5 - miR21V</pre>	e n Factor-1 alpha (EF1-alpha) /if - miR185 Tat		
<400> SEQUENCE: 33			
ccggtgccta gagaaggtgg cgcggggtaa ac	ctgggaaag tgatgtcgtg tactggctcc 60		
gcctttttcc cgagggtggg ggagaaccgt at	tataagtgc agtagtcgcc gtgaacgttc 120		
tttttcgcaa cgggtttgcc gccagaacac ag	ggtaagtgc cgtgtgtggt teeegeggge 180		
ctggcctctt tacgggttat ggcccttgcg tg	geettgaat taetteeaeg eeeetggetg 240		
cagtacgtga ttcttgatcc cgagcttcgg gt	ttggaagtg ggtgggagag ttcgaggcct 300		
tgegettaag gageeeette geetegtget tg	gagttgagg cctggcctgg gcgctggggc 360		
cgccgcgtgc gaatctggtg gcaccttcgc gc	cctgtctcg ctgctttcga taagtctcta 420		
gccatttaaa atttttgatg acctgctgcg ac	cgctttttt tctggcaaga tagtcttgta 480		
aatgcgggcc aagatctgca cactggtatt to	eggtttttg gggeegeggg eggegaeggg 540		
gcccgtgcgt cccagcgcac atgttcggcg ag	ggeggggee tgegagegeg geeacegaga 600		
atcggacggg ggtagtetea agetggeegg ee	ctgetetgg tgeetggeet egegeegeeg 660		
tgtatcgccc cgccctgggc ggcaaggctg gc	cccggtcgg caccagttgc gtgagcggaa 720		
agatggccgc ttcccggccc tgctgcaggg ag	geteaaat ggaggaegeg gegeteggga 780		
gagcgggcgg gtgagtcacc cacacaaagg aa	aaagggcct ttccgtcctc agccgtcgct 840		
tcatgtgact ccacggagta ccgggcgccg to	ccaggcacc tcgattagtt ctcgagcttt 900		
tggagtacgt cgtctttagg ttgggggggag gg	ggttttatg cgatggagtt tccccacact 960		
gagtgggtgg agactgaagt taggccagct tg	ggcacttga tgtaattctc cttggaattt 1020		
gccctttttg agtttggatc ttggttcatt ct	ccaagcete agacagtggt tcaaagtttt 1080		
tttcttccat ttcaggtgtc gtgatgtaca ag	ggtatattg ctgttgacag tgagcgactg 1140		
taaactgagc ttgctctact gtgaagccac ag	gatgggtag agcaagcaca gtttaccgct 1200		
geetactgee teggaettea aggggettee eg	gggcatete catggetgta ceacettgte 1260		
ggggggatgtg tacttctgaa cttgtgttga at	ceteatgga gtteagaaga acaeateege 1320		

142

144

# 143

actgacattt tggtatcttt catctgacca gctagcgggc ctggctcgag caggggggga	1380
gggatteege ttetteetge catagegtgg teeesteece tatggeagge agaageggea	1440
ccttccctcc caatgaccgc gtcttcgtc	1469
<210> SEQ ID NO 34 <211> LENGTH: 228 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rous Sarcoma virus (RSV) promoter	
<400> SEQUENCE: 34	
gtagtettat geaataetet tgtagtettg eaacatggta aegatgagtt ageaacatge	60
cttacaagga gagaaaaagc accgtgcatg ccgattggtg gaagtaaggt ggtacgatcg	120
tgccttatta ggaaggcaac agacgggtct gacatggatt ggacgaacca ctgaattgcc	180
gcattgcaga gatattgtat ttaagtgcct agctcgatac aataaacg	228
<210> SEQ ID NO 35 <211> LENGTH: 180 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: 5' Long terminal repeat (LTR)	
<400> SEQUENCE: 35	
ggtetetetg gttagaccag atetgageet gggagetete tggetaacta gggaacceae	60
tgettaagee teaataaage ttgeettgag tgetteaagt agtgtgtgee egtetgttgt	120
gtgactctgg taactagaga teectcagae eettttagte agtgtggaaa atetetagea	180
<210> SEQ ID NO 36 <211> LENGTH: 41 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Psi Packaging signal	
<400> SEQUENCE: 36	
tacgccaaaa attttgacta gcggaggcta gaaggagaga g	41
<210> SEQ ID NO 37 <211> LENGTH: 233 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rev response element (RRE)	
<400> SEQUENCE: 37	
aggagetttg tteettgggt tettgggage ageaggaage aetatgggeg cageeteaat	60
gacgctgacg gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt	120
getgaggget attgaggege aacageatet gttgeaaete acagtetggg geateaagea	180
getecaggea agaateetgg etgtggaaag ataeetaaag gateaaeage tee	233
<210> SEQ ID NO 38 <211> LENGTH: 118 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Central polypurine tract (cPPT)	

146

1	44	5

#### -continued

	60
agcaacagac atacaaacta aagaattaca aaaacaaatt acaaaattca aaatttta	118
<210> SEQ ID NO 39 <211> LENGTH: 250 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: 3' delta LTR	
<400> SEQUENCE: 39	
tggaagggct aattcactcc caacgaagat aagatctgct ttttgcttgt actgggtctc	60
tetggttaga ecagatetga geetgggage tetetggeta aetagggaae ecaetgetta	120
agceteaata aagettgeet tgagtgette aagtagtgtg tgeeegtetg ttgtgtgaet	180
ctggtaacta gagateeete agaeeetttt agteagtgtg gaaaatetet ageagtagta	240
gttcatgtca	250
<210> SEQ ID NO 40 <211> LENGTH: 352 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper/Rev - CMV early (CAG) enhancer - EnhanceTranscription	
<400> SEQUENCE: 40	
tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg	60
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt	120
gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca	180
atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc	240
aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta	300
catgacetta tgggaettte etaettggea gtaeatetae gtattagtea te	352
<210> SEQ ID NO 41 <211> LENGTH: 290 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper/Rev - Chicken beta actin (CAG) promoter - Transcription	
<400> SEQUENCE: 41	
getattacca tgggtegagg tgageeceae gttetgette aeteteecea teteeceece	60
ctccccaccc ccaattttgt atttatttat tttttaatta ttttgtgcag cgatgggggc	120
aaaaaaaaa aaaacacaca ccøaacaaaa caaaacaaaa caøaaaaacaa aacaaaacaø	180
ggcggagagg tgcggcggca gccaatcaga gcggcgcgct ccgaaagttt ccttttatgg	240
cgaggeggeg geggeggegg eeetataaaa agegaagege geggegggeg	290
<210> SEQ ID NO 42 <211> LENGTH: 960 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:	

<223> OTHER INFORMATION: Helper/Rev - Chicken beta actin intron -Enhance gene expression

147

### 148

#### -continued

ggagtcgctg	cgttgccttc	gccccgtgcc	ccgctccgcg	ccgcctcgcg	ccgcccgccc	60	
cggctctgac	tgaccgcgtt	actcccacag	gtgagcgggc	gggacggccc	ttctcctccg	120	
ggctgtaatt	agcgcttggt	ttaatgacgg	ctcgtttctt	ttctgtggct	gcgtgaaagc	180	
cttaaagggc	tccgggaggg	ccctttgtgc	ggggggggagc	ggeteggggg	gtgcgtgcgt	240	
gtgtgtgtgc	gtggggagcg	ccgcgtgcgg	cccgcgctgc	ccggcggctg	tgagegetge	300	
gggcgcggcg	cggggctttg	tgcgctccgc	gtgtgcgcga	ggggagcgcg	gccggggggcg	360	
gtgeeeegeg	gtgcgggggg	gctgcgaggg	gaacaaaggc	tgcgtgcggg	gtgtgtgcgt	420	
gggggggtga	gcaggggggtg	tgggcgcggc	ggtcgggctg	taaccccccc	ctgcaccccc	480	
ctccccgagt	tgctgagcac	ggcccggctt	cgggtgcggg	gctccgtgcg	gggcgtggcg	540	
cgggggctcgc	cgtgccgggc	gggggggtggc	ggcaggtggg	ggtgccgggc	ggggcgggggc	600	
cgcctcgggc	cggggagggc	tcgggggagg	ggcgcggcgg	ccccggagcg	ccggcggctg	660	
tcgaggcgcg	gcgagccgca	gccattgcct	tttatggtaa	tcgtgcgaga	gggcgcaggg	720	
acttcctttg	tcccaaatct	ggcggagccg	aaatctggga	ggcgccgccg	caccccctct	780	
agcgggcgcg	ggcgaagcgg	tgcggcgccg	gcaggaagga	aatgggcggg	gagggccttc	840	
gtgcgtcgcc	gcgccgccgt	ccccttctcc	atctccagcc	tcggggctgc	cgcaggggga	900	
cggctgcctt	cggggggggac	ggggcagggc	ggggttcggc	ttctggcgtg	tgaccggcgg	960	
<pre>&lt;212&gt; TYPE &lt;213&gt; ORGAJ &lt;220&gt; FEAT &lt;223&gt; OTHE &lt;400&gt; SEQU:</pre>	: DNA NISM: Artif: URE: R INFORMATI( ENCE: 43	icial Sequer DN: Helper/H	nce Rev - HIV Ga	ag - Viral d	capsid		
atgggtgcga	gagcgtcagt	attaagcggg	ggagaattag	atcgatggga	aaaaattcgg	60	
ttaaggccag	ggggaaagaa	aaaatataaa	ttaaaacata	tagtatgggc	aagcagggag	120	
ctagaacgat	tcgcagttaa	tcctggcctg	ttagaaacat	cagaaggctg	tagacaaata	180	
ctgggacagc	tacaaccatc	ccttcagaca	ggatcagaag	aacttagatc	attatataat	240	
acagtagcaa	ccctctattg	tgtgcatcaa	aggatagaga	taaaagacac	caaggaagct	300	
ttagacaaga	tagaggaaga	gcaaaacaaa	agtaagaaaa	aagcacagca	agcagcagct	360	
gacacaggac	acagcaatca	ggtcagccaa	aattacccta	tagtgcagaa	catccagggg	420	
caaatggtac	atcaggccat	atcacctaga	actttaaatg	catgggtaaa	agtagtagaa	480	
gagaaggett	tcagcccaga	agtgataccc	atgttttcag	cattatcaga	aggagccacc	540	
ccacaagatt	taaacaccat	gctaaacaca	gtggggggac	atcaagcagc	catgcaaatg	600	
ttaaaagaga	ccatcaatga	ggaagctgca	gaatgggata	gagtgcatcc	agtgcatgca	660	
gggcctattg	caccaggcca	gatgagagaa	ccaaggggaa	gtgacatagc	aggaactact	720	
agtacccttc	aggaacaaat	aggatggatg	acacataatc	cacctatccc	agtaggagaa	780	
atctataaaa	gatggataat	cctgggatta	aataaaatag	taagaatgta	tagccctacc	840	
agcattctgg							
	acataagaca	aggaccaaag	gaaccettta	gagactatgt	agaccgattc	900	
tataaaactc	acataagaca taagagccga	aggaccaaag gcaagcttca	gaacccttta caagaggtaa	gagactatgt aaaattggat	agaccgattc gacagaaacc	900 960	
tataaaactc ttgttggtcc	acataagaca taagagccga aaaatgcgaa	aggaccaaag gcaagcttca cccagattgt	gaacccttta caagaggtaa aagactattt	gagactatgt aaaattggat taaaagcatt	agaccgattc gacagaaacc gggaccagga	900 960 1020	

gcgacactag aagaaatgat gacagcatgt cagggagtgg ggggacccgg ccataaagca 1080

 	•
	un
-	
	-

#### -continued

150

agagttttgg ctgaagcaat gagccaagta acaaatccag ctaccataat gatacagaaa	1140
ggcaatttta ggaaccaaag aaagactgtt aagtgtttca attgtggcaa agaagggcac	1200
atagccaaaa attgcagggc ccctaggaaa aagggctgtt ggaaatgtgg aaaggaagga	1260
caccaaatga aagattgtac tgagagacag gctaattttt tagggaagat ctggccttcc	1320
cacaagggaa ggccagggaa ttttcttcag agcagaccag agccaacagc cccaccagaa	1380
gagagcttca ggtttgggga agagacaaca actccctctc agaagcagga gccgatagac	1440
aaggaactgt atcetttage tteeeteaga teactetttg geagegaeee etegteacaa	1500
taa	1503
<210> SEQ ID NO 44 <211> LENGTH: 1872 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper/Rev - HIV Pol - Protease and revers transcriptase	ae
<400> SEQUENCE: 44	
atgaatttgc caggaagatg gaaaccaaaa atgatagggg gaattggagg ttttatcaaa	60
gtaggacagt atgatcagat actcatagaa atctgcggac ataaagctat aggtacagta	120
ttagtaggac ctacacctgt caacataatt ggaagaaatc tgttgactca gattggctgc	180
actttaaatt ttcccattag tcctattgag actgtaccag taaaattaaa gccaggaatg	240
gatggcccaa aagttaaaca atggccattg acagaagaaa aaataaaagc attagtagaa	300
atttgtacag aaatggaaaa ggaaggaaaa atttcaaaaa ttgggcctga aaatccatac	360
aatactccag tatttgccat aaagaaaaaa gacagtacta aatggagaaa attagtagat	420
ttcagagaac ttaataagag aactcaagat ttctgggaag ttcaattagg aataccacat	480
cctgcagggt taaaacagaa aaaatcagta acagtactgg atgtgggcga tgcatatttt	540
tcagttccct tagataaaga cttcaggaag tatactgcat ttaccatacc tagtataaac	600
aatgagacac cagggattag atatcagtac aatgtgcttc cacagggatg gaaaggatca	660
ccagcaatat tccagtgtag catgacaaaa atcttagagc cttttagaaa acaaaatcca	720
gacatagtca tctatcaata catggatgat ttgtatgtag gatctgactt agaaataggg	780
cagcatagaa caaaaataga ggaactgaga caacatctgt tgaggtgggg atttaccaca	840
ccagacaaaa aacatcagaa agaacctcca ttcctttgga tgggttatga actccatcct	900
gataaatgga cagtacagcc tatagtgctg ccagaaaagg acagctggac tgtcaatgac	960
atacagaaat tagtgggaaa attgaattgg gcaagtcaga tttatgcagg gattaaagta	1020
aggcaattat gtaaacttct taggggaacc aaagcactaa cagaagtagt accactaaca	1080
gaagaagcag agctagaact ggcagaaaac agggagattc taaaagaacc ggtacatgga	1140
gtgtattatg acccatcaaa agacttaata gcagaaatac agaagcaggg gcaaggccaa	1200
tggacatatc aaatttatca agagccattt aaaaatctga aaacaggaaa atatgcaaqa	1260
atgaagggtg cccacactaa tgatgtgaaa caattaacag aggcagtaca aaaaataggc	1320
ananaaanna tantaatatn nnnaaanant nntaaattta aattannaat soooonnoo	1320
acting and an antipart and active active active at a second at a second at a second active ac	1440
avaryyyaay carggrgggac agagrarrgg caagccacct ggatteetga gtgggagttt	1440
gtcaataccc ctcccttagt gaagttatgg taccagttag agaaagaacc cataatagga	1500
gcagaaactt tctatgtaga tggggcagcc aatagggaaa ctaaattagg aaaagcagga	1560

-	_	-
	~	
		л

tatgtaactg acagaggaag acaaaaagtt gtccccctaa cggacacaac aaatcagaag	1620
actgagttac aagcaattca tctagctttg caggattcgg gattagaagt aaacatagtg	1680
acagactcac aatatgcatt gggaatcatt caagcacaac cagataagag tgaatcagag	1740
ttagtcagtc aaataataga gcagttaata aaaaaggaaa aagtctacct ggcatgggta	1800
ccagcacaca aaggaattgg aggaaatgaa caagtagatg ggttggtcag tgctggaatc	1860
aggaaagtac ta	1872
<210> SEQ ID NO 45 <211> LENGTH: 867 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper Rev - HIV Integrase - Integration or viral RNA	f
<400> SEQUENCE: 45	
tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga	60
gcaatggeta gtgattttaa eetaecaeet gtagtageaa aagaaatagt ageeagetgt	120
gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata	180
tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc	240
agtggatata tagaagcaga agtaatteea geagagaeag ggeaagaaae ageataette	300
ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat	360
ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaatttggc	420
atteeetaca ateeecaaag teaaggagta atagaateta tgaataaaga attaaagaaa	480
attataggac aggtaagaga tcaggctgaa catcttaaga cagcagtaca aatggcagta	540
ttcatccaca attttaaaag aaaagggggg attggggggt acagtgcagg ggaaagaata	600
gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaatt	660
caaaattttc gggtttatta cagggacagc agagatccag tttggaaagg accagcaaag	720
ctcctctgga aaggtgaagg ggcagtagta atacaagata atagtgacat aaaagtagtg	780
ccaagaagaa aagcaaagat catcagggat tatggaaaac agatggcagg tgatgattgt	840
gtggcaagta gacaggatga ggattaa	867
<210> SEQ ID NO 46 <211> LENGTH: 234 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper/Rev - HIV RRE- Binds Rev element	
<400> SEQUENCE: 46	
aggagetttg tteettgggt tettgggage ageaggaage aetatgggeg eagegteaat	60
gacgctgacg gtacaggcca gacaattatt gtctggtata gtgcagcagc agaacaattt	120
gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg gcatcaagca	180
gctccaggca agaatcctgg ctgtggaaag atacctaaag gatcaacagc tcct	234
<210> SEQ ID NO 47 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper/Rev - HIV Rev - Nuclear export and stabilize viral mRNA	

<400> SEQUENCE: 47 atggcaggaa gaagcggaga cagcgacgaa gaactcctca aggcagtcag actcatcaag 60 tttctctatc aaagcaaccc acctcccaat cccgagggga cccgacaggc ccgaaggaat 120 agaagaagaa ggtggagaga gagacagaga cagatccatt cgattagtga acggatcctt 180 agcacttatc tgggacgatc tgcggagcct gtgcctcttc agctaccacc gcttgagaga 240 cttactcttg attgtaacga ggattgtgga acttctggga cgcagggggt gggaagccct 300 caaatattgg tggaatctcc tacaatattg gagtcaggag ctaaagaata g 351 <210> SEQ ID NO 48 <211> LENGTH: 448 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper/Rev - Rabbit beta globin poly A - RNA stability <400> SEQUENCE: 48 agatetttt ceetetgeea aaaattatgg ggacateatg aageeeettg ageatetgae 60 ttctggctaa taaaggaaat ttattttcat tgcaatagtg tgttggaatt ttttgtgtct 120 ctcactcgga aggacatatg ggagggcaaa tcatttaaaa catcagaatg agtatttggt 180 ttagagtttg gcaacatatg ccatatgctg gctgccatga acaaaggtgg ctataaagag 240 gtcatcagta tatgaaacag ccccctgctg tccattcctt attccataga aaagccttga 300 cttgaggtta gattttttt atattttgtt ttgtgttatt tttttcttta acatccctaa 360 aattttcctt acatgtttta ctagccagat ttttcctcct ctcctgacta ctcccagtca 420 tagetgteee tettetetta tgaagate 448 <210> SEQ ID NO 49 <211> LENGTH: 352 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper - CMV early (CAG) enhancer -Enhancetranscription <400> SEQUENCE: 49 tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg 60 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 120 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 180 atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc 240 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta 300 catgacetta tgggaettte etaettggea gtacatetae gtattagtea te 352 <210> SEQ ID NO 50 <211> LENGTH: 290 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper - Chicken beta actin (CAG) promoter -Transcription <400> SEQUENCE: 50 gctattacca tgggtcgagg tgagccccac gttctgcttc actctcccca tctcccccc 60 ctccccaccc ccaattttgt atttatttat tttttaatta ttttgtgcag cgatgggggc 120

1	55
л	33

# 156

-	С	0	n	t	1	n	u	е	d

	ggegegeg ee	aggegggg o	cddddcdddd	cgagggggggg	ggcgggggga	180
ggcggagagg tgo	cggcggca gc	ccaatcaga g	gcggcgcgct	ccgaaagttt	ccttttatgg	240
cgaggcggcg gcg	ggeggegg ee	cctataaaa a	agcgaagcgc	gcggcgggcg		290
<pre>&lt;210&gt; SEQ ID N &lt;211&gt; LENGTH: &lt;212&gt; TYPE: DN &lt;213&gt; ORGANISN &lt;220&gt; FEATURE: &lt;223&gt; OTHER IN gene exp</pre>	NO 51 960 NA M: Artifici : NFORMATION: pression	al Sequence Helper -	ce Chicken be	ta actin in	tron - Enhance	
<400> SEQUENCE	E: 51					
ggagtcgctg cgt	ttgeette ge	eccegtgec a	ccgctccgcg	ccgcctcgcg	ccgcccgccc	60
cggctctgac tga	accgcgtt ac	ctoccacag g	gtgagcgggc	gggacggccc	ttetecteeg	120
ggctgtaatt ago	cgcttggt tt	aatgacgg d	etegtttett	ttetgtgget	gcgtgaaagc	180
cttaaagggc tco	cgggaggg co	eetttgtge g	gggggggagc	ggeteggggg	gtgcgtgcgt	240
gtgtgtgtgc gtg	ggggageg ee	cgcgtgcgg d	cccgcgctgc	ccggcggctg	tgagcgctgc	300
aaacacaaca caa	gggetttg tg	gegeteege g	gtgtgcgcga	ggggagcgcg	gccgggggcg	360
gtgccccgcg gtg	acaaaaaa ac	etgegaggg g	gaacaaaggc	tgcgtgcggg	gtgtgtgcgt	420
ggggggggtga gca	aggggggtg tg	laacacaac c	ggtcgggctg	taaccccccc	ctgcaccccc	480
ctccccgagt tgo	ctgagcac go	jeceggett o	cgggtgcggg	gctccgtgcg	gggcgtggcg	540
cgggggctcgc cgt	tgeeggge ge	aggagtaac a	ggcaggtggg	ggtgccgggc	aaaacaaaac	600
cgcctcgggc cgg	gggagggc to	ggggggagg g	ggcgcggcgg	ccccggagcg	ccggcggctg	660
tcgaggcgcg gcg	gageegea ge	cattgcct t	ttatggtaa	tcgtgcgaga	gggcgcaggg	720
acttcctttg tcc	ccaaatct gg	jeggageeg a	aaatctggga	ggegeegeeg	caccccctct	780
agcgggcgcg ggo	cgaagcgg tg	leddedeed e	gcaggaagga	aatgggcggg	gagggccttc	840
gtgegtegee gee	geegeegt ee	ecttetec a	atctccagcc	tcgggggtgc	cgcaggggga	900
eggetgeett egg	gggggggac gg	gggcagggc g	ggggttegge	ttctggcgtg	tgaccggcgg	960
<210> SEQ ID 1 <211> LENGTH: <212> TYPE: D1 <213> ORGANISN <220> FEATURE: <223> OTHER IN	NO 52 1503 NA M: Artifici : NFORMATION:	lal Sequenc Helper -	ce HIV Gag - <sup>1</sup>	Viral capsi	đ	
<400> SEQUENCE	E: 52					
atgggtgcga gag	gcgtcagt at	taagcggg g	ggagaattag	atcgatggga	aaaaattcgg	60
ttaaggccag ggg	ggaaagaa aa	aatataaa t	taaaacata	tagtatgggc	aagcagggag	120
ctagaacgat tco	gcagttaa to	ectggeetg t	tagaaacat	cagaaggctg	tagacaaata	180
ctgggacagc tao	caaccatc co	ettcagaca g	ggatcagaag	aacttagatc	attatataat	240
acagtagcaa cco	ctctattg tg	gtgcatcaa a	aggatagaga	taaaagacac	caaggaagct	300
ttagacaaga tag	gaggaaga gc	caaaacaaa a	agtaagaaaa	aagcacagca	agcagcagct	360
gacacaggac aca	agcaatca gg	gtcagccaa a	aattacccta	tagtgcagaa	catccagggg	420
caaatggtac ato	caggccat at	cacctaga a	actttaaatg	catgggtaaa	agtagtagaa	480
gagaaggett tea	agcccaga ag	gtgataccc a	atgttttcag	cattatcaga	aggagccacc	540
ccacaagatt taa	aacaccat go	ctaaacaca g	gtggggggac	atcaagcagc	catgcaaatg	600

157

#### -continued

ttaaaagaga ccatcaatga ggaagctgca gaatgggata gagtgcatcc agtgcatgca 660 gggcctattg caccaggcca gatgagagaa ccaaggggaa gtgacatagc aggaactact 720 agtaccette aggaacaaat aggatggatg acacataate cacetateee agtaggagaa 780 atctataaaa gatggataat cctgggatta aataaaatag taagaatgta tagccctacc 840 agcattetgg acataagaca aggaccaaag gaaccettta gagactatgt agaccgatte 900 tataaaactc taagagccga gcaagcttca caagaggtaa aaaattggat gacagaaacc 960 1020 ttgttggtcc aaaatgcgaa cccagattgt aagactattt taaaagcatt gggaccagga gcgacactag aagaaatgat gacagcatgt cagggagtgg ggggacccgg ccataaagca 1080 agagttttgg ctgaagcaat gagccaagta acaaatccag ctaccataat gatacagaaa 1140 ggcaatttta ggaaccaaag aaagactgtt aagtgtttca attgtggcaa agaagggcac 1200 atagccaaaa attgcagggc ccctaggaaa aagggctgtt ggaaatgtgg aaaggaagga 1260 1320 caccaaatga aagattgtac tgagagacag gctaattttt tagggaagat ctggccttcc cacaagggaa ggccagggaa ttttcttcag agcagaccag agccaacagc cccaccagaa 1380 qaqaqcttca qqtttqqqqa aqaqacaaca actccctctc aqaaqcaqqa qccqataqac 1440 aaggaactgt atcctttagc ttccctcaga tcactctttg gcagcgaccc ctcgtcacaa 1500 1503 taa <210> SEQ ID NO 53 <211> LENGTH: 1872 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper - HIV Pol - Protease and reverse transcriptase <400> SEQUENCE: 53 atgaatttgc caggaagatg gaaaccaaaa atgatagggg gaattggagg ttttatcaaa 60 gtaggacagt atgatcagat actcatagaa atctgcggac ataaagctat aggtacagta 120 ttagtaggac ctacacctgt caacataatt ggaagaaatc tgttgactca gattggctgc 180 actttaaatt ttcccattag tcctattgag actgtaccag taaaattaaa gccaggaatg 240 gatggcccaa aagttaaaca atggccattg acagaagaaa aaataaaagc attagtagaa 300 atttgtacag aaatggaaaa ggaaggaaaa atttcaaaaa ttgggcctga aaatccatac 360 aatactccag tatttgccat aaagaaaaaa gacagtacta aatggagaaa attagtagat 420 ttcagagaac ttaataagag aactcaagat ttctgggaag ttcaattagg aataccacat 480 cctgcagggt taaaacagaa aaaatcagta acagtactgg atgtgggcga tgcatatttt 540 tcagtteect tagataaaga etteaggaag tataetgeat ttaecataee tagtataaae 600 aatqaqacac caqqqattaq atatcaqtac aatqtqcttc cacaqqqatq qaaaqqatca 660 ccagcaatat tccagtgtag catgacaaaa atcttagagc cttttagaaa acaaaatcca 720 gacatagtca tctatcaata catggatgat ttgtatgtag gatctgactt agaaataggg 780 cagcatagaa caaaaataga ggaactgaga caacatctgt tgaggtgggg atttaccaca 840 ccagacaaaa aacatcagaa agaacctcca ttcctttgga tgggttatga actccatcct 900 gataaatgga cagtacagcc tatagtgctg ccagaaaagg acagctggac tgtcaatgac 960 atacagaaat tagtgggaaa attgaattgg gcaagtcaga tttatgcagg gattaaagta 1020 aggcaattat gtaaacttct taggggaacc aaagcactaa cagaagtagt accactaaca 1080

159

# 160

#### -continued

	1140
gaagaagcag agctagaact ggcagaaaac agggagattc taaaagaacc ggtacatgga	1140
gtgtattatg acccatcaaa agacttaata gcagaaatac agaagcaggg gcaaggccaa	1200
tggacatatc aaatttatca agagccattt aaaaatctga aaacaggaaa atatgcaaga	1260
atgaagggtg cccacactaa tgatgtgaaa caattaacag aggcagtaca aaaaatagcc	1320
acagaaagca tagtaatatg gggaaagact cctaaattta aattacccat acaaaaggaa	1380
acatgggaag catggtggac agagtattgg caagccacct ggatteetga gtgggagttt	1440
gtcaataccc ctcccttagt gaagttatgg taccagttag agaaagaacc cataatagga	1500
gcagaaactt tctatgtaga tggggcagcc aatagggaaa ctaaattagg aaaagcagga	1560
tatgtaactg acagaggaag acaaaaagtt gtccccctaa cggacacaac aaatcagaag	1620
actgagttac aagcaattca tctagctttg caggattcgg gattagaagt aaacatagtg	1680
acagactcac aatatgcatt gggaatcatt caagcacaac cagataagag tgaatcagag	1740
ttagtcagtc aaataataga gcagttaata aaaaaggaaa aagtctacct ggcatgggta	1800
ccagcacaca aaggaattgg aggaaatgaa caagtagatg ggttggtcag tgctggaatc	1860
aggaaagtac ta	1872
<210> SEQ 1D NO 54	
<211> LENGTH: 867 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA	ral
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54</pre>	ral
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga</pre>	ral 60
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt</pre>	ral 60 120
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata</pre>	ral 60 120 180
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc</pre>	ral 60 120 180 240
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgatttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc</pre>	ral 60 120 180 240 300
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat</pre>	ral 60 120 180 240 300 360
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TTPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgatttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaatttggc</pre>	ral 60 120 180 240 300 360 420
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaatttggc attccctaca atccccaaag tcaaggagta atagaatcta tgaataaaga attaaagaaa</pre>	ral 60 120 180 240 300 360 420 480
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TTPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgatttaa cctaccact gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagt aaaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaatttggc attccctaca atccccaaag tcaaggagta atagaatcta tgaataagaa attaaagaaa attataggac aggtaagaga tcaggctgaa catcttaaga cagcagtaca aatggcagta</pre>	ral 60 120 180 240 300 360 420 480 540
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TTPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaattggc attccctaca atccccaaag tcaaggagta atagaatcta tgaataaaga attaaagaaa attataggac aggtaagaga tcaggctga catcttaaga cagcagtaca aatggcagta ttcatccaca attttaaaag aaaagggggg attggggggt acagtgcagg ggaaagaata</pre>	ral 60 120 180 240 300 360 420 480 540 600
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TTPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgatttaa cctaccact gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagt aaaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaatttggc attataggac aggtaagaga tcaggctgaa catcttaaga cagcagtaca aatggcagta attataggac aggtaagaga tcaggctgaa catcttaaga cagcagtaca aatggcagta ttcatccaca attttaaaag aaaagggggg attggggggt acagtgcagg ggaaagaata gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaat ttcatccaca attttaaaag aaaagggggg attgggggg dacaagcag ggaaagaata gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaat gtagacataa tagcaacaga catacaact aaagaattac aaaaacaaat tacaaaaat gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaat ttcatcaca atttaaaag catacaaact aaagaattac aaaaacaaat tacaaaaat gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaat ttaacaaaat tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaat gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaat ttaataggac aggtaagaga catacaaact aaagaattac aaaaacaaat tacaaaaat</pre>	ral 60 120 180 240 300 360 420 480 540 600 660
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TTPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgattttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaattggc attacctaca atccccaaag tcaaggagta atagaatcta tgaataaaga attaaagaaa attataggac aggtaagaga tcaggctga catcttaaga cagcagtaca aatggcagta ttcatccaca attttaaaag aaaaggggg attggggggt acagtgcagg ggaaagaata gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaatt ccaaaatttc gggtttatta cagggacagc agagatccag tttggaaagg accagcaag</pre>	ral 60 120 180 240 300 360 420 480 540 600 660 720
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TTPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgatttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaac agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaattggc attataggac aggtaagaga tcaggctga catcttaaga cagcagtaca attataggac aggtaagaga tcaggctga catcttaaga cagcagtaca aatgacaat ttcacccata atccccaaag tcaaggagta atagaatcta tgaataaaga attaaagaaa attataggac aggtaagaga catacaact aaagaattac aaaagcagg ggaaagaata gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaat tacaaaaat tcaaccata tagcaacaga catacaact aaagaattac aaaaacaaat tacaaaaatt caaaatttc gggtttatta cagggacagc agagatccag tttggaaagg accagcaaag ccccttgga aaggtgaagg ggcagtagta atacaagata atagtgacat aaaagtagtg</pre>	ral 60 120 180 240 300 360 420 480 540 600 660 720 780
<pre>&lt;211&gt; LENGTH: 867 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Helper - HIV Integrase - Integration of vi RNA &lt;400&gt; SEQUENCE: 54 tttttagatg gaatagataa ggcccaagaa gaacatgaga aatatcacag taattggaga gcaatggcta gtgatttaa cctaccacct gtagtagcaa aagaaatagt agccagctgt gataaatgtc agctaaaagg ggaagccatg catggacaag tagactgtag cccaggaata tggcagctag attgtacaca tttagaagga aaagttatct tggtagcagt tcatgtagcc agtggatata tagaagcaga agtaattcca gcagagacag ggcaagaaca agcatacttc ctcttaaaat tagcaggaag atggccagta aaaacagtac atacagacaa tggcagcaat ttcaccagta ctacagttaa ggccgcctgt tggtgggcgg ggatcaagca ggaatttggc attacctaca atccccaaag tcaaggagta atagaatca tgaataaaga attaaagaaa attataggac aggtaagaga tcaggctgaa catcttaaga cagcagtaca aatggcagta ttcatccaca attttaaaag aaaagggggg attggggggt acagtgcagg ggaaagaata gtagacataa tagcaacaga catacaaact aaagaattac aaaaacaaat tacaaaaatt caaaattttc gggtttatta cagggacagc agagatccag tttggaaagg accagcaaag ctcctctgga aaggtgaagg ggcagtagta atacaagata atagtgacat aaaagtagtg ccaagaagaa aagcaaagat catcagggat tatggaaaac agatggcagg tgatgattgt</pre>	ral 60 120 180 240 300 360 420 480 540 600 660 720 780 840

<210> SEQ ID NO 55 <211> LENGTH: 234 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper - HIV RRE - Binds Rev element

1	61	

#### -continued

aggagetttg tteettgggt tettgggage ageaggaage aetatgggeg eagegteaat 60 gacgetgaeg gtaeaggeea gaeaattatt gtetggtata gtgeageage agaacaattt 120 gctgagggct attgaggcgc aacagcatct gttgcaactc acagtctggg gcatcaagca 180 gctccaggca agaatcctgg ctgtggaaag atacctaaag gatcaacagc tcct 234 <210> SEQ ID NO 56 <211> LENGTH: 448 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Helper - Rabbit beta globin poly A - RNA stability <400> SEQUENCE: 56 agatettttt ceetetgeca aaaattatgg ggacateatg aageeeettg ageatetgae 60 ttctqqctaa taaaqqaaat ttattttcat tqcaataqtq tqttqqaatt ttttqtqtct 120 ctcactcgga aggacatatg ggagggcaaa tcatttaaaa catcagaatg agtatttggt 180 ttagagtttg gcaacatatg ccatatgctg gctgccatga acaaaggtgg ctataaagag 240 gtcatcagta tatgaaacag ccccctgctg tccattcctt attccataga aaagccttga 300 cttgaggtta gattttttt atattttgtt ttgtgttatt tttttcttta acatccctaa 360 aattttcctt acatgtttta ctagccagat ttttcctcct ctcctgacta ctcccagtca 420 tagetgteee tettetetta tgaagate 448 <210> SEQ ID NO 57 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rev - RSV promoter - Transcription <400> SEQUENCE: 57 atggcaggaa gaagcggaga cagcgacgaa gaactcctca aggcagtcag actcatcaag 60 tttctctatc aaagcaaccc acctcccaat cccgagggga cccgacaggc ccgaaggaat 120 agaagaagaa ggtggagaga gagacagaga cagatccatt cgattagtga acggatcctt 180 agcacttatc tgggacgatc tgcggagcct gtgcctcttc agctaccacc gcttgagaga 240 cttactcttg attgtaacga ggattgtgga acttctggga cgcagggggt gggaagccct 300 caaatattgg tggaatctcc tacaatattg gagtcaggag ctaaagaata g 351 <210> SEQ ID NO 58 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rev - HIV Rev- Nuclear export and stabilize viral mRNA <400> SEQUENCE: 58 atggcaggaa gaagcggaga cagcgacgaa gaactcctca aggcagtcag actcatcaag 60 tttctctatc aaagcaaccc acctcccaat cccgagggga cccgacaggc ccgaaggaat 120 agaagaagaa ggtggagaga gagacagaga cagatccatt cgattagtga acggatcctt 180 agcacttate tgggacgate tgeggageet gtgeetette agetaceace gettgagaga 240 cttactcttg attgtaacga ggattgtgga acttctggga cgcagggggt gggaagccct 300

163

#### -continued

164

caaatattgg tggaatctcc tacaatattg gagtcaggag ctaaagaata g 351 <210> SEQ ID NO 59 <211> LENGTH: 450 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Rev- Rabbit beta globin poly A- RNA stability <400> SEQUENCE: 59 agatettttt ceetetgeea aaaattatgg ggacateatg aageeeettg ageatetgae 60 ttctggctaa taaaggaaat ttattttcat tgcaatagtg tgttggaatt ttttgtgtct 120 ctcactcgga aggacatatg ggagggcaaa tcatttaaaa catcagaatg agtatttggt 180 ttagagtttg gcaacatatg cccatatgct ggctgccatg aacaaaggtt ggctataaag 240 aggtcatcag tatatgaaac agccccctgc tgtccattcc ttattccata gaaaagcctt 300 360 aaaattttcc ttacatgttt tactagccag atttttcctc ctctcctgac tactcccagt 420 catagetgte cetettetet tatggagate 450 <210> SEQ ID NO 60 <211> LENGTH: 577 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- CMV promoter- Transcription <400> SEQUENCE: 60 acattgatta ttgactagtt attaatagta atcaattacg gggtcattag ttcatagccc 60 atatatggag ttccgcgtta cataacttac ggtaaatggc ccgcctggct gaccgcccaa 120 cgacccccgc ccattgacgt caataatgac gtatgttccc atagtaacgc caatagggac 180 tttccattga cgtcaatggg tggagtattt acggtaaact gcccacttgg cagtacatca 240 agtgtatcat atgccaagta cgccccctat tgacgtcaat gacggtaaat ggcccgcctg 300 gcattatgcc cagtacatga ccttatggga ctttcctact tggcagtaca tctacgtatt 360 agtcatcgct attaccatgg tgatgcggtt ttggcagtac atcaatgggc gtggatagcg 420 gtttgactca cggggatttc caagtctcca ccccattgac gtcaatggga gtttgttttg 480 gcaccaaaat caacgggact ttccaaaatg tcgtaacaac tccgccccat tgacgcaaat 540 gggcggtagg cgtgtacggt gggaggtcta tataagc 577 <210> SEQ ID NO 61 <211> LENGTH: 573 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- Beta globin intron- Enhance gene expression <400> SEQUENCE: 61 gtgagtttgg ggaccettga ttgttettte tttttegeta ttgtaaaatt eatgttatat 60 ggagggggca aagttttcag ggtgttgttt agaatgggaa gatgtccctt gtatcaccat 120 ggacceteat gataattttg tttetteae tttetaetet gttgacaaee attgteteet 180 cttattttct tttcattttc tgtaactttt tcgttaaact ttagcttgca tttgtaacga 240 atttttaaat tcacttttgt ttatttgtca gattgtaagt actttctcta atcacttttt 300

166

### 165

#### -continued

tttcaaggca atcagggtat attatattgt acttcagcac agttttagag aacaattgtt	360
ataattaaat gataaggtag aatatttetg catataaatt etggetggeg tggaaatatt	420
cttattggta gaaacaacta caccctggtc atcatcctgc ctttctcttt atggttacaa	480
tgatatacac tgtttgagat gaggataaaa tactctgagt ccaaaccggg cccctctgct	540
aaccatgttc atgccttctt ctctttccta cag	573
<210> SEQ ID NO 62 <211> LENGTH: 1519 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- VSV-G- Glycoprotein envelope-cel entry	1
<400> SEQUENCE: 62	
atgaagtgcc ttttgtactt agccttttta ttcattgggg tgaattgcaa gttcaccata	60
gtttttccac acaaccaaaa aggaaactgg aaaaatgttc cttctaatta ccattattgc	120
ccgtcaagct cagatttaaa ttggcataat gacttaatag gcacagcctt acaagtcaaa	180
atgcccaaga gtcacaaggc tattcaagca gacggttgga tgtgtcatgc ttccaaatgg	240
gtcactactt gtgatttccg ctggtatgga ccgaagtata taacacattc catccgatcc	300
ttcactccat ctgtagaaca atgcaaggaa agcattgaac aaacgaaaca aggaacttgg	360
ctgaatccag gcttccctcc tcaaagttgt ggatatgcaa ctgtgacgga tgccgaagca	420
gtgattgtcc aggtgactcc tcaccatgtg ctggttgatg aatacacagg agaatgggtt	480
gattcacagt tcatcaacgg aaaatgcagc aattacatat gccccactgt ccataactct	540
acaacctggc attctgacta taaggtcaaa gggctatgtg attctaacct catttccatg	600
gacatcacct tcttctcaga ggacggagag ctatcatccc tgggaaagga gggcacaggg	660
ttcagaagta actactttgc ttatgaaact ggaggcaagg cctgcaaaat gcaatactgc	720
aagcattggg gagtcagact cccatcaggt gtctggttcg agatggctga taaggatctc	780
tttgctgcag ccagattccc tgaatgccca gaagggtcaa gtatctctgc tccatctcag	840
acctcagtgg atgtaagtct aattcaggac gttgagagga tcttggatta ttccctctgc	900
caagaaacct ggagcaaaat cagagcgggt cttccaatct ctccagtgga tctcagctat	960
cttgctccta aaaacccagg aaccggtcct gctttcacca taatcaatgg taccctaaaa	1020
tactttgaga ccagatacat cagagtcgat attgctgctc caatcctctc aagaatggtc	1080
ggaatgatca gtggaactac cacagaaagg gaactgtggg atgactgggc accatatgaa	1140
gacgtggaaa ttggacccaa tggagttctg aggaccagtt caggatataa gtttccttta	1200
tacatgattg gacatggtat gttggactcc gatcttcatc ttagctcaaa ggctcaggtg	1260
ttcgaacatc ctcacattca agacgctgct tcgcaacttc ctgatgatga gagtttattt	1320
tttggtgata ctgggctatc caaaaatcca atcgagcttg tagaaggttg gttcagtagt	1380
tggaaaagct ctattgcctc ttttttcttt atcatagggt taatcattgg actattcttg	1440
gttctccgag ttggtatcca tctttgcatt aaattaaagc acaccaagaa aagacagatt	1500
tatacagaca tagagatga	1519

<210> SEQ ID NO 63 <211> LENGTH: 450 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:

#### -continued

<223> OTHER INFORMATION: Envelope- Rabbit beta globin poly A- F stability	RNA.
<400> SEQUENCE: 63	
agatettttt ecctetgeea aaaattatgg ggacateatg aageeeettg ageatetg	gac 60
ttctggctaa taaaggaaat ttattttcat tgcaatagtg tgttggaatt ttttgtgt	tet 120
ctcactcgga aggacatatg ggagggcaaa tcatttaaaa catcagaatg agtattto	ggt 180
ttagagtttg gcaacatatg cccatatgct ggctgccatg aacaaaggtt ggctataa	aag 240
aggtcatcag tatatgaaac agccccctgc tgtccattcc ttattccata gaaaagco	stt 300
gacttgaggt tagatttttt ttatattttg ttttgtgtta tttttttctt taacatco	201 360
aaaattttcc ttacatgttt tactagccag atttttcctc ctctcctgac tactccca	agt 420
catagetgte cetettetet tatggagate	450
<210> SEQ ID NO 64 <211> LENGTH: 1104 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Promoter- EF-1	
<400> SEQUENCE: 64	
ccggtgccta gagaaggtgg cgcggggtaa actgggaaag tgatgtcgtg tactggct	ccc 60
gcctttttcc cgagggtggg ggagaaccgt atataagtgc agtagtcgcc gtgaacgt	tc 120
tttttcgcaa cgggtttgcc gccagaacac aggtaagtgc cgtgtgtggt tcccgcgg	ggc 180
ctggcctctt tacgggttat ggcccttgcg tgccttgaat tacttccacg cccctgg	etg 240
cagtacgtga ttcttgatcc cgagcttcgg gttggaagtg ggtgggagag ttcgaggg	201 300
tgegettaag gageeeette geetegtget tgagttgagg eetggeetgg	ggc 360
cgccgcgtgc gaatctggtg gcaccttcgc gcctgtctcg ctgctttcga taagtcto	cta 420
gccatttaaa atttttgatg acctgctgcg acgctttttt tctggcaaga tagtcttg	yta 480
aatgegggee aagatetgea caetggtatt teggtttttg gggeegeggg eggegaeg	ggg 540
gecegtgegt eccagegeae atgtteggeg aggeggggee tgegagegeg gecaeega	aga 600
ateggaeggg ggtagtetea agetggeegg eetgetetgg tgeetggeet egegeege	ccg 660
tgtategeee egeeetggge ggeaaggetg geeeggtegg eaceagttge gtgagegg	gaa 720
agatggccgc ttcccggccc tgctgcaggg agctcaaaat ggaggacgcg gcgctcg	gga 780
gagcgggcgg gtgagtcacc cacacaaagg aaaagggcct ttccgtcctc agccgtc	gct 840
tcatgtgact ccacggagta ccgggcgccg tccaggcacc tcgattagtt ctcgaget	tt 900
tggagtacgt cgtctttagg ttgggggggg gggttttatg cgatggagtt tccccaca	act 960
gagtgggtgg agactgaagt taggccagct tggcacttga tgtaattete ettggaat	tt 1020
gccctttttg agtttggatc ttggttcatt ctcaagcctc agacagtggt tcaaagtt	tt 1080
tttcttccat ttcaggtgtc gtga	1104

<210> SEQ ID NO 65 <211> LENGTH: 511 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Promoter- PGK

<400> SEQUENCE: 65

#### 169

cgttgaccga atcaccgacc tctctcccca g

<213> ORGANISM: Artificial Sequence

<223> OTHER INFORMATION: Promoter- UbC

<210> SEQ ID NO 66 <211> LENGTH: 1162 <212> TYPE: DNA

<220> FEATURE:

ggggttgggg ttgcgccttt tccaaggcag ccctgggttt gcgcagggac gcggctgctc

tgggcgtggt tccgggaaac gcagcggcgc cgaccctggg tctcgcacat tcttcacgtc

cgttcgcagc gtcacccgga tcttcgccgc tacccttgtg ggccccccgg cgacgcttcc

tgctccgccc ctaagtcggg aaggttcctt gcggttcgcg gcgtgccgga cgtgacaaac

ggaagccgca cgtctcacta gtaccctcgc agacggacag cgccagggag caatggcagc

gcgccgaccg cgatgggctg tggccaatag cggctgctca gcaggggcgcg ccgagagcag

cggccgggaa ggggcggtgc gggaggcggg gtgtggggcg gtagtgtggg ccctgttcct gcccgcgcgg tgttccgcat tctgcaagcc tccggagcgc acgtcggcag tcggctccct

#### -continued

<400> SEQUI	ENCE: 66				
gcgccgggtt	ttggcgcctc	ccgcgggcgc	ccccctcctc	acggcgagcg	ctgccacgtc
agacgaaggg	cgcaggagcg	ttcctgatcc	ttccgcccgg	acgctcagga	cageggeeeg
ctgctcataa	gactcggcct	tagaacccca	gtatcagcag	aaggacattt	taggacggga
cttgggtgac	tctagggcac	tggttttctt	tccagagagc	ggaacaggcg	aggaaaagta
gtcccttctc	ggcgattctg	cggagggatc	tccgtggggc	ggtgaacgcc	gatgattata
taaggacgcg	ccgggtgtgg	cacagctagt	tccgtcgcag	ccgggatttg	ggtcgcggtt
cttgtttgtg	gatcgctgtg	atcgtcactt	ggtgagttgc	gggctgctgg	gctggccggg
gctttcgtgg	ccgccgggcc	gctcggtggg	acggaagcgt	gtggagagac	cgccaagggc
tgtagtctgg	gtccgcgagc	aaggttgccc	tgaactgggg	gttgggggga	gcgcacaaaa
tggcggctgt	tcccgagtct	tgaatggaag	acgcttgtaa	ggcgggctgt	gaggtcgttg
aaacaaggtg	ggggggcatgg	tgggcggcaa	gaacccaagg	tcttgaggcc	ttcgctaatg
cgggaaagct	cttattcggg	tgagatgggc	tggggcacca	tctggggacc	ctgacgtgaa
gtttgtcact	gactggagaa	ctcgggtttg	tcgtctggtt	gcggggggcgg	cagttatgcg
gtgccgttgg	gcagtgcacc	cgtacctttg	ggagcgcgcg	cctcgtcgtg	tcgtgacgtc
acccgttctg	ttggcttata	atgcagggtg	gggccacctg	ccggtaggtg	tgcggtaggc
ttttctccgt	cgcaggacgc	agggttcggg	cctagggtag	gctctcctga	atcgacaggc
gccggacctc	tggtgagggg	agggataagt	gaggcgtcag	tttctttggt	cggttttatg
tacctatctt	cttaagtagc	tgaagctccg	gttttgaact	atgcgctcgg	ggttggcgag
tgtgttttgt	gaagttttt	aggcaccttt	tgaaatgtaa	tcatttgggt	caatatgtaa

<210> SEQ ID NO 67 <211> LENGTH: 120 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Poly A- SV40

ttttcagtgt tagactagta aa

<400> SEQUENCE: 67

gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 60 170

60

120

180

240

300

360 420

480

511

60

120

180

240

300

360

420

480

540

600

660

720

780 840

900

960 1020

1080

1140

1162

# 172

agcattttt	tcactgcatt	ctagttgtgg	tttgtccaaa	ctcatcaatg	tatcttatca	120	
<210> SEQ 1 <211> LENG <212> TYPE <213> ORGAN <220> FEATU <223> OTHER	ID NO 68 IH: 227 : DNA NISM: Artif: JRE: R INFORMATIC	icial Sequer DN: Poly A-	nce bGH				
<400> SEQUE	ENCE: 68						
gactgtgcct	tctagttgcc	agccatctgt	tgtttgcccc	tcccccgtgc	cttccttgac	60	
cctggaaggt	gccactccca	ctgtcctttc	ctaataaaat	gaggaaattg	catcgcattg	120	
tctgagtagg	tgtcattcta	ttctgggggg	tggggtgggg	caggacagca	aggggggagga	180	
ttgggaagac	aatagcaggc	atgctgggga	tgcggtgggc	tctatgg		227	
<210> SEQ 1 <211> LENG <212> TYPE <213> ORGAN <220> FEATU <223> OTHER	ID NO 69 TH: 1512 : DNA NISM: Artif: JRE: R INFORMATIC	icial Sequer DN: HIV Gag-	nce - Bal				
<400> SEQUE	ENCE: 69						
atgggtgcga	gagcgtcagt	attaagcggg	ggagaattag	ataggtggga	aaaaattcgg	60	
ttaaggccag	ggggaaagaa	aaaatataga	ttaaaacata	tagtatgggc	aagcagggaa	120	
ctagaaagat	tcgcagtcaa	tcctggcctg	ttagaaacat	cagaaggctg	cagacaaata	180	
ctgggacagc	tacaaccatc	ccttcagaca	ggatcagaag	aacttagatc	attatataat	240	
acagtagcaa	ccctctattg	tgtacatcaa	aagatagagg	taaaagacac	caaggaagct	300	
ttagacaaaa	tagaggaaga	gcaaaacaaa	tgtaagaaaa	aggcacagca	agcagcagct	360	
gacacaggaa	acagcggtca	ggtcagccaa	aatttcccta	tagtgcagaa	cctccagggg	420	
caaatggtac	atcaggccat	atcacctaga	actttaaatg	catgggtaaa	agtaatagaa	480	
gagaaagctt	tcagcccaga	agtaataccc	atgttttcag	cattatcaga	aggagccacc	540	
ccacaagatt	taaacaccat	gctaaacaca	gtggggggac	atcaagcagc	catgcaaatg	600	
ttaaaagaac	ccatcaatga	ggaagctgca	agatgggata	gattgcatcc	cgtgcaggca	660	
gggcctgttg	caccaggcca	gataagagat	ccaaggggaa	gtgacatagc	aggaactacc	720	
agtacccttc	aggaacaaat	aggatggatg	acaagtaatc	cacctatccc	agtaggagaa	780	
atctataaaa	gatggataat	cctgggatta	aataaaatag	taaggatgta	tagccctacc	840	
agcattttgg	acataagaca	aggaccaaag	gaacccttta	gagactatgt	agaccggttc	900	
tataaaactc	taagagccga	gcaagcttca	caggaggtaa	aaaattggat	gacagaaacc	960	
ttgttggtcc	aaaatgcgaa	cccagattgt	aagactattt	taaaagcatt	gggaccagca	1020	
gctacactag	aagaaatgat	gacagcatgt	cagggagtgg	gaggacccag	ccataaagca	1080	
agaattttgg	cagaagcaat	gagccaagta	acaaattcag	ctaccataat	gatgcagaaa	1140	
ggcaatttta	ggaaccaaag	aaagattgtt	aaatgtttca	attgtggcaa	agaagggcac	1200	
atagccagaa	actgcagggc	ccctaggaaa	agggggctgtt	ggaaatgtgg	aaaggaagga	1260	
caccaaatga	aagactgtac	tgagagacag	gctaattttt	tagggaaaat	ctggccttcc	1320	
cacaaaggaa	ggccagggaa	tttccttcag	agcagaccag	agccaacagc	cccaccagcc	1380	
ccaccagaag	agagetteag	gtttggggaa	gagacaacaa	ctccctctca	gaagcaggag	1440	

174

	1500
tcgtcacaat aa	1512
<210> SEQ ID NO 70 <211> LENGTH: 1872 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: HIV Pol- Bal	
<400> SEQUENCE: 70	
atgaatttgc caggaagatg gaaaccaaaa atgatagggg gaattggagg ttttatcaaa	60
gtaagacagt atgatcagat actcatagaa atctgtggac ataaagctat aggtacagta	120
ttaataggac ctacacctgt caacataatt ggaagaaatc tgttgactca gattggttgc	180
actttaaatt ttcccattag tcctattgaa actgtaccag taaaattaaa accaggaatg	240
gatggcccaa aagttaaaca atggccactg acagaagaaa aaataaaagc attaatggaa	300
atctgtacag aaatggaaaa ggaagggaaa atttcaaaaa ttgggcctga aaatccatac	360
aatactccag tatttgccat aaagaaaaaa gacagtacta aatggagaaa attagtagat	420
ttcagagaac ttaataagaa aactcaagac ttctgggaag tacaattagg aatacacatc	480
ccgcaggggt taaaaaagaa aaaatcagta acagtactgg atgtgggtga tgcatatttt	540
tcagttccct tagataaaga attcaggaag tatactgcat ttaccatacc tagtataaac	600
aatgaaacac cagggatcag atatcagtac aatgtacttc cacagggatg gaaaggatca	660
ccagcaatat ttcaaagtag catgacaaga atcttagagc cttttagaaa acaaaatcca	720
gaaatagtga tctatcaata catggatgat ttgtatgtag gatctgactt agaaataggg	780
cagcatagaa caaaaataga ggaactgaga caacatctgt tgaggtgggg atttaccaca	840
ccagacaaaa aacatcagaa agaacctcca ttcctttgga tgggttatga actccatcct	900
gataaatgga cagtacagcc tatagtgctg ccagaaaaag acagctggac tgtcaatgac	960
atacagaagt tagtgggaaa attgaattgg gcaagtcaga tttacccagg aattaaagta	1020
aagcaattat gtaggctcct taggggaacc aaggcattaa cagaagtaat accactaaca	1080
aaagaaacag agctagaact ggcagagaac agggaaattc taaaagaacc agtacatggg	1140
gtgtattatg acccatcaaa agacttaata gcagaaatac agaagcaggg gcaaggccaa	1200
tggacatatc aaatttatca agagccattt aaaaatctga aaacaggaaa atatgcaaga	1260
atgaggggtg cccacactaa tgatgtaaaa caattaacag aggcagtgca aaaaataacc	1320
acagaaagca tagtaatatg gggaaagact cctaaattta aactacccat acaaaaagaa	1380
acatgggaaa catggtggac agagtattgg caagccacct ggattcctga gtgggagttt	1440
gtcaataccc ctcccttagt gaaattatgg taccagttag agaaagaacc cataatagga	1500
gcagaaacat tctatgtaga tggagcagct aaccgggaga ctaaattagg aaaagcagga	1560
tatgttacta acagaggaag acaaaaagtt gtctccctaa ctgacacaac aaatcagaag	1620
actgagttac aagcaattca tctagcttta caagattcag gattagaagt aaacatagta	1680
acagactcac aatatgcatt aggaatcatt caagcacaac cagataaaag tgaatcagag	1740
ttagtcagtc aaataataga acagttaata aaaaaggaaa aggtctacct ggcatgggta	1800
ccagcgcaca aaggaattgg aggaaatgaa caagtagata aattagtcag tactggaatc	1860
aggaaagtac ta	1872

175

-continued

<210> SEQ 3 <211> LENG3 <212> TYPE <213> ORGAN	ID NO 71 FH: 867 : DNA NISM: Artif:	icial Sequer	nce			
<220> FEATU <223> OTHEN	JRE: R INFORMATIO	ON: HIV Inte	egrase- Bal			
<400> SEQUI	ENCE: 71					
tttttagatg	gaatagatat	agcccaagaa	gaacatgaga	aatatcacag	taattggaga	60
gcaatggcta	gtgattttaa	cctgccacct	gtggtagcaa	aagaaatagt	agccagctgt	120
gataaatgtc	agctaaaagg	agaagccatg	catggacaag	tagactgtag	tccaggaata	180
tggcaactag	attgtacaca	tttagaagga	aaaattatcc	tggtagcagt	tcatgtagcc	240
agtggatata	tagaagcaga	agttattcca	gcagagacag	ggcaggaaac	agcatacttt	300
ctcttaaaat	tagcaggaag	atggccagta	aaaacaatac	atacagacaa	tggcagcaat	360
ttcactagta	ctacagtcaa	ggccgcctgt	tggtgggcgg	ggatcaagca	ggaatttggc	420
attccctaca	atccccaaag	tcagggagta	gtagaatcta	taaataaaga	attaaagaaa	480
attataggac	aggtaagaga	tcaggctgaa	catcttaaaa	cagcagtaca	aatggcagta	540
ttcatccaca	attttaaaag	aaaagggggg	attggggggt	atagtgcagg	ggaaagaata	600
gtagacataa	tagcaacaga	catacaaact	aaagaattac	aaaaacaaat	tacaaaaatt	660
caaaattttc	gggtttatta	cagggacagc	agagatccac	tttggaaagg	accagcaaag	720
cttctctgga	aaggtgaagg	ggcagtagta	atacaagata	atagtgacat	aaaagtagta	780
ccaagaagaa	aagcaaagat	cattagggat	tatggaaaac	agatggcagg	tgatgattgt	840
gtggcaagta	gacaggatga	ggattag				867
<210> SEQ : <211> LENG' <212> TYPE <213> ORGAN <220> FEATU <223> OTHEN	ID NO 72 IH: 1695 : DNA NISM: Artif: JRE: R INFORMATIC	icial Sequer DN: Envelope	nce 9- RD114			
<210> SEQ : <211> LENG <212> TYPE <213> ORGAI <220> FEATU <223> OTHEN <400> SEQUI	ID NO 72 TH: 1695 : DNA NISM: Artif: RE: R INFORMATIC ENCE: 72	icial Sequer DN: Envelope	nce ≥- RD114			
<210> SEQ : <211> LENG <212> TYPE <213> ORGAI <220> FEAT <223> OTHEN <400> SEQUI atgaaactcc	ID NO 72 IH: 1695 : DNA VISM: Artif: JRE: R INFORMATIC ENCE: 72 caacaggaat	icial Sequer DN: Envelope ggtcatttta	nce 2- RD114 tgtagcctaa	taatagttcg	ggcagggttt	60
<210> SEQ 3 <211> LENG <211> LENG <213> ORGA <220> FEAT <223> OTHEN <400> SEQUN atgaaactcc gacgaccccc	ID NO 72 TH: 1695 : DNA NISM: Artif: JRE: R INFORMATIC ENCE: 72 caacaggaat gcaaggctat	icial Sequer DN: Envelope ggtcatttta cgcattagta	nce E- RD114 tgtagcctaa caaaaacaac	taatagttcg atggtaaacc	ggcagggttt atgcgaatgc	60 120
<210> SEQ <211> LENG <212> TYPE <213> ORGAN <220> FEAT <223> OTHEN <400> SEQUI atgaaactcc gacgaccccc agcggagggc	ID NO 72 IH: 1695 : DNA NISM: Artif: JRE: R INFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga	icial Sequer DN: Envelope ggtcatttta cgcattagta ggccccaccg	nce e- RD114 tgtagcctaa caaaaacaac aactccatcc	taatagttcg atggtaaacc aacaggtaac	ggcagggttt atgcgaatgc ttgcccaggc	60 120 180
<pre>&lt;210&gt; SEQ : &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUN atgaaactcc gacgaccccc agcggagggc aagacggct</pre>	ID NO 72 IH: 1695 : DNA NISM: Artif: JRE: R INFORMATIO ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac	lcial Sequer DN: Envelope ggtcatttta cgcattagta ggccccaccg caaccaaaaa	nce E- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca	taatagttog atggtaaacc aacaggtaac gagtcactoc	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc	60 120 180 240
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUN atgaaactcc gacgaccccc agcggagggc aagacggcct acccctagcg</pre>	ID NO 72 IH: 1695 : DNA NISM: Artif: JRE: R INFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact	icial Sequer DN: Envelope ggtcatttta cgcattagta ggccccaccg caaccaaaaa ccagaactgc	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac	60 120 180 240 300
<pre>&lt;210&gt; SEQ : &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUN atgaaactcc gacgaccccc agcggagggc aagacggcct acccctagcg agttcttgtt</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: JRE: R INFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata	icial Sequer DN: Envelope ggtcatttta cgcattagta ggccccaccg caaccaaaaa ccagaactgc ccggcaatgc	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata	taatagttog atggtaaaco aacaggtaac gagtoactoo otttocagga ataagacata	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc	60 120 180 240 300 360
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN atgaaactcc gacgacccccc agcggagggc aagacggcct acccctagcg agttcttgtt accttgctta</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: RE: R INFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc ccggcaatgc tgggagcctc	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat	60 120 180 240 300 360 420
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUN atgaaactcc gacgaccccc agcggagggc aagacggcct acccctagcg agttcttgtt accttgctta cagctcctac</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: JRE: a INFORMATION ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc agtccccttg	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc ccggcaatgc tgggagcctc taggggctct	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca	60 120 180 240 300 360 420 480
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGA &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUI atgaaactcc gacgacccccc agcggagggc aagacggcct acccctagcg agttcttgtt accttgctta cagctcctac gcccccatcc</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: RE: RINFORMATIC GENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc agtccccttg atactccga	Icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc ccggcaatgc tgggagcctc tagggggctct tggtggagga	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc cccctcgata	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg ctaagagagt	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca gtggacagtc	60 120 180 240 360 420 480 540
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUA atgaaactcc gacgaccccc agcggagggc aagacggcct acccctagcg agttcttgtt accttgctta cagctcctac gcccccatcc caaaaaaggc</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: JRE: 2 INFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc agtccccttg atactccga tagaacaaat	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc tgggagcctc tagggggctct tggtggagga tcataaggct	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc cccctcgata atgcatcctg	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg ctaagagagt aacttcaata	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca gtggacagtc ccaccctta	60 120 180 240 300 360 420 480 540 600
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; LENG &lt;213&gt; ORGAT &lt;220&gt; FEATU &lt;223&gt; OTHEN &lt;400&gt; SEQUI atgaaactcc gacgaccccc agcggagggc aagacggct acccctagcg agttcttgtt accttgctta cagctcctac gcccccatcc caaaaaaggc gccctgccca</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: RE: CINFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc atactccga tagaacaaat aagtcagaga	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc cggcaatgc tggggggctct tggtggagga tcataaggct tggcggggga	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc cccctcgata atgcatcctg cttgatgcac	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg ctaagagagt aacttcaata ggactttga	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca gtggacagtc ccacccctta tatcctgaat	60 120 180 240 300 360 420 480 540 600 660
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; TYPE &lt;213&gt; ORGAN &lt;220&gt; FEAT &lt;223&gt; OTHEN &lt;400&gt; SEQUA atgaaactcc gacgaccccc agcggagggc aagacggcct acccctagcg agttcttgtt accttgctta cagctcctac gcccccatcc caaaaaaggc gccctgccca accattta</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: JRE: 2 INFORMATIC ENCE: 72 caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc agtccccttg atactccga tagaacaaat aagtcagaga ggttactcca	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc ccggcaatgc tgggggcctc tagggggctct tggtggagga tcataaggct tgaccttagc gatgtccaat	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc cccctcgata atgcatcctg cttgatgcac tttagccttg	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg ctaagagagt aacttcaata ggactttga	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca gtggacagtc ccaccctta tatcctgaat	60 120 180 240 300 360 420 480 540 600 660 720
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; LENG &lt;213&gt; ORGAT &lt;220&gt; FEATU &lt;223&gt; OTHEN atgaaactcc gacgaccccc agcggagggc aagacggct acccctagcg agttcttgtt accttgctta cagctcctac gcccccatcc caaaaaaggc gccctgccca accatttta ttaaaactag</pre>	ID NO 72 IH: 1695 : DNA VISM: Artif: JRE: 2 INFORMATIC Caacaggaat gcaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc agtccccttg atactccga tagaacaaat aagtcagaga ggttactcca gtacccctac	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc tggggagctc tagggggctct tggtggagga tcataaggct tgaccttagc gatgtccaat ccctttgcg	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc cccctcgata atgcatcctg cttgatgcac tttagccttg atacccactc	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg ctaagagagt aacttcaata ggacttttga cccaagattg cccaagattg	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca gtggacagtc ccacccctta tatcctgaat ttggctctgt	60 120 180 240 300 360 420 480 540 600 660 720 780
<pre>&lt;210&gt; SEQ 3 &lt;211&gt; LENG &lt;211&gt; LENG &lt;212&gt; TYPE &lt;213&gt; ORGA &lt;220&gt; FEAT &lt;223&gt; OTHEN atgaaactcc gacgaccccc agcggagggc aagacggcct acccctagcg agttcttgtt accttgctta cagctcctac gcccccatcc caaaaaaggc gccctgccca accacttta ttaaaactag gcagactccc</pre>	ID NO 72 TH: 1695 : DNA VISM: Artif: RE: CINFORMATIC GENCE: 72 Caacaggaat ggaaggctat aggtatccga acttaatgac ggggagaact atactgaata aaatacggtc atactcccqa tagaacaaat aagtcagaga ggttactcca ggtcccctac tagcgaatgc	icial Sequer DN: Envelope ggtcattta cgcattagta ggccccaccg caaccaaaaa ccagaactgc ccggcaatgc tggggggctct tggtgggggga tcataaggct tgaccttagc gatgtccaat ccctcttgcg ctcctgtcag	nce =- RD114 tgtagcctaa caaaaacaac aactccatcc tggaaatgca ccctgtaaca agggcgaata aacgaggtac ataaatcagc cccctcgata atgcatcctg cttgatgcac tttagccttg atacccactc attatacctc	taatagttcg atggtaaacc aacaggtaac gagtcactcc ctttccagga ataagacata agatattaca ccgtttgctg ctaagagagt aacttcaata ggacttttga cccaagattg cccctttaac	ggcagggttt atgcgaatgc ttgcccaggc aaaaaatctc ctcgatgcac ctacacggcc aaaccccaat gagtgccaca gtggacagtc ccaccctta tatcctgaat ttggctctgt ctactcccta	60 120 180 240 300 420 480 540 600 660 720 780 840

176

177

ttaggtgcag tcacctttac taactgcacc tctgtagcca atgtcagtag tcctttatgt

gccctaaacg ggtcagtctt cctctgtgga aataacatgg catacaccta tttaccccaa

#### -continued

aactggacag gactttgcgt ccaagcctcc	ctcctccccg acattgacat	catcccgggg 10	080
gatgagecag tecceattee tgecattgat	cattatatac atagacctaa	acgagctgta 1	40
cagttcatcc ctttactagc tggactggga	atcaccgcag cattcaccac	cggagctaca 12	200
ggcctaggtg tctccgtcac ccagtataca	aaattatccc atcagttaat	atctgatgtc 12	260
caagtettat eeggtaeeat acaagattta	caagaccagg tagactcgtt	agctgaagta 13	320
gttctccaaa ataggaggggg actggaccta	ctaacggcag aacaaggagg	aatttgttta 13	80
gccttacaag aaaaatgctg tttttatgct	aacaagtcag gaattgtgag	aaacaaaata 14	40
agaaccctac aagaagaatt acaaaaacgc	agggaaagcc tggcatccaa	ccctctctgg 15	500
accgggctgc agggctttct tccgtacctc	ctacctctcc tgggacccct	actcaccctc 15	560
ctactcatac taaccattgg gccatgcgtt	ttcaatcgat tggtccaatt	tgttaaagac 10	520
aggateteag tggteeagge tetggttttg	actcagcaat atcaccagct	aaaacccata 16	580
gagtacgagc catga		10	595
<pre>&lt;210&gt; SEQ ID NO 73 &lt;211&gt; LENGTH: 2013 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequen &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Envelope &lt;400&gt; SEQUENCE: 73</pre>	ce - GALV		
<400> SEQUENCE: /3		<b>.</b>	<u></u>
augettetea esteagees geaceacett	oggeaceaga tgagteetgg	yagctggaaa	00
agaetgatea teetettaag etgegtatte	ggagacggca aaacgagtet	geagaalaag .	.20
	eagglaeigt eesaaaeigg	ggaeguigue .	.80
tataaataa aggaagatat taaataataa		accegacyca	200
aaaagagatta gaggtoggtot tigagtottigg	actoccoctt ataaccaaat	accycecce .	260
accelerate aceacterical transferred	accedented casattered	cttctacata	120
tatacagggt geagerated regggeragg	actaggatgg taaatteett	agaateeeta	180
tactataaag aatggagtta taagaccaca	getaggaggt gtgggggget	caagteetea l	340
taagaactca taactataaa atagaaccaa	aatataaaat gagaggaaaa	atttcaaaad	510
tataacaaa cogotaata taaccoota	aagatagact teacagaaaa	aggaaaactc /	560
tocagagatt ggataacgga aaaaacctgg	gaattaaggt totatgtata	tggacaccca	72.0
ggcatacagt tgactatccg cttagaggtc	actaacatge eggttgtgge	agtgggggga	780
qaccetqtee ttqeqqaaca qqqaceteet	agcaagcccc tcactctccc	tctctcccca	340
	geggetagtg ageaaaccoc	tacaatacat (	900
	addaddadta addaddaat	ctttageett (	60
yyayaaaciy ttaccotaad ctotocgCCt	eccaccageg gegaccgaCt	atattaat	200
yuyuayyyyy correctaad orrgaarget	accaacccag gggccactaa	guduugatgg 10	120
ctctgtttgg gcatgagccc cccttattat	gaagggatag cctcttcagg	agaggtcgct 10	180
tataceteca accataceeg atgecaetgg	ggggcccaag gaaagcttac	cctcactgag 1	40
gtctccggac tcgggtcatg catagggaag	gtgcctctta cccatcaaca	tctttgcaac 12	200
cagacettae ceateaatte etetaaaaae	catcagtatc tgctcccctc	aaaccatagc 12	260

178

960

1020

179

			-001011		
tggtgggcct gcagcactgg	cctcaccccc	tgcctctcca	cctcagtttt	taatcagtct	1320
aaagacttct gtgtccaggt	ccagctgatc	ccccgcatct	attaccattc	tgaagaaacc	1380
ttgttacaag cctatgacaa	atcacccccc	aggtttaaaa	gagagcctgc	ctcacttacc	1440
ctagctgtct tcctggggtt	agggattgcg	gcaggtatag	gtactggctc	aaccgcccta	1500
attaaagggc ccatagacct	ccagcaaggc	ctaaccagcc	tccaaatcgc	cattgacgct	1560
gacctccggg cccttcagga	ı ctcaatcagc	aagctagagg	actcactgac	ttccctatct	1620
gaggtagtac tccaaaatag	gagaggcctt	gacttactat	tccttaaaga	aggaggcctc	1680
tgcgcggccc taaaagaaga	gtgctgtttt	tatgtagacc	actcaggtgc	agtacgagac	1740
tccatgaaaa aacttaaaga	aagactagat	aaaagacagt	tagagcgcca	gaaaaaccaa	1800
aactggtatg aagggtggtt	caataactcc	ccttggttta	ctaccctact	atcaaccatc	1860
gctgggcccc tattgctcct	ccttttgtta	ctcactcttg	ggccctgcat	catcaataaa	1920
ttaatccaat tcatcaatga	taggataagt	gcagtcaaaa	ttttagtcct	tagacagaaa	1980
tatcagaccc tagataacga	ggaaaacctt	taa			2013
<pre><li>LENGTH: 1530 &lt;211&gt; LENGTH: 1530 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artif &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATI &lt;400&gt; SEQUENCE: 74</li></pre>	icial Seque CON: Envelop	nce e- FUG			
atggttccgc aggttcttt	gtttgtactc	cttctgggtt	tttcgttgtg	tttcgggaag	60
ttccccattt acacgatacc	agacgaactt	ggtccctgga	gccctattga	catacaccat	120
ctcagctgtc caaataacct	ggttgtggag	gatgaaggat	gtaccaacct	gtccgagttc	180
tcctacatgg aactcaaagt	gggatacatc	tcagccatca	aagtgaacgg	gttcacttgc	240
acaggtgttg tgacagaggc	agagacctac	accaactttg	ttggttatgt	cacaaccaca	300
ttcaagagaa agcatttccg	ccccacccca	gacgcatgta	gagccgcgta	taactggaag	360
atggccggtg accccagata	tgaagagtcc	ctacacaatc	cataccccga	ctaccactgg	420
cttcgaactg taagaaccac	caaagagtcc	ctcattatca	tatccccaag	tgtgacagat	480
ttggacccat atgacaaatc	ccttcactca	agggtcttcc	ctggcggaaa	gtgctcagga	540
ataacggtgt cctctaccta	ctgctcaact	aaccatgatt	acaccatttg	gatgcccgag	600
aatccgagac caaggacacc	ttgtgacatt	tttaccaata	gcagagggaa	gagagcatcc	660
aacgggaaca agacttgcgg	ı ctttgtggat	gaaagaggcc	tgtataagtc	tctaaaagga	720
gcatgcaggc tcaagttatg	tggagttctt	ggacttagac	ttatggatgg	aacatgggtc	780
gcgatgcaaa catcagatga	u gaccaaatgg	tgccctccag	atcagttggt	gaatttgcac	840
gactttcgct cagacgagat	. cgagcatctc	gttgtggagg	agttagttaa	gaaaagagag	900
gaatgtctgg atgcattaga	d gtccatcatg	accaccaagt	cagtaagttt	cagacgtctc	960
agtcacctga gaaaacttgt	cccagggttt	ggaaaagcat	ataccatatt	caacaaaacc	1020
ttgatggagg ctgatgctca	l ctacaagtca	gtccggacct	ggaatgagat	catcccctca	1080
aaagggtgtt tgaaagttgg	aggaaggtgc	catcctcatg	tgaacggggt	gtttttcaat	1140
ggtataatat tagggcctga	cgaccatgtc	ctaatcccag	agatgcaatc	atccctcctc	1200
cagcaacata tggagttgtt	ggaatcttca	gttatccccc	tgatgcaccc	cctggcagac	1260

182

### 181

#### -continued

cettetacag titteaaaga aggigaigag geigaggatt tigtigaagt teaceteeee	1320
gatgtgtaca aacagatctc aggggttgac ctgggtctcc cgaactgggg aaagtatgta	1380
ttgatgactg caggggccat gattggcctg gtgttgatat tttccctaat gacatggtgc	1440
agagttggta tccatctttg cattaaatta aagcacacca agaaaagaca gatttataca	1500
gacatagaga tgaaccgact tggaaagtaa	1530
<210> SEQ ID NO 75 <211> LENGTH: 1497 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- LCMV	
<400> SEQUENCE: 75	
atgggtcaga ttgtgacaat gtttgaggct ctgcctcaca tcatcgatga ggtgatcaac	60
attgtcatta ttgtgcttat cgtgatcacg ggtatcaagg ctgtctacaa ttttgccacc	120
tgtgggatat tcgcattgat cagtttccta cttctggctg gcaggtcctg tggcatgtac	180
ggtettaagg gaeeegacat ttacaaagga gtttaceaat ttaagteagt ggagtttgat	240
atgtcacatc tgaacctgac catgcccaac gcatgttcag ccaacaactc ccaccattac	300
atcagtatgg ggacttctgg actagaattg accttcacca atgattccat catcagtcac	360
aacttttgca atctgacctc tgccttcaac aaaaagacct ttgaccacac actcatgagt	420
atagtttcga gcctacacct cagtatcaga gggaactcca actataaggc agtatcctgc	480
gacttcaaca atggcataac catccaatac aacttgacat tctcagatcg acaaagtgct	540
cagagccagt gtagaacctt cagaggtaga gtcctagata tgtttagaac tgccttcggg	600
gggaaataca tgaggagtgg ctggggctgg acaggctcag atggcaagac cacctggtgt	660
agccagacga gttaccaata cctgattata caaaatagaa cctgggaaaa ccactgcaca	720
tatgcaggtc cttttgggat gtccaggatt ctcctttccc aagagaagac taagttcttc	780
actaggagac tagcgggcac attcacctgg actttgtcag actcttcagg ggtggagaat	840
ccaggtggtt attgcctgac caaatggatg attcttgctg cagagcttaa gtgtttcggg	900
aacacagcag ttgcgaaatg caatgtaaat catgatgccg aattctgtga catgctgcga	960
ctaattgact acaacaaggc tgctttgagt aagttcaaag aggacgtaga atctgccttg	1020
cacttattca aaacaacagt gaattctttg atttcagatc aactactgat gaggaaccac	1080
ttgagagatc tgatgggggt gccatattgc aattactcaa agttttggta cctagaacat	1140
gcaaagaccg gcgaaactag tgtccccaag tgctggcttg tcaccaatgg ttcttactta	1200
aatgagaccc acttcagtga tcaaatcgaa caggaagccg ataacatgat tacagagatg	1260
ttgaggaagg attacataaa gaggcagggg agtacccccc tagcattgat ggaccttctg	1320
atgttttcca catctgcata tctagtcagc atcttcctgc accttgtcaa aataccaaca	1380
cacaggcaca taaaaggtgg ctcatgtcca aagccacacc gattaaccaa caaaggaatt	1440
tgtagttgtg gtgcatttaa ggtgcctggt gtaaaaaccg tctggaaaag acgctga	1497
<210> SEO ID NO 76	

<210> SEQ ID NO 76 <211> LENGTH: 1692 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- FPV

183

atgaacactc	aaatcctggt	tttcgccctt	gtggcagtca	tccccacaaa	tgcagacaaa	60
atttgtcttg	gacatcatgc	tgtatcaaat	ggcaccaaag	taaacacact	cactgagaga	120
ggagtagaag	ttgtcaatgc	aacggaaaca	gtggagcgga	caaacatccc	caaaatttgc	180
tcaaaaggga	aaagaaccac	tgatcttggc	caatgcggac	tgttagggac	cattaccgga	240
ccacctcaat	gcgaccaatt	tctagaattt	tcagctgatc	taataatcga	gagacgagaa	300
ggaaatgatg	tttgttaccc	ggggaagttt	gttaatgaag	aggcattgcg	acaaatcctc	360
agaggatcag	gtgggattga	caaagaaaca	atgggattca	catatagtgg	aataaggacc	420
aacggaacaa	ctagtgcatg	tagaagatca	gggtcttcat	tctatgcaga	aatggagtgg	480
ctcctgtcaa	atacagacaa	tgctgctttc	ccacaaatga	caaaatcata	caaaaacaca	540
aggagagaat	cagctctgat	agtctgggga	atccaccatt	caggatcaac	caccgaacag	600
accaaactat	atgggagtgg	aaataaactg	ataacagtcg	ggagttccaa	atatcatcaa	660
tcttttgtgc	cgagtccagg	aacacgaccg	cagataaatg	gccagtccgg	acggattgat	720
tttcattggt	tgatcttgga	tcccaatgat	acagttactt	ttagtttcaa	tggggctttc	780
atagctccaa	atcgtgccag	cttcttgagg	ggaaagtcca	tggggatcca	gagcgatgtg	840
caggttgatg	ccaattgcga	aggggaatgc	taccacagtg	gagggactat	aacaagcaga	900
ttgccttttc	aaaacatcaa	tagcagagca	gttggcaaat	gcccaagata	tgtaaaacag	960
gaaagtttat	tattggcaac	tgggatgaag	aacgttcccg	aaccttccaa	aaaaaggaaa	1020
aaaagaggcc	tgtttggcgc	tatagcaggg	tttattgaaa	atggttggga	aggtctggtc	1080
gacgggtggt	acggtttcag	gcatcagaat	gcacaaggag	aaggaactgc	agcagactac	1140
aaaagcaccc	aatcggcaat	tgatcagata	accggaaagt	taaatagact	cattgagaaa	1200
accaaccagc	aatttgagct	aatagataat	gaattcactg	aggtggaaaa	gcagattggc	1260
aatttaatta	actggaccaa	agactccatc	acagaagtat	ggtcttacaa	tgctgaactt	1320
cttgtggcaa	tggaaaacca	gcacactatt	gatttggctg	attcagagat	gaacaagctg	1380
tatgagcgag	tgaggaaaca	attaagggaa	aatgctgaag	aggatggcac	tggttgcttt	1440
gaaatttttc	ataaatgtga	cgatgattgt	atggctagta	taaggaacaa	tacttatgat	1500
cacagcaaat	acagagaaga	agcgatgcaa	aatagaatac	aaattgaccc	agtcaaattg	1560
agtagtggct	acaaagatgt	gatactttgg	tttagcttcg	gggcatcatg	ctttttgctt	1620
cttgccattg	caatgggcct	tgttttcata	tgtgtgaaga	acggaaacat	gcggtgcact	1680
atttgtatat	aa					1692
<210> SEQ : <211> LENG <212> TYPE <213> ORGAI <220> FEAT <223> OTHEN <400> SEQUI	ID NO 77 FH: 1266 : DNA NISM: Artif: JRE: R INFORMATIC ENCE: 77	icial Sequer DN: Envelope	nce e- RRV			
agtgtaacag	agcactttaa	tgtgtataag	gctactagac	catacctagc	acattgcgcc	60
gattgegggg	acgggtactt	ctgctatage	ccagttgcta	tcgaggagat	ccgagatgaq	120
qcqtctqatq	qcatqcttaa	qatccaaqtc	tccqcccaaa	taqqtctqqa	caaqqcaqqc	180
acceacecc	acacgaaget	ccdatatato	actagtata	atgttcagge	atctaadada	240
attactta	agatatagat	atacasas	tactactor	atacascast	aaaaaatta	200
gallellya	JJJLJLACAC	greegeageg	cyclicalac	ucyyyacyat	gggacactic	300

185

#### -continued

186

atcgtcgcac actgtccacc aggcgactac ctcaaggttt cgttcgagga cgcagattcg 360 cacgtgaagg catgtaaggt ccaatacaag cacaatccat tgccggtggg tagagagaag 420 ttcgtggtta gaccacactt tggcgtagag ctgccatgca cctcatacca gctgacaacg 480 gctcccaccg acgaggagat tgacatgcat acaccgccag atataccgga tcgcaccctg 540 600 ctatcacaga cggcgggcaa cgtcaaaata acagcaggcg gcaggactat caggtacaac tgtacctgcg gccgtgacaa cgtaggcact accagtactg acaagaccat caacacatgc 660 aagattgacc aatgccatgc tgccgtcacc agccatgaca aatggcaatt tacctctcca 720 tttgttccca gggctgatca gacagctagg aaaggcaagg tacacgttcc gttccctctg 780 actaacgtca cctgccgagt gccgttggct cgagcgccgg atgccaccta tggtaagaag 840 gaggtgaccc tgagattaca cccagatcat ccgacgctct tctcctatag gagtttagga 900 960 gccgaaccgc acccgtacga ggaatgggtt gacaagttct ctgagcgcat catcccagtg 1020 acqqaaqaaq qqattqaqta ccaqtqqqqc aacaacccqc cqqtctqcct qtqqqcqcaa ctgacgaccg agggcaaacc ccatggctgg ccacatgaaa tcattcagta ctattatgga 1080 ctataccccg ccgccactat tgccgcagta tccgggggcga gtctgatggc cctcctaact 1140 1200 ctggcqgcca catgctgcat gctggccacc gcgaqgagaa agtgcctaac accgtacgcc ctgacgccag gagcggtggt accgttgaca ctggggctgc tttgctgcgc accgagggcg 1260 1266 aatqca <210> SEQ ID NO 78 <211> LENGTH · 1266 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- MLV 10A1 <400> SEOUENCE: 78 agtgtaacag agcactttaa tgtgtataag gctactagac catacctagc acattgcgcc 60 gattgcgggg acgggtactt ctgctatagc ccagttgcta tcgaggagat ccgagatgag 120 gcgtctgatg gcatgcttaa gatccaagtc tccgcccaaa taggtctgga caaggcaggc 180 240 acccacgccc acacgaagct ccgatatatg gctggtcatg atgttcagga atctaagaga 300 gatteettga gggtgtacae gteegeageg tgeteeatae atgggaegat gggaeaette atcgtcgcac actgtccacc aggcgactac ctcaaggttt cgttcgagga cgcagattcg 360 cacgtgaagg catgtaaggt ccaatacaag cacaatccat tgccggtggg tagagagaag 420 ttcgtggtta gaccacactt tggcgtagag ctgccatgca cctcatacca gctgacaacg 480 geteceaceg acgaggagat tgacatgeat acaeegeeag atataeegga tegeaceetg 540 ctatcacaga cggcgggcaa cgtcaaaata acagcaggcg gcaggactat caggtacaac 600 660 tgtacctgcg gccgtgacaa cgtaggcact accagtactg acaagaccat caacacatgc aagattgacc aatgccatgc tgccgtcacc agccatgaca aatggcaatt tacctctcca 720 tttgttccca gggctgatca gacagctagg aaaggcaagg tacacgttcc gttccctctg 780 actaacgtca cctgccgagt gccgttggct cgagcgccgg atgccaccta tggtaagaag 840 gaggtgaccc tgagattaca cccagatcat ccgacgctct tctcctatag gagtttagga 900 gccgaaccgc acccgtacga ggaatgggtt gacaagttet etgagegeat cateccagtg 960 acggaagaag ggattgagta ccagtggggc aacaacccgc cggtctgcct gtgggcgcaa 1020

1080

ctgacgaccg agggcaaacc ccatggctgg ccacatgaaa tcattcagta ctattatgga

188

10/
-----

ctataccccg	ccgccactat	tgccgcagta	tccggggcga	gtctgatggc	cctcctaact	1140						
ctggcggcca	catgctgcat	gctggccacc	gcgaggagaa	agtgcctaac	accgtacgcc	1200						
ctgacgccag	gagcggtggt	accgttgaca	ctggggctgc	tttgctgcgc	accgagggcg	1260						
aatgca						1266						
<210> SEQ ID NO 79 <211> LENGTH: 2030 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Envelope- Ebola												
<400> SEQUENCE: 79												
atgggtgtta	caggaatatt	gcagttacct	cgtgatcgat	tcaagaggac	atcattcttt	60						
ctttgggtaa	ttatcctttt	ccaaagaaca	ttttccatcc	cacttggagt	catccacaat	120						
agcacattac	aggttagtga	tgtcgacaaa	ctggtttgcc	gtgacaaact	gtcatccaca	180						
aatcaattga	gatcagttgg	actgaatctc	gaagggaatg	gagtggcaac	tgacgtgcca	240						
tctgcaacta	aaagatgggg	cttcaggtcc	ggtgtcccac	caaaggtggt	caattatgaa	300						
gctggtgaat	gggctgaaaa	ctgctacaat	cttgaaatca	aaaaacctga	cgggagtgag	360						
tgtctaccag	cagcgccaga	cgggattcgg	ggetteecee	ggtgccggta	tgtgcacaaa	420						
gtatcaggaa	cgggaccgtg	tgccggagac	tttgccttcc	acaaagaggg	tgetttette	480						
ctgtatgacc	gacttgcttc	cacagttatc	taccgaggaa	cgactttcgc	tgaaggtgtc	540						
gttgcatttc	tgatactgcc	ccaagctaag	aaggacttct	tcagctcaca	ccccttgaga	600						
gagccggtca	atgcaacgga	ggacccgtct	agtggctact	attctaccac	aattagatat	660						
caagctaccg	gttttggaac	caatgagaca	gagtatttgt	tcgaggttga	caatttgacc	720						
tacgtccaac	ttgaatcaag	attcacacca	cagtttctgc	tccagctgaa	tgagacaata	780						
tatacaagtg	ggaaaaggag	caataccacg	ggaaaactaa	tttggaaggt	caaccccgaa	840						
attgatacaa	caatcgggga	gtgggccttc	tgggaaacta	aaaaaacctc	actagaaaaa	900						
ttcgcagtga	agagttgtct	ttcacagetg	tatcaaacag	agccaaaaac	atcagtggtc	960						
agagtccggc	gcgaacttct	tccgacccag	ggaccaacac	aacaactgaa	gaccacaaaa	1020						
tcatggcttc	agaaaattcc	tctgcaatgg	ttcaagtgca	cagtcaagga	agggaagctg	1080						
cagtgtcgca	tctgacaacc	cttgccacaa	tctccacgag	tcctcaaccc	cccacaacca	1140						
aaccaggtcc	ggacaacagc	acccacaata	cacccgtgta	taaacttgac	atctctgagg	1200						
caactcaagt	tgaacaacat	caccgcagaa	cagacaacga	cagcacagcc	teegacaete	1260						
cccccgccac	gaccgcagcc	ggacccctaa	aagcagagaa	caccaacacg	agcaagggta	1320						
ccgacctcct	ggaccccgcc	accacaacaa	gtccccaaaa	ccacagcgag	accgctggca	1380						
acaacaacac	tcatcaccaa	gataccggag	aagagagtgc	cagcagcggg	aagctaggct	1440						
taattaccaa	tactattgct	ggagtcgcag	gactgatcac	aggcgggagg	agagctcgaa	1500						
gagaagcaat	tgtcaatgct	caacccaaat	gcaaccctaa	tttacattac	tggactactc	1560						
aggatgaagg	tgctgcaatc	ggactggcct	ggataccata	tttcgggcca	gcagccgagg	1620						
gaatttacat	agaggggctg	atgcacaatc	aagatggttt	aatctgtggg	ttgagacagc	1680						
tggccaacga	gacgactcaa	gctcttcaac	tgttcctgag	agccacaacc	gagctacgca	1740						
ccttttcaat	cctcaaccgt	aaggcaattg	atttcttgct	gcagcgatgg	ggcggcacat	1800						

190

gccacatttt gggaccggac tgctgtatcg aaccacatga ttggaccaag aacataacag 1860									
acaaaattga tcagattatt catgattttg ttgataaaac ccttccggac cagggggaca 1920									
atgacaattg gtggacagga tggagacaat ggataccggc aggtattgga gttacaggcg 1980									
ttataattge agttateget ttattetgta tatgeaaatt tgtettttag 2030									
<210> SEQ ID NO 80 <211> LENGTH: 389 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Short WPRE sequence									
<400> SEQUENCE: 80									
aatcaacctc tggattacaa aatttgtgaa agattgactg atattcttaa ctatgttgct 60									
ccttttacgc tgtgtggata tgctgcttta atgcctctgt atcatgctat tgcttcccgt 120									
acggettteg tttteteete ettgtataaa teetggttge tgtetettta tgaggagttg 180									
tggcccgttg tccgtcaacg tggcgtggtg tgctctgtgt ttgctgacgc aacccccact 240									
ggetggggea ttgecaceae etgteaaete etttetggga etttegettt eeeeeteeeg 300									
atcgccacgg cagaactcat cgccgcctgc cttgcccgct gctggacagg ggctaggttg 360									
ctgggcactg ataatteegt ggtgttgte 389									
<pre>&lt;210&gt; SEQ ID NO 81 &lt;211&gt; LENGTH: 31 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Primer</pre>									
<400> SEQUENCE: 81									
taagcagaat tcatgaattt gccaggaaga t 31									
<pre>&lt;210&gt; SEQ ID NO 82 &lt;211&gt; LENGTH: 36 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Primer</pre>									
<pre>&lt;210&gt; SEQ ID NO 83 &lt;211&gt; LENGTH: 2745 &lt;212&gt; TYPE: DNA &lt;211&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: Gag, Pol, Integrase fragment</pre>									
<400> SEQUENCE: 83									
gaattcatga atttgccagg aagatggaaa ccaaaaatga tagggggaat tggaggtttt 60									
atcaaagtaa gacagtatga tcagatactc atagaaatct gcggacataa agctataggt 120									
acagtattag taggacctac acctgtcaac ataattggaa gaaatctgtt gactcagatt 180									
ggctgcactt taaattttcc cattagtcct attgagactg taccagtaaa attaaagcca 240									
ggaatggatg gcccaaaagt taaacaatgg ccattgacag aagaaaaaat aaaagcatta 300									
gtagaaattt gtacagaaat ggaaaaggaa ggaaaaattt caaaaattgg gcctgaaaat 360									
ccatacaata ctccagtatt tgccataaag aaaaaagaca gtactaaatg gagaaaatta 420									

191

#### -continued

gtagatttca	gagaacttaa	taagagaact	caagatttct	gggaagttca	attaggaata	480
ccacatcctg	cagggttaaa	acagaaaaaa	tcagtaacag	tactggatgt	gggcgatgca	540
tatttttcag	ttcccttaga	taaagacttc	aggaagtata	ctgcatttac	catacctagt	600
ataaacaatg	agacaccagg	gattagatat	cagtacaatg	tgcttccaca	gggatggaaa	660
ggatcaccag	caatattcca	gtgtagcatg	acaaaaatct	tagagccttt	tagaaaacaa	720
aatccagaca	tagtcatcta	tcaatacatg	gatgatttgt	atgtaggatc	tgacttagaa	780
atagggcagc	atagaacaaa	aatagaggaa	ctgagacaac	atctgttgag	gtggggattt	840
accacaccag	acaaaaaaca	tcagaaagaa	cctccattcc	tttggatggg	ttatgaactc	900
catcctgata	aatggacagt	acagcctata	gtgctgccag	aaaaggacag	ctggactgtc	960
aatgacatac	agaaattagt	gggaaaattg	aattgggcaa	gtcagattta	tgcagggatt	1020
aaagtaaggc	aattatgtaa	acttcttagg	ggaaccaaag	cactaacaga	agtagtacca	1080
ctaacagaag	aagcagagct	agaactggca	gaaaacaggg	agattctaaa	agaaccggta	1140
catggagtgt	attatgaccc	atcaaaagac	ttaatagcag	aaatacagaa	gcaggggcaa	1200
ggccaatgga	catatcaaat	ttatcaagag	ccatttaaaa	atctgaaaac	aggaaagtat	1260
gcaagaatga	agggtgccca	cactaatgat	gtgaaacaat	taacagaggc	agtacaaaaa	1320
atagccacag	aaagcatagt	aatatgggga	aagactccta	aatttaaatt	acccatacaa	1380
aaggaaacat	gggaagcatg	gtggacagag	tattggcaag	ccacctggat	tcctgagtgg	1440
gagtttgtca	atacccctcc	cttagtgaag	ttatggtacc	agttagagaa	agaacccata	1500
ataggagcag	aaactttcta	tgtagatggg	gcagccaata	gggaaactaa	attaggaaaa	1560
gcaggatatg	taactgacag	aggaagacaa	aaagttgtcc	ccctaacgga	cacaacaaat	1620
cagaagactg	agttacaagc	aattcatcta	gctttgcagg	attcgggatt	agaagtaaac	1680
atagtgacag	actcacaata	tgcattggga	atcattcaag	cacaaccaga	taagagtgaa	1740
tcagagttag	tcagtcaaat	aatagagcag	ttaataaaaa	aggaaaaagt	ctacctggca	1800
tgggtaccag	cacacaaagg	aattggagga	aatgaacaag	tagataaatt	ggtcagtgct	1860
ggaatcagga	aagtactatt	tttagatgga	atagataagg	cccaagaaga	acatgagaaa	1920
tatcacagta	attggagagc	aatggctagt	gattttaacc	taccacctgt	agtagcaaaa	1980
gaaatagtag	ccagctgtga	taaatgtcag	ctaaaagggg	aagccatgca	tggacaagta	2040
gactgtagcc	caggaatatg	gcagctagat	tgtacacatt	tagaaggaaa	agttatcttg	2100
gtagcagttc	atgtagccag	tggatatata	gaagcagaag	taattccagc	agagacaggg	2160
caagaaacag	catacttcct	cttaaaatta	gcaggaagat	ggccagtaaa	aacagtacat	2220
acagacaatg	gcagcaattt	caccagtact	acagttaagg	ccgcctgttg	gtgggcgggg	2280
atcaagcagg	aatttggcat	tccctacaat	ccccaaagtc	aaggagtaat	agaatctatg	2340
aataaagaat	taaagaaaat	tataggacag	gtaagagatc	aggctgaaca	tcttaagaca	2400
gcagtacaaa	tggcagtatt	catccacaat	tttaaaagaa	aagggggggat	tggggggtac	2460
agtgcagggg	aaagaatagt	agacataata	gcaacagaca	tacaaactaa	agaattacaa	2520
aaacaaatta	caaaaattca	aaattttcgg	gtttattaca	gggacagcag	agatccagtt	2580
tggaaaggac	cagcaaagct	cctctggaaa	ggtgaagggg	cagtagtaat	acaagataat	2640
agtgacataa	aagtagtgcc	aagaagaaaa	gcaaagatca	tcagggatta	tggaaaacag	2700
atggcaggtg	atgattgtgt	ggcaagtaga	caggatgagg	attaa		2745

192
<210> SEQ ID NO 84 <211> LENGTH: 1586 -continued

<212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: DNA Fragment containing Rev, RRE and rabbit beta globin poly A <400> SEQUENCE: 84 tetagaatgg caggaagaag eggagaeage gaegaagage teateagaae agteagaete 60 atcaagette tetatcaaag caacceacet eccaateeeg aggggaceeg acaggeeega 120 aggaatagaa gaagaaggtg gagagagaga cagagacaga tccattcgat tagtgaacgg 180 atccttggca cttatctggg acgatctgcg gagcctgtgc ctcttcagct accaccgctt 240 gagagactta ctcttgattg taacgaggat tgtggaactt ctgggacgca gggggtggga 300 agccctcaaa tattggtgga atctcctaca atattggagt caggagctaa agaatagagg 360 agetttgtte ettgggttet tgggageage aggaageaet atgggegeag egteaatgae 420 gctgacggta caggccagac aattattgtc tggtatagtg cagcagcaga acaatttgct 480 qaqqqctatt qaqqcqcaac aqcatctqtt qcaactcaca qtctqqqqca tcaaqcaqct 540 ccaggcaaga atcctggctg tggaaagata cctaaaggat caacagctcc tagatcttt 600 teeetetgee aaaaattatg gggacateat gaageeeett gageatetga ettetggeta 660 ataaaggaaa tttattttca ttgcaatagt gtgttggaat tttttgtgtc tctcactcgg 720 aaggacatat gggagggcaa atcatttaaa acatcagaat gagtatttgg tttagagttt 780 ggcaacatat gccatatgct ggctgccatg aacaaaggtg gctataaaga ggtcatcagt 840 atatgaaaca gccccctgct gtccattcct tattccatag aaaagccttg acttgaggtt 900 agatttttt tatattttgt tttgtgttat ttttttcttt aacatcccta aaattttcct 960 tacatgtttt actagecaga ttttteetee teteetgaet acteecagte atagetgtee 1020 ctcttctctt atgaagatcc ctcgacctgc agcccaagct tggcgtaatc atggtcatag 1080 ctgtttcctg tgtgaaattg ttatccgctc acaattccac acaacatacg agccggaagc 1140 ataaagtgta aagcctgggg tgcctaatga gtgagctaac tcacattaat tgcgttgcgc 1200 tcactgcccg ctttccagtc gggaaacctg tcgtgccagc ggatccgcat ctcaattagt 1260 cagcaaccat agtcccgccc ctaactccgc ccatcccgcc cctaactccg cccagttccg 1320 cccattetee geeceatgge tgactaattt tttttattta tgeagaggee gaggeegeet 1380 cggcctctga gctattccag aagtagtgag gaggcttttt tggaggccta ggcttttgca 1440 aaaagctaac ttgtttattg cagcttataa tggttacaaa taaagcaata gcatcacaaa 1500 tttcacaaat aaagcatttt tttcactgca ttctagttgt ggtttgtcca aactcatcaa 1560 tgtatettat cageggeege eeeggg 1586 <210> SEQ ID NO 85 <211> LENGTH: 1614 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: DNA fragment containing the CAG enhancer/ promoter/intron sequence <400> SEQUENCE: 85 acgcgttagt tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga 60 gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgccca acgacccccg 120

195

#### -continued

cccattgacg	tcaataatga	cgtatgttcc	catagtaacg	ccaataggga	ctttccattg	180
acgtcaatgg	gtggactatt	tacggtaaac	tgcccacttg	gcagtacatc	aagtgtatca	240
tatgccaagt	acgcccccta	ttgacgtcaa	tgacggtaaa	tggcccgcct	ggcattatgc	300
ccagtacatg	accttatggg	actttcctac	ttggcagtac	atctacgtat	tagtcatcgc	360
tattaccatg	ggtcgaggtg	agccccacgt	tctgcttcac	tctccccatc	tccccccct	420
ccccaccccc	aattttgtat	ttatttattt	tttaattatt	ttgtgcagcg	atgggggcgg	480
aaaaaaaaaa	ggcgcgcgcc	aggcgggggcg	gggcgggggcg	aggggcgggg	cggggcgagg	540
cggagaggtg	cggcggcagc	caatcagagc	ggcgcgctcc	gaaagtttcc	ttttatggcg	600
aggcggcggc	ggcggcggcc	ctataaaaag	cgaagcgcgc	aacaaacaaa	agtcgctgcg	660
ttgccttcgc	cccgtgcccc	gctccgcgcc	gcctcgcgcc	gcccgccccg	gctctgactg	720
accgcgttac	tcccacaggt	gagcgggcgg	gacggccctt	ctcctccggg	ctgtaattag	780
cgcttggttt	aatgacggct	cgtttcttt	ctgtggctgc	gtgaaagcct	taaagggctc	840
cgggagggcc	ctttgtgcgg	gggggagcgg	ctcgggggggt	gcgtgcgtgt	gtgtgtgcgt	900
ggggagcgcc	gcgtgcggcc	cgcgctgccc	ggcggctgtg	agcgctgcgg	gcgcggcgcg	960
gggctttgtg	cgctccgcgt	gtgcgcgagg	ggagcgcggc	cggggggcggt	gccccgcggt	1020
acaaaaaaaac	tgcgagggga	acaaaggctg	cgtgcggggt	gtgtgcgtgg	gggggtgagc	1080
aggggggtgtg	ggcgcggcgg	tcgggctgta	accccccct	gcacccccct	ccccgagttg	1140
ctgagcacgg	cccggcttcg	ggtgcggggc	tccgtgcggg	gcgtggcgcg	gggctcgccg	1200
tgccgggcgg	ggggtggcgg	caggtggggg	tgccgggcgg	ggcgggggccg	cctcgggccg	1260
gggaggggtc	gggggagggg	cgcggcggcc	ccggagcgcc	ggcggctgtc	gaggcgcggc	1320
gagccgcagc	cattgccttt	tatggtaatc	gtgcgagagg	gcgcagggac	tteetttgte	1380
ccaaatctgg	cggagccgaa	atctgggagg	cgccgccgca	ccccctctag	cgggcgcggg	1440
cgaagcggtg	cggcgccggc	aggaaggaaa	tgggcgggga	gggccttcgt	gcgtcgccgc	1500
gccgccgtcc	ccttctccat	ctccagcctc	ggggctgccg	caggggggacg	gctgccttcg	1560
ggggggacgg	ggcagggcgg	ggttcggctt	ctggcgtgtg	accggcggga	attc	1614
<210> SEQ ID NO 86 <211> LENGTH: 1531 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: DNA fragment containing VSV-G						
<400> SEQUE	ENCE: 86					
gaattcatga	agtgcctttt	gtacttagcc	tttttattca	ttggggtgaa	ttgcaagttc	60
accatagttt	ttccacacaa	ccaaaaagga	aactggaaaa	atgttccttc	taattaccat	120
tattgcccgt	caagctcaga	tttaaattgg	cataatgact	taataggcac	agccttacaa	180
gtcaaaatgc	ccaagagtca	caaggctatt	caagcagacg	gttggatgtg	tcatgcttcc	240
aaatgggtca	ctacttgtga	tttccgctgg	tatggaccga	agtatataac	acattccatc	300
cgatccttca	ctccatctgt	agaacaatgc	aaggaaagca	ttgaacaaac	gaaacaagga	360
acttggctga	atccaggctt	ccctcctcaa	agttgtggat	atgcaactgt	gacggatgcc	420
gaagcagtga	ttgtccaggt	gactcctcac	catgtgctgg	ttgatgaata	cacaggagaa	480
tgggttgatt	cacagttcat	caacggaaaa	tgcagcaatt	acatatgccc	cactgtccat	540

197

#### -continued

tecatogada		Lyactataay	greaaaggge	Largigatic	taacctcatt	600
ooodojjaca	tcaccttctt	ctcagaggac	ggagagctat	catccctggg	aaaggagggc	660
acagggttca	gaagtaacta	ctttgcttat	gaaactggag	gcaaggcctg	caaaatgcaa	720
tactgcaagc	attggggagt	cagactccca	tcaggtgtct	ggttcgagat	ggctgataag	780
gatctctttg	ctgcagccag	attccctgaa	tgcccagaag	ggtcaagtat	ctctgctcca	840
tctcagacct	cagtggatgt	aagtctaatt	caggacgttg	agaggatett	ggattattcc	900
ctctgccaag	aaacctggag	caaaatcaga	gcgggtcttc	caatctctcc	agtggatctc	960
agctatcttg	ctcctaaaaa	cccaggaacc	ggtcctgctt	tcaccataat	caatggtacc	1020
ctaaaatact	ttgagaccag	atacatcaga	gtcgatattg	ctgctccaat	cctctcaaga	1080
atggtcggaa	tgatcagtgg	aactaccaca	gaaagggaac	tgtgggatga	ctgggcacca	1140
tatgaagacg	tggaaattgg	acccaatgga	gttctgagga	ccagttcagg	atataagttt	1200
cctttataca	tgattggaca	tggtatgttg	gactccgatc	ttcatcttag	ctcaaaggct	1260
caggtgttcg	aacatcctca	cattcaagac	gctgcttcgc	aacttcctga	tgatgagagt	1320
ttatttttg	gtgatactgg	gctatccaaa	aatccaatcg	agcttgtaga	aggttggttc	1380
agtagttgga	aaagctctat	tgeetettt	ttctttatca	tagggttaat	cattggacta	1440
ttettggtte	tccgagttgg	tatccatctt	tgcattaaat	taaagcacac	caagaaaaga	1500
cagatttata	cagacataga	gatgagaatt	с			1531
<pre>&lt;211&gt; HENG &lt;212&gt; TYPE &lt;213&gt; ORGAI &lt;220&gt; FEAT &lt;223&gt; OTHEI </pre>	: DNA NISM: Artifi JRE: R INFORMATIC	icial Sequer DN: Helper H	nce plasmid cont	aining RRE	and rabbit	beta
giop	in poly A			5	and fubble	
9100 <400> SEQU	in poly A ENCE: 87			5		
glob <400> SEQU tctagaagga	in poly A ENCE: 87 gctttgttcc	ttgggttett	gggagcagca	ggaagcacta	tgggcgcagc	60
glob <400> SEQU tctagaagga gtcaatgacg	in poly A ENCE: 87 gctttgttcc ctgacggtac	ttgggttctt aggccagaca	gggagcagca attattgtct	ggaagcacta ggtatagtgc	tgggcgcagc agcagcagaa	60 120
glob <400> SEQU tctagaagga gtcaatgacg caatttgctg	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg	ttgggttett aggeeagaea aggegeaaea	gggagcagca attattgtct gcatctgttg	ggaagcacta ggtatagtgc caactcacag	tgggcgcagc agcagcagaa tctggggcat	60 120 180
glob <400> SEQU tctagaagga gtcaatgacg caattgctg caagcagctc	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa	ttgggttctt aggccagaca aggcgcaaca tcctggctgt	gggagcagca attattgtct gcatctgttg ggaaagatac	ggaagcacta ggtatagtgc caactcacag ctaaaggatc	tgggcgcagc agcagcagaa tctggggcat aacagctcct	60 120 180 240
glob <400> SEQU tctagaagga gtcaatgacg caatttgctg caagcagctc agatctttt	in poly A ENCE: 87 getttgttec etgaeggtae agggetattg eaggeaagaa ccetetgeca	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac	60 120 180 240 300
glob <400> SEQU tctagaagga gtcaatgacg caattgctg caagcagctc agatctttt ttctggctaa	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct	60 120 180 240 300 360
glob <400> SEQU tctagaagga gtcaatgacg caatttgctg caagcagctc agatctttt ttctggctaa ctcactcgga	in poly A ENCE: 87 getttgttcc etgaeggtac agggetattg caggeaagaa ecetetgeea taaaggaaat aggaeatatg	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt	60 120 180 240 300 360 420
glob <400> SEQU tctagaagga gtcaatgacg caattgctg caagcagctc agatctttt ttctggctaa ctcactcgga ttagagtttg	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat aggacatatg gcaacatatg	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag	60 120 180 240 360 420 480
glob <400> SEQU tctagaagga gtcaatgacg caagtagctg caagcagctc agatctttt ttctggctaa ctcactcgga ttagagtttg gtcatcagta	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat aggacatatg gcaacatatg tatgaaacag	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga	60 120 180 240 300 360 420 480 540
GIOD <400> SEQU tctagaagga gtcaatgacg caagtagctc agatctttt ttctggctaa ctcactcgga ttagagtttg gtcatcagta cttgaggtta	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat ggaacatatg gcaacatatg tatgaaacag gattttttt	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg cccctgctg atattttgtt	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga	60 120 180 240 300 360 420 480 540 600
GIOD <400> SEQU tctagaagga gtcaatgacg caagtagctc agatctttt ttctggctaa ctcactcgga ttagagtttg gtcatcagta cttgaggtta aattttcctt	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggacatatg gcaacatatg tatgaaacag gattttttt	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg accetgtg atattttgtt	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga ctcccagtca	60 120 180 240 300 360 420 480 540 600 660
GIOD <400> SEQU tctagaagga gtcaatgacg caagtagctc agatctttt ttctggctaa ctcactcgga ttagagtttg gtcatcagta cttgaggtta aatttcctt tagctgtccc	In poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat ggacatatg gcaacatatg tatgaaacag gatttttt acatgttta	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg cccctgctg atattttgtt ctagccagat tgaagatccc	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt ttttcctcct	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta ctcctgacta gcccaagctt	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga ctcccagtca ggcgtaatca	60 120 180 240 300 360 420 480 540 600 660 720
GIOD <400> SEQU tctagaagga gtcaatgacg caattgctg caagcagctc agatctttt ttctggctaa ctcactcgga ttagagtttg gtcatcagta aatttcctt tagctgtccc tggtcatagc	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat ggacatatg tatgaaacag gattttttt acatgtttta tcttcctta	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg ccccctgctg atattttgtt ctagccagat tgaagatccc gtgaaattgt	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt ttttcctcct tcgacctgca tatccgctca	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta ctcctgacta gcccaagctt caattccaca	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga ctcccagtca ggcgtaatca caacatacga	60 120 180 240 300 360 420 480 540 600 660 720 780
glob <400> SEQU tctagaagga gtcaatgacg caattgctg caagcagctc agatctttt ttctggctaa ctcactcgga ttagagttg gtcatcagta aatttcctt tagctgtccc tggtcatagc gccggaagca	in poly A ENCE: 87 getttgttec etgaeggtae agggetattg caggeaagaa ceetetgeea taaaggaeatatg geaacatatg tatgaaacag gattttttt acatgtttta tetteetta tggtteetgt taaagtgtaa	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg cccctgctg atattttgtt ctagccagat tgaagatccc gtgaaattgt agcctggggt	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt ttttcctcct tcgacctgca gcctaatgag	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta ctcctgacta gcccaagctt caattccaca	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag acagccttga ctcccagtca ggcgtaatca caacatacga cacattaatt	60 120 180 240 300 360 420 480 540 600 660 720 780 840
GIOD <400> SEQU tctagaagga gtcaatgacg caattgctg caagcagctc agatctttt ttctggctaa ctcactcgga ttagagttg gtcatcagta cttgaggtta aattttcctt tagctgtccc tggtcatagc gccggaagca gcgttgcgct	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggaaat ggacatatg gcaacatatg tatgaaacag gatttttt acatgtttta tcttctctta tgttcctgt taaagtgtaa cactgcccgc	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg ccccctgctg atattttgtt ctagccagat tgaagatccc gtgaaattgt agcctggggt	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt ttttcctcct tcgacctgca tatccgctca gcctaatgag ggaaacctgt	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta ctcctgacta gcccaagctt caattccaca tgagctaact cgtgccagcg	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga ctcccagtca ggcgtaatca caacatacga cacattaatt gatccgcatc	60 120 180 240 300 420 480 540 600 660 720 780 840 900
GIOD <400> SEQU tctagaagga gtcaatgacg caagtagctc agatctttt ttctggctaa ctcactcgga gtcatcagta cttgaggtta aatttcctt tagctgtccc tggtcatagc gccggaagca gcgttgcgct tcaattagtc	in poly A ENCE: 87 gctttgttcc ctgacggtac agggctattg caggcaagaa ccctctgcca taaaggacatatg gcaacatatg tatgaaacag gattttttt acatgtttta tcttctctta tgtttcctgt taaagtgtaa cactgcccgc agcaaccata	ttgggttctt aggccagaca aggcgcaaca tcctggctgt aaaattatgg ttattttcat ggagggcaaa ccatatgctg acatatgctg atattttgtt ctagccagat tgaagatccc gtgaaattgt agcctggggt tttccagtcg	gggagcagca attattgtct gcatctgttg ggaaagatac ggacatcatg tgcaatagtg tcatttaaaa gctgccatga tccattcctt ttgtgttatt ttttcctcct tcgacctgca gcctaatgag ggaaacctgt taactccgcc	ggaagcacta ggtatagtgc caactcacag ctaaaggatc aagccccttg tgttggaatt catcagaatg acaaaggtgg attccataga tttttcttta ctcctgacta gcccaagctt caattccaca tgagctaact cgtgccagcg catcccgccc	tgggcgcagc agcagcagaa tctggggcat aacagctcct agcatctgac ttttgtgtct agtatttggt ctataaagag aaagccttga ctcccagtca ggcgtaatca cacattaatt gatccgcatc ctaactccg	60 120 180 240 300 420 420 480 540 600 660 720 780 840 900 960

198

200

# 199

#### -continued

aggccgcctc ggcctctgag ctattccaga agtagtgagg aggctttttt ggaggcctag	1080
gcttttgcaa aaagctaact tgtttattgc agcttataat ggttacaaat aaagcaatag	1140
catcacaaat ttcacaaata aagcattttt ttcactgcat tctagttgtg gtttgtccaa	1200
actcatcaat gtatcttatc acccggg	1227
<210> SEQ ID NO 88 <211> LENGTH: 884 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: RSV promoter and HIV Rev	
<400> SEQUENCE: 88	
caattgcgat gtacgggcca gatatacgcg tatctgaggg gactagggtg tgtttaggcg	60
aaaagcgggg cttcggttgt acgcggttag gagtcccctc aggatatagt agtttcgctt	120
ttgcataggg agggggaaat gtagtcttat gcaatacact tgtagtcttg caacatggta	180
acgatgagtt agcaacatgc cttacaagga gagaaaaagc accgtgcatg ccgattggtg	240
gaagtaaggt ggtacgatcg tgccttatta ggaaggcaac agacaggtct gacatggatt	300
ggacgaacca ctgaattccg cattgcagag ataattgtat ttaagtgcct agctcgatac	360
aataaacgcc atttgaccat tcaccacatt ggtgtgcacc tccaagctcg agctcgttta	420
gtgaaccgtc agatcgcctg gagacgccat ccacgctgtt ttgacctcca tagaagacac	480
cgggaccgat ccagcctccc ctcgaagcta gcgattaggc atctcctatg gcaggaagaa	540
geggagaeag egaegaagaa eteeteaagg eagteagaet eateaagttt etetateaaa	600
gcaacccacc teccaateee gaggggaeee gacaggeeeg aaggaataga agaagaaggt	660
ggagagagag acagagacag atccattcga ttagtgaacg gatccttagc acttatctgg	720
gacgatetge ggageetgtg eetetteage taceaeeget tgagagaett actettgatt	780
gtaacgagga ttgtggaact tctgggacgc agggggtggg aagccctcaa atattggtgg	840
aatctcctac aatattggag tcaggagcta aagaatagtc taga	884
<210> SEQ ID NO 89 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Target sequence <400> SEQUENCE: 89	
atggcaggaa gaagcggag	19
<pre>&lt;210&gt; SEQ ID NO 90 &lt;211&gt; LENGTH: 52 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: shRNA sequence </pre>	
<400> SEQUENCE: 90	
atggcaggaa gaagcggagt tcaagagact ccgcttcttc ctgccatttt tt	52
<210> SEQ ID NO 91 <211> LENGTH: 279 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: H1 promoter and shRT sequence	

<400> SEQUENCE: 91 gaacgctgac gtcatcaacc cgctccaagg aatcgcgggc ccagtgtcac taggcgggaa 60 cacccagege gegtgegeee tggeaggaag atggetgtga gggaeagggg agtggegeee 120 tgcaatattt gcatgtcgct atgtgttctg ggaaatcacc ataaacgtga aatgtctttg 180 gatttgggaa tettataagt tetgtatgag accaettgga teegeggaga cagegaegaa 240 gagetteaag agagetette gtegetgtet eegetttt 279 <210> SEQ ID NO 92 <211> LENGTH: 275 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: H1 CCR5 sequence <400> SEQUENCE: 92 gaacgetgae gteateaace egeteeaagg aategeggge eeagtgteae taggegggaa 60 cacccagcgc gcgtgcgccc tggcaggaag atggctgtga gggacagggg agtggcgccc 120 tgcaatattt gcatgtcgct atgtgttctg ggaaatcacc ataaacgtga aatgtctttg 180 gatttgggaa tettataagt tetgtatgag accaettgga teegtgteaa gteeaateta 240 tgttcaagag acatagattg gacttgacac ttttt 275 <210> SEQ ID NO 93 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 93 aggaattgat ggcgagaagg 20 <210> SEQ ID NO 94 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 94 ccccaaagaa ggtcaaggta atca 24 <210> SEQ ID NO 95 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 95 agcgcggcta cagcttca 18 <210> SEO ID NO 96 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <220> FEATURE: <221> NAME/KEY: misc\_feature

<sup>&</sup>lt;222> LOCATION: (20)..(20)

203		204
	-continued	
<223> OTHER INFORMATION: n = p		
<400> SEQUENCE: 96		
ggcgacgtag cacagetten	20	
<210> SEQ ID NO 97 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: AGT103 CCR5 miR30		
<400> SEQUENCE: 97		
tgtaaactga gcttgctcta	20	
<210> SEQ ID NO 98 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: AGT103-R5-1		
<400> SEQUENCE: 98		
tgtaaactga gcttgctcgc	20	
<pre>&lt;210&gt; SEQ ID NO 99 &lt;211&gt; LENGTH: 19 &lt;212&gt; TYPE: DNA &lt;213&gt; ORGANISM: Artificial Sequence &lt;220&gt; FEATURE: &lt;223&gt; OTHER INFORMATION: AGT103-R5-2 &lt;400&gt; SEQUENCE: 99</pre>		
catagattgg acttgacac	19	
<210> SEQ ID NO 100 <211> LENGTH: 642 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: CAG promoter		
<400> SEQUENCE: 100		
tagttattaa tagtaatcaa ttacggggtc attagttcat ag	gcccatata tggagttccg 60	
cgttacataa cttacggtaa atggcccgcc tggctgaccg cc	ccaacgacc cccgcccatt 120	
gacgtcaata atgacgtatg ttcccatagt aacgccaata gg	ggactttcc attgacgtca 180	
atgggtggac tatttacggt aaactgccca cttggcagta ca	atcaagtgt atcatatgcc 240	
aagtacgccc cctattgacg tcaatgacgg taaatggccc gc	cctggcatt atgcccagta 300	
catgacetta tgggaettte etaettggea gtacatetae gt	tattagtca tcgctattac 360	
catgggtcga ggtgagcccc acgttctgct tcactctccc ca	atctccccc ccctccccac 420	
ccccaatttt gtatttattt attttttaat tattttgtgc ag	gcgatgggg gcgggggggg 480	
aaaaaaca caccwaacaa aacaaaacaa aacawaaaac ac	gggcggggc gaggcggaga 540	
ggtgcggcgg cagccaatca gagcggcgcg ctccgaaagt tt	teetttat ggegaggegg 600	
cggcggcggc ggccctataa aaagcgaagc gcgcggcggg cg	g 642	

<210> SEQ ID NO 101 <211> LENGTH: 217 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence

206

1	n	5
4	υ	5

-continued

<220> FEATURE: <223> OTHER INFORMATION: H1 element <400> SEOUENCE: 101 gaacgctgac gtcatcaacc cgctccaagg aatcgcgggc ccagtgtcac taggcgggaa 60 120 cacccagcgc gcgtgcgccc tggcaggaag atggctgtga gggacagggg agtggcgccc tgcaatattt gcatgtcgct atgtgttctg ggaaatcacc ataaacgtga aatgtctttg 180 217 gatttgggaa tettataagt tetgtatgag accaett <210> SEQ ID NO 102 <211> LENGTH: 250 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: 3' LTR <400> SEQUENCE: 102 tggaagggct aattcactcc caacgaagat aagatctgct ttttgcttgt actgggtctc 60 tctggttaga ccagatctga gcctgggagc tctctggcta actagggaac ccactgctta 120 ageetcaata aagettgeet tgagtgette aagtagtgtg tgeeegtetg ttgtgtgaet 180 ctggtaacta gagateeete agaeeetttt agteagtgtg gaaaatetet ageagtagta 240 gttcatgtca 250 <210> SEO ID NO 103 <211> LENGTH: 243 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: 7SK promoter <400> SEQUENCE: 103 ctgcagtatt tagcatgccc cacccatctg caaggcattc tggatagtgt caaaacagcc 60 ggaaatcaag tccgtttatc tcaaacttta gcattttggg aataaatgat atttgctatg 120 ctggttaaat tagattttag ttaaatttcc tgctgaagct ctagtacgat aagcaacttg 180 acctaagtgt aaagttgaga tttccttcag gtttatatag cttgtgcgcc gcctggctac 240 243 ctc <210> SEQ ID NO 104 <211> LENGTH: 132 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: miR155 Tat <400> SEQUENCE: 104 ctggaggett getgaagget gtatgetgte egettettee tgeeataggg ttttggeeae 60 tgactgaccc tatggggaag aagcggacag gacacaaggc ctgttactag cactcacatg 120 132 gaacaaatgg cc

What is claimed is:

60

**1**. A lentiviral vector comprising at least one encoded genetic element, wherein the at least one encoded genetic element comprises

at least two of: (i) a sequence comprising at least 80% <sub>65</sub> sequence identity with SEQ ID NO: 1, (ii) a sequence comprising at least 80% sequence identity with SEQ ID

NO: 2, and (iii) a sequence comprising at least 80% sequence identity with SEQ ID NO: 3; or

each of: (iv) a sequence comprising at least 80% sequence identity with SEQ ID NO: 97, (v) a sequence comprising at least 80% sequence identity with SEQ ID NO: 6, and (vi) a sequence comprising at least 80% sequence identity with SEQ ID NO: 7.

40

50

2. The lentiviral vector of claim 1, wherein the at least one encoded genetic element comprises:

at least two of: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; or

each of: SEQ ID NO: 97, SEQ ID NO: 6, and SEQ ID NO: <sup>5</sup> 7.

**3**. A lentiviral vector system for expressing a lentiviral particle, the system comprising:

a lentiviral vector according to claim 1;

- an envelope plasmid for expressing an envelope protein <sup>10</sup> optimized for infecting a cell; and
- at least one helper plasmid for expressing gag, pol, and rev genes,
- wherein the lentiviral vector, the envelope plasmid, and the at least one helper plasmid are capable of transfecting a packaging cell line, and wherein, upon such transfection, the packaging cell line is capable of producing a lentiviral particle capable of inhibiting production of chemokine receptor CCR5 or targeting an 20 HIV RNA sequence.

**4**. The lentiviral vector system of claim **3**, wherein the at least one helper plasmid comprises a first plasmid for expressing the gag and pol genes, and a second plasmid for expressing the rev gene.

**5**. A lentiviral particle capable of infecting a cell, the lentiviral particle comprising an envelope protein optimized for infecting a cell, and a lentiviral vector according to claim **1**.

**6**. The lentiviral particle of claim **5**, wherein the envelope 30 protein is optimized for infecting a T cell.

7. The lentiviral particle of claim  $\mathbf{6}$ , wherein the envelope protein is optimized for infecting a CD4+ T cell.

**8**. A modified cell comprising a CD4+ T cell, wherein the CD4+ T cell has been transfected with a lentiviral particle 35 according to claim **5**.

**9**. The modified cell of claim **8**, wherein the CD4+ T cell is capable of recognizing an HIV antigen.

**10**. The modified cell of claim **9**, wherein the HIV antigen comprises a gag antigen.

**11**. The modified cell of claim **8**, wherein the CD4+ T cell expresses a decreased level of CCR5 following infection with the lentiviral particle.

**12**. A method of treating cells infected with HIV, the method comprising:

- (a) obtaining, or having obtained, peripheral blood mononuclear cells (PBMC) from a subject infected with HIV, wherein the subject has been previously immunized with a therapeutically effective amount of a first stimulatory agent;
- (b) contacting, or having contacted, the PBMC with a therapeutically effective amount of a second stimulatory agent, wherein the contacting is carried out ex vivo;
- (c) transducing, or having transduced, the PBMC ex vivo 55 with a viral delivery system encoding at least one genetic element, wherein at least one encoded genetic element comprises:
  - at least two of: (i) a sequence comprising at least 80% sequence identity with SEQ ID NO: 1, (ii) a 60 sequence comprising at least 80% sequence identity with SEQ ID NO: 2, and (iii) a sequence comprising at least 80% sequence identity with SEQ ID NO: 3; or
  - each of: (iv) a sequence comprising at least 80% 65 sequence identity with SEQ ID NO: 97, (v) a sequence comprising at least 80% sequence identity

with SEQ ID NO: 6, and (vi) a sequence comprising at least 80% sequence identity with SEQ ID NO: 7; and

(d) culturing, or having cultured, the transduced PBMC for at least 1 day.

**13**. The method of claim **12**, wherein the transduced PBMC are cultured from about 1 to about 35 days.

14. The method of claim 12, further comprising infusing, or having infused, the transduced PBMC into a subject.

15. The method of claim 14, wherein the subject is a human.

- 16. The method of claim 12, wherein at least one of the first stimulatory agent and the second stimulatory agent comprises a peptide.
- 17. The method of claim 16, wherein the peptide comprises a gag peptide.

18. The method of claim 12, wherein at least one of the first stimulatory agent and the second stimulatory agent comprises a vaccine.

**19**. The method of claim **18**, wherein the vaccine comprises an HIV vaccine.

**20**. The method of claim **19**, wherein the HIV vaccine comprises a MVA/HIV62B vaccine or a variant thereof.

**21**. The method of claim **12**, wherein the first stimulatory agent and the second stimulatory agent are the same.

**22**. The method of claim **12**, wherein the viral delivery system comprises a lentiviral particle.

**23**. The method of claim **12**, wherein the at least one genetic element, when expressed, is capable of targeting an HIV RNA sequence.

24. The method of claim 23, wherein, when the at least one encoded genetic element comprises a sequence having at least 80% sequence identity with SEQ ID NO: 1, or a sequence having at least 80% sequence identity with SEQ ID NO: 97, the at least one genetic element, when expressed, is also capable of inhibiting production of chemokine receptor CCR5.

**25**. The method of claim **12**, wherein the at least one encoded genetic element comprises:

at least two of: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; or

each of: SEQ ID NO: 97, SEQ ID NO: 6, and SEQ ID NO: 7.

**26**. A method of treating HIV infection in a subject, the 45 method comprising:

- (a) removing, or having removed, leukocytes from the subject, wherein the subject has been previously immunized with a therapeutically effective amount of a first stimulatory agent;
- (b) purifying, or having purified, peripheral blood mononuclear cells (PBMC) ex vivo from the leukocytes;
- (c) contacting, or having contacted, the PBMC ex vivo with a therapeutically effective amount of a second stimulatory agent;
- (d) transducing, of having transduced, the PBMC ex vivo with a viral delivery system encoding at least one genetic element, wherein the at least one genetic element comprises:
  - at least two of: (i) a sequence comprising at least 80% sequence identity with SEQ ID NO: 1, (ii) a sequence comprising at least 80% sequence identity with SEQ ID NO: 2, and (iii) a sequence comprising at least 80% sequence identity with SEQ ID NO: 3; or
  - each of: (iv) a sequence comprising at least 80% sequence identity with SEQ ID NO: 97, (v) a sequence comprising at least 80% sequence identity

5

with SEQ ID NO: 6, and (vi) a sequence comprising at least 80% sequence identity with SEQ ID NO: 7; and

(e) culturing, or having cultured, the transduced PBMC for at least 1 day.

27. The method of claim 26, wherein the transduced PBMC are cultured from about 1 to about 35 days.

**28**. The method of claim **26**, further comprising infusing, or having infused, the transduced PBMC into the subject.

**29**. The method of claim **26**, wherein the subject is a  $_{10}$  human.

**30**. The method of claim **26**, wherein at least one of the first stimulatory agent and the second stimulatory agent comprises a peptide.

**31**. The method of claim **30**, wherein the peptide comprises a gag peptide.  $^{15}$ 

**32**. The method of claim **26**, wherein at least one of the first stimulatory agent and the second stimulatory agent comprises a vaccine.

**33**. The method of claim **32**, wherein the vaccine comprises an HIV vaccine.

**34**. The method of claim **33**, wherein the HIV vaccine comprises a MVA/HIV62B vaccine or a variant thereof.

**35**. The method of claim **26**, wherein the first stimulatory agent and the second stimulatory agent are the same.

**36**. The method of claim **26**, wherein the viral delivery system comprises a lentiviral particle.

**37**. The method of claim **26**, wherein the at least one genetic element comprises at least one small RNA capable of targeting an HIV RNA sequence.

**38**. The method of claim **37**, wherein, when the at least one genetic element comprises a sequence having at least 80% sequence identity with SEQ ID NO: 1, or a sequence having at least 80% sequence identity with SEQ ID NO: 97, the at least one genetic element, when expressed, is also capable of inhibiting production of chemokine receptor CCR5.

**39**. The method of claim **26**, wherein the at least one genetic element comprises:

at least two of: SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; or

20 each of: SEQ ID NO: 97, SEQ ID NO: 6, and SEQ ID NO: 7.

\* \* \* \* \*